<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7912645</article-id><article-id pub-id-type="pmid">33499150</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics13020143</article-id><article-id pub-id-type="publisher-id">pharmaceutics-13-00143</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Delivery of Natural Agents by Means of Mesoporous Silica Nanospheres as a Promising Anticancer Strategy</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8413-6738</contrib-id><name><surname>AbouAitah</surname><given-names>Khaled</given-names></name><xref ref-type="aff" rid="af1-pharmaceutics-13-00143">1</xref><xref ref-type="aff" rid="af2-pharmaceutics-13-00143">2</xref><xref rid="c1-pharmaceutics-13-00143" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8521-0688</contrib-id><name><surname>Lojkowski</surname><given-names>Witold</given-names></name><xref ref-type="aff" rid="af1-pharmaceutics-13-00143">1</xref><xref rid="c1-pharmaceutics-13-00143" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Bousbaa</surname><given-names>Hassan</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Giovagnoli</surname><given-names>Stefano</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-13-00143"><label>1</label>Laboratory of Nanostructures and Nanomedicine, Institute of High Pressure Physics, Polish Academy of Sciences, Sokolowska 29/37, 01-142 Warsaw, Poland</aff><aff id="af2-pharmaceutics-13-00143"><label>2</label>Medicinal and Aromatic Plants Research Department, Pharmaceutical and Drug Industries Research Division, National Research Centre (NRC), 33 El-Behouth St., Dokki 12622, Giza, Egypt</aff><author-notes><corresp id="c1-pharmaceutics-13-00143"><label>*</label>Correspondence: <email>k.abouaitah@labnano.pl</email> (K.A.); <email>w.lojkowski@labnano.pl</email> (W.L.); Tel.: +48-22-888-0429 or +48-22-632-4302 (K.A. &#x00026; W.L.); Fax: +48-22-632-4218 (K.A. &#x00026; W.L.)</corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>1</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2021</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>143</elocation-id><history><date date-type="received"><day>30</day><month>11</month><year>2020</year></date><date date-type="accepted"><day>14</day><month>1</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Natural prodrugs derived from different natural origins (e.g., medicinal plants, microbes, animals) have a long history in traditional medicine. They exhibit a broad range of pharmacological activities, including anticancer effects in vitro and in vivo. They have potential as safe, cost-effective treatments with few side effects, but are lacking in solubility, bioavailability, specific targeting and have short half-lives. These are barriers to clinical application. Nanomedicine has the potential to offer solutions to circumvent these limitations and allow the use of natural pro-drugs in cancer therapy. Mesoporous silica nanoparticles (MSNs) of various morphology have attracted considerable attention in the search for targeted drug delivery systems. MSNs are characterized by chemical stability, easy synthesis and functionalization, large surface area, tunable pore sizes and volumes, good biocompatibility, controlled drug release under different conditions, and high drug-loading capacity, enabling multifunctional purposes. In vivo pre-clinical evaluations, a significant majority of results indicate the safety profile of MSNs if they are synthesized in an optimized way. Here, we present an overview of synthesis methods, possible surface functionalization, cellular uptake, biodistribution, toxicity, loading strategies, delivery designs with controlled release, and cancer targeting and discuss the future of anticancer nanotechnology-based natural prodrug delivery systems.</p></abstract><kwd-group><kwd>mesoporous silica nanoparticles</kwd><kwd>controlled release</kwd><kwd>drug delivery systems</kwd><kwd>anticancer natural prodrugs</kwd><kwd>natural products</kwd><kwd>cancer targeting</kwd><kwd>nanoformulations/nanomedicine applications</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-13-00143"><title>1. Introduction</title><p>In 2001, Vallet-Regi et al. [<xref rid="B1-pharmaceutics-13-00143" ref-type="bibr">1</xref>] introduced a mesoporous silica material called MCM-41 that can be used as a drug carrier. The nanostructure (e.g., pore size) of MCM-41 can be optimized using different surfactants. Since then, many efforts and attempts have been made to synthesize versatile mesoporous silica nanoparticles (MSNs) with different nanostructures and morphologies to meet the demand for pharmaceutical and medical applications. The history of the synthesis of mesoporous silica materials dates back to 1992, when they were discovered by the Mobile Oil Corporation [<xref rid="B2-pharmaceutics-13-00143" ref-type="bibr">2</xref>]. Silica is one of the most abundant minerals in the Earth&#x02019;s crust and is also found in the food chain and the human body [<xref rid="B3-pharmaceutics-13-00143" ref-type="bibr">3</xref>]. As a biomaterial, silica is extensively used in many applications such as dentistry, orthopedics, and dermatology. MSNs have a characteristic mesoporous nanostructure that offers many advantages for medical applications in disease diagnosis and therapy [<xref rid="B4-pharmaceutics-13-00143" ref-type="bibr">4</xref>]. The unique features include easy synthesis, the possibility of various surface modifications, the ability to obtain a tunable particle size, uniform pore size, high surface area to pore volume, good biocompatibility, and chemical stability [<xref rid="B5-pharmaceutics-13-00143" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-13-00143" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-13-00143" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-13-00143" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceutics-13-00143" ref-type="bibr">9</xref>]. In addition, easy functionalization to achieve magnetic, fluorescent, and photothermal properties increases the chance of using MSNs in bioimaging. MSN nanostructures can provide excellent nanoplatforms to fabricate smart drug delivery systems (DDSs) with a high drug loading capacity and stimuli-responsive drug release effect compared to other nanocarriers [<xref rid="B6-pharmaceutics-13-00143" ref-type="bibr">6</xref>,<xref rid="B10-pharmaceutics-13-00143" ref-type="bibr">10</xref>]. Several nanocarriers have been used to deliver and control drug release, including niosomes, liposomes, dendrimers, lipid nanoparticles, and polymeric nanoparticles, but most of them have low stability and need external stabilization during synthesis. In contrast, MSNs have a strong Si-O bond that makes them stable (chemically and mechanically) to external responses in the surrounding environment [<xref rid="B11-pharmaceutics-13-00143" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceutics-13-00143" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-13-00143" ref-type="bibr">13</xref>]. It is generally accepted that encapsulation of drugs or therapeutic agents into MSNs can enhance their therapeutic activity, solubility, and bioavailability, as indicated by many studies [<xref rid="B14-pharmaceutics-13-00143" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-13-00143" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-13-00143" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceutics-13-00143" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-13-00143" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-13-00143" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceutics-13-00143" ref-type="bibr">20</xref>].</p><p>A consequence of these advantages is that MSNs have gained much attention and popularity in DDSs during the last few decades for the delivery of cargo to specific sites in the organism. A large number of in vivo studies indicate the high biocompatibility/safety profile and low toxicity of MSNs if they are synthesized using an optimized way [<xref rid="B21-pharmaceutics-13-00143" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceutics-13-00143" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceutics-13-00143" ref-type="bibr">23</xref>]. A careful optimization process is needed because many details of the nanostructure of engineered MSNs, i.e., size, shape, surface, presence of surfactant, and other factors like dose, administration route affect the safety profile. According to many animal studies, the toxicity of MSNs can be diminished by optimizing the synthesis parameters and surface modification, resulting in safe nanoparticles [<xref rid="B24-pharmaceutics-13-00143" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-13-00143" ref-type="bibr">25</xref>]. </p><p>The administration route is an important characteristic for constructing any DDS. MSNs can be applied via different routes, including oral and intravenous injection [<xref rid="B26-pharmaceutics-13-00143" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-13-00143" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-13-00143" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-13-00143" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-13-00143" ref-type="bibr">30</xref>]. Many choices in the development of pharmaceutical formulations depend on the target tissues and organs in the human body. An important advantage of DDS-based MSNs is that the amorphous forms of silica and silicates are generally recognized as safe materials for use as oral delivery ingredients (up to 1500 mg per day) according to the US Food and Drug Administration and the European Food Safety Authority [<xref rid="B27-pharmaceutics-13-00143" ref-type="bibr">27</xref>]. MSNs are promising materials because they exhibit low toxicity levels in animals when applied, i.e., orally, injection [<xref rid="B31-pharmaceutics-13-00143" ref-type="bibr">31</xref>]. </p><p>The global market for nanomedicine accounts for 5% when novel nanomedicines translated from the lab to the clinics are concerned [<xref rid="B32-pharmaceutics-13-00143" ref-type="bibr">32</xref>]. Recently, the first clinical trial in humans was conducted with oral delivery of fenofibrate formulation based on the ordered mesoporous silica [<xref rid="B33-pharmaceutics-13-00143" ref-type="bibr">33</xref>]. </p><p>Despite these promising results for nanotechnology application in building DDSs, most research for targeted cancer therapy has been focused on drugs and therapeutic molecules of a synthetic nature. Combating cancers with synthetic drugs is an established therapy, however, progress in this area of medicine is slow and the treatments are frequently associated with undesirable effects: side effects and also insufficient patient compliance. For this reason, extensive research is carried out to apply natural prodrugs (known also as natural products and natural agents) in anticancer therapies. </p><p>Nature is a huge source of therapeutic substances, which can be derived from plants, microbes, and animals. Natural medicines account for 60% of anticancer agents used in clinical applications [<xref rid="B34-pharmaceutics-13-00143" ref-type="bibr">34</xref>]. For example, vincristine, taxanes, and camptothecin are used in the treatment and prevention of cancer. There are still hundreds of promising new active natural anticancer agents to be discovered and renewed for cancer therapy [<xref rid="B35-pharmaceutics-13-00143" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceutics-13-00143" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceutics-13-00143" ref-type="bibr">37</xref>]. The main advantages to using and developing natural prodrugs are that they offer safe, cost-effective, and have versatile pharmacological properties [<xref rid="B38-pharmaceutics-13-00143" ref-type="bibr">38</xref>]. The main limitations for their use in cancer therapy are their poor water solubility, low bioavailability, short half-life, and non-specific targeting. </p><p>Nanotechnology offers many ways to overcome these obstacles [<xref rid="B39-pharmaceutics-13-00143" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceutics-13-00143" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceutics-13-00143" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-13-00143" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-13-00143" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-13-00143" ref-type="bibr">44</xref>]. Natural pro-drugs can be embedded into MSNs, which can serve as effective nanocarriers for the delivery of anticancer natural prodrugs to target cancers. In this review, we present an overview of synthesis methods, surface functionalization, as well as biodistribution, biocompatibility, toxicity, biological performance. Additionally, drug loading and release strategies, and active targeting approaches for MSNs will be addressed. We also discuss delivery and controlled release systems for selected prodrugs using MSNs.</p><p>Available data provide considerable evidence that MSNs allow the limitations associated with prodrugs, such as poor water solubility, poor bioavailability, and low specific targeting ability, to be overcome. Compared to organic delivery systems (e.g., lipid nanoparticles, polymeric nanoparticles) [<xref rid="B45-pharmaceutics-13-00143" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceutics-13-00143" ref-type="bibr">46</xref>], the delivery of natural prodrugs by means of MSNs allows high drug loading and permits multifunctional delivery or co-delivery systems. Generally, MSNs allow long-term release compared to organic nanoparticles. This is because the prodrugs are trapped inside nano-pores. In the case of encapsulation of prodrugs into organic nanoparticles, fast degradation of the organic substance leads to quick pro-drug release. The MSN-based nanomedicine technology is mature enough to be extended to thousands of prodrugs not yet investigated in clinical applications. </p><p>To the best of our knowledge, this is the first review considering MSNs as delivery systems for anticancer natural prodrugs. The need for such a review is a consequence of rapid development in the field. This review may help researchers accelerate research and development of this important field of nanomedicine and, ultimately, clinical applications. </p></sec><sec id="sec2-pharmaceutics-13-00143"><title>2. Synthesis of Mesoporous Silica Nanostructures</title><p>Numerous synthesis methods have been developed to obtain MSNs with different morphological, structural, and pore geometry. Particular attention was paid to the production of biocompatible MSNs for medicine. <xref ref-type="fig" rid="pharmaceutics-13-00143-f001">Figure 1</xref> presents the number of scientific publications (research articles, review articles, and book chapters) as an indicator of the growth in MSN synthesis methods due to their emergence as nanostructures for various promising applications.</p><sec id="sec2dot1-pharmaceutics-13-00143"><title>2.1. Discovery, Synthesis, and Properties of MSNs</title><p>Porous materials (natural or artificial) are characterized by the presence of pores, including cavities, channels, or interstices. The properties of these materials vary depending on the characteristics of their pores: size, arrangement/structure, shape, porosity, and chemical composition. They have been extensively studied in different areas, including water purification, gas separation, catalysts, energy storage, adsorbents, electronics, engineering, tissue engineering, and drug delivery systems, among others [<xref rid="B47-pharmaceutics-13-00143" ref-type="bibr">47</xref>]. Depending on the predominant pore size, the International Union of Pure and Applied Chemistry (IUPAC) classifies porous materials into three categories as shown in <xref rid="pharmaceutics-13-00143-t001" ref-type="table">Table 1</xref> [<xref rid="B48-pharmaceutics-13-00143" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceutics-13-00143" ref-type="bibr">49</xref>].</p><p>The history of MSN materials dates back to the early 1990s, when the Kuroda group at Waseda University and researchers from the Mobil Company discovered Mobil crystalline materials (MCMs), nanoparticles with a hexagonal porous structure [<xref rid="B2-pharmaceutics-13-00143" ref-type="bibr">2</xref>]. In 1992 with the discovery of MCM-41, a material prepared using the cooperative assembly of surfactant with silicates, a breakthrough in the area of ordered mesoporous structures and their successful preparation occurred [<xref rid="B50-pharmaceutics-13-00143" ref-type="bibr">50</xref>,<xref rid="B51-pharmaceutics-13-00143" ref-type="bibr">51</xref>]. In addition, an ionic template, such as cetyltrimethylammonium bromide (CTAB), could be employed as a structure-directing agent to produce MCM-41 and MCM-48 with pore sizes of 2 to 10 nm [<xref rid="B50-pharmaceutics-13-00143" ref-type="bibr">50</xref>,<xref rid="B51-pharmaceutics-13-00143" ref-type="bibr">51</xref>]. MCM-41 has a hexagonal pore shape and MCM-84 has a cubic pore shape. For DDSs purpose, MCM-41 is considered to be one of the most widely explored materials. The synthesis mechanism for MCM-41 is shown in <xref ref-type="fig" rid="pharmaceutics-13-00143-f002">Figure 2</xref> and electron microscope images in <xref ref-type="fig" rid="pharmaceutics-13-00143-f003">Figure 3</xref>.</p><p>In 1996, another kind of MSN was discovered that has a non-ordered pore structure, named KIT-1 (Korea Advanced Institute of Science and Technology Number 1) [<xref rid="B53-pharmaceutics-13-00143" ref-type="bibr">53</xref>]. The KIT family currently has many members, such as KIT-6, which has a hexagonal arrangement of pores [<xref rid="B54-pharmaceutics-13-00143" ref-type="bibr">54</xref>], and KIT-5, which has a cubic ordered structure [<xref rid="B55-pharmaceutics-13-00143" ref-type="bibr">55</xref>]. In 1998, the SBA-15 type (pore size 4&#x02013;6 nm) MSNs introduced by Santa Barbara Amorphous (SBA), which have a hexagonal or cubic pore structure, were developed by means of nonionic surfactants in acidic conditions [<xref rid="B56-pharmaceutics-13-00143" ref-type="bibr">56</xref>]. The cubic SBA-11, 3D hexagonal SBA-12, hexagonal SBA-15, and SBA-16 are mainly prepared based on non-ionic triblock copolymers, such as alkyl poly(ethylene oxide) (PEO) oligomeric surfactants and poly(alkylene oxide) block copolymers [<xref rid="B10-pharmaceutics-13-00143" ref-type="bibr">10</xref>]. The typical synthesis of SBA-15 is dependent on tetramethyl-orthosilicate (TMOS) or tetraethyl-orthosilicate (TEOS) as the silica precursor reacting with a series of block-copolymer surfactants as structure-directing agents. The MCM and SBA materials are recognized as the first generation of hexagonally ordered pore structures and are the common MSNs used in research. A variety of strategies have been designed to attain tunable pore sizes (from less than 2 nm up to 30 nm). In this scenario, the adjustments are made depending on the surfactant template&#x02019;s properties [<xref rid="B57-pharmaceutics-13-00143" ref-type="bibr">57</xref>], pore swelling agents, such as mesitylene [<xref rid="B50-pharmaceutics-13-00143" ref-type="bibr">50</xref>], or hydrothermal treatments [<xref rid="B58-pharmaceutics-13-00143" ref-type="bibr">58</xref>]. </p><p>Importantly, in 2010, high surface-area silica nanospheres with a fibrous morphology and non-ordered pore structure were discovered by a research group of the Catalysis Center at King Abdullah University of Science and Technology (KAUST Catalysis Center, KCC) [<xref rid="B59-pharmaceutics-13-00143" ref-type="bibr">59</xref>]. This material, KCC-1, features a high surface area due to the presence of dendrimeric silica fibers and their respective channels, making KCC-1 a first-of-its-kind material. It is a spherical particle with 3D tomography, a uniform size ranging from 250 nm to 500 nm, high surface area, and large pore size in a non-ordered structure (<xref ref-type="fig" rid="pharmaceutics-13-00143-f004">Figure 4</xref>). Synthesis of KCC-1 [<xref rid="B59-pharmaceutics-13-00143" ref-type="bibr">59</xref>] was accomplished by a microwave-assisted, templated, solvothermal strategy using cetylpyridinium bromide (CPB) or cetyltrimethylammonium bromide (CTAB) as a surfactant (template), 1-pentanol as a co-surfactant, TEOS as the silica source, urea (catalyst-hydrolyzing agent), and a mixture of the cyclohexane solvent and water (as the reaction solvent). The chemicals were introduced to the reaction system stepwise with mixing and microwave-assisted heating applied (in a closed vessel &#x0003e;1200 &#x000b0;C) for a predetermined time for the reaction. Finally, the solution was filtered or centrifuged, washed, and the obtained material calcinated at high temperature (&#x0003e;550 &#x000b0;C). Many research groups changed the surface of substances used in the synthesis in addition to the parameters. For example, Bayal et al. [<xref rid="B60-pharmaceutics-13-00143" ref-type="bibr">60</xref>] showed that changing the concentrations of urea, surfactant (CTAB instead of CPB), or solvent (1-pentanol), the reaction time, or temperature can result in various particle sizes, fiber densities, surface areas, and pore volumes for KCC-1. Such easy manipulation and controlled synthesis of this material make KCC-1 a good solution for versatile applications in the environment, energy, biology, medicine, and other fields [<xref rid="B42-pharmaceutics-13-00143" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-13-00143" ref-type="bibr">43</xref>,<xref rid="B61-pharmaceutics-13-00143" ref-type="bibr">61</xref>,<xref rid="B62-pharmaceutics-13-00143" ref-type="bibr">62</xref>,<xref rid="B63-pharmaceutics-13-00143" ref-type="bibr">63</xref>,<xref rid="B64-pharmaceutics-13-00143" ref-type="bibr">64</xref>,<xref rid="B65-pharmaceutics-13-00143" ref-type="bibr">65</xref>,<xref rid="B66-pharmaceutics-13-00143" ref-type="bibr">66</xref>,<xref rid="B67-pharmaceutics-13-00143" ref-type="bibr">67</xref>,<xref rid="B68-pharmaceutics-13-00143" ref-type="bibr">68</xref>]. KCC-1 could be recommended for different small or large drug/therapeutic agents, possibly for any design and pathological disorder due to KCC-1 s unique physicochemical features. Our research team is among the first to study KCC-1 for DDSs [<xref rid="B42-pharmaceutics-13-00143" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-13-00143" ref-type="bibr">43</xref>,<xref rid="B68-pharmaceutics-13-00143" ref-type="bibr">68</xref>,<xref rid="B69-pharmaceutics-13-00143" ref-type="bibr">69</xref>], and we think that research on KCC-1 will increase soon. In the literature, there are references to &#x0201c;spherical wrinkled mesoporous silica&#x0201d; (WMS) [<xref rid="B70-pharmaceutics-13-00143" ref-type="bibr">70</xref>,<xref rid="B71-pharmaceutics-13-00143" ref-type="bibr">71</xref>,<xref rid="B72-pharmaceutics-13-00143" ref-type="bibr">72</xref>] and KCC-1 is known also &#x0201c;dendritic fibrous nano-silica&#x0201d; (DFNS) [<xref rid="B73-pharmaceutics-13-00143" ref-type="bibr">73</xref>]. They were all obtained based on changing the synthesis conditions and parameters of the original synthesis method for KCC-1 particles.</p><p>Unlimited opportunities exist for the synthesis of MSNs in pure, doped, composite, and modified forms by employing different templates (soft and hard), conditions, and methods [<xref rid="B74-pharmaceutics-13-00143" ref-type="bibr">74</xref>]. </p><p>Due to the unique properties of the KCC-1 family, they offer a wide range of possible applications. It seems that KCC-1 has comparable potential as the commonly used members of the MCM and SBA families, as well as Stober silica, solid silica discovered before all the families [<xref rid="B73-pharmaceutics-13-00143" ref-type="bibr">73</xref>]. <xref rid="pharmaceutics-13-00143-t002" ref-type="table">Table 2</xref> presents the major physicochemical properties for fibrous KCC-1, MCM-41, SBA-15, and others. Below, we highlight the common and promising families that could be favored for drug delivery and medical applications. Numerous interesting review articles have been published on MSN synthesis strategies and applications that we recommend for further reading [<xref rid="B10-pharmaceutics-13-00143" ref-type="bibr">10</xref>,<xref rid="B22-pharmaceutics-13-00143" ref-type="bibr">22</xref>,<xref rid="B32-pharmaceutics-13-00143" ref-type="bibr">32</xref>,<xref rid="B73-pharmaceutics-13-00143" ref-type="bibr">73</xref>,<xref rid="B75-pharmaceutics-13-00143" ref-type="bibr">75</xref>,<xref rid="B76-pharmaceutics-13-00143" ref-type="bibr">76</xref>,<xref rid="B77-pharmaceutics-13-00143" ref-type="bibr">77</xref>,<xref rid="B78-pharmaceutics-13-00143" ref-type="bibr">78</xref>,<xref rid="B79-pharmaceutics-13-00143" ref-type="bibr">79</xref>,<xref rid="B80-pharmaceutics-13-00143" ref-type="bibr">80</xref>,<xref rid="B81-pharmaceutics-13-00143" ref-type="bibr">81</xref>,<xref rid="B82-pharmaceutics-13-00143" ref-type="bibr">82</xref>,<xref rid="B83-pharmaceutics-13-00143" ref-type="bibr">83</xref>].</p></sec><sec id="sec2dot2-pharmaceutics-13-00143"><title>2.2. Surface Modification of MSNs for Drug Delivery</title><p>The keystone in the development of DDSs is to functionalize their surface [<xref rid="B84-pharmaceutics-13-00143" ref-type="bibr">84</xref>,<xref rid="B85-pharmaceutics-13-00143" ref-type="bibr">85</xref>] to increase their drug loading and release, leading to high therapeutic effects. The surface chemistry modulates the interaction of MSNs with the surrounding media. The MSNs have a high density of silanol groups (Si-OH) on their surface, allowing surface modification by various organic functionalities (e.g., silanes, polymers, proteins, and targeting moieties). Thus, MSNs can load various drugs with high capacity and release them in a sustained or controlled manner. A variety of functional groups can be used, such as amine, carboxylate, phosphonate, polyethylene glycol, octadecyl, thiol, carboxylic acid, and octadecyl groups. To introduce functional groups on the surface of MSNs, covalent bonding and electrostatic interactions are generally used [<xref rid="B86-pharmaceutics-13-00143" ref-type="bibr">86</xref>]. The common approach to modify MSNs is to use organic silane groups via direct covalent attachment by means of co-condensation or post-synthetic grafting. </p><p>The co-condensation method is referred to as a one-pot synthesis method [<xref rid="B87-pharmaceutics-13-00143" ref-type="bibr">87</xref>,<xref rid="B88-pharmaceutics-13-00143" ref-type="bibr">88</xref>] as presented in <xref ref-type="fig" rid="pharmaceutics-13-00143-f005">Figure 5</xref>A. The desired functional group of silanes, such as 3-aminopropyl-triethoxysilane (APTES &#x0201c;NH<sub>2</sub>&#x0201d;) is added during the sol-gel synthesis process together with the silica source (e.g., TEOS). Next, the template is removed (<xref ref-type="fig" rid="pharmaceutics-13-00143-f005">Figure 5</xref>A) [<xref rid="B52-pharmaceutics-13-00143" ref-type="bibr">52</xref>,<xref rid="B87-pharmaceutics-13-00143" ref-type="bibr">87</xref>,<xref rid="B89-pharmaceutics-13-00143" ref-type="bibr">89</xref>]. To remove the surfactant template, an extractive method using alcoholic/acidic solution under reflux can be used [<xref rid="B90-pharmaceutics-13-00143" ref-type="bibr">90</xref>]. Removing the template anchors the organic residue covalently to the porous walls of the MSNs. This approach has the advantages of easy preparation, more homogeneous distribution of organic units, and high drug loading [<xref rid="B52-pharmaceutics-13-00143" ref-type="bibr">52</xref>,<xref rid="B83-pharmaceutics-13-00143" ref-type="bibr">83</xref>]. Despite these advantages, disadvantages are a potential change in the mesoscopic order, disordering the porosity and reducing the pore diameter, pore volume, and specific surface areas [<xref rid="B52-pharmaceutics-13-00143" ref-type="bibr">52</xref>]. </p><p>A post-synthetic approach refers to the subsequent modification of the inner/outer surface of MSNs by covalent and electrostatic interactions. The modification is usually achieved after surfactant removal from MSNs (<xref ref-type="fig" rid="pharmaceutics-13-00143-f005">Figure 5</xref>B). The most remarkable advantages of this approach are selective functionalization (either external or internal surfaces) and retention of the mesostructure of MSNs during synthesis. The major disadvantages include reduced pore size and non-homogeneous distribution of functional groups into/onto pores [<xref rid="B52-pharmaceutics-13-00143" ref-type="bibr">52</xref>,<xref rid="B91-pharmaceutics-13-00143" ref-type="bibr">91</xref>,<xref rid="B92-pharmaceutics-13-00143" ref-type="bibr">92</xref>].</p></sec><sec id="sec2dot3-pharmaceutics-13-00143"><title>2.3. The Biological Performance of MSNs</title><sec id="sec2dot3dot1-pharmaceutics-13-00143"><title>2.3.1. Cellular Uptake</title><p>Any nanocarriers have to cross the cell membrane boundary to enter cells, allowing the therapeutic effects of the delivered drugs. The internalization of nanoparticles carrying therapeutic agents into cells represents the initial step in successful drug delivery [<xref rid="B93-pharmaceutics-13-00143" ref-type="bibr">93</xref>,<xref rid="B94-pharmaceutics-13-00143" ref-type="bibr">94</xref>]. The acting mechanisms and surface chemistry of nanocarriers are the major parameters in designing a preferred DDS for any pathological disease [<xref rid="B78-pharmaceutics-13-00143" ref-type="bibr">78</xref>]. Nanoparticles mainly access the cell interior via simple diffusion or translocation as an energy-dependent process [<xref rid="B95-pharmaceutics-13-00143" ref-type="bibr">95</xref>]. The most common mechanism of their internalization is the energy-dependent endocytosis, which allows the uptake of nanoparticles and submicron particles from an extracellular environment to the cell plasma membrane [<xref rid="B96-pharmaceutics-13-00143" ref-type="bibr">96</xref>]. The mechanisms can generally be classified into phagocytosis, pinocytosis, micropinocytosis, receptor-mediated endocytosis, clathrin-mediated endocytosis, caveolin-mediated endocytosis, and others (e.g., Arf-6, Rho-A or IL2Rb-dependent pathway, flotillin, or CDC42 (CLIC/GEEC)-dependent endocytosis) [<xref rid="B93-pharmaceutics-13-00143" ref-type="bibr">93</xref>]. The intracellular uptake and trafficking mechanisms by which nanoparticles are internalized in cells vary broadly depending on many factors, including size, shape, charge, and surface modification. Therefore, these factors should be taken into consideration in constructing DDSs.</p><sec><title>Size of MSNs</title><p>Particle size determines the intracellular uptake of MSNs (<xref ref-type="fig" rid="pharmaceutics-13-00143-f006">Figure 6</xref>) [<xref rid="B97-pharmaceutics-13-00143" ref-type="bibr">97</xref>]. It is generally accepted that particles with the smaller size of 50 nm can internalize into cells via non-phagocytosis [<xref rid="B98-pharmaceutics-13-00143" ref-type="bibr">98</xref>]. Nanoparticles up to 150 and 200 nm in size are internalized by pinocytosis, such as clathrin-mediated endocytosis and caveolin-mediated endocytosis, respectively [<xref rid="B99-pharmaceutics-13-00143" ref-type="bibr">99</xref>,<xref rid="B100-pharmaceutics-13-00143" ref-type="bibr">100</xref>]. In contrast, particles from 250 nm to 3 &#x003bc;m in size can internalize the cells by macropinocytosis and phagocytosis [<xref rid="B101-pharmaceutics-13-00143" ref-type="bibr">101</xref>]. It is also accepted that the microparticles are efficiently taken up through phagocytosis but the process depends also on other parameters, such as geometry, surface charges, and functional groups of microparticles [<xref rid="B102-pharmaceutics-13-00143" ref-type="bibr">102</xref>]. Particles with sizes ranging from 30 to 50 nm internalize also efficiently via receptor-mediated endocytosis [<xref rid="B103-pharmaceutics-13-00143" ref-type="bibr">103</xref>]. Despite extensive investigations exploring the relationship between particle size and uptake pathways, the results are inconsistent [<xref rid="B101-pharmaceutics-13-00143" ref-type="bibr">101</xref>,<xref rid="B104-pharmaceutics-13-00143" ref-type="bibr">104</xref>,<xref rid="B105-pharmaceutics-13-00143" ref-type="bibr">105</xref>,<xref rid="B106-pharmaceutics-13-00143" ref-type="bibr">106</xref>]. The main reason for such contradictions can be attributed to the complexity of control of structural parameters, such as shape and surface charges. For successful internalization, particles should avoid degradation (within endosomal/lysosomal vesicles) and release their cargo in the cytoplasm [<xref rid="B107-pharmaceutics-13-00143" ref-type="bibr">107</xref>]. Therefore, particle size is important in tailoring DDSs. It is also important for their intersections with the reticulo-endothelial system (RES), which is responsible for elimination of nanoparticles from the body, and prolong the circulation time in the blood. In this context, several studies have shown that increasing the particle size increases clearance from the body, reducing the therapeutic impact [<xref rid="B108-pharmaceutics-13-00143" ref-type="bibr">108</xref>,<xref rid="B109-pharmaceutics-13-00143" ref-type="bibr">109</xref>,<xref rid="B110-pharmaceutics-13-00143" ref-type="bibr">110</xref>,<xref rid="B111-pharmaceutics-13-00143" ref-type="bibr">111</xref>,<xref rid="B112-pharmaceutics-13-00143" ref-type="bibr">112</xref>].</p><p>Lu et al. [<xref rid="B103-pharmaceutics-13-00143" ref-type="bibr">103</xref>] investigated the impact of various sizes (30, 50, 110, 170 nm) of MSNs on cellular uptake by HeLa cancer cells using MSNs labeled with fluorescein isothiocyanate (FITC) green fluorescence (MSN-FITC) and confocal laser scanning microscopy. They found that the MSNs were internalized as non-uniform green-fluorescent aggregates in the perinuclear region, and no MSNs penetrated the nucleus (<xref ref-type="fig" rid="pharmaceutics-13-00143-f007">Figure 7</xref>). Quantifying the internalization of MSNs, they concluded that the cellular uptake is highly particle size-dependent, observing the order 50 &#x0003e; 30 &#x0003e; 110 &#x0003e; 280 &#x0003e; 170 nm (<xref ref-type="fig" rid="pharmaceutics-13-00143-f008">Figure 8</xref>). Haddick et al. [<xref rid="B113-pharmaceutics-13-00143" ref-type="bibr">113</xref>] demonstrated that MSNs with a size of 160 nm had the fastest cellular internalization in T24 bladder cancer cells through receptor-mediated cellular internalization compared to 60, 80, 100, and 130 nm, leading to the highest level of gene knock-down for antitumoral effects. Yang et al. [<xref rid="B114-pharmaceutics-13-00143" ref-type="bibr">114</xref>] tested different sizes of rod-shaped SBA-15 (from 80 to 200 nm) and spherical MCM-41 particles, as well as their intracellular uptake in human osteosarcoma cancer cells (KHOS). They found that the cellular uptake efficiency depends on the particle size and shape.</p></sec><sec><title>Surface Charges of MSNs</title><p>Another critical factor influencing the cellular uptake of nanoparticles is the surface charge. MSNs are characterized by silanol groups permitting to add different functional groups, modifying their surface to be either cationic or anionic [<xref rid="B115-pharmaceutics-13-00143" ref-type="bibr">115</xref>]. Most cells have a negatively charged cell membrane, enhancing the uptake of positively charged nanoparticles. Several studies have shown that positively charged nanoparticles internalize with higher uptake than neutral and negatively charged nanoparticles [<xref rid="B116-pharmaceutics-13-00143" ref-type="bibr">116</xref>,<xref rid="B117-pharmaceutics-13-00143" ref-type="bibr">117</xref>,<xref rid="B118-pharmaceutics-13-00143" ref-type="bibr">118</xref>,<xref rid="B119-pharmaceutics-13-00143" ref-type="bibr">119</xref>]. Furthermore, neutral nanoparticles usually have lower cellular uptake compared to negatively charged nanoparticles [<xref rid="B98-pharmaceutics-13-00143" ref-type="bibr">98</xref>,<xref rid="B120-pharmaceutics-13-00143" ref-type="bibr">120</xref>]. As a result of the internalization of nanoparticles by cells, their interaction with the cell membrane can occur by means of gelation of membranes (with negatively charged nanoparticles) or fluidity of membranes (with positively charged nanoparticles) [<xref rid="B121-pharmaceutics-13-00143" ref-type="bibr">121</xref>,<xref rid="B122-pharmaceutics-13-00143" ref-type="bibr">122</xref>]. On the one hand, the positively charged nanoparticles mainly enter cells via micropinocytosis; on the other hand, the negatively charged nanoparticles always enter cells by clathrin- or caveolae-independent endocytosis [<xref rid="B123-pharmaceutics-13-00143" ref-type="bibr">123</xref>].</p><p>Positively charged MSNs generally exhibit higher endocytosis efficiency compared to negatively charged MSNs due to the higher affinity for the negatively charged cell membranes. Jambhrunkar et al. [<xref rid="B124-pharmaceutics-13-00143" ref-type="bibr">124</xref>] prepared MCM-41 with negative and positive charges for delivering curcumin. They found that the positively charged MCM-41-NH<sub>2</sub> had more efficient uptake in the human squamous cell carcinoma cell line (SCC25) than negatively charged particles. Baghirov et al. [<xref rid="B125-pharmaceutics-13-00143" ref-type="bibr">125</xref>] studied spherical and rod-shaped MSNs that were either non-modified or modified with a poly(ethylene glycol)-poly(ethylene imine) (PEG-PEI) block copolymer in in vitro models of the blood&#x02013;brain barrier. The results showed that the modified MSN-PEG-PEI particles exhibited robust uptake in RBE4 rat brain endothelial cells and Madin&#x02013;Darby canine kidney epithelial cells. Our group performed a comprehensive study of cellular uptake using two types of MSNs: KCC-1 and MCM-41 (non-modified, positive charges with -NH<sub>2</sub>, and folic acid ligands) [<xref rid="B42-pharmaceutics-13-00143" ref-type="bibr">42</xref>]. The FA-conjugated MSNs exhibited higher cellular uptake than MSNs-NH<sub>2</sub> and non-modified MSNs.</p></sec><sec><title>Morphological Structures of MSNs</title><p>The morphological structures (i.e., different shapes) play an important role in the cellular uptake and trafficking of nanoparticles into cells or organs. Trewyn et al. [<xref rid="B126-pharmaceutics-13-00143" ref-type="bibr">126</xref>] studied the impact of different MSN shapes on cellular uptake in vitro, finding that a tubular structure achieves more efficient uptake by both cancer and normal cells than those of spherical morphology. Huang et al. [<xref rid="B127-pharmaceutics-13-00143" ref-type="bibr">127</xref>] investigated the effect of three differently shaped particles on non-specific cellular uptake by human melanoma (A375) cells. Their results proved that particles with a larger aspect ratio are efficiently internalized by cells in large amounts at faster rates. Another study tested the core&#x02013;shell MSNs with spherical or rod-like shapes for cellular uptake, showing that a rod shape results in more internalization by cells than a spherical shape [<xref rid="B128-pharmaceutics-13-00143" ref-type="bibr">128</xref>] It is generally accepted that this effect could be due to the larger contact area of the rod than a sphere, permitting high favored internalization of nanoparticles in cell membranes [<xref rid="B116-pharmaceutics-13-00143" ref-type="bibr">116</xref>,<xref rid="B128-pharmaceutics-13-00143" ref-type="bibr">128</xref>] Furthermore, rod-shaped MSNs exhibit superior intracellular uptake compared to spherical MSNs [<xref rid="B129-pharmaceutics-13-00143" ref-type="bibr">129</xref>]. The shape of the nanoparticles can allow a specific mechanism of intracellular uptake. In this context, Hao et al. [<xref rid="B130-pharmaceutics-13-00143" ref-type="bibr">130</xref>] reported that the spherical particles are taken up by cells via clathrin-mediated endocytosis, whereas the rod-shaped particles enter cells through caveolae-mediated endocytosis. </p></sec><sec><title>Other Features of MSNs</title><p>One significant characteristic of any nanocarrier delivery system is hydrophobicity. Nanoparticles that have a hydrophobic nature exhibit a higher affinity for interacting with the cell membrane than those with a hydrophilic nature, contributing to improved cellular uptake [<xref rid="B94-pharmaceutics-13-00143" ref-type="bibr">94</xref>].</p></sec></sec><sec id="sec2dot3dot2-pharmaceutics-13-00143"><title>2.3.2. Biocompatibility and Biodistribution of MSNs</title><p>Any DDSs introduced into clinical investigations should exhibit biocompatibility with body tissues and organs. The biocompatibility is dependent on many MSN characteristics, such as size, shape, surface functionality, porosity, route of administration, and structure (<xref ref-type="fig" rid="pharmaceutics-13-00143-f009">Figure 9</xref>) [<xref rid="B131-pharmaceutics-13-00143" ref-type="bibr">131</xref>].</p><p>Most animal studies indicate the high biocompatibility and safety of MSNs [<xref rid="B31-pharmaceutics-13-00143" ref-type="bibr">31</xref>,<xref rid="B132-pharmaceutics-13-00143" ref-type="bibr">132</xref>,<xref rid="B133-pharmaceutics-13-00143" ref-type="bibr">133</xref>]. The degree of biocompatibility of MSNs can vary according to many factors such as synthesis conditions, suitable structural features, and appropriate route at the right dosage [<xref rid="B8-pharmaceutics-13-00143" ref-type="bibr">8</xref>,<xref rid="B133-pharmaceutics-13-00143" ref-type="bibr">133</xref>,<xref rid="B134-pharmaceutics-13-00143" ref-type="bibr">134</xref>,<xref rid="B135-pharmaceutics-13-00143" ref-type="bibr">135</xref>,<xref rid="B136-pharmaceutics-13-00143" ref-type="bibr">136</xref>,<xref rid="B137-pharmaceutics-13-00143" ref-type="bibr">137</xref>]. As with other nanomaterials, for future translation to clinical applications, the safety aspects of MSNs should be considered carefully for each type [<xref rid="B133-pharmaceutics-13-00143" ref-type="bibr">133</xref>]. Below, we present some studies highlighting the biocompatibility of MSNs in vitro and in vivo. Park et al. [<xref rid="B138-pharmaceutics-13-00143" ref-type="bibr">138</xref>] investigated the biodistribution and biocompatibility of MSNs intravenously injected into mice at 20 mg/kg. The histopathological examination showed no significant toxicity compared to the control group. Their studies also indicated that MSNs are mostly cleared from the liver, spleen, heart, kidneys, brain, and lungs after 4 weeks. Hudson et al. [<xref rid="B139-pharmaceutics-13-00143" ref-type="bibr">139</xref>] examined the biocompatibility of non-modified MSNs with particle sizes of ~150 (pores about 3 nm), 800 nm (pores about 7 nm), and ~4 &#x000b5;m (pores about 16 nm) at different does/concentrations. In vitro results in mesothelial cells showed that the cytotoxicity depends on the concentration; increasing concentration increases cytotoxicity towards cells. For in vivo studies, mcice were injected (intra-peritoneal, intra-peritoneal, and subcutaneous) at single dose of 30 mg/mL per mouse. The biocompatibility of MSNs in vivo depends on the dose and the route of administration. The subcutaneous injection of MSNs in rats indicates good biocompatibility, whereas intraperitoneal and intravenous injections at very high dose ~1.2 g/kg is lethal for mice due to toxicity or distress necessitating euthanasia, but at dose of ~40 mg/kg is safe. This severe systemic toxicity can be mitigated by further surface modification of the MSNs. Lu et al. [<xref rid="B23-pharmaceutics-13-00143" ref-type="bibr">23</xref>] evaluated various doses of MSNs intravenously injected in mice (twice per week) for 14 days, they concluded that dose at 50 mg/kg is well tolerated in mice, no toxicity, no apparent abnormalities on the histopathological level or lesions were observed. They also revealed that this dose is adequate for the pharmacological application in cancer therapy.</p><p>Huang et al. [<xref rid="B30-pharmaceutics-13-00143" ref-type="bibr">30</xref>] evaluated the biocompatibility of differently shaped and PEGylated MSNs (<xref ref-type="fig" rid="pharmaceutics-13-00143-f010">Figure 10</xref>, <xref ref-type="fig" rid="pharmaceutics-13-00143-f011">Figure 11</xref> and <xref ref-type="fig" rid="pharmaceutics-13-00143-f012">Figure 12</xref>), measuring various blood and serum biochemical indicators 24 h and 18 days after injection of MSNs at a dose of 20 mg/kg. All hematology markers were within normal ranges without any considerable toxicity, showing excellent biocompatibility. The results indicated that these particles do not influence liver function, and other parameters were also in the normal range. Concerning the quantitative determination of biodistribution and clearance, approximately 80% of MSNs are trapped in RES of the liver, spleen, and lung after 2 h of administration. Comparing the Si contents of different organs (at 2 h, 24 h, and 7 days), the Si content obviously decreased over time, indicating the possible degradation and clearance of MSNs from the liver, spleen, lung, and kidney. Moreover, the circulation time of MSNs in blood shows that long rod MSN (NLR) has a longer blood circulation time than short rod MSN (NSR), and the effect of surface modification by PEGylation is partially dependent on the shape.</p><p>Yildirim et al. [<xref rid="B140-pharmaceutics-13-00143" ref-type="bibr">140</xref>] evaluated the interactions of MSNs with different surface functional groups (ionic, polar, neutral, and hydrophobic) on blood parameters (hemolytic activity, thrombogenicity, and adsorption of blood proteins) to understand their biocompatibility. They concluded that the blood compatibility of MSNs positively improves with surface functional groups. <xref rid="pharmaceutics-13-00143-t003" ref-type="table">Table 3</xref> shows some data reported on the biocompatibility, biodistribution, and clearance of MSNs in vitro and in vivo.</p></sec><sec id="sec2dot3dot3-pharmaceutics-13-00143"><title>2.3.3. Toxicity of MSNs</title><p>For preclinical and further clinical investigations, nanocarriers should be optimized to avoid undesirable characteristics (e.g., toxicity, side effects, non-specific interactions) and to allow good biological performance [<xref rid="B131-pharmaceutics-13-00143" ref-type="bibr">131</xref>]. As one of the most abundant materials on Earth, silica (or silicon dioxide) in crystalline form can be found in nature as sand or quartz [<xref rid="B149-pharmaceutics-13-00143" ref-type="bibr">149</xref>]. In contrast, the amorphous form is present in biological materials, including plants, cells, microbes (e.g., bacteria), vertebrates, and invertebrates [<xref rid="B150-pharmaceutics-13-00143" ref-type="bibr">150</xref>]. Silica is also endogenous to human tissues, such as cartilage and bone [<xref rid="B151-pharmaceutics-13-00143" ref-type="bibr">151</xref>]. Several efforts are underway to identify the toxicity of both the crystalline and amorphous forms of silica in different methods of application [<xref rid="B10-pharmaceutics-13-00143" ref-type="bibr">10</xref>]. Crystalline silica mainly results in toxicity as a result of breathing fine crystalline powders created by the extraction of stone materials in soil [<xref rid="B86-pharmaceutics-13-00143" ref-type="bibr">86</xref>]. Because it is found in vegetables, whole grains, and seafood, silica is a considerable part of the human diet (approximately 20&#x02013;50 mg silicon/day for Western populations and reaching 200 mg/day for people whose diet is mainly plant-based as in China and India) [<xref rid="B152-pharmaceutics-13-00143" ref-type="bibr">152</xref>]. Furthermore, after ingestion of silica, it circulates in the blood plasma and is absorbed in the form of silicic acid; up to 41% of silicic acid is excreted in the urine [<xref rid="B153-pharmaceutics-13-00143" ref-type="bibr">153</xref>]. Silica nanomaterials are hydrolytically unstable and dissolve into the soluble form of silicic acid (Si(OH)4, pKa 9.6) [<xref rid="B152-pharmaceutics-13-00143" ref-type="bibr">152</xref>]. This can occur through three different processes: hydration, hydrolysis, and ion-exchange [<xref rid="B154-pharmaceutics-13-00143" ref-type="bibr">154</xref>]. A schematic representation of silica degradation is shown in <xref ref-type="fig" rid="pharmaceutics-13-00143-f013">Figure 13</xref> [<xref rid="B155-pharmaceutics-13-00143" ref-type="bibr">155</xref>]. Silicic acid has good bioavailability, contributing many health benefits, such as maintaining bone health [<xref rid="B154-pharmaceutics-13-00143" ref-type="bibr">154</xref>,<xref rid="B156-pharmaceutics-13-00143" ref-type="bibr">156</xref>,<xref rid="B157-pharmaceutics-13-00143" ref-type="bibr">157</xref>]. The FDA has approved silica as &#x0201c;generally recognized as safe&#x0201d; for use in food additives and pharmaceutical products [<xref rid="B86-pharmaceutics-13-00143" ref-type="bibr">86</xref>,<xref rid="B155-pharmaceutics-13-00143" ref-type="bibr">155</xref>]. Silica nanoparticles have also been approved by the FDA for cancer imaging in clinical trials [<xref rid="B158-pharmaceutics-13-00143" ref-type="bibr">158</xref>] and MSNs being developed with high potential for DDSs in clinical investigations [<xref rid="B159-pharmaceutics-13-00143" ref-type="bibr">159</xref>]. </p><p>The biosafety of engineered MSNs has been confirmed by several studies. As shown in the literature, MSNs have insignificant toxicity, and the degree of toxicity is identified as low from in vivo studies. Additionally, even such insignificant toxicity can be reduced with the optimization of the synthesis process. However, a few reported data [<xref rid="B160-pharmaceutics-13-00143" ref-type="bibr">160</xref>,<xref rid="B161-pharmaceutics-13-00143" ref-type="bibr">161</xref>,<xref rid="B162-pharmaceutics-13-00143" ref-type="bibr">162</xref>,<xref rid="B163-pharmaceutics-13-00143" ref-type="bibr">163</xref>] provide contrary reports. The plausible reason for this is that there are many factors affecting the biocompatibility and safety of MSNs (e.g., shape, size, surface functional groups, physicochemical properties). For example, the method of removing the surfactant/template after MSNs synthesis (by calcination or by refluxing) influences the final cytotoxicity [<xref rid="B139-pharmaceutics-13-00143" ref-type="bibr">139</xref>]. According to a number of in vivo experiments, a coherent message regarding the toxicity of MSNs is that that the toxicity depends on the dose/concentration used. For example, Hudson et al. [<xref rid="B139-pharmaceutics-13-00143" ref-type="bibr">139</xref>] investigated the toxicity for MSNs (single dose) in vivo, they evaluated various doses and administration routes. They concluded that a very high dose (1.2 g/kg) is lethal for mice compared to the half dose which is well-tolerated and safe when applied by intraperitoneal or intravenous injection. Liu et al. [<xref rid="B164-pharmaceutics-13-00143" ref-type="bibr">164</xref>] studied the single and repeated dose of MSNs via intravenous administration in mice. In the single-dose toxicity investigations, they found that the LD50 is higher than 1000 mg/kg. They also demonstrated that the groups that received low doses of MSNs did not show any behavioral, hematology, and pathological changes, whereas the groups that received high doses (1280 mg/kg) did not survive. In the repeated dose toxicity experiments, the mice groups were given continuously for 14 days followed by observation for a month. The results display that no mortality and no remarkable changes (in pathology or blood parameters) were detected. They also reported that the treatment of MSNs at daily doses (80 mg/kg) for 14 days is safe without any adverse effects in animals. Fu et al. [<xref rid="B29-pharmaceutics-13-00143" ref-type="bibr">29</xref>] evaluated toxicity of MSNs (110 nm) in ICR mice treated by different routes: hypodermic, intramuscular, intravenous injections, and oral administration. They found that the oral route is well tolerated in mice even when increased to 5000 mg/kg compared to the intravenous route which shows the least threshold. As such results and others available from literature generated evidence to show that MSNs are well tolerated and safe in animals by various routes of administrations, i.e., oral, and intravenous injections [<xref rid="B29-pharmaceutics-13-00143" ref-type="bibr">29</xref>,<xref rid="B133-pharmaceutics-13-00143" ref-type="bibr">133</xref>,<xref rid="B164-pharmaceutics-13-00143" ref-type="bibr">164</xref>,<xref rid="B165-pharmaceutics-13-00143" ref-type="bibr">165</xref>]. However, there is no doubt that optimized production of MSNs and the final nanoformulation can achieve good biocompatibility and safe nanoparticles for treating diseases. <xref rid="pharmaceutics-13-00143-t004" ref-type="table">Table 4</xref> lists some studies that have explored the toxicity of MSNs and their delivery systems. For more reading concerning the toxicity and biosafety of MSNs, there are several extensive reviews [<xref rid="B10-pharmaceutics-13-00143" ref-type="bibr">10</xref>,<xref rid="B137-pharmaceutics-13-00143" ref-type="bibr">137</xref>,<xref rid="B151-pharmaceutics-13-00143" ref-type="bibr">151</xref>,<xref rid="B166-pharmaceutics-13-00143" ref-type="bibr">166</xref>,<xref rid="B167-pharmaceutics-13-00143" ref-type="bibr">167</xref>,<xref rid="B168-pharmaceutics-13-00143" ref-type="bibr">168</xref>]. The toxicity of any material/object, including MSNs, in a given environment is dependent on the dose [<xref rid="B168-pharmaceutics-13-00143" ref-type="bibr">168</xref>]. As reviewed by Croissant et al. [<xref rid="B168-pharmaceutics-13-00143" ref-type="bibr">168</xref>], there are mainly two mechanisms governing the toxicity of MSNs on the cellular level [<xref rid="B88-pharmaceutics-13-00143" ref-type="bibr">88</xref>]. The first mechanism is surface silanolates that lead to membranolysis after the electrostatic interactions between MSNs and phospholipids of the cell membrane occur [<xref rid="B169-pharmaceutics-13-00143" ref-type="bibr">169</xref>]. The second mechanism is reactive oxygen species (ROS) generation, which leads to cell death (by necrosis or apoptosis) by means of membranolysis [<xref rid="B170-pharmaceutics-13-00143" ref-type="bibr">170</xref>]. Reducing the possible toxicity and improving the biosafety of MSNs can be achieved by optimizing the synthesis properties of MSNs for drug delivery and biomedical applications.</p></sec></sec></sec><sec id="sec3-pharmaceutics-13-00143"><title>3. Drug Loading and Release Strategies</title><sec id="sec3dot1-pharmaceutics-13-00143"><title>3.1. Drug Loading Strategies</title><p>A unique feature of MSNs (e.g., large pore volume, high surface, pores, stability) makes them one of the most common nanocarriers exploited for drug delivery with a high drug loading capacity for a variety of drugs. Generally, drugs or therapeutic molecules can be loaded into MSNs with or without pore-capping. In the first technique without pore-capping, hydrophobic or hydrophilic therapeutic agents directly load MSNs with covalent or noncovalent bonding or electrostatic interactions. Loading of drugs or therapeutic agents into the mesopore network of MSNs delivers them to target tissues while simultaneously saving them from undesirable factors found in the surrounding environment (e.g., enzymatic degradation in the body) [<xref rid="B9-pharmaceutics-13-00143" ref-type="bibr">9</xref>]. To load a suitable amount of drug, MSNs are immersed in the desired stock solution of the drug or therapeutic agent under stirring/shaking, during which the drug loading is highly driven by the concentration gradient, the competition between drug (adsorbate) and MSNs (adsorbent), adsorbate and solvent, and adsorbent and solvent [<xref rid="B177-pharmaceutics-13-00143" ref-type="bibr">177</xref>,<xref rid="B178-pharmaceutics-13-00143" ref-type="bibr">178</xref>]. As such, a loading process has been reported with a variety of drugs, such as camptothecin (hydrophobic anticancer molecule) [<xref rid="B90-pharmaceutics-13-00143" ref-type="bibr">90</xref>], doxorubicin (Dox) hydrochloride [<xref rid="B179-pharmaceutics-13-00143" ref-type="bibr">179</xref>], curcumin [<xref rid="B69-pharmaceutics-13-00143" ref-type="bibr">69</xref>], quercetin [<xref rid="B68-pharmaceutics-13-00143" ref-type="bibr">68</xref>], 5-fluorouracil (5-FU) [<xref rid="B180-pharmaceutics-13-00143" ref-type="bibr">180</xref>], erythromycin [<xref rid="B181-pharmaceutics-13-00143" ref-type="bibr">181</xref>], alendronate [<xref rid="B182-pharmaceutics-13-00143" ref-type="bibr">182</xref>], silymarin [<xref rid="B183-pharmaceutics-13-00143" ref-type="bibr">183</xref>], and paclitaxel (PTX) [<xref rid="B184-pharmaceutics-13-00143" ref-type="bibr">184</xref>]. Importantly, the degree of drug loading can be maximized by choosing the desired solvent for the drug, modifying the MSN surface, and adjusting the loading parameters (e.g., time, temperature) [<xref rid="B10-pharmaceutics-13-00143" ref-type="bibr">10</xref>,<xref rid="B86-pharmaceutics-13-00143" ref-type="bibr">86</xref>,<xref rid="B185-pharmaceutics-13-00143" ref-type="bibr">185</xref>].</p><p>In the second strategy with capping as the &#x0201c;gatekeeper&#x0201d; for the pore openings of MSNs [<xref rid="B168-pharmaceutics-13-00143" ref-type="bibr">168</xref>], the first stage is to engineer the outer surface of MSNs via many techniques: molecular or supramolecular functionalization, capping with nanoparticles, and coating with polymer, protein, or lipid. This approach can control the release and delivery of therapeutic agents. In the molecular or supramolecular approach, caps are mainly rotaxanes, pseudorotaxanes, and others consisting of a long chain-like molecule that is threaded via a cyclic molecule [<xref rid="B186-pharmaceutics-13-00143" ref-type="bibr">186</xref>]. Under certain conditions (e.g., pH, redox), the cyclic molecule can attract rotaxane (to one end of it), with the presence of a stimulus allowing it to slide to the other end. By attaching the thread near the pore opening on MSNs, the sliding cyclic molecule blocks the pore when it is near the particle or opens if it slides away. The idea of nanoparticles as gatekeepers was pioneered by Lin and co-workers [<xref rid="B187-pharmaceutics-13-00143" ref-type="bibr">187</xref>,<xref rid="B188-pharmaceutics-13-00143" ref-type="bibr">188</xref>,<xref rid="B189-pharmaceutics-13-00143" ref-type="bibr">189</xref>,<xref rid="B190-pharmaceutics-13-00143" ref-type="bibr">190</xref>] with many nanoparticles, such as iron oxide nanoparticles and gold nanoparticles. These small nanoparticles can graft on top of MSNs loaded with cargos through chemical bonding upon cleavage of the chemical bonds linking the nanoparticles with MSNs. Consequently, under certain conditions (pH, redox), external stimuli can trigger the release of cargos in a controlled manner. Next, in the coating strategy, different types of biomaterials, such as polymer, proteins, and lipids, can be introduced onto the surface of MSNs loaded with drugs. Drug release can occur upon degradation of these biomaterials or changing the surrounding environment stimuli, either external or internal [<xref rid="B191-pharmaceutics-13-00143" ref-type="bibr">191</xref>,<xref rid="B192-pharmaceutics-13-00143" ref-type="bibr">192</xref>,<xref rid="B193-pharmaceutics-13-00143" ref-type="bibr">193</xref>]. <xref rid="pharmaceutics-13-00143-t005" ref-type="table">Table 5</xref> lists some examples of reported studies on prodrug loading in MSNs and their loading capacity. <xref rid="pharmaceutics-13-00143-t006" ref-type="table">Table 6</xref> provides the different loading strategies and their relationship to stimulate release under various conditions for MSNs, showing the connection between loading and release effects.</p></sec><sec id="sec3dot2-pharmaceutics-13-00143"><title>3.2. Drug Delivery Strategies</title><p>In this section, we provide a summary of delivery strategies that have been developed to treat cancer. This topic is well discussed in several reports for MSN delivery systems, and the readers are referred to these selected reviews [<xref rid="B15-pharmaceutics-13-00143" ref-type="bibr">15</xref>,<xref rid="B32-pharmaceutics-13-00143" ref-type="bibr">32</xref>,<xref rid="B79-pharmaceutics-13-00143" ref-type="bibr">79</xref>,<xref rid="B168-pharmaceutics-13-00143" ref-type="bibr">168</xref>,<xref rid="B218-pharmaceutics-13-00143" ref-type="bibr">218</xref>,<xref rid="B219-pharmaceutics-13-00143" ref-type="bibr">219</xref>,<xref rid="B220-pharmaceutics-13-00143" ref-type="bibr">220</xref>,<xref rid="B221-pharmaceutics-13-00143" ref-type="bibr">221</xref>]. Open pores on MSNs, the so-called cavities due to their porous structure, are not only used to load therapeutic agents, but also allow them to diffuse out in the surrounding solution. Closing these pores loaded with therapeutic agents is an essential step to avoid their premature release into the blood vessels, protecting from several side effects because of non-specific release [<xref rid="B221-pharmaceutics-13-00143" ref-type="bibr">221</xref>]. Much effort has been made in controlled delivery systems with the stimulated or responsive release of therapeutic agents under certain conditions. Two major common strategies for delivering drugs have been reported by internal stimuli release (typical of the treated pathology), such as pH, redox potential, and enzymes, or by external stimuli (remotely applied by the clinician), such as magnetic fields, ultrasound, and light (<xref ref-type="fig" rid="pharmaceutics-13-00143-f014">Figure 14</xref>) [<xref rid="B32-pharmaceutics-13-00143" ref-type="bibr">32</xref>].</p><sec id="sec3dot2dot1-pharmaceutics-13-00143"><title>3.2.1. Internal Stimuli-Responsive Drug Release from MSNs</title><sec><title>pH-Responsive Release</title><p>Cancer is well-known for its acidic tumor microenvironment with a lower pH than healthy cells/tissues. Consequently, pH-sensitive release is one of the approaches used in cancer nanomedicines. The most investigated pH-responsive delivery systems for anticancer therapeutic drugs have been inspired by applying diverse techniques and vary according to the loading strategies. In this section, we focus on some examples of recent studies published for natural anticancer prodrugs with pH-sensitive release. Nasab et al. [<xref rid="B222-pharmaceutics-13-00143" ref-type="bibr">222</xref>] fabricated MSNs (MCM-41) capped with chitosan polymer and subsequently loaded with curcumin. This pH-responsive design depends on the degradation of chitosan, allowing high curcumin release at a low pH of 5.5 and resulting in low release at normal physiological pH (7.4). This is favorable for killing U87MG glioblastoma cancer cells. Mishra et al. [<xref rid="B223-pharmaceutics-13-00143" ref-type="bibr">223</xref>] synthesized MSNs (SBA-15), followed by folic acid functionalization and further loading with quercetin and acid-labile magnetic nanoparticles (<xref ref-type="fig" rid="pharmaceutics-13-00143-f015">Figure 15</xref>). The system was investigated in vitro and in vivo in HCT-116 human colorectal carcinoma cells. The results showed that quercetin release was a pH-dependent effect, increasing with decreasing pH. Eventually, the system exhibits promising chemo-theranostic effects for managing colon carcinoma. In this context, Rashidi et al. [<xref rid="B224-pharmaceutics-13-00143" ref-type="bibr">224</xref>] reported that the release of gallic acid (GA) from MSNs strongly depends on the pH levels of the release media. Furthermore, a pH-sensitive delivery system for ursolic acid prodrug was synthesized by incorporating an acid-sensitive linkage between the drug and MSNs [<xref rid="B200-pharmaceutics-13-00143" ref-type="bibr">200</xref>]. This sustained release of ursolic acid enhances the anticancer effects against hepatocellular carcinoma cancer. A pH-responsive release of evodiamine and berberine was also achieved by loading them into lipid-coated MSNs [<xref rid="B225-pharmaceutics-13-00143" ref-type="bibr">225</xref>]. In another strategy using Fe3O4 nanoparticles as gatekeepers, artemisinin is initially loaded into the inner space of hollow MSNs and Fe3O4 capped onto the pore outlets through acid-labile acetal linkers. The results proved that the system is stable under neutral conditions at pH 7.4 (no release), but it releases the prodrug upon exposure to the acidic lysosomal compartment (pH 3.8&#x02013;5.0). The acetal linkers can be hydrolyzed under acidic conditions. This delivery system has an efficient and desirable anticancer action [<xref rid="B226-pharmaceutics-13-00143" ref-type="bibr">226</xref>].</p></sec><sec><title>Redox-Responsive Release </title><p>The delivery systems that consider redox-sensitive release are popular in cancer-targeted therapy. They take advantage of intracellular conditions and rely specifically on the presence of glutathione (GSH) with a high level of expression in cancer cells compared to normal cells [<xref rid="B227-pharmaceutics-13-00143" ref-type="bibr">227</xref>]. For example, Lin et al. [<xref rid="B228-pharmaceutics-13-00143" ref-type="bibr">228</xref>] prepared pH and redox dual-stage responsive release of curcumin with Dox through specific cleavable PEGylation and hydrogel coating (crosslinked by disulfide bonds). The used MSNs were loaded with Dox, whereas the curcumin was encapsulated in a hydrogel coating. The results indicated that dual-responsive release by means of GSH and pH allows efficient and specific cancer targeting (<xref ref-type="fig" rid="pharmaceutics-13-00143-f016">Figure 16</xref>). In another example, Xu et al. [<xref rid="B229-pharmaceutics-13-00143" ref-type="bibr">229</xref>] developed a stimuli-responsive delivery for curcumin gatekeepers based on MSNs characterized by large pores (named LP). In this design, curcumin is anchored to the surface of LP using thiol-ene as the click chemistry approach, followed by a coating of the pluronic polymer (F127) on the surface by means of self-assembly. The release studies proved that curcumin exhibits a redox-responsive release depending on the absence or presence of GSH at different pH levels. </p></sec><sec><title>Enzyme-Responsive Release</title><p>In the human body, many chemicals and enzymes are inherently expressed during pathological conditions, including cancers, which are explored to trigger drug release from numerous MSN types [<xref rid="B10-pharmaceutics-13-00143" ref-type="bibr">10</xref>]. A delivery system tailored for anticancer treatment with enzyme-responsive release, in which matrix metalloproteinase (MMP) substrate peptide containing PLGLAR, which is sensitive to MMPs, is immobilized onto amine-modified MSNs and further capped with bovine serum albumin by covalent bonding. The results revealed that the nanoplatform delivery exhibits enzyme-triggered release of drug and efficiently inhibits tumor growth in vivo. MMP enzyme-trigger release of cisplatin-based MSNs was reported by Vaghasiya [<xref rid="B230-pharmaceutics-13-00143" ref-type="bibr">230</xref>]. The system constructed by coating collagen on the surface of drug-loaded MSNs eventually results in sensitive enzyme release. </p></sec></sec><sec id="sec3dot2dot2-pharmaceutics-13-00143"><title>3.2.2. External Stimuli-Responsive Drug Release from MSNs</title><sec><title>Responsive Release Using Magnetic Fields</title><p>This approach is largely employed for responsive release due to the magnetic guidance by a permanent magnetic field and locally increases the internal temperature by changing the magnetic field potential [<xref rid="B32-pharmaceutics-13-00143" ref-type="bibr">32</xref>]. The delivery systems concerning this method widely use magnetic nanoparticles (superparamagnetic iron oxide-SPIONs) 5&#x02013;10 nm in size as a core and mesoporous silica shell permitting drug loading and release [<xref rid="B231-pharmaceutics-13-00143" ref-type="bibr">231</xref>]. Regarding natural prodrugs, the nano platform developed by Janus MSNs consists of magnetic nanoparticles to achieve magnetic targeting and delivery of berberine. This system produces a sustained release and exerts extraordinarily site-specific internalization into hepatocellular carcinoma cells, facilitating a high antitumor effect against liver cancer due to an external magnetic field [<xref rid="B232-pharmaceutics-13-00143" ref-type="bibr">232</xref>]. Another very recent example is Asgari et al. [<xref rid="B233-pharmaceutics-13-00143" ref-type="bibr">233</xref>] developing a novel in situ encapsulation delivery for curcumin consisting of magnetite-silica core-shell nanocomposites. The system could be effective for clinical application by means of magnetic hyperthermia therapy. In addition, nanoparticles of DNA-capped magnetic mesoporous silica composite exhibit temperature-dependent release of Dox and magnetic hyperthermia effects against cancer [<xref rid="B234-pharmaceutics-13-00143" ref-type="bibr">234</xref>].</p></sec><sec><title>Responsive Release of Drugs Using Light</title><p>As a non-invasive and spatiotemporal strategy, different wavelengths of ultraviolet, visible, or near-infrared light can be employed to trigger and control drugs from MSNs. The main advantages are easy application by the clinician and focalization to the target tissue [<xref rid="B235-pharmaceutics-13-00143" ref-type="bibr">235</xref>,<xref rid="B236-pharmaceutics-13-00143" ref-type="bibr">236</xref>,<xref rid="B237-pharmaceutics-13-00143" ref-type="bibr">237</xref>]. </p><p>Kuang et al. [<xref rid="B238-pharmaceutics-13-00143" ref-type="bibr">238</xref>] developed a curcumin delivery system by means of photodynamic therapy, achieving PEGylated MSNs loaded with curcumin (<xref ref-type="fig" rid="pharmaceutics-13-00143-f017">Figure 17</xref>). The results demonstrated that the developed system, &#x0201c;MSN-PEG@Cur&#x0201d;, exhibits efficient endocytosis into cells and the release of curcumin. As a photodynamic therapy, it promptly generates ROS upon irradiation, allowing effective treatment for cancer. In another example, Li et al. [<xref rid="B239-pharmaceutics-13-00143" ref-type="bibr">239</xref>] preloaded berberine into folic acid-modified Janus gold MSNs. The in vitro and in vivo results demonstrated that the delivery system verifies sustained release dependent on light and an efficient anti-tumor effect with good biosafety for normal tissue. Feng et al. [<xref rid="B225-pharmaceutics-13-00143" ref-type="bibr">225</xref>] fabricated a dual delivery platform for evodiamine and berberine loaded into lipid-coated MSNs with thermo-sensitive release. Their results suggest that the temperature-responsive release is promising for both hydrophobic and hydrophilic drugs. Using an important natural prodrug of capsaicin, the main ingredient in red or hot chili pepper, Yu et al. [<xref rid="B240-pharmaceutics-13-00143" ref-type="bibr">240</xref>] reported a novel design of NIR-triggered plasmonic nanodot-capped MSNs for inhibiting metastasis of human papillary thyroid carcinoma. The nanoplatform consisting of gold nanodot-capped MSNs loaded the prodrug. The results depicted that the delivery of capsaicin by the developed nanoformulation exhibited strong cytotoxicity against the FTC-133 and B-CPAP cell lines compared to free capsaicin. </p></sec><sec><title>Responsive Release of Drugs by Ultrasound</title><p>Ultrasound is considered an interesting and efficient approach to trigger the release of drugs from MSNs. The main advantages include deep penetration of living tissues without causing damage, and it is non-invasive and can be concentrated to the desired tissue [<xref rid="B32-pharmaceutics-13-00143" ref-type="bibr">32</xref>,<xref rid="B241-pharmaceutics-13-00143" ref-type="bibr">241</xref>]. In this approach, drugs can be released from pores of MSNs due to the thermal effect of ultrasound radiation on chemical bonds and thermosensitive polymers while closing in the absence of a radiation effect [<xref rid="B242-pharmaceutics-13-00143" ref-type="bibr">242</xref>,<xref rid="B243-pharmaceutics-13-00143" ref-type="bibr">243</xref>,<xref rid="B244-pharmaceutics-13-00143" ref-type="bibr">244</xref>]. An example is MSNs modified with amine groups covered by sodium alginate polymer and subsequently loaded with a model cargo (rhodamine B) [<xref rid="B245-pharmaceutics-13-00143" ref-type="bibr">245</xref>]. The results indicated that rhodamine B releases based on changing the ultrasound potential (ultrasound on&#x02013;off responsiveness).</p></sec></sec></sec></sec><sec id="sec4-pharmaceutics-13-00143"><title>4. Selective Targeting Strategies for Cancer</title><p>One of the hottest areas in delivery systems is the delivery of drugs or therapeutic agents directly to specific tissues where the desired therapy is required. The main goal of nanomedicine application for cancers is avoiding the expected side effects from drugs and damaging the healthy cells surrounding the tumor site [<xref rid="B21-pharmaceutics-13-00143" ref-type="bibr">21</xref>,<xref rid="B246-pharmaceutics-13-00143" ref-type="bibr">246</xref>]. Two routes have been used depending on nano-particulate delivery for cancers, passive and active selective targeting. </p><p>Passive targeting was first postulated by Matsumura and Maeda in 1986 [<xref rid="B247-pharmaceutics-13-00143" ref-type="bibr">247</xref>]. Nanoparticles can accumulate in tumor tissue by the enhanced permeability and retention (EPR) effect. They hypothesized that the localization of macromolecules and particles of certain sizes differ, which is attributed to the tumor microenvironment, the relatively slow elimination rate, and poor lymphatic drainage. Particle size, surface charge, or hydrophobicity can be mediated by the so-called EPR effect, or passive targeting [<xref rid="B248-pharmaceutics-13-00143" ref-type="bibr">248</xref>,<xref rid="B249-pharmaceutics-13-00143" ref-type="bibr">249</xref>] (<xref ref-type="fig" rid="pharmaceutics-13-00143-f018">Figure 18</xref>). Passive targeting is due to abnormalities in tumor blood vessels, which have wide interendothelial junctions with pores (700 nm). Injected nanoparticles travel through the bloodstream and accumulate in the tumor interstitium because of this characteristic of tumor vessels [<xref rid="B247-pharmaceutics-13-00143" ref-type="bibr">247</xref>,<xref rid="B249-pharmaceutics-13-00143" ref-type="bibr">249</xref>]. The nanoparticles already located in the tumor would remain there because of the ineffective lymphatic drainage with the fast growth of the tumor tissue [<xref rid="B221-pharmaceutics-13-00143" ref-type="bibr">221</xref>]. However, the EPR effect is often not efficient enough to selectively deliver and reduce the side effects of anticancer drugs [<xref rid="B250-pharmaceutics-13-00143" ref-type="bibr">250</xref>]. </p><p>Active targeting is used to enhance the ability of a nanoparticle delivery platform carrying drugs to be taken up and bind to cancer cells via specific receptors on their surfaces compared to normal cells [<xref rid="B251-pharmaceutics-13-00143" ref-type="bibr">251</xref>]. It is well known that some tumor cells overexpress certain receptors on their surface. Thus, nano-delivery systems functionalized with various ligands permit a high affinity for receptors facilitating specific retention and uptake by cancer cells. Thus, the role of targeting ligands is to allow the nanocarriers to selectively enter the cancerous cells, but not normal cells. This not only reduces the administration dosage, but also diminishes toxic side effects of drugs during circulation [<xref rid="B252-pharmaceutics-13-00143" ref-type="bibr">252</xref>]. Many ligands have been investigated to functionalize/decorate nano-delivery systems based on MSNs for selectively targeting cancers (<xref ref-type="fig" rid="pharmaceutics-13-00143-f018">Figure 18</xref>). These include antibodies, proteins, peptides, aptamers, small molecules, and saccharides [<xref rid="B221-pharmaceutics-13-00143" ref-type="bibr">221</xref>]. For example, transferrin [<xref rid="B237-pharmaceutics-13-00143" ref-type="bibr">237</xref>], folic acid [<xref rid="B42-pharmaceutics-13-00143" ref-type="bibr">42</xref>], epidermal growth factor (EGF) [<xref rid="B253-pharmaceutics-13-00143" ref-type="bibr">253</xref>], methotrexate [<xref rid="B254-pharmaceutics-13-00143" ref-type="bibr">254</xref>], RGD-type peptide [<xref rid="B255-pharmaceutics-13-00143" ref-type="bibr">255</xref>], anti-HER2/neu [<xref rid="B256-pharmaceutics-13-00143" ref-type="bibr">256</xref>], hyaluronic acid [<xref rid="B257-pharmaceutics-13-00143" ref-type="bibr">257</xref>], and mannose [<xref rid="B258-pharmaceutics-13-00143" ref-type="bibr">258</xref>]. </p><p>As an example, Kundu et al. [<xref rid="B203-pharmaceutics-13-00143" ref-type="bibr">203</xref>] designed targeted delivery for umbelliferone prodrug, with the system consisting of umbelliferone loaded in MSNs and capped with a pH-sensitive poly acrylic acid and further grafted with folic acid on the surface. The delivery with folic acid conjugation increases the anticancer potential of umbelliferone against breast cancer cells. In another example, Yinxue et al. [<xref rid="B199-pharmaceutics-13-00143" ref-type="bibr">199</xref>] investigated myricetin prodrug (Myr)-loaded MSNs combined with multidrug resistance protein (MRP-1) siRNA and the surface modified with folic acid to treat non-small cell lung cancer (NSCLC). In vivo fluorescence demonstrated that folic acid-conjugated MSNs with Myr and MRP-1 nanoparticles could specifically accumulate at tumor sites. Compared to free Myr and MSNs combined with MRP-1/Myr nanoparticles, folic acid-conjugated MSNs loaded with Myr and MRP-1 nanoparticles could more effectively suppress tumor growth with few side effects. Overall, a folic acid-conjugated nanoparticle system could provide a novel and effective platform for the treatment of NSCLC. We also reported a targeted delivery system consisting of folic acid conjugated to amine-modified MSNs (KCC-1 and MCM-41) and subsequently loaded with various prodrugs (curcumin, colchicine, and quercetin) [<xref rid="B42-pharmaceutics-13-00143" ref-type="bibr">42</xref>]. The nanoformulation containing curcumin exhibited the highest anticancer activity against liver cancer cells through apoptosis via caspase-3, H2O2, c-MET, and MCL-1 (<xref ref-type="fig" rid="pharmaceutics-13-00143-f019">Figure 19</xref>). <xref rid="pharmaceutics-13-00143-t007" ref-type="table">Table 7</xref> lists some other examples of targeted delivery systems for anticancer natural prodrugs.</p></sec><sec id="sec5-pharmaceutics-13-00143"><title>5. Motivation towards Natural Anticancer Agents</title><p>Nature is a great source of thousands of chemical substances/compounds generally considered natural products, as well as natural prodrugs if they are used for treating diseases [<xref rid="B269-pharmaceutics-13-00143" ref-type="bibr">269</xref>,<xref rid="B270-pharmaceutics-13-00143" ref-type="bibr">270</xref>]. Natural products (of natural origin) and herbal medicines have been used in traditional and modern medicine to treat cancer, and account for nearly 60% of pharmaceutical drugs [<xref rid="B271-pharmaceutics-13-00143" ref-type="bibr">271</xref>,<xref rid="B272-pharmaceutics-13-00143" ref-type="bibr">272</xref>,<xref rid="B273-pharmaceutics-13-00143" ref-type="bibr">273</xref>,<xref rid="B274-pharmaceutics-13-00143" ref-type="bibr">274</xref>,<xref rid="B275-pharmaceutics-13-00143" ref-type="bibr">275</xref>,<xref rid="B276-pharmaceutics-13-00143" ref-type="bibr">276</xref>,<xref rid="B277-pharmaceutics-13-00143" ref-type="bibr">277</xref>,<xref rid="B278-pharmaceutics-13-00143" ref-type="bibr">278</xref>,<xref rid="B279-pharmaceutics-13-00143" ref-type="bibr">279</xref>]. Natural prodrugs provide medical effects against cancers as either chemotherapeutics or chemopreventive drugs. Regarding chemotherapeutics, anticancer natural prodrugs have been utilized for various cancer treatments and are becoming rising stars in the field of drug discovery for their contributions [<xref rid="B280-pharmaceutics-13-00143" ref-type="bibr">280</xref>]. Some available drugs used in clinical applications for cancer patients diagnosed with different cancers are derived from plants, including vincristine, vinblastine, topotecan, and taxol [<xref rid="B281-pharmaceutics-13-00143" ref-type="bibr">281</xref>]. There are also some examples of anticancer drugs originating from microbes, including Dox, daunorubicin, and bleomycin. Regarding cancer prevention, there are numerous natural substances (e.g., in fruits and vegetables) that have also been applied in cancer prevention along with human health enhancement with no detectable side effects [<xref rid="B282-pharmaceutics-13-00143" ref-type="bibr">282</xref>]. To achieve cancer prevention goals, by completely preventing or delaying cancer, the main strategies that can be used, such as maintenance (healthy lifestyle), avoidance (exposure to toxicants/carcinogens), and dietary consumption (chemopreventive substances to drugs) [<xref rid="B283-pharmaceutics-13-00143" ref-type="bibr">283</xref>]. There is no doubt that prevention leads to better management and treatment of tumor growth and the risk for developing metastases, secondary tumors, and recurrence [<xref rid="B283-pharmaceutics-13-00143" ref-type="bibr">283</xref>]. Eliminating cancer, decreasing metastasis, reducing reappearance, and improving patient survival are key to curing cancers [<xref rid="B284-pharmaceutics-13-00143" ref-type="bibr">284</xref>].</p><p>Among the main natural sources, plants are a considerable domain for supplying a variety of natural products with diverse chemical structures with a wide range of health benefits. The natural products are the main secondary metabolites produced by plants and can be classified into four major classes: phenolics and polyphenolics, terpenes, nitrogen-containing alkaloids, and sulfur-containing compounds (<xref ref-type="fig" rid="pharmaceutics-13-00143-f020">Figure 20</xref>) [<xref rid="B285-pharmaceutics-13-00143" ref-type="bibr">285</xref>,<xref rid="B286-pharmaceutics-13-00143" ref-type="bibr">286</xref>,<xref rid="B287-pharmaceutics-13-00143" ref-type="bibr">287</xref>].</p><p>In recent years, attention has been focused on solving the problems associated with natural prodrug substances to increase their use in cancers and other pathological disorders. As an advanced strategy, nanotechnology application in medicine, called nanomedicine, is a promising approach being developed to overcome the limitations of natural prodrugs and improve their efficiency in cancer therapy. The advent of nanomedicine for cancer therapy occurred recently, and the rate of its progress and transformation in cancer treatments has also been rapid [<xref rid="B285-pharmaceutics-13-00143" ref-type="bibr">285</xref>]. This technology can solve the major drawbacks of natural anticancer prodrugs, including low aqueous solubility, low bioavailability, multidrug resistance, and non-specific targeting. The developed nanoformulations for delivery of natural anticancer prodrugs are intentionally being explored with several classes of prodrugs based on various organic and inorganic nanocarriers [<xref rid="B285-pharmaceutics-13-00143" ref-type="bibr">285</xref>,<xref rid="B288-pharmaceutics-13-00143" ref-type="bibr">288</xref>,<xref rid="B289-pharmaceutics-13-00143" ref-type="bibr">289</xref>,<xref rid="B290-pharmaceutics-13-00143" ref-type="bibr">290</xref>,<xref rid="B291-pharmaceutics-13-00143" ref-type="bibr">291</xref>,<xref rid="B292-pharmaceutics-13-00143" ref-type="bibr">292</xref>,<xref rid="B293-pharmaceutics-13-00143" ref-type="bibr">293</xref>,<xref rid="B294-pharmaceutics-13-00143" ref-type="bibr">294</xref>,<xref rid="B295-pharmaceutics-13-00143" ref-type="bibr">295</xref>,<xref rid="B296-pharmaceutics-13-00143" ref-type="bibr">296</xref>,<xref rid="B297-pharmaceutics-13-00143" ref-type="bibr">297</xref>,<xref rid="B298-pharmaceutics-13-00143" ref-type="bibr">298</xref>]. By reviewing in vitro and in vivo cancer models in the literature, it seems that nanoplatforms for delivering anticancer natural prodrugs have potentially improved the therapeutic activity, specific targeting, solubility, and bioavailability, and reduced side effects. The better patient response and survival are accompanied by possible enhancement of the pharmacological impacts and clinical outcome. Below, we discuss the delivery systems that have been established for select anticancer natural prodrugs employing MSNs. </p><sec id="sec5dot1-pharmaceutics-13-00143"><title>5.1. Curcumin</title><p>Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is a natural hydrophobic polyphenol compound, and is the major constituent derived from turmeric rhizome (<italic>Curcuma longa</italic> L.). Turmeric is a well-known spice in the kitchen and has a long history in traditional medicine for a wide range of diseases. Curcumin has numerous pharmacological activities, including anticancer, antiviral, antioxidant, anti-inflammatory, wound healing, and antimicrobial, among others [<xref rid="B299-pharmaceutics-13-00143" ref-type="bibr">299</xref>,<xref rid="B300-pharmaceutics-13-00143" ref-type="bibr">300</xref>,<xref rid="B301-pharmaceutics-13-00143" ref-type="bibr">301</xref>,<xref rid="B302-pharmaceutics-13-00143" ref-type="bibr">302</xref>,<xref rid="B303-pharmaceutics-13-00143" ref-type="bibr">303</xref>,<xref rid="B304-pharmaceutics-13-00143" ref-type="bibr">304</xref>,<xref rid="B305-pharmaceutics-13-00143" ref-type="bibr">305</xref>,<xref rid="B306-pharmaceutics-13-00143" ref-type="bibr">306</xref>,<xref rid="B307-pharmaceutics-13-00143" ref-type="bibr">307</xref>,<xref rid="B308-pharmaceutics-13-00143" ref-type="bibr">308</xref>,<xref rid="B309-pharmaceutics-13-00143" ref-type="bibr">309</xref>,<xref rid="B310-pharmaceutics-13-00143" ref-type="bibr">310</xref>,<xref rid="B311-pharmaceutics-13-00143" ref-type="bibr">311</xref>,<xref rid="B312-pharmaceutics-13-00143" ref-type="bibr">312</xref>,<xref rid="B313-pharmaceutics-13-00143" ref-type="bibr">313</xref>,<xref rid="B314-pharmaceutics-13-00143" ref-type="bibr">314</xref>,<xref rid="B315-pharmaceutics-13-00143" ref-type="bibr">315</xref>].</p><p>Despite these potential pharmacological activities, the pharmacokinetics of curcumin show inherently poor solubility and bioavailability because of the limited absorption, rapid metabolism, and quick systematic elimination [<xref rid="B316-pharmaceutics-13-00143" ref-type="bibr">316</xref>,<xref rid="B317-pharmaceutics-13-00143" ref-type="bibr">317</xref>,<xref rid="B318-pharmaceutics-13-00143" ref-type="bibr">318</xref>,<xref rid="B319-pharmaceutics-13-00143" ref-type="bibr">319</xref>]. To take advantage of the medical actions of curcumin and improve the inherent limitations, versatile nanoplatform delivery systems have been constructed and studied, including MSNs. Concerning MSNs for curcumin delivery contribution, MSN-based nanosystems show great promise for combating cancers and will be seen soon in clinical stages. </p><p>Ma&#x02019;mani and co-workers [<xref rid="B196-pharmaceutics-13-00143" ref-type="bibr">196</xref>] fabricated guanidine-functionalized PEGylated KIT-6 MSNs 60&#x02013;70 nm in size for delivery of curcumin to breast cancer cells. The system exhibited pH-sustained release of curcumin with long-term anticancer efficacy in human breast cancer cells (MCF-7 human breast adenocarcinoma cells, 4T1 mouse breast cancer cells, and MCF10A human mammary epithelial cells). A similar trend was observed for MSNs, namely MSU-2 and MCM-41 loaded with curcumin showing significant anticancer effects against different cancer cells (A549 human lung carcinoma cells, MCF-7 human breast cancer cells, and B16F10 mouse melanoma cells) compared to pure curcumin [<xref rid="B320-pharmaceutics-13-00143" ref-type="bibr">320</xref>]. In further investigations, they found that the plausible mechanism contributing to anticancer effects is the generation of intracellular ROS and the induction of apoptosis. Lin et al. [<xref rid="B228-pharmaceutics-13-00143" ref-type="bibr">228</xref>] tailored a co-delivery system of Dox loaded into MSNs as the core and curcumin loaded into the polymeric coating shell. The results indicate the long duration of blood circulation due to the PEG shell, GSH-sensitive release effect for drugs, and high cellular uptake resulting in synergistic anticancer effects through enhanced apoptosis of Hela cells. As an interesting nanoplatform, the fabricated lipid bilayer-coated curcumin-based MSNs unveiled a controllable and highly biocompatible theranostic nanosystem for cancer delivery [<xref rid="B321-pharmaceutics-13-00143" ref-type="bibr">321</xref>]. Another recent strategy for building a delivery system for curcumin is by loading the prodrug into amino-MSNs using APTES silanes (KIL-2 and KIT-6), then coated by polyelectrolyte polymer complex by means of the layer-by-layer technique [<xref rid="B197-pharmaceutics-13-00143" ref-type="bibr">197</xref>]. Based on the comparative data from this study, the nanoformulation exerts an anticancer effect on human cell lines, namely HL-60, EJ, and HEK-293, compared to free curcumin, demonstrating the promising delivery of prodrug with a sustained release effect. Considering active cancer-targeting designs, our group constructed selective targeted anticancer delivery of curcumin using MSNs (KCC-1-NH2-FA-CUR and MCM-41-NH2-FA-CUR) showing selective targeting of liver cancer cells (HepG2). The killing mechanism was found to be apoptosis [<xref rid="B42-pharmaceutics-13-00143" ref-type="bibr">42</xref>]. The aspartic acid-functionalized PEGylated MSN-graphene oxide loaded with curcumin exhibited pH-sensitive release and excellent killing of breast cancer cells (MCF-7) [<xref rid="B322-pharmaceutics-13-00143" ref-type="bibr">322</xref>]. With the occurrence of drug resistance in come cancers, silver-decorated SBA-15 (as metal-doped nanocomposites) coated with melanin-like polydopamine was used to deliver curcumin [<xref rid="B323-pharmaceutics-13-00143" ref-type="bibr">323</xref>]. They found that the utilization of a nanoplatform containing curcumin enhances anticancer efficiency against select cancer cells (HeLa and taxol-resistant NSCLC (A549/TAX) compared to free curcumin.</p><p>To verify the antitumor action against breast cancer in vivo, Gao et al. investigated PEGylated lipid bilayer-coated MSNs for a dual-delivery of PTX and curcumin with prolonged release to determine their pharmacokinetic properties, uptake, subcellular localization, biodistribution and tumor site targeting, and effectiveness [<xref rid="B324-pharmaceutics-13-00143" ref-type="bibr">324</xref>]. The delivery system could significantly increase the anti-tumor effect either by intravenous or intratumoral administration compared to free drug. The nanoplatform effectively led to the accumulation of the nanoformulation carrying drugs in the tumor site, resulting in highly efficient therapeutic effects in breast cancer. As such evidence of utilization of curcumin for co-delivery systems is important for further improvements and reducing side effects and drug resistance in cancers, which is the main issue for conventional cancer therapy. Sun et al. [<xref rid="B325-pharmaceutics-13-00143" ref-type="bibr">325</xref>] conducted a study of cancer targeting by means of folic acid and PEI-modified-MSNs for curcumin; they concluded that the system exhibits sustained release (pH-sensitive delivery), which is suitable for antineoplastic drugs. Several studies have reported the delivery of curcumin in different cancers in vitro or in vivo (<xref rid="pharmaceutics-13-00143-t008" ref-type="table">Table 8</xref>).</p></sec><sec id="sec5dot2-pharmaceutics-13-00143"><title>5.2. Quercetin</title><p>Quercetin is a dietary flavonoid compound derived from plants (e.g., medicinal plants, vegetable, fruits). It is a 3,3&#x02032;,4&#x02032;,5,7-pentahydroxyflvanone named by the International Union of Pure and Applied Chemistry (IUPAC) [<xref rid="B337-pharmaceutics-13-00143" ref-type="bibr">337</xref>]. Quercetin has unique biological properties that play an important role in mental/physical performance, as well as reducing infection risk [<xref rid="B338-pharmaceutics-13-00143" ref-type="bibr">338</xref>]. It has shown numerous pharmacological actions, including anti-oxidant, anti-microbial, anti-diabetic, anti-inflammatory, anti-cancer, anti-Alzheimer, psychostimulant, mitochondrial biogenesis stimulant, lipid peroxidation inhibitor, platelet aggregation inhibitor, and capillary permeability inhibitor, among others [<xref rid="B339-pharmaceutics-13-00143" ref-type="bibr">339</xref>,<xref rid="B340-pharmaceutics-13-00143" ref-type="bibr">340</xref>,<xref rid="B341-pharmaceutics-13-00143" ref-type="bibr">341</xref>,<xref rid="B342-pharmaceutics-13-00143" ref-type="bibr">342</xref>,<xref rid="B343-pharmaceutics-13-00143" ref-type="bibr">343</xref>,<xref rid="B344-pharmaceutics-13-00143" ref-type="bibr">344</xref>,<xref rid="B345-pharmaceutics-13-00143" ref-type="bibr">345</xref>,<xref rid="B346-pharmaceutics-13-00143" ref-type="bibr">346</xref>,<xref rid="B347-pharmaceutics-13-00143" ref-type="bibr">347</xref>,<xref rid="B348-pharmaceutics-13-00143" ref-type="bibr">348</xref>]. The dietary intake of quercetin varies in many countries. The estimated intake dosage of flavonoid (quercetin accounts for nearly 75%) ranges from 50&#x02013;800 mg/day according to the consumption of fruits, vegetables, tea, and herbals [<xref rid="B349-pharmaceutics-13-00143" ref-type="bibr">349</xref>]. In addition, quercetin is safe with a single dose of up to 4000 mg orally and up to 100 mg via intravenous administration [<xref rid="B350-pharmaceutics-13-00143" ref-type="bibr">350</xref>]. Quercetin is an excellent free radical scavenging antioxidant [<xref rid="B344-pharmaceutics-13-00143" ref-type="bibr">344</xref>] and is considered one of the most effective antioxidants [<xref rid="B351-pharmaceutics-13-00143" ref-type="bibr">351</xref>]. Consequently, quercetin exhibits promising effects against cancer [<xref rid="B339-pharmaceutics-13-00143" ref-type="bibr">339</xref>,<xref rid="B352-pharmaceutics-13-00143" ref-type="bibr">352</xref>] in vitro and in vivo [<xref rid="B353-pharmaceutics-13-00143" ref-type="bibr">353</xref>,<xref rid="B354-pharmaceutics-13-00143" ref-type="bibr">354</xref>,<xref rid="B355-pharmaceutics-13-00143" ref-type="bibr">355</xref>,<xref rid="B356-pharmaceutics-13-00143" ref-type="bibr">356</xref>,<xref rid="B357-pharmaceutics-13-00143" ref-type="bibr">357</xref>,<xref rid="B358-pharmaceutics-13-00143" ref-type="bibr">358</xref>,<xref rid="B359-pharmaceutics-13-00143" ref-type="bibr">359</xref>,<xref rid="B360-pharmaceutics-13-00143" ref-type="bibr">360</xref>]. Nevertheless, its potential impacts in clinical applications are drastically limited due to its poor solubility, low bioavailability, and instability [<xref rid="B361-pharmaceutics-13-00143" ref-type="bibr">361</xref>]. According to the pharmacokinetics of quercetin in humans, only ~2% is bioavailable (from single dose) with an absorption rate of 3 to 17% (from 100 mg applied in individual healthy persons) [<xref rid="B337-pharmaceutics-13-00143" ref-type="bibr">337</xref>]. The factors affecting oral bioavailability are low absorption, extensive metabolism, and/or rapid elimination, in addition to low solubility and non-selective targeting of cancers. Several nanoplatform delivery systems focus on overcoming these challenges to introduce quercetin into clinical applications soon for cancer [<xref rid="B362-pharmaceutics-13-00143" ref-type="bibr">362</xref>,<xref rid="B363-pharmaceutics-13-00143" ref-type="bibr">363</xref>,<xref rid="B364-pharmaceutics-13-00143" ref-type="bibr">364</xref>,<xref rid="B365-pharmaceutics-13-00143" ref-type="bibr">365</xref>,<xref rid="B366-pharmaceutics-13-00143" ref-type="bibr">366</xref>,<xref rid="B367-pharmaceutics-13-00143" ref-type="bibr">367</xref>,<xref rid="B368-pharmaceutics-13-00143" ref-type="bibr">368</xref>].</p><p>The use of MSNs to develop new delivery systems for quercetin against cancers has attracted many research groups. Liu et al. [<xref rid="B369-pharmaceutics-13-00143" ref-type="bibr">369</xref>] fabricated a system for dual delivery of PTX and quercetin into MSNs to overcome multidrug resistance in breast cancer. The nanosystem exhibited CD44 receptor-mediated active targeting for MCF-7/ADR cells. At the same time, the addition of quercetin with PTX significantly improves the sensitivity of MCF-7/ADR cells to PTX, providing a solution to multidrug resistance in breast cancer. Huang et al. [<xref rid="B370-pharmaceutics-13-00143" ref-type="bibr">370</xref>] designed a novel nanoformulation consisting of quercetin-loaded MSNs coating cancer cell membranes for enhanced tumor targeting and radiotherapy. In vitro and in vivo investigations revealed that the system has many advantages, including excellent tumor targeting ability and efficient inhibition of tumor growth. The platform fulfills innovative ideas for targeting cancer and improving therapy. In another attempt, polydopamine-coated hollow MSNs combining Dox hydrochloride with quercetin efficiently overcame multidrug resistance in taxol and Dox double-resistant human colorectal cancer cells (HCT-8/TAX cells) [<xref rid="B371-pharmaceutics-13-00143" ref-type="bibr">371</xref>]. Fang et al. [<xref rid="B262-pharmaceutics-13-00143" ref-type="bibr">262</xref>] developed a hyaluronic acid-modified MSNs that co-deliver quercetin and Dox to enhance the efficacy of chemotherapy for gastric carcinoma. They found that the system enables stability, sustained release, and selective killing effects. An in vivo study disclosed that the co-delivery significantly enhances the anticancer efficacy compared to a single drug, showing the importance of quercetin in clinical application. In this context, Murugan et al. [<xref rid="B264-pharmaceutics-13-00143" ref-type="bibr">264</xref>] loaded topotecan into the pores of MSNs, followed by poly(acrylic acid)-chitosan as an outer layer to further conjugate quercetin, and then grafting with arginine-glycine-aspartic acid (cRGD) peptide on the surface as targeting ligands for cancers. The system released the drugs as a function of pH and uptake occurred through integrin receptor-mediated endocytosis, enabling efficient anti-tumor effects in multidrug resistant breast cancer cells and animal studies. As far as active targeting and bioavailability are concerned, MSNs conjugated with folic acid and loaded with quercetin exhibit higher cellular uptake and more quercetin bioavailability in breast cancer cells, as well as an enhanced antitumor effect through apoptosis [<xref rid="B265-pharmaceutics-13-00143" ref-type="bibr">265</xref>]. These studies demonstrate the prospective application of quercetin in cancers by means of single or co-delivery, facilitating efficient targeting and antitumor effects, creating new possibilities for clinical applications.</p></sec><sec id="sec5dot3-pharmaceutics-13-00143"><title>5.3. Resveratrol</title><p>Resveratrol (RSV, 3,5,4&#x02032;-trihydroxy-trans-stilbene) is a natural polystilbene and non-flavonoid polyphenol. As a phytoestrogen compound, RSV is present in a wide range of plants and is abundant in extracts from the grape skin and other fruits and vegetables. RSV has been reported to exert multiple pharmacological effects, including anti-inflammatory, anti-viral, anti-microbial, anti-Alzheimer, anticancer, cardioprotective, neuroprotective, and immunomodulatory actions [<xref rid="B372-pharmaceutics-13-00143" ref-type="bibr">372</xref>,<xref rid="B373-pharmaceutics-13-00143" ref-type="bibr">373</xref>,<xref rid="B374-pharmaceutics-13-00143" ref-type="bibr">374</xref>,<xref rid="B375-pharmaceutics-13-00143" ref-type="bibr">375</xref>,<xref rid="B376-pharmaceutics-13-00143" ref-type="bibr">376</xref>,<xref rid="B377-pharmaceutics-13-00143" ref-type="bibr">377</xref>,<xref rid="B378-pharmaceutics-13-00143" ref-type="bibr">378</xref>,<xref rid="B379-pharmaceutics-13-00143" ref-type="bibr">379</xref>,<xref rid="B380-pharmaceutics-13-00143" ref-type="bibr">380</xref>,<xref rid="B381-pharmaceutics-13-00143" ref-type="bibr">381</xref>,<xref rid="B382-pharmaceutics-13-00143" ref-type="bibr">382</xref>,<xref rid="B383-pharmaceutics-13-00143" ref-type="bibr">383</xref>,<xref rid="B384-pharmaceutics-13-00143" ref-type="bibr">384</xref>,<xref rid="B385-pharmaceutics-13-00143" ref-type="bibr">385</xref>,<xref rid="B386-pharmaceutics-13-00143" ref-type="bibr">386</xref>]. Concerning the anticancer effects on the preclinical level, RSV has also been reported to possess important antitumor actions in several preclinical animal models [<xref rid="B387-pharmaceutics-13-00143" ref-type="bibr">387</xref>,<xref rid="B388-pharmaceutics-13-00143" ref-type="bibr">388</xref>,<xref rid="B389-pharmaceutics-13-00143" ref-type="bibr">389</xref>,<xref rid="B390-pharmaceutics-13-00143" ref-type="bibr">390</xref>,<xref rid="B391-pharmaceutics-13-00143" ref-type="bibr">391</xref>,<xref rid="B392-pharmaceutics-13-00143" ref-type="bibr">392</xref>,<xref rid="B393-pharmaceutics-13-00143" ref-type="bibr">393</xref>,<xref rid="B394-pharmaceutics-13-00143" ref-type="bibr">394</xref>,<xref rid="B395-pharmaceutics-13-00143" ref-type="bibr">395</xref>,<xref rid="B396-pharmaceutics-13-00143" ref-type="bibr">396</xref>,<xref rid="B397-pharmaceutics-13-00143" ref-type="bibr">397</xref>,<xref rid="B398-pharmaceutics-13-00143" ref-type="bibr">398</xref>]. The clinical prospective of RSV has also been evaluated in a few clinical trials. The first clinical trial by Nguyen et al. [<xref rid="B399-pharmaceutics-13-00143" ref-type="bibr">399</xref>] indicated that the freeze-dried grape powder (containing RSV) effectively inhibits colon cancer in patients. In addition, Patel et al. [<xref rid="B374-pharmaceutics-13-00143" ref-type="bibr">374</xref>] showed that a daily dose of RSV at 0.5 or 1.0 g produces sufficient anticarcinogenic effects in colorectal cancer. Furthermore, Howells et al. [<xref rid="B400-pharmaceutics-13-00143" ref-type="bibr">400</xref>] demonstrated that RSV given at micronized formulation with 5.0 g daily for 14 days in patients with colorectal cancer and hepatic metastases prevented malignancies by increasing apoptosis.</p><p>Despite promising preclinical (in vitro and in vivo) and prospective clinical results as an anticancer agent, RSV still has many challenges due to the pharmacokinetics, metabolism, bioavailability, and toxicity in cancer patients [<xref rid="B374-pharmaceutics-13-00143" ref-type="bibr">374</xref>,<xref rid="B401-pharmaceutics-13-00143" ref-type="bibr">401</xref>]. These associated properties prevent translation into more clinical trials and human benefits. In addition, RSV has shown poor bioavailability due to its quick extensive metabolism, and large doses (up to 5 g/day) should be applied to provide anticancer therapeutic activity [<xref rid="B402-pharmaceutics-13-00143" ref-type="bibr">402</xref>]. Such high doses result in adverse effects (e.g., diarrhea, nausea, and abdominal pain with &#x0003e;1 g/day) [<xref rid="B402-pharmaceutics-13-00143" ref-type="bibr">402</xref>]. As the poor bioavailability limits the RSV activity, there are various approaches for overwhelming the bioavailability, including co-delivery with piperine prodrug [<xref rid="B403-pharmaceutics-13-00143" ref-type="bibr">403</xref>], micronized powders [<xref rid="B403-pharmaceutics-13-00143" ref-type="bibr">403</xref>], and nanoplatform delivery [<xref rid="B404-pharmaceutics-13-00143" ref-type="bibr">404</xref>,<xref rid="B405-pharmaceutics-13-00143" ref-type="bibr">405</xref>,<xref rid="B406-pharmaceutics-13-00143" ref-type="bibr">406</xref>,<xref rid="B407-pharmaceutics-13-00143" ref-type="bibr">407</xref>]. Application of nanomedicine can improve the stability and bioavailability, and minimize side effects of RSV, which is making RSV a prospective candidate for treating many diseases, including cancers.</p><p>Few investigations in recent years have used MSNs for the delivery of RSV. Chaudhary et al. [<xref rid="B408-pharmaceutics-13-00143" ref-type="bibr">408</xref>] loaded RSV into MSN-modified phosphonate or MSN-modified amine to improve the anti-proliferative activity and sensitization of drug-resistant prostate cancer. The RSV is released as a function of pH, and the phosphonate-modified nanoparticles effectively kill cancer cells better than amine-modified nanoparticles. Hu et al. [<xref rid="B267-pharmaceutics-13-00143" ref-type="bibr">267</xref>] constructed a dual delivery system for anti-miR21 and RSV using MSNs conjugated with hyaluronic acid to target gastric carcinoma through overexpression of the CD44 receptor on cell membranes. They found that this nanoformulation has a superior anticancer effect due to synergistic effects specifically delivered by combining anti-miR21 and RSV in gastric cancer cells. Furthermore, Summerlin et al. [<xref rid="B409-pharmaceutics-13-00143" ref-type="bibr">409</xref>] encapsulated RSV in colloidal MCM-48 and found that the nanoformulation enhances saturated solubility (&#x0223c;95%) and release effect compared to pure RSV. The nanoformulation also possesses a higher killing ability for HT-29 and LS147T colon cancer cells compared to pure RSV by mediating the PARP and cIAP1 pathways.</p></sec><sec id="sec5dot4-pharmaceutics-13-00143"><title>5.4. Berberine</title><p>Berberine is an isoquinoline alkaloid found in a handful of plants widely used in botanical medical practice, such as <italic>Hydrastis canadensis</italic> (Goldenseal), <italic>Berberis aquifolium</italic> (Oregon grape), <italic>Berberis vulgaris</italic> (Barberry), and <italic>Coptis chinensis</italic> (Chinese Goldthread) [<xref rid="B410-pharmaceutics-13-00143" ref-type="bibr">410</xref>,<xref rid="B411-pharmaceutics-13-00143" ref-type="bibr">411</xref>]. Versatile pharmacological activities have been reported for berberine, including anti-viral, anti-microbial, anticancer, anti-diabetic, anti-diarrhea, and anti-inflammatory, and treatment for congestive heart failure, cardiac arrhythmia, and hypertension. Recently, berberine extract or pure compound has gained much attention in the newly published research and is among the top pharmaceutical supplements on shelves [<xref rid="B412-pharmaceutics-13-00143" ref-type="bibr">412</xref>]. The preclinical evidence from huge studies reveals the capability of berberine to treat many diseases [<xref rid="B411-pharmaceutics-13-00143" ref-type="bibr">411</xref>,<xref rid="B413-pharmaceutics-13-00143" ref-type="bibr">413</xref>,<xref rid="B414-pharmaceutics-13-00143" ref-type="bibr">414</xref>,<xref rid="B415-pharmaceutics-13-00143" ref-type="bibr">415</xref>,<xref rid="B416-pharmaceutics-13-00143" ref-type="bibr">416</xref>,<xref rid="B417-pharmaceutics-13-00143" ref-type="bibr">417</xref>,<xref rid="B418-pharmaceutics-13-00143" ref-type="bibr">418</xref>,<xref rid="B419-pharmaceutics-13-00143" ref-type="bibr">419</xref>]. Thus, berberine is clinically studied for many diseases, such as diabetes [<xref rid="B410-pharmaceutics-13-00143" ref-type="bibr">410</xref>,<xref rid="B420-pharmaceutics-13-00143" ref-type="bibr">420</xref>,<xref rid="B421-pharmaceutics-13-00143" ref-type="bibr">421</xref>,<xref rid="B422-pharmaceutics-13-00143" ref-type="bibr">422</xref>,<xref rid="B423-pharmaceutics-13-00143" ref-type="bibr">423</xref>]. Particular attention has been given to berberine in cancers, so it is expected to be one of the most common natural compounds under the scope of extensive clinical investigations of cancers [<xref rid="B424-pharmaceutics-13-00143" ref-type="bibr">424</xref>]. The main challenges in translating berberine to the clinical application are low solubility, poor aqueous solubility, slight absorption, and low bioavailability. There are some strategies to deal with these limitations, such as producing berberine hydrochloride to increase its solubility. Another approach is encapsulating berberine into nanocarriers for nanoplatform delivery [<xref rid="B425-pharmaceutics-13-00143" ref-type="bibr">425</xref>,<xref rid="B426-pharmaceutics-13-00143" ref-type="bibr">426</xref>,<xref rid="B427-pharmaceutics-13-00143" ref-type="bibr">427</xref>].</p><p>Berberine loaded into folic acid-conjugated gold-MSNs shows superb anticancer effects, good biosafety, and protection of normal tissue in vitro and in vivo for chemo-radiotherapy of liver cancer [<xref rid="B239-pharmaceutics-13-00143" ref-type="bibr">239</xref>]. Another conformation obtained by Feng et al. [<xref rid="B225-pharmaceutics-13-00143" ref-type="bibr">225</xref>] showed that MSNs based on dual delivery of hydrophobic prodrugs with berberine and evodiamine through thermo/pH-responsiveness improves antitumor effects in vitro and in vivo. Other results propose that the berberine-loaded Janus nanocarriers (MSNs containing iron oxide) driven by a magnetic field provide an effective and safe approach against hepatocellular carcinoma [<xref rid="B232-pharmaceutics-13-00143" ref-type="bibr">232</xref>]. As with other drugs, berberine can be released depending on different conditions; by disulfide bond linking, berberine releases from MSNs under glutathione conditions upon breakage of the disulfide bond, promoting the anticancer action against liver cancer [<xref rid="B428-pharmaceutics-13-00143" ref-type="bibr">428</xref>].</p></sec><sec id="sec5dot5-pharmaceutics-13-00143"><title>5.5. Thymoquinone</title><p>Thymoquinone (TQ, 2-methyl-5-isopropyl-1,4-benzoquinone), a monoterpene diketone compound, is the main active component in essential oil (volatile oil) of <italic>Nigella sativa</italic> L. (known as black seed or black cumin). TQ was isolated for the first time in 1963 [<xref rid="B429-pharmaceutics-13-00143" ref-type="bibr">429</xref>] and exhibits various pharmacological activities in vitro and in preclinical investigations. The most reported activities are anticancer, antioxidant, anti-microbial, neuroprotective, anti-inflammatory, anti-microbial, and anti-diabetic [<xref rid="B430-pharmaceutics-13-00143" ref-type="bibr">430</xref>,<xref rid="B431-pharmaceutics-13-00143" ref-type="bibr">431</xref>,<xref rid="B432-pharmaceutics-13-00143" ref-type="bibr">432</xref>,<xref rid="B433-pharmaceutics-13-00143" ref-type="bibr">433</xref>,<xref rid="B434-pharmaceutics-13-00143" ref-type="bibr">434</xref>,<xref rid="B435-pharmaceutics-13-00143" ref-type="bibr">435</xref>,<xref rid="B436-pharmaceutics-13-00143" ref-type="bibr">436</xref>,<xref rid="B437-pharmaceutics-13-00143" ref-type="bibr">437</xref>,<xref rid="B438-pharmaceutics-13-00143" ref-type="bibr">438</xref>,<xref rid="B439-pharmaceutics-13-00143" ref-type="bibr">439</xref>,<xref rid="B440-pharmaceutics-13-00143" ref-type="bibr">440</xref>]. A considerable amount of available data from preclinical studies encourage the translation of TQ into clinical settings. There is no doubt of the promising anticancer effects of TQ, but the lack of bioavailability and pharmacokinetic parameters delay the use of TQ in clinical applications. The main issues are low bioavailability, solubility, biodistribution in the body, rapid metabolism, and excretion [<xref rid="B441-pharmaceutics-13-00143" ref-type="bibr">441</xref>,<xref rid="B442-pharmaceutics-13-00143" ref-type="bibr">442</xref>,<xref rid="B443-pharmaceutics-13-00143" ref-type="bibr">443</xref>]. In recent years, several strategies have been investigated to improve these limitations, such as the development of novel analogs [<xref rid="B444-pharmaceutics-13-00143" ref-type="bibr">444</xref>], use of different routes (e.g., oral, intraperitoneal, intravenous), and nano-delivery systems [<xref rid="B296-pharmaceutics-13-00143" ref-type="bibr">296</xref>,<xref rid="B445-pharmaceutics-13-00143" ref-type="bibr">445</xref>,<xref rid="B446-pharmaceutics-13-00143" ref-type="bibr">446</xref>].</p><p>Few delivery systems have been designed for TQ based on MSNs. The TQ-loaded MSNs produce more anticancer effects against MCF-7 and HeLa cells than pure TQ [<xref rid="B447-pharmaceutics-13-00143" ref-type="bibr">447</xref>]. In addition, both TQ-loaded MSNs and pure TQ exert their anticancer activity by means of ROS-mediated apoptosis. To enhance the targeting ability towards glioma cells, we fabricated core&#x02013;shell nanoformulations [<xref rid="B44-pharmaceutics-13-00143" ref-type="bibr">44</xref>], with the core consisting of MSNs loaded with TQ and the shell consisting of whey protein&#x02013;Arabic gum or chitosan&#x02013;stearic acid complex. Interestingly, TQ releases as a function of pH and induces selective killing of cancer cells compared to normal cells. Furthermore, the core&#x02013;shell nanoformulations significantly kill glioma cancer cells via apoptosis-mediated pathways due to caspase-3 activation, cytochrome c triggers, and cell cycle arrest at G2/M signaling. In this sense, the efficient anticancer effects against brain cancers can be attributed to the distribution of TQ-loaded MSNs [<xref rid="B448-pharmaceutics-13-00143" ref-type="bibr">448</xref>]. The study showed that encapsulating TQ in MSNs improves delivery to some brain areas, including the cortex, thalamus, hypothalamus, and midbrain, but reduces its delivery to the cerebellum compared to pure TQ. The results also indicated that neither free TQ nor MSN-TQ reaches the hippocampus. Thus, MSNs potentially target TQ to certain brain areas.</p></sec><sec id="sec5dot6-pharmaceutics-13-00143"><title>5.6. Gallic Acid</title><p>GA (3,4,5-trihydroxybenzoic acid) is one of the most abundant phenolic acids present in plants (e.g., fruits and medicinal plants. GA can be isolated from different plants of <italic>Quercus</italic> spp. and has extensive applications in the food and pharmaceutical industries [<xref rid="B449-pharmaceutics-13-00143" ref-type="bibr">449</xref>]. The therapeutic uses include antimicrobial [<xref rid="B450-pharmaceutics-13-00143" ref-type="bibr">450</xref>], anticancer, gastrointestinal disease, cardiovascular disease, metabolic disease, neuropsychological disease, and other miscellaneous diseases [<xref rid="B449-pharmaceutics-13-00143" ref-type="bibr">449</xref>,<xref rid="B451-pharmaceutics-13-00143" ref-type="bibr">451</xref>,<xref rid="B452-pharmaceutics-13-00143" ref-type="bibr">452</xref>,<xref rid="B453-pharmaceutics-13-00143" ref-type="bibr">453</xref>,<xref rid="B454-pharmaceutics-13-00143" ref-type="bibr">454</xref>,<xref rid="B455-pharmaceutics-13-00143" ref-type="bibr">455</xref>]. GA has a potential antioxidant action modulated by various signaling pathways (e.g., inflammatory cytokines, and enzymatic and nonenzymatic antioxidants) that lead to its therapeutic effects [<xref rid="B453-pharmaceutics-13-00143" ref-type="bibr">453</xref>]. However, as with many prodrugs, limitations still exist for clinical use of GA and to confirm its therapeutic outcomes. Several nanostructures have been used to fabricate delivery systems to solve these limitations and achieve effectiveness to translate GA into clinical investigations [<xref rid="B456-pharmaceutics-13-00143" ref-type="bibr">456</xref>,<xref rid="B457-pharmaceutics-13-00143" ref-type="bibr">457</xref>,<xref rid="B458-pharmaceutics-13-00143" ref-type="bibr">458</xref>,<xref rid="B459-pharmaceutics-13-00143" ref-type="bibr">459</xref>,<xref rid="B460-pharmaceutics-13-00143" ref-type="bibr">460</xref>]. </p><p>Only a few studies have been reported on MSN nanosystems for GA. MSNs functionalized with amino acid and coated with chitosan exhibit a high loading capacity of ~20&#x02013;38%, leading to better killing potency of MCF-7cells than pure GA [<xref rid="B195-pharmaceutics-13-00143" ref-type="bibr">195</xref>]. GA is an unstable molecule under specific pH; by encapsulating it in MSNs, the release of GA can be controlled by media with different pH and released in the presence of higher antioxidant activity [<xref rid="B224-pharmaceutics-13-00143" ref-type="bibr">224</xref>]. With respect to the anticancer effect, incorporation of GA into MSNs by means of covalent bonding increases its activity against HeLa and KB cells, with a killing efficiency of up to 67% [<xref rid="B461-pharmaceutics-13-00143" ref-type="bibr">461</xref>]. Thus, GA-loaded MSNs easily internalize into Caco-2 cells, releasing GA to enhance cytotoxic effects against colon cancer [<xref rid="B462-pharmaceutics-13-00143" ref-type="bibr">462</xref>].</p></sec><sec id="sec5dot7-pharmaceutics-13-00143"><title>5.7. Essential Oils</title><p>Among the plant natural prodrugs, the essential oils (also known as volatile oils) have particular importance in many sectors (e.g., pharmaceutical, cosmetic, agricultural, and food) [<xref rid="B463-pharmaceutics-13-00143" ref-type="bibr">463</xref>,<xref rid="B464-pharmaceutics-13-00143" ref-type="bibr">464</xref>]. With a long history in many cultures, essential oils can be used for different purposes [<xref rid="B465-pharmaceutics-13-00143" ref-type="bibr">465</xref>]. For example, Ancient Egyptians used essential oils as early as 4500&#x02009;BC for cosmetics and ointments [<xref rid="B466-pharmaceutics-13-00143" ref-type="bibr">466</xref>]. They made a mixture of many herbals containing essential oils (e.g., aniseed, cedar, onion, myrrh, grapes, etc.) as preparations in perfume or medicine. In recent years, the most important use of essential oils has been aromatherapy due to their curative effects [<xref rid="B467-pharmaceutics-13-00143" ref-type="bibr">467</xref>]. Essential oils are complex mixtures of volatile compounds found especially in aromatic plants, such as clary sage (<italic>Salvia sclarea</italic> L.), eucalyptus (<italic>Eucalyptus globulus</italic> Labill.), geranium (<italic>Pelargonium graveolens</italic> L.), lavender (<italic>Lavandula officinalis</italic> Chaix), lemon (<italic>Citrus limon</italic> L.), peppermint (<italic>Mentha piperita</italic> L.), roman chamomile (<italic>Anthemis nobilis</italic> L.), rosemary (<italic>Rosmarinus officinalis</italic> L.), basil (<italic>Ocimum basilicum</italic>), rosemary (<italic>Rosmarinus officinalis</italic>), and ginger (<italic>Zingiber officinale</italic>). The essential oils are obtained from plant sources by several methods, such as hydrodistillation, steam distillation, cold pressing, solvent extraction, microwave-assisted processing, and carbon dioxide extraction. Concerning their chemical composition, essential oils were originally characterized as monoterpene and sesquiterpene hydrocarbons together with their oxygenated derivatives, besides the aliphatic aldehydes, alcohols, and ester structures [<xref rid="B466-pharmaceutics-13-00143" ref-type="bibr">466</xref>]. Due to the chemical compositions of essential oils with versatile compounds that possess many roles and modes of action in various pharmacological entities and therapeutics, including anticancer, cardiovascular disease treatment, anti-bacterial, anti-viral, anti-oxidants, analgesics, and antidiabetics [<xref rid="B468-pharmaceutics-13-00143" ref-type="bibr">468</xref>,<xref rid="B469-pharmaceutics-13-00143" ref-type="bibr">469</xref>]. The main applications are enhanced transdermal drug delivery due to their skin penetration, and aroma and massage therapy [<xref rid="B470-pharmaceutics-13-00143" ref-type="bibr">470</xref>]. Essential oil compounds have been reported to have potential anticancer effects in vitro and in animal models [<xref rid="B471-pharmaceutics-13-00143" ref-type="bibr">471</xref>,<xref rid="B472-pharmaceutics-13-00143" ref-type="bibr">472</xref>,<xref rid="B473-pharmaceutics-13-00143" ref-type="bibr">473</xref>,<xref rid="B474-pharmaceutics-13-00143" ref-type="bibr">474</xref>,<xref rid="B475-pharmaceutics-13-00143" ref-type="bibr">475</xref>,<xref rid="B476-pharmaceutics-13-00143" ref-type="bibr">476</xref>,<xref rid="B477-pharmaceutics-13-00143" ref-type="bibr">477</xref>]. However, essential oils generally have low stability, high volatility, and a high risk of deterioration by exposure to direct heat, humidity, light, or oxygen [<xref rid="B478-pharmaceutics-13-00143" ref-type="bibr">478</xref>]. Nanoformulations are a recent strategy being developed for essential oils and their constituents to solve these problems [<xref rid="B463-pharmaceutics-13-00143" ref-type="bibr">463</xref>,<xref rid="B479-pharmaceutics-13-00143" ref-type="bibr">479</xref>,<xref rid="B480-pharmaceutics-13-00143" ref-type="bibr">480</xref>,<xref rid="B481-pharmaceutics-13-00143" ref-type="bibr">481</xref>,<xref rid="B482-pharmaceutics-13-00143" ref-type="bibr">482</xref>].</p><p>To the best of our knowledge, no anticancer nanoformulations have been designed for essential oils and their constituents. MSNs are efficient particles for the high loading of essential oil substances. Melendez-Rodriguez et al. demonstrated that eugenol, an important component in various essential oils of herbs, is efficiently encapsulated in pores of MSNs up to 50 wt.%. by means of vapor adsorption [<xref rid="B483-pharmaceutics-13-00143" ref-type="bibr">483</xref>]. Ebadollahi et al. [<xref rid="B484-pharmaceutics-13-00143" ref-type="bibr">484</xref>] reported that the loading of essential oils of thymus species into MCM-41 increases their stability and persistence up to 20 days. Furthermore, Janatova et al. [<xref rid="B485-pharmaceutics-13-00143" ref-type="bibr">485</xref>] demonstrated that different encapsulated essential oil components in MCM-41 provide long-term effects through controlled release compared to the same pure substances. In addition, Jobdeedamrong et al. [<xref rid="B486-pharmaceutics-13-00143" ref-type="bibr">486</xref>] showed that the release of essential oils (peppermint, thyme, cinnamon, and clove oil) is controlled by loading them into MSN-functionalized particles and grafting them with hyaluronic acid. Confirmation of delayed volatilization was reported for lavender oil loaded into MSNs [<xref rid="B487-pharmaceutics-13-00143" ref-type="bibr">487</xref>]. Jin et al. [<xref rid="B488-pharmaceutics-13-00143" ref-type="bibr">488</xref>] showed that MCM-41 modified nanoparticles enable high loading of pepper fragrant along with bactericidal activities against different microbes. Thus, the incorporation of essential oils from different herbs could be used effectively for infectious diseases [<xref rid="B489-pharmaceutics-13-00143" ref-type="bibr">489</xref>,<xref rid="B490-pharmaceutics-13-00143" ref-type="bibr">490</xref>] and treating biofilm [<xref rid="B491-pharmaceutics-13-00143" ref-type="bibr">491</xref>]. </p></sec><sec id="sec5dot8-pharmaceutics-13-00143"><title>5.8. Other Natural Products </title><p>Artemisinin is a sesquiterpene lactone derived from <italic>Artemisia annua</italic>. It is used as an antimalarial for treating multi-drug-resistant strains of falciparum malaria. It has also shown promising anticancer effects [<xref rid="B492-pharmaceutics-13-00143" ref-type="bibr">492</xref>]. Artemisinin loaded into pores of hollow MSNs and capped with Fe3O4 nanoparticles act as gatekeepers [<xref rid="B226-pharmaceutics-13-00143" ref-type="bibr">226</xref>]. The system shows a pH-dependent release effect, with stable release achieved at pH 7.4 and higher artemisinin release at low pH (3.8&#x02013;5.0). This system exhibits excellent anticancer efficacy. Another multifunctional nanocarrier, Fe3O4@C/Ag@mSiO2 loaded with a high amount of artemisinin, allows pH-stimuli release and more killing of HeLa cancer cells compared to free artemisinin [<xref rid="B493-pharmaceutics-13-00143" ref-type="bibr">493</xref>].</p><p>Some natural prodrugs are toxic compounds, and this toxicity prevents them from being used to treat cancers. An important example is colchicine, a natural alkaloid derived mainly from <italic>Colchicum automnale</italic>. It has long been used clinically to treat gout and familial Mediterranean fever. Colchicine is an important antimitotic prodrug and efficiently kills cancer cells [<xref rid="B494-pharmaceutics-13-00143" ref-type="bibr">494</xref>], but the major challenge to its use is its toxicity. Earlier, Cauda et al. reported a one-step fabrication of colchicine-loaded in lipid bilayer-coated MSNs, making the system more stable and leading to effective microtubule depolymerization upon cell uptake [<xref rid="B495-pharmaceutics-13-00143" ref-type="bibr">495</xref>]. We also loaded colchicine into folic acid-conjugated MCM-41 and KCC-1 for anticancer and antioxidant effects, obtaining higher anticancer effects than with free colchicine [<xref rid="B42-pharmaceutics-13-00143" ref-type="bibr">42</xref>]. Very recently, we developed a novel DDS for colchicine. The system consisted of KCC-1-functionalized with phosphonate groups and loaded with colchicine, and subsequently coated with folic acid chitosan&#x02013;glycine complex (MSNsPCOL/CG-FA) [<xref rid="B43-pharmaceutics-13-00143" ref-type="bibr">43</xref>]. This nanoformulation revealed enhanced selective killing towards cancer cells compared to free colchicine in this order: colon cancer (HCT116) &#x0003e; liver cancer (HepG2) &#x0003e; prostate cancer (PC3). As its cytotoxicity is a major concern, the system is also promising because it exhibits low cytotoxicity (4%) compared to free colchicine (~60%) in normal BJ1 cells. The main mechanism of action was studied in detail for HCT116 cells, indicating primarily intrinsic apoptosis as a result of enhanced antimitotic effects with a contribution of genetic regulation by MALAT 1 and mir-205 and immunotherapy effects by Ang-2 protein and PD-1. </p><p>Loading glabridin, a prodrug compound obtained from the root extract of <italic>Glycyrrhiza glabra,</italic> on MSNs leads to remarkable improvement in its saturation solubility and dissolution velocity [<xref rid="B496-pharmaceutics-13-00143" ref-type="bibr">496</xref>]. In this context, loading of breviscapine in MSNs significantly improves the solubility and bioavailability [<xref rid="B17-pharmaceutics-13-00143" ref-type="bibr">17</xref>]. In addition, Ibrahim et al. [<xref rid="B183-pharmaceutics-13-00143" ref-type="bibr">183</xref>] concluded that incorporating silymarin in MSNs within a lyophilized tablet remarkably increases the dissolution rate and saturation solubility. Similarly, loading of glabridin in MSNs improves the saturation solubility and dissolution velocity [<xref rid="B496-pharmaceutics-13-00143" ref-type="bibr">496</xref>]. The biological activity, including anticancer activity, of polyphenols and flavonoids obtained from black chokeberry fruits is efficient compared to the free forms when loaded in MCM-41 and ZnO-MCM-41 [<xref rid="B497-pharmaceutics-13-00143" ref-type="bibr">497</xref>] Co-delivery of topotecan and quercetin by MSNs results in pH-responsive release, subsequently increasing the intracellular release in cancer cells. Ultimately, it induces notable molecular activation (structural changes in tumor cell: endoplasmic reticulum, nucleus, and mitochondria) leading to cancer cell death [<xref rid="B264-pharmaceutics-13-00143" ref-type="bibr">264</xref>]. Similar evidence has been obtained with targeted delivery of epigallocatechin-3-gallate-loaded MSNs for breast cancer treatment in vivo [<xref rid="B266-pharmaceutics-13-00143" ref-type="bibr">266</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec6-pharmaceutics-13-00143"><title>6. Conclusions and Future Perspective</title><p>Engineered MSNs with a variety of nanostructures are important inorganic nanocarriers for drug delivery in nanomedicine applications. MSNs have various unique physiochemical properties, including high pore volume, high specific surface area and porosity. In addition, various organic functional groups can be used for their surface modification by facile processes. MSNs are generally accepted to have good biocompatibility, being safe and showing no-significant side effects. The toxicity of MSNs as in the case of any drug or nanomaterial depends on dose/concentration, material properties, application routes. The degree of toxicity is low as indicated by several studies if the synthesis is performed in optimized conditions or overdose is avoided. Additionally, according to many animal studies, the toxicity of MSNs can diminish by optimizing the synthesis parameters and surface modification. Most in vivo studies generate data stipulating that the suggested average dose of 50 mg/kg is well tolerated in animals and safe without any toxicity or apparent abnormalities. This is considered as an adequate dose to be used, e.g., in cancer therapy. This dose can be increased for oral route administration compared to intraperitoneal or intravenous injection. Importantly, the use of MSN-drug-loaded nanoformulations can allow the use of an even higher dose (three or more times) [<xref rid="B174-pharmaceutics-13-00143" ref-type="bibr">174</xref>]. As with other nanomaterials, for future translation to clinical applications, the safety aspects of MSNs should be considered carefully for each type because many nanostructures are reported. Recently, the first clinical trial in humans was conducted with oral delivery of fenofibrate formulation based on the ordered mesoporous silica [<xref rid="B33-pharmaceutics-13-00143" ref-type="bibr">33</xref>]. </p><p>MSNs can be used as multifunctional targeted anticancer delivery systems, delivering a variety of drugs, therapeutic proteins, and antibodies. Furthermore, due to their nanoporous structure, MSNs have a high loading capacity for therapeutic agents and are excellent nanocarriers for internal- and external-responsive release of drugs (e.g., pH, GSH, redox, light, magnetic direction, and ultrasound). The available data indicate that the use of MSNs as prodrug nanocarriers can overcome the present barriers in their application: poor water solubility, low bioavailability, and insufficient targeting. Therefore, the available literature suggests a high potential of MSNs as natural prodrug delivery vehicles. The present pre-clinical and clinical tests show that MSNs are promising drug delivery carriers from a biocompatibility/safety perspective, opening the door towards the clinical nanomedicine application for cancer therapy.</p><p>For future research directions, we suggest the importance of co-delivery systems in which two or more anticancer natural prodrugs are combined, as well as exploring thousands of natural prodrugs that have not been thoroughly investigated yet. Furthermore, scientists can investigate loading MSNs with crude extract from plant materials. This can also be explored in synergistic therapy with crude extract containing many prodrug components together. Particularly promising prodrug substances are essential oils applied using MSN-based delivery systems. Their traditional use is only limited to cosmetics and some pharmaceutical applications. The essential oil nanoformulations will add value to cancer therapy. </p><p>The core&#x02013;shell nanoformulations containing a core of MSNs loaded with prodrugs and a shell of organic substances, such as chitosan, Arabic gum, or others, are highly recommended to establish prodrug delivery systems. As an important parameter, the stability and dispersibility of nanoformulations should be taken into consideration because they affect the biological performance and therapeutic actions. Additionally, we think that the large-scale production for each type of MSNs will lead to obtaining safe material by optimizing and stabilizing the material parameters. In our opinion, animal and reported clinical studies open the doors to develop MSNs-based nanoformulations to be translated into clinical evaluations for cancers soon.</p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to thank the Institute of High Pressure Physics (IHPP), Polish Academy of Sciences (PAS), Poland, for the financial support.</p></ack><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, K.A. and W.L.; literature review, K.A.; writing&#x02014;original draft preparation, K.A.; writing-review and editing, K.A. and W.L.; visualization, K.A. and W.L.; supervision, W.L. Both authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This work was funded by the Institute of High Pressure Physics (IHPP), Polish Academy of Sciences (PAS), Poland and The APC was also funded by IHPP.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest regarding the publication of this paper.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-13-00143"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallet-Regi</surname><given-names>M.</given-names></name><name><surname>R&#x000e1;mila</surname><given-names>A.</given-names></name><name><surname>del Real</surname><given-names>R.P.</given-names></name><name><surname>P&#x000e9;rez-Pariente</surname><given-names>J.</given-names></name></person-group><article-title>A New Property of MCM-41:&#x02009; Drug Delivery System</article-title><source>Chem. Mater.</source><year>2001</year><volume>13</volume><fpage>308</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1021/cm0011559</pub-id></element-citation></ref><ref id="B2-pharmaceutics-13-00143"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kresge</surname><given-names>C.T.</given-names></name><name><surname>Leonowicz</surname><given-names>M.E.</given-names></name><name><surname>Roth</surname><given-names>W.J.</given-names></name><name><surname>Vartuli</surname><given-names>J.C.</given-names></name><name><surname>Beck</surname><given-names>J.S.</given-names></name></person-group><article-title>Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism</article-title><source>Nature</source><year>1992</year><volume>359</volume><fpage>710</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1038/359710a0</pub-id></element-citation></ref><ref id="B3-pharmaceutics-13-00143"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gon&#x000e7;alves</surname><given-names>M.C.</given-names></name></person-group><article-title>Sol-Gel Silica Nanoparticles in Medicine: A Natural Choice. Design, Synthesis and Products</article-title><source>Molecules</source><year>2018</year><volume>23</volume><elocation-id>2021</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23082021</pub-id></element-citation></ref><ref id="B4-pharmaceutics-13-00143"><label>4.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pednekar</surname><given-names>P.P.</given-names></name><name><surname>Godiyal</surname><given-names>S.C.</given-names></name><name><surname>Jadhav</surname><given-names>K.R.</given-names></name><name><surname>Kadam</surname><given-names>V.J.</given-names></name></person-group><article-title>Chapter 23&#x02014;Mesoporous silica nanoparticles: A promising multifunctional drug delivery system</article-title><source>Nanostructures for Cancer Therapy</source><person-group person-group-type="editor"><name><surname>Ficai</surname><given-names>A.</given-names></name><name><surname>Grumezescu</surname><given-names>A.M.</given-names></name></person-group><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2017</year><fpage>593</fpage><lpage>621</lpage></element-citation></ref><ref id="B5-pharmaceutics-13-00143"><label>5.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Le Hoang Doan</surname><given-names>T.</given-names></name><name><surname>Mai</surname><given-names>N.X.D.</given-names></name><name><surname>Matsumoto</surname><given-names>K.</given-names></name><name><surname>Tamanoi</surname><given-names>F.</given-names></name></person-group><article-title>Chapter 4&#x02014;Tumor Targeting and Tumor Growth Inhibition Capability of Mesoporous Silica Nanoparticles in Mouse Models</article-title><source>The Enzymes</source><person-group person-group-type="editor"><name><surname>Tamanoi</surname><given-names>F.</given-names></name></person-group><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2018</year><volume>Volume 44</volume><fpage>61</fpage><lpage>82</lpage></element-citation></ref><ref id="B6-pharmaceutics-13-00143"><label>6.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mitran</surname><given-names>R.-A.</given-names></name><name><surname>Deaconu</surname><given-names>M.</given-names></name><name><surname>Matei</surname><given-names>C.</given-names></name><name><surname>Berger</surname><given-names>D.</given-names></name></person-group><article-title>Chapter 11&#x02014;Mesoporous Silica as Carrier for Drug-Delivery Systems</article-title><source>Nanocarriers for Drug Delivery</source><person-group person-group-type="editor"><name><surname>Mohapatra</surname><given-names>S.S.</given-names></name><name><surname>Ranjan</surname><given-names>S.</given-names></name><name><surname>Dasgupta</surname><given-names>N.</given-names></name><name><surname>Mishra</surname><given-names>R.K.</given-names></name><name><surname>Thomas</surname><given-names>S.</given-names></name></person-group><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2019</year><fpage>351</fpage><lpage>374</lpage></element-citation></ref><ref id="B7-pharmaceutics-13-00143"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mekaru</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Tamanoi</surname><given-names>F.</given-names></name></person-group><article-title>Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy</article-title><source>Adv. Drug Deliv. Rev.</source><year>2015</year><volume>95</volume><fpage>40</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2015.09.009</pub-id><pub-id pub-id-type="pmid">26434537</pub-id></element-citation></ref><ref id="B8-pharmaceutics-13-00143"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slowing</surname><given-names>I.I.</given-names></name><name><surname>Vivero-Escoto</surname><given-names>J.L.</given-names></name><name><surname>Wu</surname><given-names>C.-W.</given-names></name><name><surname>Lin</surname><given-names>V.S.Y.</given-names></name></person-group><article-title>Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers</article-title><source>Adv. Drug Deliv. Rev.</source><year>2008</year><volume>60</volume><fpage>1278</fpage><lpage>1288</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2008.03.012</pub-id><pub-id pub-id-type="pmid">18514969</pub-id></element-citation></ref><ref id="B9-pharmaceutics-13-00143"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mamaeva</surname><given-names>V.</given-names></name><name><surname>Sahlgren</surname><given-names>C.</given-names></name><name><surname>Lind&#x000e9;n</surname><given-names>M.</given-names></name></person-group><article-title>Mesoporous silica nanoparticles in medicine&#x02014;Recent advances</article-title><source>Adv. Drug Deliv. Rev.</source><year>2013</year><volume>65</volume><fpage>689</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2012.07.018</pub-id><pub-id pub-id-type="pmid">22921598</pub-id></element-citation></ref><ref id="B10-pharmaceutics-13-00143"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narayan</surname><given-names>R.</given-names></name><name><surname>Nayak</surname><given-names>U.Y.</given-names></name><name><surname>Raichur</surname><given-names>A.M.</given-names></name><name><surname>Garg</surname><given-names>S.</given-names></name></person-group><article-title>Mesoporous Silica Nanoparticles: A Comprehensive Review on Synthesis and Recent Advances</article-title><source>Pharmaceutics</source><year>2018</year><volume>10</volume><elocation-id>118</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics10030118</pub-id></element-citation></ref><ref id="B11-pharmaceutics-13-00143"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>S.</given-names></name><name><surname>Singh</surname><given-names>R.K.</given-names></name><name><surname>Perez</surname><given-names>R.A.</given-names></name><name><surname>Abou Neel</surname><given-names>E.A.</given-names></name><name><surname>Kim</surname><given-names>H.W.</given-names></name><name><surname>Chrzanowski</surname><given-names>W.</given-names></name></person-group><article-title>Silica-based mesoporous nanoparticles for controlled drug delivery</article-title><source>J. Tissue Eng.</source><year>2013</year><volume>4</volume><fpage>2041731413503357</fpage><pub-id pub-id-type="doi">10.1177/2041731413503357</pub-id><pub-id pub-id-type="pmid">24020012</pub-id></element-citation></ref><ref id="B12-pharmaceutics-13-00143"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liong</surname><given-names>M.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Kovochich</surname><given-names>M.</given-names></name><name><surname>Xia</surname><given-names>T.</given-names></name><name><surname>Ruehm</surname><given-names>S.G.</given-names></name><name><surname>Nel</surname><given-names>A.E.</given-names></name><name><surname>Tamanoi</surname><given-names>F.</given-names></name><name><surname>Zink</surname><given-names>J.I.</given-names></name></person-group><article-title>Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery</article-title><source>ACS Nano</source><year>2008</year><volume>2</volume><fpage>889</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1021/nn800072t</pub-id><pub-id pub-id-type="pmid">19206485</pub-id></element-citation></ref><ref id="B13-pharmaceutics-13-00143"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x000e9;rez-Esteve</surname><given-names>&#x000c9;.</given-names></name><name><surname>Ruiz-Rico</surname><given-names>M.</given-names></name><name><surname>de la Torre</surname><given-names>C.</given-names></name><name><surname>Llorca</surname><given-names>E.</given-names></name><name><surname>Sancen&#x000f3;n</surname><given-names>F.</given-names></name><name><surname>Marcos</surname><given-names>M.D.</given-names></name><name><surname>Amor&#x000f3;s</surname><given-names>P.</given-names></name><name><surname>Guillem</surname><given-names>C.</given-names></name><name><surname>Mart&#x000ed;nez-M&#x000e1;&#x000f1;ez</surname><given-names>R.</given-names></name><name><surname>Barat</surname><given-names>J.M.</given-names></name></person-group><article-title>Stability of different mesoporous silica particles during an in vitro digestion</article-title><source>Microporous Mesoporous Mater.</source><year>2016</year><volume>230</volume><fpage>196</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/j.micromeso.2016.05.004</pub-id></element-citation></ref><ref id="B14-pharmaceutics-13-00143"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riikonen</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Lehto</surname><given-names>V.-P.</given-names></name></person-group><article-title>Mesoporous systems for poorly soluble drugs&#x02014;Recent trends</article-title><source>Int. J. Pharm.</source><year>2018</year><volume>536</volume><fpage>178</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.11.054</pub-id><?supplied-pmid 29183856?><pub-id pub-id-type="pmid">29183856</pub-id></element-citation></ref><ref id="B15-pharmaceutics-13-00143"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maleki</surname><given-names>A.</given-names></name><name><surname>Kettiger</surname><given-names>H.</given-names></name><name><surname>Schoubben</surname><given-names>A.</given-names></name><name><surname>Rosenholm</surname><given-names>J.M.</given-names></name><name><surname>Ambrogi</surname><given-names>V.</given-names></name><name><surname>Hamidi</surname><given-names>M.</given-names></name></person-group><article-title>Mesoporous silica materials: From physico-chemical properties to enhanced dissolution of poorly water-soluble drugs</article-title><source>J. Control. Release</source><year>2017</year><volume>262</volume><fpage>329</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2017.07.047</pub-id><pub-id pub-id-type="pmid">28778479</pub-id></element-citation></ref><ref id="B16-pharmaceutics-13-00143"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambrogi</surname><given-names>V.</given-names></name><name><surname>Perioli</surname><given-names>L.</given-names></name><name><surname>Pagano</surname><given-names>C.</given-names></name><name><surname>Latterini</surname><given-names>L.</given-names></name><name><surname>Marmottini</surname><given-names>F.</given-names></name><name><surname>Ricci</surname><given-names>M.</given-names></name><name><surname>Rossi</surname><given-names>C.</given-names></name></person-group><article-title>MCM-41 for furosemide dissolution improvement</article-title><source>Microporous Mesoporous Mater.</source><year>2012</year><volume>147</volume><fpage>343</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1016/j.micromeso.2011.07.007</pub-id></element-citation></ref><ref id="B17-pharmaceutics-13-00143"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>F.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Yuan</surname><given-names>Y.</given-names></name></person-group><article-title>Improving Solubility and Bioavailability of Breviscapine with Mesoporous Silica Nanoparticles Prepared Using Ultrasound-Assisted Solution-Enhanced Dispersion by Supercritical Fluids Method</article-title><source>Int. J. Nanomed.</source><year>2020</year><volume>15</volume><fpage>1661</fpage><lpage>1675</lpage><pub-id pub-id-type="doi">10.2147/IJN.S238337</pub-id><?supplied-pmid 32210559?><pub-id pub-id-type="pmid">32210559</pub-id></element-citation></ref><ref id="B18-pharmaceutics-13-00143"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>C.A.</given-names></name><name><surname>Ahern</surname><given-names>R.J.</given-names></name><name><surname>Dontireddy</surname><given-names>R.</given-names></name><name><surname>Ryan</surname><given-names>K.B.</given-names></name><name><surname>Crean</surname><given-names>A.M.</given-names></name></person-group><article-title>Mesoporous silica formulation strategies for drug dissolution enhancement: A review</article-title><source>Expert Opin. Drug Deliv.</source><year>2016</year><volume>13</volume><fpage>93</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1517/17425247.2016.1100165</pub-id><?supplied-pmid 26549623?><pub-id pub-id-type="pmid">26549623</pub-id></element-citation></ref><ref id="B19-pharmaceutics-13-00143"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>D.</given-names></name><name><surname>Sailaja Chirravuri</surname><given-names>S.V.</given-names></name><name><surname>Shastri</surname><given-names>N.R.</given-names></name></person-group><article-title>Impact of surface area of silica particles on dissolution rate and oral bioavailability of poorly water soluble drugs: A case study with aceclofenac</article-title><source>Int. J. Pharm.</source><year>2014</year><volume>461</volume><fpage>459</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2013.12.017</pub-id><pub-id pub-id-type="pmid">24368106</pub-id></element-citation></ref><ref id="B20-pharmaceutics-13-00143"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Zu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>Enhanced Solubility and Bioavailability of Apigenin via Preparation of Solid Dispersions of Mesoporous Silica Nanoparticles</article-title><source>Iran. J. Pharm. Res.</source><year>2019</year><volume>18</volume><fpage>168</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">31089353</pub-id></element-citation></ref><ref id="B21-pharmaceutics-13-00143"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>P.-Z.</given-names></name><name><surname>Nguyen</surname><given-names>K.T.</given-names></name><name><surname>Wang</surname><given-names>X.-J.</given-names></name><name><surname>Luo</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Tan</surname><given-names>N.S.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>Biocompatible, Uniform, and Redispersible Mesoporous Silica Nanoparticles for Cancer-Targeted Drug Delivery In Vivo</article-title><source>Adv. Funct. Mater.</source><year>2014</year><volume>24</volume><fpage>2450</fpage><lpage>2461</lpage><pub-id pub-id-type="doi">10.1002/adfm.201302988</pub-id></element-citation></ref><ref id="B22-pharmaceutics-13-00143"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Argyo</surname><given-names>C.</given-names></name><name><surname>Weiss</surname><given-names>V.</given-names></name><name><surname>Br&#x000e4;uchle</surname><given-names>C.</given-names></name><name><surname>Bein</surname><given-names>T.</given-names></name></person-group><article-title>Multifunctional Mesoporous Silica Nanoparticles as a Universal Platform for Drug Delivery</article-title><source>Chem. Mater.</source><year>2014</year><volume>26</volume><fpage>435</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1021/cm402592t</pub-id></element-citation></ref><ref id="B23-pharmaceutics-13-00143"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Liong</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Zink</surname><given-names>J.I.</given-names></name><name><surname>Tamanoi</surname><given-names>F.</given-names></name></person-group><article-title>Biocompatibility, Biodistribution, and Drug-Delivery Efficiency of Mesoporous Silica Nanoparticles for Cancer Therapy in Animals</article-title><source>Small</source><year>2010</year><volume>6</volume><fpage>1794</fpage><lpage>1805</lpage><pub-id pub-id-type="doi">10.1002/smll.201000538</pub-id><?supplied-pmid 20623530?><pub-id pub-id-type="pmid">20623530</pub-id></element-citation></ref><ref id="B24-pharmaceutics-13-00143"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>D.</given-names></name><name><surname>Cha</surname><given-names>B.G.</given-names></name><name><surname>Cho</surname><given-names>Y.</given-names></name><name><surname>Min</surname><given-names>J.</given-names></name><name><surname>Park</surname><given-names>E.B.</given-names></name><name><surname>Kang</surname><given-names>S.J.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name></person-group><article-title>Extra-Large Pore Mesoporous Silica Nanoparticles for Directing in Vivo M2 Macrophage Polarization by Delivering IL-4</article-title><source>Nano Lett.</source><year>2017</year><volume>17</volume><fpage>2747</fpage><lpage>2756</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.6b04130</pub-id><?supplied-pmid 28422506?><pub-id pub-id-type="pmid">28422506</pub-id></element-citation></ref><ref id="B25-pharmaceutics-13-00143"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malvindi</surname><given-names>M.A.</given-names></name><name><surname>Brunetti</surname><given-names>V.</given-names></name><name><surname>Vecchio</surname><given-names>G.</given-names></name><name><surname>Galeone</surname><given-names>A.</given-names></name><name><surname>Cingolani</surname><given-names>R.</given-names></name><name><surname>Pompa</surname><given-names>P.P.</given-names></name></person-group><article-title>SiO2 nanoparticles biocompatibility and their potential for gene delivery and silencing</article-title><source>Nanoscale</source><year>2012</year><volume>4</volume><fpage>486</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1039/C1NR11269D</pub-id><pub-id pub-id-type="pmid">22095171</pub-id></element-citation></ref><ref id="B26-pharmaceutics-13-00143"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abeer</surname><given-names>M.M.</given-names></name><name><surname>Rewatkar</surname><given-names>P.</given-names></name><name><surname>Qu</surname><given-names>Z.</given-names></name><name><surname>Talekar</surname><given-names>M.</given-names></name><name><surname>Kleitz</surname><given-names>F.</given-names></name><name><surname>Schmid</surname><given-names>R.</given-names></name><name><surname>Lind&#x000e9;n</surname><given-names>M.</given-names></name><name><surname>Kumeria</surname><given-names>T.</given-names></name><name><surname>Popat</surname><given-names>A.</given-names></name></person-group><article-title>Silica nanoparticles: A promising platform for enhanced oral delivery of macromolecules</article-title><source>J. Control. Release</source><year>2020</year><volume>326</volume><fpage>544</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.07.021</pub-id><?supplied-pmid 32687941?><pub-id pub-id-type="pmid">32687941</pub-id></element-citation></ref><ref id="B27-pharmaceutics-13-00143"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diab</surname><given-names>R.</given-names></name><name><surname>Canilho</surname><given-names>N.</given-names></name><name><surname>Pavel</surname><given-names>I.A.</given-names></name><name><surname>Haffner</surname><given-names>F.B.</given-names></name><name><surname>Girardon</surname><given-names>M.</given-names></name><name><surname>Pasc</surname><given-names>A.</given-names></name></person-group><article-title>Silica-based systems for oral delivery of drugs, macromolecules and cells</article-title><source>Adv. Colloid Interface Sci.</source><year>2017</year><volume>249</volume><fpage>346</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1016/j.cis.2017.04.005</pub-id><?supplied-pmid 28473052?><pub-id pub-id-type="pmid">28473052</pub-id></element-citation></ref><ref id="B28-pharmaceutics-13-00143"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammadpour</surname><given-names>R.</given-names></name><name><surname>Cheney</surname><given-names>D.L.</given-names></name><name><surname>Grunberger</surname><given-names>J.W.</given-names></name><name><surname>Yazdimamaghani</surname><given-names>M.</given-names></name><name><surname>Jedrzkiewicz</surname><given-names>J.</given-names></name><name><surname>Isaacson</surname><given-names>K.J.</given-names></name><name><surname>Dobrovolskaia</surname><given-names>M.A.</given-names></name><name><surname>Ghandehari</surname><given-names>H.</given-names></name></person-group><article-title>One-year chronic toxicity evaluation of single dose intravenously administered silica nanoparticles in mice and their Ex vivo human hemocompatibility</article-title><source>J. Control. Release</source><year>2020</year><volume>324</volume><fpage>471</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.05.027</pub-id><pub-id pub-id-type="pmid">32464151</pub-id></element-citation></ref><ref id="B29-pharmaceutics-13-00143"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Tang</surname><given-names>F.</given-names></name></person-group><article-title>The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes</article-title><source>Biomaterials</source><year>2013</year><volume>34</volume><fpage>2565</fpage><lpage>2575</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2012.12.043</pub-id><pub-id pub-id-type="pmid">23332175</pub-id></element-citation></ref><ref id="B30-pharmaceutics-13-00143"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Hao</surname><given-names>N.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Tang</surname><given-names>F.</given-names></name></person-group><article-title>The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo</article-title><source>ACS Nano</source><year>2011</year><volume>5</volume><fpage>5390</fpage><lpage>5399</lpage><pub-id pub-id-type="doi">10.1021/nn200365a</pub-id><pub-id pub-id-type="pmid">21634407</pub-id></element-citation></ref><ref id="B31-pharmaceutics-13-00143"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watermann</surname><given-names>A.</given-names></name><name><surname>Brieger</surname><given-names>J.</given-names></name></person-group><article-title>Mesoporous Silica Nanoparticles as Drug Delivery Vehicles in Cancer</article-title><source>Nanomaterials</source><year>2017</year><volume>7</volume><elocation-id>189</elocation-id><pub-id pub-id-type="doi">10.3390/nano7070189</pub-id></element-citation></ref><ref id="B32-pharmaceutics-13-00143"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallet-Reg&#x000ed;</surname><given-names>M.</given-names></name><name><surname>Colilla</surname><given-names>M.</given-names></name><name><surname>Izquierdo-Barba</surname><given-names>I.</given-names></name><name><surname>Manzano</surname><given-names>M.</given-names></name></person-group><article-title>Mesoporous Silica Nanoparticles for Drug Delivery: Current Insights</article-title><source>Molecules</source><year>2018</year><volume>23</volume><elocation-id>47</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23010047</pub-id></element-citation></ref><ref id="B33-pharmaceutics-13-00143"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bukara</surname><given-names>K.</given-names></name><name><surname>Schueller</surname><given-names>L.</given-names></name><name><surname>Rosier</surname><given-names>J.</given-names></name><name><surname>Martens</surname><given-names>M.A.</given-names></name><name><surname>Daems</surname><given-names>T.</given-names></name><name><surname>Verheyden</surname><given-names>L.</given-names></name><name><surname>Eelen</surname><given-names>S.</given-names></name><name><surname>Van Speybroeck</surname><given-names>M.</given-names></name><name><surname>Libanati</surname><given-names>C.</given-names></name><name><surname>Martens</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Ordered mesoporous silica to enhance the bioavailability of poorly water-soluble drugs: Proof of concept in man</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2016</year><volume>108</volume><fpage>220</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2016.08.020</pub-id><pub-id pub-id-type="pmid">27648957</pub-id></element-citation></ref><ref id="B34-pharmaceutics-13-00143"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cragg</surname><given-names>G.M.</given-names></name><name><surname>Newman</surname><given-names>D.J.</given-names></name></person-group><article-title>Plants as a source of anti-cancer agents</article-title><source>J. Ethnopharmacol.</source><year>2005</year><volume>100</volume><fpage>72</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2005.05.011</pub-id><?supplied-pmid 16009521?><pub-id pub-id-type="pmid">16009521</pub-id></element-citation></ref><ref id="B35-pharmaceutics-13-00143"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>A.L.</given-names></name></person-group><article-title>Natural products in drug discovery</article-title><source>Drug Discov. Today</source><year>2008</year><volume>13</volume><fpage>894</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2008.07.004</pub-id><?supplied-pmid 18691670?><pub-id pub-id-type="pmid">18691670</pub-id></element-citation></ref><ref id="B36-pharmaceutics-13-00143"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hostettmann</surname><given-names>K.</given-names></name><name><surname>Marston</surname><given-names>A.</given-names></name></person-group><article-title>The Search for New Drugs from Higher Plants</article-title><source>Chim. Int. J. Chem.</source><year>2007</year><volume>61</volume><fpage>322</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.2533/chimia.2007.322</pub-id></element-citation></ref><ref id="B37-pharmaceutics-13-00143"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atanasov</surname><given-names>A.G.</given-names></name><name><surname>Waltenberger</surname><given-names>B.</given-names></name><name><surname>Pferschy-Wenzig</surname><given-names>E.M.</given-names></name><name><surname>Linder</surname><given-names>T.</given-names></name><name><surname>Wawrosch</surname><given-names>C.</given-names></name><name><surname>Uhrin</surname><given-names>P.</given-names></name><name><surname>Temml</surname><given-names>V.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Schwaiger</surname><given-names>S.</given-names></name><name><surname>Heiss</surname><given-names>E.H.</given-names></name><etal/></person-group><article-title>Discovery and resupply of pharmacologically active plant-derived natural products: A review</article-title><source>Biotechnol. Adv.</source><year>2015</year><volume>33</volume><fpage>1582</fpage><lpage>1614</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2015.08.001</pub-id><pub-id pub-id-type="pmid">26281720</pub-id></element-citation></ref><ref id="B38-pharmaceutics-13-00143"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>H.-F.</given-names></name><name><surname>Li</surname><given-names>X.-J.</given-names></name><name><surname>Zhang</surname><given-names>H.-Y.</given-names></name></person-group><article-title>Natural products and drug discovery</article-title><source>EMBO Rep.</source><year>2009</year><volume>10</volume><fpage>194</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1038/embor.2009.12</pub-id><pub-id pub-id-type="pmid">19229284</pub-id></element-citation></ref><ref id="B39-pharmaceutics-13-00143"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watkins</surname><given-names>R.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Davis</surname><given-names>R.M.</given-names></name><name><surname>Xu</surname><given-names>B.</given-names></name></person-group><article-title>Natural product-based nanomedicine: Recent advances and issues</article-title><source>Int. J. Nanomed.</source><year>2015</year><volume>10</volume><fpage>6055</fpage><lpage>6074</lpage><pub-id pub-id-type="doi">10.2147/ijn.s92162</pub-id></element-citation></ref><ref id="B40-pharmaceutics-13-00143"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aljuffali</surname><given-names>I.A.</given-names></name><name><surname>Fang</surname><given-names>C.L.</given-names></name><name><surname>Chen</surname><given-names>C.H.</given-names></name><name><surname>Fang</surname><given-names>J.Y.</given-names></name></person-group><article-title>Nanomedicine as a Strategy for Natural Compound Delivery to Prevent and Treat Cancers</article-title><source>Curr. Pharm. Des.</source><year>2016</year><volume>22</volume><fpage>4219</fpage><lpage>4231</lpage><pub-id pub-id-type="doi">10.2174/1381612822666160620072539</pub-id><pub-id pub-id-type="pmid">27323758</pub-id></element-citation></ref><ref id="B41-pharmaceutics-13-00143"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fonseca-Santos</surname><given-names>B.</given-names></name><name><surname>Chorilli</surname><given-names>M.</given-names></name></person-group><article-title>The uses of resveratrol for neurological diseases treatment and insights for nanotechnology based-drug delivery systems</article-title><source>Int. J. Pharm.</source><year>2020</year><fpage>119832</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119832</pub-id><pub-id pub-id-type="pmid">32877730</pub-id></element-citation></ref><ref id="B42-pharmaceutics-13-00143"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>AbouAitah</surname><given-names>K.</given-names></name><name><surname>Swiderska-Sroda</surname><given-names>A.</given-names></name><name><surname>Farghali</surname><given-names>A.A.</given-names></name><name><surname>Wojnarowicz</surname><given-names>J.</given-names></name><name><surname>Stefanek</surname><given-names>A.</given-names></name><name><surname>Gierlotka</surname><given-names>S.</given-names></name><name><surname>Opalinska</surname><given-names>A.</given-names></name><name><surname>Allayeh</surname><given-names>A.K.</given-names></name><name><surname>Ciach</surname><given-names>T.</given-names></name><name><surname>Lojkowski</surname><given-names>W.</given-names></name></person-group><article-title>Folic acid-conjugated mesoporous silica particles as nanocarriers of natural prodrugs for cancer targeting and antioxidant action</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>26466</fpage><lpage>26490</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.25470</pub-id><pub-id pub-id-type="pmid">29899871</pub-id></element-citation></ref><ref id="B43-pharmaceutics-13-00143"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>AbouAitah</surname><given-names>K.</given-names></name><name><surname>Hassan</surname><given-names>H.A.</given-names></name><name><surname>Swiderska-Sroda</surname><given-names>A.</given-names></name><name><surname>Gohar</surname><given-names>L.</given-names></name><name><surname>Shaker</surname><given-names>O.G.</given-names></name><name><surname>Wojnarowicz</surname><given-names>J.</given-names></name><name><surname>Opalinska</surname><given-names>A.</given-names></name><name><surname>Smalc-Koziorowska</surname><given-names>J.</given-names></name><name><surname>Gierlotka</surname><given-names>S.</given-names></name><name><surname>Lojkowski</surname><given-names>W.</given-names></name></person-group><article-title>Targeted Nano-Drug Delivery of Colchicine against Colon Cancer Cells by Means of Mesoporous Silica Nanoparticles</article-title><source>Cancers</source><year>2020</year><volume>12</volume><elocation-id>144</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12010144</pub-id></element-citation></ref><ref id="B44-pharmaceutics-13-00143"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahein</surname><given-names>S.A.</given-names></name><name><surname>Aboul-Enein</surname><given-names>A.M.</given-names></name><name><surname>Higazy</surname><given-names>I.M.</given-names></name><name><surname>Abou-Elella</surname><given-names>F.</given-names></name><name><surname>Lojkowski</surname><given-names>W.</given-names></name><name><surname>Ahmed</surname><given-names>E.R.</given-names></name><name><surname>Mousa</surname><given-names>S.A.</given-names></name><name><surname>AbouAitah</surname><given-names>K.</given-names></name></person-group><article-title>Targeted anticancer potential against glioma cells of thymoquinone delivered by mesoporous silica core-shell nanoformulations with pH-dependent release</article-title><source>Int. J. Nanomed.</source><year>2019</year><volume>14</volume><fpage>5503</fpage><lpage>5526</lpage><pub-id pub-id-type="doi">10.2147/IJN.S206899</pub-id></element-citation></ref><ref id="B45-pharmaceutics-13-00143"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bisht</surname><given-names>S.</given-names></name><name><surname>Feldmann</surname><given-names>G.</given-names></name><name><surname>Soni</surname><given-names>S.</given-names></name><name><surname>Ravi</surname><given-names>R.</given-names></name><name><surname>Karikar</surname><given-names>C.</given-names></name><name><surname>Maitra</surname><given-names>A.</given-names></name><name><surname>Maitra</surname><given-names>A.</given-names></name></person-group><article-title>Polymeric nanoparticle-encapsulated curcumin (&#x0201c;nanocurcumin&#x0201d;): A novel strategy for human cancer therapy</article-title><source>J. Nanobiotechnol.</source><year>2007</year><volume>5</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1186/1477-3155-5-3</pub-id><?supplied-pmid 17439648?><pub-id pub-id-type="pmid">17439648</pub-id></element-citation></ref><ref id="B46-pharmaceutics-13-00143"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pool</surname><given-names>H.</given-names></name><name><surname>Quintanar</surname><given-names>D.</given-names></name><name><surname>Figueroa</surname><given-names>J.D.D.</given-names></name><name><surname>Marinho Mano</surname><given-names>C.</given-names></name><name><surname>Bechara</surname><given-names>J.E.H.</given-names></name><name><surname>God&#x000ed;nez</surname><given-names>L.A.</given-names></name><name><surname>Mendoza</surname><given-names>S.</given-names></name></person-group><article-title>Antioxidant Effects of Quercetin and Catechin Encapsulated into PLGA Nanoparticles</article-title><source>J. Nanomater.</source><year>2012</year><volume>2012</volume><fpage>145380</fpage><pub-id pub-id-type="doi">10.1155/2012/145380</pub-id></element-citation></ref><ref id="B47-pharmaceutics-13-00143"><label>47.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>Q.</given-names></name><name><surname>Sculley</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>H.C.J.</given-names></name><name><surname>Zhu</surname><given-names>G.</given-names></name></person-group><article-title>5.01&#x02014;Porous Metal&#x02013;Organic Frameworks</article-title><source>Comprehensive Nanoscience and Technology</source><person-group person-group-type="editor"><name><surname>Andrews</surname><given-names>D.L.</given-names></name><name><surname>Scholes</surname><given-names>G.D.</given-names></name><name><surname>Wiederrecht</surname><given-names>G.P.</given-names></name></person-group><publisher-name>Academic Press</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2011</year><fpage>1</fpage><lpage>20</lpage></element-citation></ref><ref id="B48-pharmaceutics-13-00143"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sing</surname><given-names>K.S.W.</given-names></name></person-group><article-title>Reporting physisorption data for gas/solid systems</article-title><source>Pure Appl. Chem.</source><year>1982</year><volume>54</volume><fpage>2201</fpage><lpage>2218</lpage><pub-id pub-id-type="doi">10.1351/pac198254112201</pub-id></element-citation></ref><ref id="B49-pharmaceutics-13-00143"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sing</surname><given-names>K.S.W.</given-names></name></person-group><article-title>Reporting physisorption data for gas/solid systems with special reference to the determination of surface area and porosity (Recommendations 1984)</article-title><source>Pure Appl. Chem.</source><year>1985</year><volume>57</volume><fpage>603</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1351/pac198557040603</pub-id></element-citation></ref><ref id="B50-pharmaceutics-13-00143"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>J.S.</given-names></name><name><surname>Vartuli</surname><given-names>J.C.</given-names></name><name><surname>Roth</surname><given-names>W.J.</given-names></name><name><surname>Leonowicz</surname><given-names>M.E.</given-names></name><name><surname>Kresge</surname><given-names>C.T.</given-names></name><name><surname>Schmitt</surname><given-names>K.D.</given-names></name><name><surname>Chu</surname><given-names>C.T.W.</given-names></name><name><surname>Olson</surname><given-names>D.H.</given-names></name><name><surname>Sheppard</surname><given-names>E.W.</given-names></name><name><surname>McCullen</surname><given-names>S.B.</given-names></name><etal/></person-group><article-title>A new family of mesoporous molecular sieves prepared with liquid crystal templates</article-title><source>J. Am. Chem. Soc.</source><year>1992</year><volume>114</volume><fpage>10834</fpage><lpage>10843</lpage><pub-id pub-id-type="doi">10.1021/ja00053a020</pub-id></element-citation></ref><ref id="B51-pharmaceutics-13-00143"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inagaki</surname><given-names>S.</given-names></name><name><surname>Fukushima</surname><given-names>Y.</given-names></name><name><surname>Kuroda</surname><given-names>K.</given-names></name></person-group><article-title>Synthesis of highly ordered mesoporous materials from a layered polysilicate</article-title><source>J. Chem. Soc. Chem. Commun.</source><year>1993</year><fpage>680</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1039/c39930000680</pub-id></element-citation></ref><ref id="B52-pharmaceutics-13-00143"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>F.</given-names></name><name><surname>Cornelius</surname><given-names>M.</given-names></name><name><surname>Morell</surname><given-names>J.</given-names></name><name><surname>Fr&#x000f6;ba</surname><given-names>M.</given-names></name></person-group><article-title>Silica-Based Mesoporous Organic&#x02013;Inorganic Hybrid Materials</article-title><source>Angew. Chem. Int. Ed.</source><year>2006</year><volume>45</volume><fpage>3216</fpage><lpage>3251</lpage><pub-id pub-id-type="doi">10.1002/anie.200503075</pub-id></element-citation></ref><ref id="B53-pharmaceutics-13-00143"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryoo</surname><given-names>R.</given-names></name><name><surname>Kim</surname><given-names>J.M.</given-names></name><name><surname>Ko</surname><given-names>C.H.</given-names></name><name><surname>Shin</surname><given-names>C.H.</given-names></name></person-group><article-title>Disordered Molecular Sieve with Branched Mesoporous Channel Network</article-title><source>J. Phys. Chem.</source><year>1996</year><volume>100</volume><fpage>17718</fpage><lpage>17721</lpage><pub-id pub-id-type="doi">10.1021/jp9620835</pub-id></element-citation></ref><ref id="B54-pharmaceutics-13-00143"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>C.Y.</given-names></name><name><surname>Qi</surname><given-names>N.</given-names></name><name><surname>Jiang</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>Z.Q.</given-names></name></person-group><article-title>Pore structure of mesoporous silica (KIT-6) synthesized at different temperatures using positron as a nondestructive probe</article-title><source>Appl. Surf. Sci.</source><year>2018</year><volume>450</volume><fpage>31</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.apsusc.2018.03.223</pub-id></element-citation></ref><ref id="B55-pharmaceutics-13-00143"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deka</surname><given-names>J.R.</given-names></name><name><surname>Lin</surname><given-names>Y.-H.</given-names></name><name><surname>Kao</surname><given-names>H.-M.</given-names></name></person-group><article-title>Ordered cubic mesoporous silica KIT-5 functionalized with carboxylic acid groups for dye removal</article-title><source>RSC Adv.</source><year>2014</year><volume>4</volume><fpage>49061</fpage><lpage>49069</lpage><pub-id pub-id-type="doi">10.1039/C4RA08819K</pub-id></element-citation></ref><ref id="B56-pharmaceutics-13-00143"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>D.</given-names></name><name><surname>Feng</surname><given-names>J.</given-names></name><name><surname>Huo</surname><given-names>Q.</given-names></name><name><surname>Melosh</surname><given-names>N.</given-names></name><name><surname>Fredrickson</surname><given-names>G.H.</given-names></name><name><surname>Chmelka</surname><given-names>B.F.</given-names></name><name><surname>Stucky</surname><given-names>G.D.</given-names></name></person-group><article-title>Triblock Copolymer Syntheses of Mesoporous Silica with Periodic 50 to 300 Angstrom Pores</article-title><source>Science</source><year>1998</year><volume>279</volume><fpage>548</fpage><pub-id pub-id-type="doi">10.1126/science.279.5350.548</pub-id><?supplied-pmid 9438845?><pub-id pub-id-type="pmid">9438845</pub-id></element-citation></ref><ref id="B57-pharmaceutics-13-00143"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Widenmeyer</surname><given-names>M.</given-names></name><name><surname>Anwander</surname><given-names>R.</given-names></name></person-group><article-title>Pore Size Control of Highly Ordered Mesoporous Silica MCM-48</article-title><source>Chem. Mater.</source><year>2002</year><volume>14</volume><fpage>1827</fpage><lpage>1831</lpage><pub-id pub-id-type="doi">10.1021/cm011273b</pub-id></element-citation></ref><ref id="B58-pharmaceutics-13-00143"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>L.-C.</given-names></name><name><surname>Thirumavalavan</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>Y.-T.</given-names></name><name><surname>Lee</surname><given-names>J.-F.</given-names></name></person-group><article-title>Surface area and pore size tailoring of mesoporous silica materials by different hydrothermal treatments and adsorption of heavy metal ions</article-title><source>Colloids Surf. A Physicochem. Eng. Asp.</source><year>2010</year><volume>369</volume><fpage>223</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfa.2010.08.032</pub-id></element-citation></ref><ref id="B59-pharmaceutics-13-00143"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polshettiwar</surname><given-names>V.</given-names></name><name><surname>Cha</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Basset</surname><given-names>J.M.</given-names></name></person-group><article-title>High-Surface-Area Silica Nanospheres (KCC-1) with a Fibrous Morphology</article-title><source>Angew. Chem. Int. Ed.</source><year>2010</year><volume>49</volume><fpage>9652</fpage><lpage>9656</lpage><pub-id pub-id-type="doi">10.1002/anie.201003451</pub-id><?supplied-pmid 20680958?><pub-id pub-id-type="pmid">20680958</pub-id></element-citation></ref><ref id="B60-pharmaceutics-13-00143"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bayal</surname><given-names>N.</given-names></name><name><surname>Singh</surname><given-names>B.</given-names></name><name><surname>Singh</surname><given-names>R.</given-names></name><name><surname>Polshettiwar</surname><given-names>V.</given-names></name></person-group><article-title>Size and Fiber Density Controlled Synthesis of Fibrous Nanosilica Spheres (KCC-1)</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>24888</fpage><pub-id pub-id-type="doi">10.1038/srep24888</pub-id><?supplied-pmid 27118152?><pub-id pub-id-type="pmid">27118152</pub-id></element-citation></ref><ref id="B61-pharmaceutics-13-00143"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Qian</surname><given-names>Y.</given-names></name><name><surname>Ahn</surname><given-names>W.-S.</given-names></name></person-group><article-title>Catalytic dehydrogenation of formic acid over palladium nanoparticles immobilized on fibrous mesoporous silica KCC-1</article-title><source>Chin. J. Catal.</source><year>2019</year><volume>40</volume><fpage>1704</fpage><lpage>1712</lpage><pub-id pub-id-type="doi">10.1016/S1872-2067(19)63303-6</pub-id></element-citation></ref><ref id="B62-pharmaceutics-13-00143"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarei</surname><given-names>F.</given-names></name><name><surname>Marjani</surname><given-names>A.</given-names></name><name><surname>Soltani</surname><given-names>R.</given-names></name></person-group><article-title>Novel and green nanocomposite-based adsorbents from functionalised mesoporous KCC-1 and chitosan-oleic acid for adsorption of Pb(II)</article-title><source>Eur. Polym. J.</source><year>2019</year><volume>119</volume><fpage>400</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1016/j.eurpolymj.2019.07.043</pub-id></element-citation></ref><ref id="B63-pharmaceutics-13-00143"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soleymani</surname><given-names>J.</given-names></name><name><surname>Hasanzadeh</surname><given-names>M.</given-names></name><name><surname>Somi</surname><given-names>M.H.</given-names></name><name><surname>Shadjou</surname><given-names>N.</given-names></name><name><surname>Jouyban</surname><given-names>A.</given-names></name></person-group><article-title>Highly sensitive and specific cytosensing of HT 29 colorectal cancer cells using folic acid functionalized-KCC-1 nanoparticles</article-title><source>Biosens. Bioelectron.</source><year>2019</year><volume>132</volume><fpage>122</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.bios.2019.02.052</pub-id><pub-id pub-id-type="pmid">30870638</pub-id></element-citation></ref><ref id="B64-pharmaceutics-13-00143"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbasy</surname><given-names>L.</given-names></name><name><surname>Mohammadzadeh</surname><given-names>A.</given-names></name><name><surname>Hasanzadeh</surname><given-names>M.</given-names></name><name><surname>Ehsani</surname><given-names>M.</given-names></name><name><surname>Mokhtarzadeh</surname><given-names>A.</given-names></name></person-group><article-title>Biosensing of prostate specific antigen (PSA) in human plasma samples using biomacromolecule encapsulation into KCC-1-npr-NH2: A new platform for prostate cancer detection</article-title><source>Int. J. Biol. Macromol.</source><year>2020</year><volume>154</volume><fpage>584</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2020.03.093</pub-id><pub-id pub-id-type="pmid">32173432</pub-id></element-citation></ref><ref id="B65-pharmaceutics-13-00143"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>Z.</given-names></name><name><surname>Tian</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Ali</surname><given-names>N.</given-names></name><name><surname>Khan</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name></person-group><article-title>Immobilization of lipase on mesoporous silica nanoparticles with hierarchical fibrous pore</article-title><source>J. Mol. Catal. B Enzym.</source><year>2016</year><volume>134</volume><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.molcatb.2016.10.011</pub-id></element-citation></ref><ref id="B66-pharmaceutics-13-00143"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Follmann</surname><given-names>H.D.M.</given-names></name><name><surname>Oliveira</surname><given-names>O.N.</given-names></name><name><surname>Martins</surname><given-names>A.C.</given-names></name><name><surname>Lazarin-Bid&#x000f3;ia</surname><given-names>D.</given-names></name><name><surname>Nakamura</surname><given-names>C.V.</given-names></name><name><surname>Rubira</surname><given-names>A.F.</given-names></name><name><surname>Silva</surname><given-names>R.</given-names></name><name><surname>Asefa</surname><given-names>T.</given-names></name></person-group><article-title>Nanofibrous silica microparticles/polymer hybrid aerogels for sustained delivery of poorly water-soluble camptothecin</article-title><source>J. Colloid Interface Sci.</source><year>2020</year><volume>567</volume><fpage>92</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.jcis.2020.01.110</pub-id><?supplied-pmid 32036118?><pub-id pub-id-type="pmid">32036118</pub-id></element-citation></ref><ref id="B67-pharmaceutics-13-00143"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>P.</given-names></name></person-group><article-title>One-pot synthesis of primary amides on bifunctional Rh(OH)x/TS-1@KCC-1 catalysts</article-title><source>Chin. J. Catal.</source><year>2013</year><volume>34</volume><fpage>2057</fpage><lpage>2065</lpage><pub-id pub-id-type="doi">10.1016/S1872-2067(12)60670-6</pub-id></element-citation></ref><ref id="B68-pharmaceutics-13-00143"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>AbouAitah</surname><given-names>K.E.A.</given-names></name><name><surname>Farghali</surname><given-names>A.A.</given-names></name><name><surname>Swiderska-Sroda</surname><given-names>A.</given-names></name><name><surname>Lojkowski</surname><given-names>W.</given-names></name><name><surname>Razin</surname><given-names>A.M.</given-names></name></person-group><article-title>Mesoporous silica materials in drug delivery system: pH/glutathione-responsive release of poorly water-soluble pro-drug quercetin from two and three-dimensional pore-structure nanoparticles</article-title><source>J. Nanomed. Nanotechnol.</source><year>2016</year><fpage>7</fpage><pub-id pub-id-type="doi">10.4172/2157-7439.1000360</pub-id></element-citation></ref><ref id="B69-pharmaceutics-13-00143"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>AbouAitah</surname><given-names>K.E.A.</given-names></name><name><surname>Farghali</surname><given-names>A.A.</given-names></name><name><surname>Swiderska-Sroda</surname><given-names>A.</given-names></name><name><surname>Lojkowski</surname><given-names>W.</given-names></name><name><surname>Razin</surname><given-names>A.M.</given-names></name></person-group><article-title>pH-controlled release system for curcumin based on functionalized dendritic mesoporous silica nanoparticles</article-title><source>J. Nanomed. Nanotechnol.</source><year>2016</year><volume>7</volume><fpage>1</fpage><lpage>11</lpage></element-citation></ref><ref id="B70-pharmaceutics-13-00143"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J.</given-names></name><name><surname>Peng</surname><given-names>C.</given-names></name><name><surname>Ravi</surname><given-names>S.</given-names></name><name><surname>Siddiki</surname><given-names>A.K.M.N.A.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Balkus</surname><given-names>K.J.</given-names></name></person-group><article-title>Biphenyl Wrinkled Mesoporous Silica Nanoparticles for pH-Responsive Doxorubicin Drug Delivery</article-title><source>Materials</source><year>2020</year><volume>13</volume><elocation-id>1998</elocation-id><pub-id pub-id-type="doi">10.3390/ma13081998</pub-id></element-citation></ref><ref id="B71-pharmaceutics-13-00143"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>D.-S.</given-names></name><name><surname>Lee</surname><given-names>J.-K.</given-names></name></person-group><article-title>Tunable Synthesis of Hierarchical Mesoporous Silica Nanoparticles with Radial Wrinkle Structure</article-title><source>Langmuir</source><year>2012</year><volume>28</volume><fpage>12341</fpage><lpage>12347</lpage><pub-id pub-id-type="doi">10.1021/la302145j</pub-id><pub-id pub-id-type="pmid">22861383</pub-id></element-citation></ref><ref id="B72-pharmaceutics-13-00143"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Habib</surname><given-names>E.</given-names></name><name><surname>Zhu</surname><given-names>X.X.</given-names></name></person-group><article-title>Synthesis of wrinkled mesoporous silica and its reinforcing effect for dental resin composites</article-title><source>Dent. Mater.</source><year>2017</year><volume>33</volume><fpage>1139</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1016/j.dental.2017.07.012</pub-id><pub-id pub-id-type="pmid">28797746</pub-id></element-citation></ref><ref id="B73-pharmaceutics-13-00143"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maity</surname><given-names>A.</given-names></name><name><surname>Polshettiwar</surname><given-names>V.</given-names></name></person-group><article-title>Dendritic Fibrous Nanosilica for Catalysis, Energy Harvesting, Carbon Dioxide Mitigation, Drug Delivery, and Sensing</article-title><source>ChemSusChem</source><year>2017</year><volume>10</volume><fpage>3866</fpage><lpage>3913</lpage><pub-id pub-id-type="doi">10.1002/cssc.201701076</pub-id><pub-id pub-id-type="pmid">28834600</pub-id></element-citation></ref><ref id="B74-pharmaceutics-13-00143"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szcz&#x00119;&#x0015b;niak</surname><given-names>B.</given-names></name><name><surname>Choma</surname><given-names>J.</given-names></name><name><surname>Jaroniec</surname><given-names>M.</given-names></name></person-group><article-title>Major advances in the development of ordered mesoporous materials</article-title><source>Chem. Commun.</source><year>2020</year><volume>56</volume><fpage>7836</fpage><lpage>7848</lpage><pub-id pub-id-type="doi">10.1039/D0CC02840A</pub-id></element-citation></ref><ref id="B75-pharmaceutics-13-00143"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>C.</given-names></name><name><surname>Lei</surname><given-names>C.</given-names></name><name><surname>Yu</surname><given-names>C.</given-names></name></person-group><article-title>Mesoporous Silica Nanoparticles for Protein Protection and Delivery</article-title><source>Front. Chem.</source><year>2019</year><volume>7</volume><fpage>290</fpage><pub-id pub-id-type="doi">10.3389/fchem.2019.00290</pub-id><pub-id pub-id-type="pmid">31119124</pub-id></element-citation></ref><ref id="B76-pharmaceutics-13-00143"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douroumis</surname><given-names>D.</given-names></name><name><surname>Onyesom</surname><given-names>I.</given-names></name><name><surname>Maniruzzaman</surname><given-names>M.</given-names></name><name><surname>Mitchell</surname><given-names>J.</given-names></name></person-group><article-title>Mesoporous silica nanoparticles in nanotechnology</article-title><source>Crit. Rev. Biotechnol.</source><year>2013</year><volume>33</volume><fpage>229</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.3109/07388551.2012.685860</pub-id><pub-id pub-id-type="pmid">22724458</pub-id></element-citation></ref><ref id="B77-pharmaceutics-13-00143"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>S.-H.</given-names></name><name><surname>Mou</surname><given-names>C.-Y.</given-names></name><name><surname>Lin</surname><given-names>H.-P.</given-names></name></person-group><article-title>Synthesis of mesoporous silica nanoparticles</article-title><source>Chem. Soc. Rev.</source><year>2013</year><volume>42</volume><fpage>3862</fpage><lpage>3875</lpage><pub-id pub-id-type="doi">10.1039/c3cs35405a</pub-id><?supplied-pmid 23403864?><pub-id pub-id-type="pmid">23403864</pub-id></element-citation></ref><ref id="B78-pharmaceutics-13-00143"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farjadian</surname><given-names>F.</given-names></name><name><surname>Roointan</surname><given-names>A.</given-names></name><name><surname>Mohammadi-Samani</surname><given-names>S.</given-names></name><name><surname>Hosseini</surname><given-names>M.</given-names></name></person-group><article-title>Mesoporous silica nanoparticles: Synthesis, pharmaceutical applications, biodistribution, and biosafety assessment</article-title><source>Chem. Eng. J.</source><year>2019</year><volume>359</volume><fpage>684</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1016/j.cej.2018.11.156</pub-id></element-citation></ref><ref id="B79-pharmaceutics-13-00143"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castillo</surname><given-names>R.R.</given-names></name><name><surname>Lozano</surname><given-names>D.</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>B.</given-names></name><name><surname>Manzano</surname><given-names>M.</given-names></name><name><surname>Izquierdo-Barba</surname><given-names>I.</given-names></name><name><surname>Vallet-Reg&#x000ed;</surname><given-names>M.</given-names></name></person-group><article-title>Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: An update</article-title><source>Expert Opin. Drug Deliv.</source><year>2019</year><volume>16</volume><fpage>415</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1080/17425247.2019.1598375</pub-id><?supplied-pmid 30897978?><pub-id pub-id-type="pmid">30897978</pub-id></element-citation></ref><ref id="B80-pharmaceutics-13-00143"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paris</surname><given-names>J.L.</given-names></name><name><surname>Vallet-Reg&#x000ed;</surname><given-names>M.</given-names></name></person-group><article-title>Mesoporous Silica Nanoparticles for Co-Delivery of Drugs and Nucleic Acids in Oncology: A Review</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>526</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12060526</pub-id></element-citation></ref><ref id="B81-pharmaceutics-13-00143"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aquib</surname><given-names>M.</given-names></name><name><surname>Farooq</surname><given-names>M.A.</given-names></name><name><surname>Banerjee</surname><given-names>P.</given-names></name><name><surname>Akhtar</surname><given-names>F.</given-names></name><name><surname>Filli</surname><given-names>M.S.</given-names></name><name><surname>Boakye-Yiadom</surname><given-names>K.O.</given-names></name><name><surname>Kesse</surname><given-names>S.</given-names></name><name><surname>Raza</surname><given-names>F.</given-names></name><name><surname>Maviah</surname><given-names>M.B.J.</given-names></name><name><surname>Mavlyanova</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Targeted and stimuli&#x02013;responsive mesoporous silica nanoparticles for drug delivery and theranostic use</article-title><source>J. Biomed. Mater. Res. Part A</source><year>2019</year><volume>107</volume><fpage>2643</fpage><lpage>2666</lpage><pub-id pub-id-type="doi">10.1002/jbm.a.36770</pub-id></element-citation></ref><ref id="B82-pharmaceutics-13-00143"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadipour Moghaddam</surname><given-names>S.P.</given-names></name><name><surname>Mohammadpour</surname><given-names>R.</given-names></name><name><surname>Ghandehari</surname><given-names>H.</given-names></name></person-group><article-title>In vitro and in vivo evaluation of degradation, toxicity, biodistribution, and clearance of silica nanoparticles as a function of size, porosity, density, and composition</article-title><source>J. Control. Release</source><year>2019</year><volume>311&#x02013;312</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2019.08.028</pub-id></element-citation></ref><ref id="B83-pharmaceutics-13-00143"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Feng</surname><given-names>N.</given-names></name></person-group><article-title>Mesoporous silica nanoparticles: Synthesis, classification, drug loading, pharmacokinetics, biocompatibility, and application in drug delivery</article-title><source>Expert Opin. Drug Deliv.</source><year>2019</year><volume>16</volume><fpage>219</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1080/17425247.2019.1575806</pub-id><pub-id pub-id-type="pmid">30686075</pub-id></element-citation></ref><ref id="B84-pharmaceutics-13-00143"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieto</surname><given-names>A.</given-names></name><name><surname>Colilla</surname><given-names>M.</given-names></name><name><surname>Balas</surname><given-names>F.</given-names></name><name><surname>Vallet-Reg&#x000ed;</surname><given-names>M.</given-names></name></person-group><article-title>Surface Electrochemistry of Mesoporous Silicas as a Key Factor in the Design of Tailored Delivery Devices</article-title><source>Langmuir</source><year>2010</year><volume>26</volume><fpage>5038</fpage><lpage>5049</lpage><pub-id pub-id-type="doi">10.1021/la904820k</pub-id><pub-id pub-id-type="pmid">20222698</pub-id></element-citation></ref><ref id="B85-pharmaceutics-13-00143"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallet-Reg&#x000ed;</surname><given-names>M.</given-names></name><name><surname>Balas</surname><given-names>F.</given-names></name><name><surname>Arcos</surname><given-names>D.</given-names></name></person-group><article-title>Mesoporous Materials for Drug Delivery</article-title><source>Angew. Chem. Int. Ed.</source><year>2007</year><volume>46</volume><fpage>7548</fpage><lpage>7558</lpage><pub-id pub-id-type="doi">10.1002/anie.200604488</pub-id><?supplied-pmid 17854012?><pub-id pub-id-type="pmid">17854012</pub-id></element-citation></ref><ref id="B86-pharmaceutics-13-00143"><label>86.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rahikkala</surname><given-names>A.</given-names></name><name><surname>Rosenholm</surname><given-names>J.M.</given-names></name><name><surname>Santos</surname><given-names>H.A.</given-names></name></person-group><article-title>Chapter 16&#x02014;Biofunctionalized Mesoporous Silica Nanomaterials for Targeted Drug Delivery</article-title><source>Biomedical Applications of Functionalized Nanomaterials</source><person-group person-group-type="editor"><name><surname>Sarmento</surname><given-names>B.</given-names></name><name><surname>das Neves</surname><given-names>J.</given-names></name></person-group><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2018</year><fpage>489</fpage><lpage>520</lpage></element-citation></ref><ref id="B87-pharmaceutics-13-00143"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>A.</given-names></name><name><surname>Melde</surname><given-names>B.J.</given-names></name><name><surname>Schroden</surname><given-names>R.C.</given-names></name></person-group><article-title>Hybrid Inorganic&#x02013;Organic Mesoporous Silicates&#x02014;Nanoscopic Reactors Coming of Age</article-title><source>Adv. Mater.</source><year>2000</year><volume>12</volume><fpage>1403</fpage><lpage>1419</lpage><pub-id pub-id-type="doi">10.1002/1521-4095(200010)12:19&#x0003c;1403::AID-ADMA1403&#x0003e;3.0.CO;2-X</pub-id></element-citation></ref><ref id="B88-pharmaceutics-13-00143"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarn</surname><given-names>D.</given-names></name><name><surname>Ashley</surname><given-names>C.E.</given-names></name><name><surname>Xue</surname><given-names>M.</given-names></name><name><surname>Carnes</surname><given-names>E.C.</given-names></name><name><surname>Zink</surname><given-names>J.I.</given-names></name><name><surname>Brinker</surname><given-names>C.J.</given-names></name></person-group><article-title>Mesoporous Silica Nanoparticle Nanocarriers: Biofunctionality and Biocompatibility</article-title><source>Acc. Chem. Res.</source><year>2013</year><volume>46</volume><fpage>792</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1021/ar3000986</pub-id><?supplied-pmid 23387478?><pub-id pub-id-type="pmid">23387478</pub-id></element-citation></ref><ref id="B89-pharmaceutics-13-00143"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huh</surname><given-names>S.</given-names></name><name><surname>Wiench</surname><given-names>J.W.</given-names></name><name><surname>Yoo</surname><given-names>J.-C.</given-names></name><name><surname>Pruski</surname><given-names>M.</given-names></name><name><surname>Lin</surname><given-names>V.S.Y.</given-names></name></person-group><article-title>Organic Functionalization and Morphology Control of Mesoporous Silicas via a Co-Condensation Synthesis Method</article-title><source>Chem. Mater.</source><year>2003</year><volume>15</volume><fpage>4247</fpage><lpage>4256</lpage><pub-id pub-id-type="doi">10.1021/cm0210041</pub-id></element-citation></ref><ref id="B90-pharmaceutics-13-00143"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Liong</surname><given-names>M.</given-names></name><name><surname>Zink</surname><given-names>J.I.</given-names></name><name><surname>Tamanoi</surname><given-names>F.</given-names></name></person-group><article-title>Mesoporous Silica Nanoparticles as a Delivery System for Hydrophobic Anticancer Drugs</article-title><source>Small</source><year>2007</year><volume>3</volume><fpage>1341</fpage><lpage>1346</lpage><pub-id pub-id-type="doi">10.1002/smll.200700005</pub-id><?supplied-pmid 17566138?><pub-id pub-id-type="pmid">17566138</pub-id></element-citation></ref><ref id="B91-pharmaceutics-13-00143"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sayari</surname><given-names>A.</given-names></name><name><surname>Hamoudi</surname><given-names>S.</given-names></name></person-group><article-title>Periodic Mesoporous Silica-Based Organic&#x02212;Inorganic Nanocomposite Materials</article-title><source>Chem. Mater.</source><year>2001</year><volume>13</volume><fpage>3151</fpage><lpage>3168</lpage><pub-id pub-id-type="doi">10.1021/cm011039l</pub-id></element-citation></ref><ref id="B92-pharmaceutics-13-00143"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>S.-H.</given-names></name><name><surname>Hung</surname><given-names>Y.</given-names></name><name><surname>Mou</surname><given-names>C.-Y.</given-names></name></person-group><article-title>Mesoporous silica nanoparticles as nanocarriers</article-title><source>Chem. Commun.</source><year>2011</year><volume>47</volume><fpage>9972</fpage><lpage>9985</lpage><pub-id pub-id-type="doi">10.1039/c1cc11760b</pub-id><?supplied-pmid 21716992?><pub-id pub-id-type="pmid">21716992</pub-id></element-citation></ref><ref id="B93-pharmaceutics-13-00143"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manzanares</surname><given-names>D.</given-names></name><name><surname>Ce&#x000f1;a</surname><given-names>V.</given-names></name></person-group><article-title>Endocytosis: The Nanoparticle and Submicron Nanocompounds Gateway into the Cell</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>371</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12040371</pub-id></element-citation></ref><ref id="B94-pharmaceutics-13-00143"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kou</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Zhai</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>Z.</given-names></name></person-group><article-title>The endocytosis and intracellular fate of nanomedicines: Implication for rational design</article-title><source>Asian J. Pharm. Sci.</source><year>2013</year><volume>8</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.ajps.2013.07.001</pub-id></element-citation></ref><ref id="B95-pharmaceutics-13-00143"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borb&#x000e1;s</surname><given-names>E.</given-names></name><name><surname>Sink&#x000f3;</surname><given-names>B.</given-names></name><name><surname>Tsinman</surname><given-names>O.</given-names></name><name><surname>Tsinman</surname><given-names>K.</given-names></name><name><surname>Kiserdei</surname><given-names>&#x000c9;.</given-names></name><name><surname>D&#x000e9;muth</surname><given-names>B.</given-names></name><name><surname>Balogh</surname><given-names>A.</given-names></name><name><surname>Bod&#x000e1;k</surname><given-names>B.</given-names></name><name><surname>Domokos</surname><given-names>A.</given-names></name><name><surname>Darg&#x000f3;</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Investigation and Mathematical Description of the Real Driving Force of Passive Transport of Drug Molecules from Supersaturated Solutions</article-title><source>Mol. Pharm.</source><year>2016</year><volume>13</volume><fpage>3816</fpage><lpage>3826</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.6b00613</pub-id><pub-id pub-id-type="pmid">27611057</pub-id></element-citation></ref><ref id="B96-pharmaceutics-13-00143"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doherty</surname><given-names>G.J.</given-names></name><name><surname>McMahon</surname><given-names>H.T.</given-names></name></person-group><article-title>Mechanisms of Endocytosis</article-title><source>Annu. Rev. Biochem.</source><year>2009</year><volume>78</volume><fpage>857</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.78.081307.110540</pub-id><?supplied-pmid 19317650?><pub-id pub-id-type="pmid">19317650</pub-id></element-citation></ref><ref id="B97-pharmaceutics-13-00143"><label>97.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rewatkar</surname><given-names>P.</given-names></name><name><surname>Kumeria</surname><given-names>T.</given-names></name><name><surname>Popat</surname><given-names>A.</given-names></name></person-group><article-title>Chapter 5&#x02014;Size, shape and surface charge considerations of orally delivered nanomedicines</article-title><source>Nanotechnology for Oral Drug Delivery</source><person-group person-group-type="editor"><name><surname>Martins</surname><given-names>J.P.</given-names></name><name><surname>Santos</surname><given-names>H.A.</given-names></name></person-group><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2020</year><fpage>143</fpage><lpage>176</lpage></element-citation></ref><ref id="B98-pharmaceutics-13-00143"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>C.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Yin</surname><given-names>L.</given-names></name><name><surname>Tang</surname><given-names>C.</given-names></name><name><surname>Yin</surname><given-names>C.</given-names></name></person-group><article-title>Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles</article-title><source>Biomaterials</source><year>2010</year><volume>31</volume><fpage>3657</fpage><lpage>3666</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2010.01.065</pub-id><?supplied-pmid 20138662?><pub-id pub-id-type="pmid">20138662</pub-id></element-citation></ref><ref id="B99-pharmaceutics-13-00143"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMahon</surname><given-names>H.T.</given-names></name><name><surname>Boucrot</surname><given-names>E.</given-names></name></person-group><article-title>Molecular mechanism and physiological functions of clathrin-mediated endocytosis</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2011</year><volume>12</volume><fpage>517</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1038/nrm3151</pub-id><?supplied-pmid 21779028?><pub-id pub-id-type="pmid">21779028</pub-id></element-citation></ref><ref id="B100-pharmaceutics-13-00143"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahay</surname><given-names>G.</given-names></name><name><surname>Alakhova</surname><given-names>D.Y.</given-names></name><name><surname>Kabanov</surname><given-names>A.V.</given-names></name></person-group><article-title>Endocytosis of nanomedicines</article-title><source>J. Control. Release</source><year>2010</year><volume>145</volume><fpage>182</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2010.01.036</pub-id><pub-id pub-id-type="pmid">20226220</pub-id></element-citation></ref><ref id="B101-pharmaceutics-13-00143"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foroozandeh</surname><given-names>P.</given-names></name><name><surname>Aziz</surname><given-names>A.A.</given-names></name></person-group><article-title>Insight into Cellular Uptake and Intracellular Trafficking of Nanoparticles</article-title><source>Nanoscale Res. Lett.</source><year>2018</year><volume>13</volume><fpage>339</fpage><pub-id pub-id-type="doi">10.1186/s11671-018-2728-6</pub-id><pub-id pub-id-type="pmid">30361809</pub-id></element-citation></ref><ref id="B102-pharmaceutics-13-00143"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gustafson</surname><given-names>H.H.</given-names></name><name><surname>Holt-Casper</surname><given-names>D.</given-names></name><name><surname>Grainger</surname><given-names>D.W.</given-names></name><name><surname>Ghandehari</surname><given-names>H.</given-names></name></person-group><article-title>Nanoparticle Uptake: The Phagocyte Problem</article-title><source>Nano Today</source><year>2015</year><volume>10</volume><fpage>487</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1016/j.nantod.2015.06.006</pub-id><pub-id pub-id-type="pmid">26640510</pub-id></element-citation></ref><ref id="B103-pharmaceutics-13-00143"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>F.</given-names></name><name><surname>Wu</surname><given-names>S.-H.</given-names></name><name><surname>Hung</surname><given-names>Y.</given-names></name><name><surname>Mou</surname><given-names>C.-Y.</given-names></name></person-group><article-title>Size Effect on Cell Uptake in Well-Suspended, Uniform Mesoporous Silica Nanoparticles</article-title><source>Small</source><year>2009</year><volume>5</volume><fpage>1408</fpage><lpage>1413</lpage><pub-id pub-id-type="doi">10.1002/smll.200900005</pub-id><pub-id pub-id-type="pmid">19296554</pub-id></element-citation></ref><ref id="B104-pharmaceutics-13-00143"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gratton</surname><given-names>S.E.A.</given-names></name><name><surname>Ropp</surname><given-names>P.A.</given-names></name><name><surname>Pohlhaus</surname><given-names>P.D.</given-names></name><name><surname>Luft</surname><given-names>J.C.</given-names></name><name><surname>Madden</surname><given-names>V.J.</given-names></name><name><surname>Napier</surname><given-names>M.E.</given-names></name><name><surname>DeSimone</surname><given-names>J.M.</given-names></name></person-group><article-title>The effect of particle design on cellular internalization pathways</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>11613</fpage><lpage>11618</lpage><pub-id pub-id-type="doi">10.1073/pnas.0801763105</pub-id><pub-id pub-id-type="pmid">18697944</pub-id></element-citation></ref><ref id="B105-pharmaceutics-13-00143"><label>105.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Min</surname><given-names>Y.</given-names></name><name><surname>Akbulut</surname><given-names>M.</given-names></name><name><surname>Kristiansen</surname><given-names>K.</given-names></name><name><surname>Golan</surname><given-names>Y.</given-names></name><name><surname>Israelachvili</surname><given-names>J.</given-names></name></person-group><article-title>The role of interparticle and external forces in nanoparticle assembly</article-title><source>Nanoscience and Technology: A Collection of Reviews from Nature Journals</source><publisher-name>World Scientific</publisher-name><publisher-loc>Singapore</publisher-loc><year>2010</year><fpage>38</fpage><lpage>49</lpage></element-citation></ref><ref id="B106-pharmaceutics-13-00143"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Man</surname><given-names>N.</given-names></name><name><surname>Wen</surname><given-names>L.</given-names></name></person-group><article-title>C60 (Nd) nanoparticles enhance chemotherapeutic susceptibility of cancer cells by modulation of autophagy</article-title><source>Nanotechnology</source><year>2010</year><volume>21</volume><fpage>495101</fpage><pub-id pub-id-type="doi">10.1088/0957-4484/21/49/495101</pub-id><pub-id pub-id-type="pmid">21071824</pub-id></element-citation></ref><ref id="B107-pharmaceutics-13-00143"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Wengang</surname><given-names>L.</given-names></name><name><surname>Niveen</surname><given-names>M.K.</given-names></name></person-group><article-title>Stimuli responsive nanomaterials for controlled release applications</article-title><source>Nanotechnol. Rev.</source><year>2012</year><volume>1</volume><fpage>493</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1515/ntrev-2012-0033</pub-id></element-citation></ref><ref id="B108-pharmaceutics-13-00143"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behzadi</surname><given-names>S.</given-names></name><name><surname>Serpooshan</surname><given-names>V.</given-names></name><name><surname>Tao</surname><given-names>W.</given-names></name><name><surname>Hamaly</surname><given-names>M.A.</given-names></name><name><surname>Alkawareek</surname><given-names>M.Y.</given-names></name><name><surname>Dreaden</surname><given-names>E.C.</given-names></name><name><surname>Brown</surname><given-names>D.</given-names></name><name><surname>Alkilany</surname><given-names>A.M.</given-names></name><name><surname>Farokhzad</surname><given-names>O.C.</given-names></name><name><surname>Mahmoudi</surname><given-names>M.</given-names></name></person-group><article-title>Cellular uptake of nanoparticles: Journey inside the cell</article-title><source>Chem. Soc. Rev.</source><year>2017</year><volume>46</volume><fpage>4218</fpage><lpage>4244</lpage><pub-id pub-id-type="doi">10.1039/C6CS00636A</pub-id><?supplied-pmid 28585944?><pub-id pub-id-type="pmid">28585944</pub-id></element-citation></ref><ref id="B109-pharmaceutics-13-00143"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>A.K.</given-names></name><name><surname>Islam</surname><given-names>M.R.</given-names></name><name><surname>Choudhury</surname><given-names>Z.S.</given-names></name><name><surname>Mostafa</surname><given-names>A.</given-names></name><name><surname>Kadir</surname><given-names>M.F.</given-names></name></person-group><article-title>Nanotechnology based approaches in cancer therapeutics</article-title><source>Adv. Nat. Sci. Nanosci. Nanotechnol.</source><year>2014</year><volume>5</volume><fpage>043001</fpage><pub-id pub-id-type="doi">10.1088/2043-6262/5/4/043001</pub-id></element-citation></ref><ref id="B110-pharmaceutics-13-00143"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neuberger</surname><given-names>T.</given-names></name><name><surname>Sch&#x000f6;pf</surname><given-names>B.</given-names></name><name><surname>Hofmann</surname><given-names>H.</given-names></name><name><surname>Hofmann</surname><given-names>M.</given-names></name><name><surname>von Rechenberg</surname><given-names>B.</given-names></name></person-group><article-title>Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system</article-title><source>J. Magn. Magn. Mater.</source><year>2005</year><volume>293</volume><fpage>483</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1016/j.jmmm.2005.01.064</pub-id></element-citation></ref><ref id="B111-pharmaceutics-13-00143"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruyama</surname><given-names>K.</given-names></name></person-group><article-title>Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects</article-title><source>Adv. Drug Deliv. Rev.</source><year>2011</year><volume>63</volume><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2010.09.003</pub-id><pub-id pub-id-type="pmid">20869415</pub-id></element-citation></ref><ref id="B112-pharmaceutics-13-00143"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Sawa</surname><given-names>T.</given-names></name><name><surname>Matsumura</surname><given-names>Y.</given-names></name><name><surname>Hori</surname><given-names>K.</given-names></name></person-group><article-title>Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review</article-title><source>J. Control. Release</source><year>2000</year><volume>65</volume><fpage>271</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/S0168-3659(99)00248-5</pub-id><pub-id pub-id-type="pmid">10699287</pub-id></element-citation></ref><ref id="B113-pharmaceutics-13-00143"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddick</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Reinhard</surname><given-names>S.</given-names></name><name><surname>M&#x000f6;ller</surname><given-names>K.</given-names></name><name><surname>Engelke</surname><given-names>H.</given-names></name><name><surname>Wagner</surname><given-names>E.</given-names></name><name><surname>Bein</surname><given-names>T.</given-names></name></person-group><article-title>Particle-Size-Dependent Delivery of Antitumoral miRNA Using Targeted Mesoporous Silica Nanoparticles</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>505</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12060505</pub-id></element-citation></ref><ref id="B114-pharmaceutics-13-00143"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Karmakar</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>Mitter</surname><given-names>N.</given-names></name><name><surname>Yu</surname><given-names>C.</given-names></name></person-group><article-title>Synthesis of SBA-15 rods with small sizes for enhanced cellular uptake</article-title><source>J. Mater. Chem. B</source><year>2014</year><volume>2</volume><fpage>4929</fpage><lpage>4934</lpage><pub-id pub-id-type="doi">10.1039/C4TB00595C</pub-id><pub-id pub-id-type="pmid">32261785</pub-id></element-citation></ref><ref id="B115-pharmaceutics-13-00143"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>M.</given-names></name><name><surname>Nie</surname><given-names>G.</given-names></name><name><surname>Meng</surname><given-names>H.</given-names></name><name><surname>Xia</surname><given-names>T.</given-names></name><name><surname>Nel</surname><given-names>A.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>Physicochemical Properties Determine Nanomaterial Cellular Uptake, Transport, and Fate</article-title><source>Acc. Chem. Res.</source><year>2013</year><volume>46</volume><fpage>622</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1021/ar300031y</pub-id><pub-id pub-id-type="pmid">22891796</pub-id></element-citation></ref><ref id="B116-pharmaceutics-13-00143"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panariti</surname><given-names>A.</given-names></name><name><surname>Miserocchi</surname><given-names>G.</given-names></name><name><surname>Rivolta</surname><given-names>I.</given-names></name></person-group><article-title>The effect of nanoparticle uptake on cellular behavior: Disrupting or enabling functions?</article-title><source>Nanotechnol. Sci. Appl.</source><year>2012</year><volume>5</volume><fpage>87</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.2147/NSA.S25515</pub-id><pub-id pub-id-type="pmid">24198499</pub-id></element-citation></ref><ref id="B117-pharmaceutics-13-00143"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adjei</surname><given-names>I.M.</given-names></name><name><surname>Sharma</surname><given-names>B.</given-names></name><name><surname>Labhasetwar</surname><given-names>V.</given-names></name></person-group><article-title>Nanoparticles: Cellular uptake and cytotoxicity</article-title><source>Adv. Exp. Med. Biol</source><year>2014</year><volume>811</volume><fpage>73</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1007/978-94-017-8739-0_5</pub-id><pub-id pub-id-type="pmid">24683028</pub-id></element-citation></ref><ref id="B118-pharmaceutics-13-00143"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marano</surname><given-names>F.</given-names></name><name><surname>Hussain</surname><given-names>S.</given-names></name><name><surname>Rodrigues-Lima</surname><given-names>F.</given-names></name><name><surname>Baeza-Squiban</surname><given-names>A.</given-names></name><name><surname>Boland</surname><given-names>S.</given-names></name></person-group><article-title>Nanoparticles: Molecular targets and cell signalling</article-title><source>Arch. Toxicol.</source><year>2011</year><volume>85</volume><fpage>733</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1007/s00204-010-0546-4</pub-id><?supplied-pmid 20502881?><pub-id pub-id-type="pmid">20502881</pub-id></element-citation></ref><ref id="B119-pharmaceutics-13-00143"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fr&#x000f6;hlich</surname><given-names>E.</given-names></name></person-group><article-title>The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles</article-title><source>Int. J. Nanomed.</source><year>2012</year><volume>7</volume><fpage>5577</fpage><lpage>5591</lpage><pub-id pub-id-type="doi">10.2147/IJN.S36111</pub-id><?supplied-pmid 23144561?><pub-id pub-id-type="pmid">23144561</pub-id></element-citation></ref><ref id="B120-pharmaceutics-13-00143"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>T.M.</given-names></name><name><surname>Austin</surname><given-names>G.A.</given-names></name><name><surname>Chonn</surname><given-names>A.</given-names></name><name><surname>Lin</surname><given-names>L.</given-names></name><name><surname>Lee</surname><given-names>K.C.</given-names></name></person-group><article-title>Uptake of liposomes by cultured mouse bone marrow macrophages: Influence of liposome composition and size</article-title><source>Biochim. Biophys. Acta (BBA) Biomembr.</source><year>1991</year><volume>1061</volume><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/0005-2736(91)90268-D</pub-id></element-citation></ref><ref id="B121-pharmaceutics-13-00143"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arvizo</surname><given-names>R.R.</given-names></name><name><surname>Miranda</surname><given-names>O.R.</given-names></name><name><surname>Thompson</surname><given-names>M.A.</given-names></name><name><surname>Pabelick</surname><given-names>C.M.</given-names></name><name><surname>Bhattacharya</surname><given-names>R.</given-names></name><name><surname>Robertson</surname><given-names>J.D.</given-names></name><name><surname>Rotello</surname><given-names>V.M.</given-names></name><name><surname>Prakash</surname><given-names>Y.S.</given-names></name><name><surname>Mukherjee</surname><given-names>P.</given-names></name></person-group><article-title>Effect of Nanoparticle Surface Charge at the Plasma Membrane and Beyond</article-title><source>Nano Lett.</source><year>2010</year><volume>10</volume><fpage>2543</fpage><lpage>2548</lpage><pub-id pub-id-type="doi">10.1021/nl101140t</pub-id><pub-id pub-id-type="pmid">20533851</pub-id></element-citation></ref><ref id="B122-pharmaceutics-13-00143"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Bae</surname><given-names>S.C.</given-names></name><name><surname>Granick</surname><given-names>S.</given-names></name></person-group><article-title>Nanoparticle-induced surface reconstruction of phospholipid membranes</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>18171</fpage><lpage>18175</lpage><pub-id pub-id-type="doi">10.1073/pnas.0807296105</pub-id><pub-id pub-id-type="pmid">19011086</pub-id></element-citation></ref><ref id="B123-pharmaceutics-13-00143"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dausend</surname><given-names>J.</given-names></name><name><surname>Musyanovych</surname><given-names>A.</given-names></name><name><surname>Dass</surname><given-names>M.</given-names></name><name><surname>Walther</surname><given-names>P.</given-names></name><name><surname>Schrezenmeier</surname><given-names>H.</given-names></name><name><surname>Landfester</surname><given-names>K.</given-names></name><name><surname>Mail&#x000e4;nder</surname><given-names>V.</given-names></name></person-group><article-title>Uptake Mechanism of Oppositely Charged Fluorescent Nanoparticles in HeLa Cells</article-title><source>Macromol. Biosci.</source><year>2008</year><volume>8</volume><fpage>1135</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.1002/mabi.200800123</pub-id><pub-id pub-id-type="pmid">18698581</pub-id></element-citation></ref><ref id="B124-pharmaceutics-13-00143"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jambhrunkar</surname><given-names>S.</given-names></name><name><surname>Qu</surname><given-names>Z.</given-names></name><name><surname>Popat</surname><given-names>A.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Noonan</surname><given-names>O.</given-names></name><name><surname>Acauan</surname><given-names>L.</given-names></name><name><surname>Ahmad Nor</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>C.</given-names></name><name><surname>Karmakar</surname><given-names>S.</given-names></name></person-group><article-title>Effect of Surface Functionality of Silica Nanoparticles on Cellular Uptake and Cytotoxicity</article-title><source>Mol. Pharm.</source><year>2014</year><volume>11</volume><fpage>3642</fpage><lpage>3655</lpage><pub-id pub-id-type="doi">10.1021/mp500385n</pub-id><pub-id pub-id-type="pmid">25166282</pub-id></element-citation></ref><ref id="B125-pharmaceutics-13-00143"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baghirov</surname><given-names>H.</given-names></name><name><surname>Karaman</surname><given-names>D.</given-names></name><name><surname>Viitala</surname><given-names>T.</given-names></name><name><surname>Duchanoy</surname><given-names>A.</given-names></name><name><surname>Lou</surname><given-names>Y.-R.</given-names></name><name><surname>Mamaeva</surname><given-names>V.</given-names></name><name><surname>Pryazhnikov</surname><given-names>E.</given-names></name><name><surname>Khiroug</surname><given-names>L.</given-names></name><name><surname>de Lange Davies</surname><given-names>C.</given-names></name><name><surname>Sahlgren</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Feasibility Study of the Permeability and Uptake of Mesoporous Silica Nanoparticles across the Blood-Brain Barrier</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0160705</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0160705</pub-id><pub-id pub-id-type="pmid">27547955</pub-id></element-citation></ref><ref id="B126-pharmaceutics-13-00143"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trewyn</surname><given-names>B.G.</given-names></name><name><surname>Nieweg</surname><given-names>J.A.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Lin</surname><given-names>V.S.Y.</given-names></name></person-group><article-title>Biocompatible mesoporous silica nanoparticles with different morphologies for animal cell membrane penetration</article-title><source>Chem. Eng. J.</source><year>2008</year><volume>137</volume><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.cej.2007.09.045</pub-id></element-citation></ref><ref id="B127-pharmaceutics-13-00143"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Teng</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Tang</surname><given-names>F.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name></person-group><article-title>The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function</article-title><source>Biomaterials</source><year>2010</year><volume>31</volume><fpage>438</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2009.09.060</pub-id><pub-id pub-id-type="pmid">19800115</pub-id></element-citation></ref><ref id="B128-pharmaceutics-13-00143"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dias</surname><given-names>D.R.</given-names></name><name><surname>Moreira</surname><given-names>A.F.</given-names></name><name><surname>Correia</surname><given-names>I.J.</given-names></name></person-group><article-title>The effect of the shape of gold core&#x02013;mesoporous silica shell nanoparticles on the cellular behavior and tumor spheroid penetration</article-title><source>J. Mater. Chem. B</source><year>2016</year><volume>4</volume><fpage>7630</fpage><lpage>7640</lpage><pub-id pub-id-type="doi">10.1039/C6TB02668K</pub-id><?supplied-pmid 32263819?><pub-id pub-id-type="pmid">32263819</pub-id></element-citation></ref><ref id="B129-pharmaceutics-13-00143"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pada</surname><given-names>A.-K.</given-names></name><name><surname>Desai</surname><given-names>D.</given-names></name><name><surname>Sun</surname><given-names>K.</given-names></name><name><surname>Prakirth Govardhanam</surname><given-names>N.</given-names></name><name><surname>T&#x000f6;rnquist</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Rosenholm</surname><given-names>J.M.</given-names></name></person-group><article-title>Comparison of Polydopamine-Coated Mesoporous Silica Nanorods and Spheres for the Delivery of Hydrophilic and Hydrophobic Anticancer Drugs</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><elocation-id>3408</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20143408</pub-id><?supplied-pmid 31336697?><pub-id pub-id-type="pmid">31336697</pub-id></element-citation></ref><ref id="B130-pharmaceutics-13-00143"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>N.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Tang</surname><given-names>F.</given-names></name></person-group><article-title>Shape matters when engineering mesoporous silica-based nanomedicines</article-title><source>Biomater. Sci.</source><year>2016</year><volume>4</volume><fpage>575</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1039/C5BM00589B</pub-id><?supplied-pmid 26818852?><pub-id pub-id-type="pmid">26818852</pub-id></element-citation></ref><ref id="B131-pharmaceutics-13-00143"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name></person-group><article-title>Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery</article-title><source>Adv. Mater.</source><year>2012</year><volume>24</volume><fpage>1504</fpage><lpage>1534</lpage><pub-id pub-id-type="doi">10.1002/adma.201104763</pub-id><pub-id pub-id-type="pmid">22378538</pub-id></element-citation></ref><ref id="B132-pharmaceutics-13-00143"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niculescu</surname><given-names>V.-C.</given-names></name></person-group><article-title>Mesoporous Silica Nanoparticles for Bio-Applications</article-title><source>Front. Mater.</source><year>2020</year><fpage>7</fpage><pub-id pub-id-type="doi">10.3389/fmats.2020.00036</pub-id></element-citation></ref><ref id="B133-pharmaceutics-13-00143"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosseinpour</surname><given-names>S.</given-names></name><name><surname>Walsh</surname><given-names>L.J.</given-names></name><name><surname>Xu</surname><given-names>C.</given-names></name></person-group><article-title>Biomedical application of mesoporous silica nanoparticles as delivery systems: A biological safety perspective</article-title><source>J. Mater. Chem. B</source><year>2020</year><volume>8</volume><fpage>9863</fpage><lpage>9876</lpage><pub-id pub-id-type="doi">10.1039/D0TB01868F</pub-id><pub-id pub-id-type="pmid">33047764</pub-id></element-citation></ref><ref id="B134-pharmaceutics-13-00143"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trewyn</surname><given-names>B.G.</given-names></name><name><surname>Giri</surname><given-names>S.</given-names></name><name><surname>Slowing</surname><given-names>I.I.</given-names></name><name><surname>Lin</surname><given-names>V.S.Y.</given-names></name></person-group><article-title>Mesoporous silica nanoparticle based controlled release, drug delivery, and biosensor systems</article-title><source>Chem. Commun.</source><year>2007</year><fpage>3236</fpage><lpage>3245</lpage><pub-id pub-id-type="doi">10.1039/b701744h</pub-id></element-citation></ref><ref id="B135-pharmaceutics-13-00143"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manzano</surname><given-names>M.</given-names></name><name><surname>Colilla</surname><given-names>M.</given-names></name><name><surname>Vallet-Reg&#x000ed;</surname><given-names>M.</given-names></name></person-group><article-title>Drug delivery from ordered mesoporous matrices</article-title><source>Expert Opin Drug Deliv</source><year>2009</year><volume>6</volume><fpage>1383</fpage><lpage>1400</lpage><pub-id pub-id-type="doi">10.1517/17425240903304024</pub-id><pub-id pub-id-type="pmid">19941412</pub-id></element-citation></ref><ref id="B136-pharmaceutics-13-00143"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vivero-Escoto</surname><given-names>J.L.</given-names></name><name><surname>Slowing</surname><given-names>I.I.</given-names></name><name><surname>Trewyn</surname><given-names>B.G.</given-names></name><name><surname>Lin</surname><given-names>V.S.Y.</given-names></name></person-group><article-title>Mesoporous Silica Nanoparticles for Intracellular Controlled Drug Delivery</article-title><source>Small</source><year>2010</year><volume>6</volume><fpage>1952</fpage><lpage>1967</lpage><pub-id pub-id-type="doi">10.1002/smll.200901789</pub-id><pub-id pub-id-type="pmid">20690133</pub-id></element-citation></ref><ref id="B137-pharmaceutics-13-00143"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asefa</surname><given-names>T.</given-names></name><name><surname>Tao</surname><given-names>Z.</given-names></name></person-group><article-title>Biocompatibility of Mesoporous Silica Nanoparticles</article-title><source>Chem. Res. Toxicol.</source><year>2012</year><volume>25</volume><fpage>2265</fpage><lpage>2284</lpage><pub-id pub-id-type="doi">10.1021/tx300166u</pub-id><pub-id pub-id-type="pmid">22823891</pub-id></element-citation></ref><ref id="B138-pharmaceutics-13-00143"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.-H.</given-names></name><name><surname>Gu</surname><given-names>L.</given-names></name><name><surname>von Maltzahn</surname><given-names>G.</given-names></name><name><surname>Ruoslahti</surname><given-names>E.</given-names></name><name><surname>Bhatia</surname><given-names>S.N.</given-names></name><name><surname>Sailor</surname><given-names>M.J.</given-names></name></person-group><article-title>Biodegradable luminescent porous silicon nanoparticles for in vivo applications</article-title><source>Nat. Mater.</source><year>2009</year><volume>8</volume><fpage>331</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1038/nmat2398</pub-id><?supplied-pmid 19234444?><pub-id pub-id-type="pmid">19234444</pub-id></element-citation></ref><ref id="B139-pharmaceutics-13-00143"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudson</surname><given-names>S.P.</given-names></name><name><surname>Padera</surname><given-names>R.F.</given-names></name><name><surname>Langer</surname><given-names>R.</given-names></name><name><surname>Kohane</surname><given-names>D.S.</given-names></name></person-group><article-title>The biocompatibility of mesoporous silicates</article-title><source>Biomaterials</source><year>2008</year><volume>29</volume><fpage>4045</fpage><lpage>4055</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2008.07.007</pub-id><?supplied-pmid 18675454?><pub-id pub-id-type="pmid">18675454</pub-id></element-citation></ref><ref id="B140-pharmaceutics-13-00143"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yildirim</surname><given-names>A.</given-names></name><name><surname>Ozgur</surname><given-names>E.</given-names></name><name><surname>Bayindir</surname><given-names>M.</given-names></name></person-group><article-title>Impact of mesoporous silica nanoparticle surface functionality on hemolytic activity, thrombogenicity and non-specific protein adsorption</article-title><source>J. Mater. Chem. B</source><year>2013</year><volume>1</volume><fpage>1909</fpage><lpage>1920</lpage><pub-id pub-id-type="doi">10.1039/c3tb20139b</pub-id><?supplied-pmid 32260904?><pub-id pub-id-type="pmid">32260904</pub-id></element-citation></ref><ref id="B141-pharmaceutics-13-00143"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrido-Cano</surname><given-names>I.</given-names></name><name><surname>Candela-Noguera</surname><given-names>V.</given-names></name><name><surname>Herrera</surname><given-names>G.</given-names></name><name><surname>Cejalvo</surname><given-names>J.M.</given-names></name><name><surname>Lluch</surname><given-names>A.</given-names></name><name><surname>Marcos</surname><given-names>M.D.</given-names></name><name><surname>Sancenon</surname><given-names>F.</given-names></name><name><surname>Eroles</surname><given-names>P.</given-names></name><name><surname>Mart&#x000ed;nez-M&#x000e1;&#x000f1;ez</surname><given-names>R.</given-names></name></person-group><article-title>Biocompatibility and internalization assessment of bare and functionalised mesoporous silica nanoparticles</article-title><source>Microporous Mesoporous Mater.</source><year>2021</year><fpage>310</fpage><pub-id pub-id-type="doi">10.1016/j.micromeso.2020.110593</pub-id></element-citation></ref><ref id="B142-pharmaceutics-13-00143"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Gao</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name></person-group><article-title>In vivo Biodistribution and Urinary Excretion of Mesoporous Silica Nanoparticles: Effects of Particle Size and PEGylation</article-title><source>Small</source><year>2011</year><volume>7</volume><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1002/smll.201001459</pub-id><pub-id pub-id-type="pmid">21213393</pub-id></element-citation></ref><ref id="B143-pharmaceutics-13-00143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Hubbard</surname><given-names>D.</given-names></name><name><surname>Ray</surname><given-names>A.</given-names></name><name><surname>Ghandehari</surname><given-names>H.</given-names></name></person-group><article-title>In vivo biodistribution and pharmacokinetics of silica nanoparticles as a function of geometry, porosity and surface characteristics</article-title><source>J. Control. Release</source><year>2012</year><volume>163</volume><fpage>46</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2012.05.046</pub-id><pub-id pub-id-type="pmid">22684119</pub-id></element-citation></ref><ref id="B144-pharmaceutics-13-00143"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Fu</surname><given-names>C.</given-names></name><name><surname>Tan</surname><given-names>L.</given-names></name><name><surname>Meng</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name></person-group><article-title>Biodistribution, excretion, and toxicity of mesoporous silica nanoparticles after oral administration depend on their shape</article-title><source>Nanomed. Nanotechnol. Biol. Med.</source><year>2015</year><volume>11</volume><fpage>1915</fpage><lpage>1924</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2015.07.004</pub-id></element-citation></ref><ref id="B145-pharmaceutics-13-00143"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Ran</surname><given-names>F.</given-names></name><name><surname>Cui</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name></person-group><article-title>A comparison between sphere and rod nanoparticles regarding their in vivo biological behavior and pharmacokinetics</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>4131</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-03834-2</pub-id><pub-id pub-id-type="pmid">28646143</pub-id></element-citation></ref><ref id="B146-pharmaceutics-13-00143"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jan&#x000df;en</surname><given-names>H.C.</given-names></name><name><surname>Warwas</surname><given-names>D.P.</given-names></name><name><surname>Dahlhaus</surname><given-names>D.</given-names></name><name><surname>Mei&#x000df;ner</surname><given-names>J.</given-names></name><name><surname>Taptimthong</surname><given-names>P.</given-names></name><name><surname>Kietzmann</surname><given-names>M.</given-names></name><name><surname>Behrens</surname><given-names>P.</given-names></name><name><surname>Reifenrath</surname><given-names>J.</given-names></name><name><surname>Angrisani</surname><given-names>N.</given-names></name></person-group><article-title>In vitro and in vivo accumulation of magnetic nanoporous silica nanoparticles on implant materials with different magnetic properties</article-title><source>J. Nanobiotechnol.</source><year>2018</year><volume>16</volume><fpage>96</fpage><pub-id pub-id-type="doi">10.1186/s12951-018-0422-6</pub-id></element-citation></ref><ref id="B147-pharmaceutics-13-00143"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Wei</surname><given-names>M.</given-names></name></person-group><article-title>Evaluation of biomimetically synthesized mesoporous silica nanoparticles as drug carriers: Structure, wettability, degradation, biocompatibility and brain distribution</article-title><source>Mater. Sci. Eng. C</source><year>2019</year><volume>94</volume><fpage>453</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1016/j.msec.2018.09.053</pub-id></element-citation></ref><ref id="B148-pharmaceutics-13-00143"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>M.</given-names></name><name><surname>Cho</surname><given-names>W.-S.</given-names></name><name><surname>Choi</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>S.J.</given-names></name><name><surname>Han</surname><given-names>B.S.</given-names></name><name><surname>Kim</surname><given-names>S.H.</given-names></name><name><surname>Kim</surname><given-names>H.O.</given-names></name><name><surname>Sheen</surname><given-names>Y.Y.</given-names></name><name><surname>Jeong</surname><given-names>J.</given-names></name></person-group><article-title>The impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticles</article-title><source>Toxicol. Lett.</source><year>2009</year><volume>189</volume><fpage>177</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2009.04.017</pub-id><?supplied-pmid 19397964?><pub-id pub-id-type="pmid">19397964</pub-id></element-citation></ref><ref id="B149-pharmaceutics-13-00143"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hornung</surname><given-names>V.</given-names></name><name><surname>Bauernfeind</surname><given-names>F.</given-names></name><name><surname>Halle</surname><given-names>A.</given-names></name><name><surname>Samstad</surname><given-names>E.O.</given-names></name><name><surname>Kono</surname><given-names>H.</given-names></name><name><surname>Rock</surname><given-names>K.L.</given-names></name><name><surname>Fitzgerald</surname><given-names>K.A.</given-names></name><name><surname>Latz</surname><given-names>E.</given-names></name></person-group><article-title>Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization</article-title><source>Nat. Immunol.</source><year>2008</year><volume>9</volume><fpage>847</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1038/ni.1631</pub-id><?supplied-pmid 18604214?><pub-id pub-id-type="pmid">18604214</pub-id></element-citation></ref><ref id="B150-pharmaceutics-13-00143"><label>150.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>L.H.P.</given-names></name><name><surname>Handreck</surname><given-names>K.A.</given-names></name></person-group><article-title>Silica In Soils, Plants, and Animals</article-title><source>Advances in Agronomy</source><person-group person-group-type="editor"><name><surname>Norman</surname><given-names>A.G.</given-names></name></person-group><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>1967</year><volume>Volume 19</volume><fpage>107</fpage><lpage>149</lpage></element-citation></ref><ref id="B151-pharmaceutics-13-00143"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenholm</surname><given-names>J.M.</given-names></name><name><surname>Mamaeva</surname><given-names>V.</given-names></name><name><surname>Sahlgren</surname><given-names>C.</given-names></name><name><surname>Lind&#x000e9;n</surname><given-names>M.</given-names></name></person-group><article-title>Nanoparticles in targeted cancer therapy: Mesoporous silica nanoparticles entering preclinical development stage</article-title><source>Nanomedicine</source><year>2012</year><volume>7</volume><fpage>111</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.2217/nnm.11.166</pub-id><?supplied-pmid 22191780?><pub-id pub-id-type="pmid">22191780</pub-id></element-citation></ref><ref id="B152-pharmaceutics-13-00143"><label>152.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>K.R.</given-names></name></person-group><article-title>Silicon: The Health Benefits of a Metalloid</article-title><source>Interrelations between Essential Metal Ions and Human Diseases</source><person-group person-group-type="editor"><name><surname>Sigel</surname><given-names>A.</given-names></name><name><surname>Sigel</surname><given-names>H.</given-names></name><name><surname>Sigel</surname><given-names>R.K.O.</given-names></name></person-group><publisher-name>Springer</publisher-name><publisher-loc>Dordrecht, The Netherlands</publisher-loc><year>2013</year><fpage>451</fpage><lpage>473</lpage></element-citation></ref><ref id="B153-pharmaceutics-13-00143"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrlich</surname><given-names>H.</given-names></name><name><surname>Demadis</surname><given-names>K.D.</given-names></name><name><surname>Pokrovsky</surname><given-names>O.S.</given-names></name><name><surname>Koutsoukos</surname><given-names>P.G.</given-names></name></person-group><article-title>Modern Views on Desilicification: Biosilica and Abiotic Silica Dissolution in Natural and Artificial Environments</article-title><source>Chem. Rev.</source><year>2010</year><volume>110</volume><fpage>4656</fpage><lpage>4689</lpage><pub-id pub-id-type="doi">10.1021/cr900334y</pub-id><?supplied-pmid 20441201?><pub-id pub-id-type="pmid">20441201</pub-id></element-citation></ref><ref id="B154-pharmaceutics-13-00143"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>K.R.</given-names></name></person-group><article-title>The chemistry of silica and its potential health benefits</article-title><source>J. Nutr. Health Aging</source><year>2007</year><volume>11</volume><fpage>94</fpage><lpage>97</lpage><?supplied-pmid 17435951?><pub-id pub-id-type="pmid">17435951</pub-id></element-citation></ref><ref id="B155-pharmaceutics-13-00143"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croissant</surname><given-names>J.G.</given-names></name><name><surname>Fatieiev</surname><given-names>Y.</given-names></name><name><surname>Khashab</surname><given-names>N.M.</given-names></name></person-group><article-title>Degradability and Clearance of Silicon, Organosilica, Silsesquioxane, Silica Mixed Oxide, and Mesoporous Silica Nanoparticles</article-title><source>Adv. Mater.</source><year>2017</year><volume>29</volume><fpage>1604634</fpage><pub-id pub-id-type="doi">10.1002/adma.201604634</pub-id></element-citation></ref><ref id="B156-pharmaceutics-13-00143"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlisle</surname><given-names>E.M.</given-names></name></person-group><article-title>Silicon: A Possible Factor in Bone Calcification</article-title><source>Science</source><year>1970</year><volume>167</volume><fpage>279</fpage><pub-id pub-id-type="doi">10.1126/science.167.3916.279</pub-id><pub-id pub-id-type="pmid">5410261</pub-id></element-citation></ref><ref id="B157-pharmaceutics-13-00143"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jugdaohsingh</surname><given-names>R.</given-names></name></person-group><article-title>Silicon and bone health</article-title><source>J. Nutr Health Aging</source><year>2007</year><volume>11</volume><fpage>99</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">17435952</pub-id></element-citation></ref><ref id="B158-pharmaceutics-13-00143"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benezra</surname><given-names>M.</given-names></name><name><surname>Penate-Medina</surname><given-names>O.</given-names></name><name><surname>Zanzonico</surname><given-names>P.B.</given-names></name><name><surname>Schaer</surname><given-names>D.</given-names></name><name><surname>Ow</surname><given-names>H.</given-names></name><name><surname>Burns</surname><given-names>A.</given-names></name><name><surname>DeStanchina</surname><given-names>E.</given-names></name><name><surname>Longo</surname><given-names>V.</given-names></name><name><surname>Herz</surname><given-names>E.</given-names></name><name><surname>Iyer</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma</article-title><source>J. Clin. Investig.</source><year>2011</year><volume>121</volume><fpage>2768</fpage><lpage>2780</lpage><pub-id pub-id-type="doi">10.1172/JCI45600</pub-id><pub-id pub-id-type="pmid">21670497</pub-id></element-citation></ref><ref id="B159-pharmaceutics-13-00143"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quan</surname><given-names>G.</given-names></name><name><surname>Pan</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Dian</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name></person-group><article-title>Lactosaminated mesoporous silica nanoparticles for asialoglycoprotein receptor targeted anticancer drug delivery</article-title><source>J. Nanobiotechnol.</source><year>2015</year><volume>13</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/s12951-015-0068-6</pub-id></element-citation></ref><ref id="B160-pharmaceutics-13-00143"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napierska</surname><given-names>D.</given-names></name><name><surname>Thomassen</surname><given-names>L.C.J.</given-names></name><name><surname>Lison</surname><given-names>D.</given-names></name><name><surname>Martens</surname><given-names>J.A.</given-names></name><name><surname>Hoet</surname><given-names>P.H.</given-names></name></person-group><article-title>The nanosilica hazard: Another variable entity</article-title><source>Part. Fibre Toxicol.</source><year>2010</year><volume>7</volume><fpage>39</fpage><pub-id pub-id-type="doi">10.1186/1743-8977-7-39</pub-id><?supplied-pmid 21126379?><pub-id pub-id-type="pmid">21126379</pub-id></element-citation></ref><ref id="B161-pharmaceutics-13-00143"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Pasqua</surname><given-names>A.J.</given-names></name><name><surname>Sharma</surname><given-names>K.K.</given-names></name><name><surname>Shi</surname><given-names>Y.-L.</given-names></name><name><surname>Toms</surname><given-names>B.B.</given-names></name><name><surname>Ouellette</surname><given-names>W.</given-names></name><name><surname>Dabrowiak</surname><given-names>J.C.</given-names></name><name><surname>Asefa</surname><given-names>T.</given-names></name></person-group><article-title>Cytotoxicity of mesoporous silica nanomaterials</article-title><source>J. Inorg. Biochem.</source><year>2008</year><volume>102</volume><fpage>1416</fpage><lpage>1423</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2007.12.028</pub-id><?supplied-pmid 18279965?><pub-id pub-id-type="pmid">18279965</pub-id></element-citation></ref><ref id="B162-pharmaceutics-13-00143"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Yun</surname><given-names>H.-S.</given-names></name><name><surname>Kim</surname><given-names>S.-H.</given-names></name></person-group><article-title>The comparative effects of mesoporous silica nanoparticles and colloidal silica on inflammation and apoptosis</article-title><source>Biomaterials</source><year>2011</year><volume>32</volume><fpage>9434</fpage><lpage>9443</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2011.08.042</pub-id><?supplied-pmid 21889200?><pub-id pub-id-type="pmid">21889200</pub-id></element-citation></ref><ref id="B163-pharmaceutics-13-00143"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Jin</surname><given-names>M.</given-names></name><name><surname>Du</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Guo</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>P.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name></person-group><article-title>Size-dependent cytotoxicity of amorphous silica nanoparticles in human hepatoma HepG2 cells</article-title><source>Toxicol. In Vitro</source><year>2011</year><volume>25</volume><fpage>1343</fpage><lpage>1352</lpage><pub-id pub-id-type="doi">10.1016/j.tiv.2011.05.003</pub-id><pub-id pub-id-type="pmid">21575712</pub-id></element-citation></ref><ref id="B164-pharmaceutics-13-00143"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Teng</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Ren</surname><given-names>J.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Tang</surname><given-names>F.</given-names></name></person-group><article-title>Single and repeated dose toxicity of mesoporous hollow silica nanoparticles in intravenously exposed mice</article-title><source>Biomaterials</source><year>2011</year><volume>32</volume><fpage>1657</fpage><lpage>1668</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2010.10.035</pub-id><pub-id pub-id-type="pmid">21093905</pub-id></element-citation></ref><ref id="B165-pharmaceutics-13-00143"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>G.C.</given-names></name><name><surname>S&#x000e1;bio</surname><given-names>R.M.</given-names></name><name><surname>de C&#x000e1;ssia Ribeiro</surname><given-names>T.</given-names></name><name><surname>Monteiro</surname><given-names>A.S.</given-names></name><name><surname>Pereira</surname><given-names>D.V.</given-names></name><name><surname>Ribeiro</surname><given-names>S.J.L.</given-names></name><name><surname>Chorilli</surname><given-names>M.</given-names></name></person-group><article-title>Highlights in Mesoporous Silica Nanoparticles as a Multifunctional Controlled Drug Delivery Nanoplatform for Infectious Diseases Treatment</article-title><source>Pharm. Res.</source><year>2020</year><volume>37</volume><fpage>191</fpage><pub-id pub-id-type="doi">10.1007/s11095-020-02917-6</pub-id><pub-id pub-id-type="pmid">32895867</pub-id></element-citation></ref><ref id="B166-pharmaceutics-13-00143"><label>166.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Petushkov</surname><given-names>A.</given-names></name><name><surname>Ndiege</surname><given-names>N.</given-names></name><name><surname>Salem</surname><given-names>A.K.</given-names></name><name><surname>Larsen</surname><given-names>S.C.</given-names></name></person-group><article-title>Chapter 7&#x02014;Toxicity of Silica Nanomaterials: Zeolites, Mesoporous Silica, and Amorphous Silica Nanoparticles</article-title><source>Advances in Molecular Toxicology</source><person-group person-group-type="editor"><name><surname>Fishbein</surname><given-names>J.C.</given-names></name></person-group><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2010</year><volume>Volume 4</volume><fpage>223</fpage><lpage>266</lpage></element-citation></ref><ref id="B167-pharmaceutics-13-00143"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murugadoss</surname><given-names>S.</given-names></name><name><surname>Lison</surname><given-names>D.</given-names></name><name><surname>Godderis</surname><given-names>L.</given-names></name><name><surname>Van Den Brule</surname><given-names>S.</given-names></name><name><surname>Mast</surname><given-names>J.</given-names></name><name><surname>Brassinne</surname><given-names>F.</given-names></name><name><surname>Sebaihi</surname><given-names>N.</given-names></name><name><surname>Hoet</surname><given-names>P.H.</given-names></name></person-group><article-title>Toxicology of silica nanoparticles: An update</article-title><source>Arch. Toxicol.</source><year>2017</year><volume>91</volume><fpage>2967</fpage><lpage>3010</lpage><pub-id pub-id-type="doi">10.1007/s00204-017-1993-y</pub-id><pub-id pub-id-type="pmid">28573455</pub-id></element-citation></ref><ref id="B168-pharmaceutics-13-00143"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croissant</surname><given-names>J.G.</given-names></name><name><surname>Fatieiev</surname><given-names>Y.</given-names></name><name><surname>Almalik</surname><given-names>A.</given-names></name><name><surname>Khashab</surname><given-names>N.M.</given-names></name></person-group><article-title>Mesoporous Silica and Organosilica Nanoparticles: Physical Chemistry, Biosafety, Delivery Strategies, and Biomedical Applications</article-title><source>Adv. Healthc. Mater.</source><year>2018</year><volume>7</volume><fpage>1700831</fpage><pub-id pub-id-type="doi">10.1002/adhm.201700831</pub-id></element-citation></ref><ref id="B169-pharmaceutics-13-00143"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nash</surname><given-names>T.</given-names></name><name><surname>Allison</surname><given-names>A.C.</given-names></name><name><surname>Harington</surname><given-names>J.S.</given-names></name></person-group><article-title>Physico-Chemical Properties of Silica in Relation to its Toxicity</article-title><source>Nature</source><year>1966</year><volume>210</volume><fpage>259</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1038/210259a0</pub-id><pub-id pub-id-type="pmid">4289018</pub-id></element-citation></ref><ref id="B170-pharmaceutics-13-00143"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Dunphy</surname><given-names>D.R.</given-names></name><name><surname>Jiang</surname><given-names>X.</given-names></name><name><surname>Meng</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>B.</given-names></name><name><surname>Tarn</surname><given-names>D.</given-names></name><name><surname>Xue</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Lin</surname><given-names>S.</given-names></name><name><surname>Ji</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Processing Pathway Dependence of Amorphous Silica Nanoparticle Toxicity: Colloidal vs Pyrolytic</article-title><source>J. Am. Chem. Soc.</source><year>2012</year><volume>134</volume><fpage>15790</fpage><lpage>15804</lpage><pub-id pub-id-type="doi">10.1021/ja304907c</pub-id><pub-id pub-id-type="pmid">22924492</pub-id></element-citation></ref><ref id="B171-pharmaceutics-13-00143"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhavsar</surname><given-names>D.</given-names></name><name><surname>Patel</surname><given-names>V.</given-names></name><name><surname>Sawant</surname><given-names>K.</given-names></name></person-group><article-title>Systematic investigation of in vitro and in vivo safety, toxicity and degradation of mesoporous silica nanoparticles synthesized using commercial sodium silicate</article-title><source>Microporous Mesoporous Mater.</source><year>2019</year><volume>284</volume><fpage>343</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1016/j.micromeso.2019.04.050</pub-id></element-citation></ref><ref id="B172-pharmaceutics-13-00143"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rascol</surname><given-names>E.</given-names></name><name><surname>Daurat</surname><given-names>M.</given-names></name><name><surname>Da Silva</surname><given-names>A.</given-names></name><name><surname>Maynadier</surname><given-names>M.</given-names></name><name><surname>Dorandeu</surname><given-names>C.</given-names></name><name><surname>Charnay</surname><given-names>C.</given-names></name><name><surname>Garcia</surname><given-names>M.</given-names></name><name><surname>Lai-Kee-Him</surname><given-names>J.</given-names></name><name><surname>Bron</surname><given-names>P.</given-names></name><name><surname>Auffan</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Biological Fate of Fe3O4 Core-Shell Mesoporous Silica Nanoparticles Depending on Particle Surface Chemistry</article-title><source>Nanomaterials</source><year>2017</year><volume>7</volume><elocation-id>162</elocation-id><pub-id pub-id-type="doi">10.3390/nano7070162</pub-id></element-citation></ref><ref id="B173-pharmaceutics-13-00143"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rascol</surname><given-names>E.</given-names></name><name><surname>Pisani</surname><given-names>C.</given-names></name><name><surname>Dorandeu</surname><given-names>C.</given-names></name><name><surname>Nyalosaso</surname><given-names>J.L.</given-names></name><name><surname>Charnay</surname><given-names>C.</given-names></name><name><surname>Daurat</surname><given-names>M.</given-names></name><name><surname>Da Silva</surname><given-names>A.</given-names></name><name><surname>Devoisselle</surname><given-names>J.-M.</given-names></name><name><surname>Gaillard</surname><given-names>J.-C.</given-names></name><name><surname>Armengaud</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Biosafety of Mesoporous Silica Nanoparticles</article-title><source>Biomimetics</source><year>2018</year><volume>3</volume><elocation-id>22</elocation-id><pub-id pub-id-type="doi">10.3390/biomimetics3030022</pub-id></element-citation></ref><ref id="B174-pharmaceutics-13-00143"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasr</surname><given-names>S.S.</given-names></name><name><surname>Nasra</surname><given-names>M.M.A.</given-names></name><name><surname>Hazzah</surname><given-names>H.A.</given-names></name><name><surname>Abdallah</surname><given-names>O.Y.</given-names></name></person-group><article-title>Mesoporous silica nanoparticles, a safe option for silymarin delivery: Preparation, characterization, and in vivo evaluation</article-title><source>Drug Deliv. Transl. Res.</source><year>2019</year><volume>9</volume><fpage>968</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1007/s13346-019-00640-3</pub-id><?supplied-pmid 31001719?><pub-id pub-id-type="pmid">31001719</pub-id></element-citation></ref><ref id="B175-pharmaceutics-13-00143"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rawat</surname><given-names>N.</given-names></name><name><surname>Sandhya</surname></name><name><surname>Subaharan</surname><given-names>K.</given-names></name><name><surname>Eswaramoorthy</surname><given-names>M.</given-names></name><name><surname>Kaul</surname><given-names>G.</given-names></name></person-group><article-title>Comparative in vivo toxicity assessment places multiwalled carbon nanotubes at a higher level than mesoporous silica nanoparticles</article-title><source>Toxicol. Ind. Health</source><year>2016</year><volume>33</volume><fpage>182</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1177/0748233715622307</pub-id><?supplied-pmid 26818179?><pub-id pub-id-type="pmid">26818179</pub-id></element-citation></ref><ref id="B176-pharmaceutics-13-00143"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>M.S.</given-names></name><name><surname>Lee</surname><given-names>D.</given-names></name><name><surname>Kwon</surname><given-names>T.K.</given-names></name><name><surname>Khang</surname><given-names>D.</given-names></name><name><surname>Yun</surname><given-names>H.S.</given-names></name><name><surname>Kim</surname><given-names>S.H.</given-names></name></person-group><article-title>The comparative immunotoxicity of mesoporous silica nanoparticles and colloidal silica nanoparticles in mice</article-title><source>Int. J. Nanomed.</source><year>2013</year><volume>8</volume><fpage>147</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.2147/ijn.s39534</pub-id></element-citation></ref><ref id="B177-pharmaceutics-13-00143"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Limnell</surname><given-names>T.</given-names></name><name><surname>Santos</surname><given-names>H.A.</given-names></name><name><surname>M&#x000e4;kil&#x000e4;</surname><given-names>E.</given-names></name><name><surname>Heikkil&#x000e4;</surname><given-names>T.</given-names></name><name><surname>Salonen</surname><given-names>J.</given-names></name><name><surname>Murzin</surname><given-names>D.Y.</given-names></name><name><surname>Kumar</surname><given-names>N.</given-names></name><name><surname>Laaksonen</surname><given-names>T.</given-names></name><name><surname>Peltonen</surname><given-names>L.</given-names></name><name><surname>Hirvonen</surname><given-names>J.</given-names></name></person-group><article-title>Drug delivery formulations of ordered and nonordered mesoporous silica: Comparison of three drug loading methods</article-title><source>J. Pharm. Sci.</source><year>2011</year><volume>100</volume><fpage>3294</fpage><lpage>3306</lpage><pub-id pub-id-type="doi">10.1002/jps.22577</pub-id><?supplied-pmid 21520084?><pub-id pub-id-type="pmid">21520084</pub-id></element-citation></ref><ref id="B178-pharmaceutics-13-00143"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenholm</surname><given-names>J.M.</given-names></name><name><surname>Lind&#x000e9;n</surname><given-names>M.</given-names></name></person-group><article-title>Towards establishing structure-activity relationships for mesoporous silica in drug delivery applications</article-title><source>J. Control. Release</source><year>2008</year><volume>128</volume><fpage>157</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2008.02.013</pub-id><?supplied-pmid 18439699?><pub-id pub-id-type="pmid">18439699</pub-id></element-citation></ref><ref id="B179-pharmaceutics-13-00143"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Ji</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name></person-group><article-title>Mesoporous Silica-Coated Gold Nanorods as a Light-Mediated Multifunctional Theranostic Platform for Cancer Treatment</article-title><source>Adv. Mater.</source><year>2012</year><volume>24</volume><fpage>1418</fpage><lpage>1423</lpage><pub-id pub-id-type="doi">10.1002/adma.201104714</pub-id><?supplied-pmid 22318874?><pub-id pub-id-type="pmid">22318874</pub-id></element-citation></ref><ref id="B180-pharmaceutics-13-00143"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>She</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>He</surname><given-names>C.</given-names></name><name><surname>He</surname><given-names>L.</given-names></name><name><surname>Kong</surname><given-names>L.</given-names></name></person-group><article-title>Functionalization of Hollow Mesoporous Silica Nanoparticles for Improved 5-FU Loading</article-title><source>J. Nanomater.</source><year>2015</year><volume>2015</volume><fpage>872035</fpage><pub-id pub-id-type="doi">10.1155/2015/872035</pub-id></element-citation></ref><ref id="B181-pharmaceutics-13-00143"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doadrio</surname><given-names>J.C.</given-names></name><name><surname>Sousa</surname><given-names>E.M.B.</given-names></name><name><surname>Izquierdo-Barba</surname><given-names>I.</given-names></name><name><surname>Doadrio</surname><given-names>A.L.</given-names></name><name><surname>Perez-Pariente</surname><given-names>J.</given-names></name><name><surname>Vallet-Reg&#x000ed;</surname><given-names>M.</given-names></name></person-group><article-title>Functionalization of mesoporous materials with long alkyl chains as a strategy for controlling drug delivery pattern</article-title><source>J. Mater. Chem.</source><year>2006</year><volume>16</volume><fpage>462</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1039/B510101H</pub-id></element-citation></ref><ref id="B182-pharmaceutics-13-00143"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balas</surname><given-names>F.</given-names></name><name><surname>Manzano</surname><given-names>M.</given-names></name><name><surname>Horcajada</surname><given-names>P.</given-names></name><name><surname>Vallet-Reg&#x000ed;</surname><given-names>M.</given-names></name></person-group><article-title>Confinement and Controlled Release of Bisphosphonates on Ordered Mesoporous Silica-Based Materials</article-title><source>J. Am. Chem. Soc.</source><year>2006</year><volume>128</volume><fpage>8116</fpage><lpage>8117</lpage><pub-id pub-id-type="doi">10.1021/ja062286z</pub-id><?supplied-pmid 16787058?><pub-id pub-id-type="pmid">16787058</pub-id></element-citation></ref><ref id="B183-pharmaceutics-13-00143"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>A.H.</given-names></name><name><surname>Sm&#x000e5;tt</surname><given-names>J.-H.</given-names></name><name><surname>Govardhanam</surname><given-names>N.P.</given-names></name><name><surname>Ibrahim</surname><given-names>H.M.</given-names></name><name><surname>Ismael</surname><given-names>H.R.</given-names></name><name><surname>Afouna</surname><given-names>M.I.</given-names></name><name><surname>Samy</surname><given-names>A.M.</given-names></name><name><surname>Rosenholm</surname><given-names>J.M.</given-names></name></person-group><article-title>Formulation and optimization of drug-loaded mesoporous silica nanoparticle-based tablets to improve the dissolution rate of the poorly water-soluble drug silymarin</article-title><source>Eur. J. Pharm. Sci.</source><year>2020</year><volume>142</volume><fpage>105103</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2019.105103</pub-id><?supplied-pmid 31648050?><pub-id pub-id-type="pmid">31648050</pub-id></element-citation></ref><ref id="B184-pharmaceutics-13-00143"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>S.</given-names></name><name><surname>Long</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name></person-group><article-title>Mesoporous silica nanoparticles as potential carriers for enhanced drug solubility of paclitaxel</article-title><source>Mater. Sci. Eng. C</source><year>2017</year><volume>78</volume><fpage>12</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.msec.2017.04.049</pub-id><?supplied-pmid 28575958?><pub-id pub-id-type="pmid">28575958</pub-id></element-citation></ref><ref id="B185-pharmaceutics-13-00143"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Quan</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Niu</surname><given-names>B.</given-names></name><name><surname>Wu</surname><given-names>B.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Pan</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name></person-group><article-title>Mesoporous silica nanoparticles for drug and gene delivery</article-title><source>Acta Pharm. Sin. B</source><year>2018</year><volume>8</volume><fpage>165</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2018.01.007</pub-id><pub-id pub-id-type="pmid">29719777</pub-id></element-citation></ref><ref id="B186-pharmaceutics-13-00143"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>C.-A.</given-names></name><name><surname>Deng</surname><given-names>T.</given-names></name><name><surname>Lin</surname><given-names>F.-C.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Zink</surname><given-names>J.I.</given-names></name></person-group><article-title>Supramolecular Nanomachines as Stimuli-Responsive Gatekeepers on Mesoporous Silica Nanoparticles for Antibiotic and Cancer Drug Delivery</article-title><source>Theranostics</source><year>2019</year><volume>9</volume><fpage>3341</fpage><lpage>3364</lpage><pub-id pub-id-type="doi">10.7150/thno.34576</pub-id><pub-id pub-id-type="pmid">31244957</pub-id></element-citation></ref><ref id="B187-pharmaceutics-13-00143"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torney</surname><given-names>F.</given-names></name><name><surname>Trewyn</surname><given-names>B.G.</given-names></name><name><surname>Lin</surname><given-names>V.S.Y.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name></person-group><article-title>Mesoporous silica nanoparticles deliver DNA and chemicals into plants</article-title><source>Nat. Nanotechnol.</source><year>2007</year><volume>2</volume><fpage>295</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1038/nnano.2007.108</pub-id><pub-id pub-id-type="pmid">18654287</pub-id></element-citation></ref><ref id="B188-pharmaceutics-13-00143"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giri</surname><given-names>S.</given-names></name><name><surname>Trewyn</surname><given-names>B.G.</given-names></name><name><surname>Stellmaker</surname><given-names>M.P.</given-names></name><name><surname>Lin</surname><given-names>V.S.Y.</given-names></name></person-group><article-title>Stimuli-Responsive Controlled-Release Delivery System Based on Mesoporous Silica Nanorods Capped with Magnetic Nanoparticles</article-title><source>Angew. Chem. Int. Ed.</source><year>2005</year><volume>44</volume><fpage>5038</fpage><lpage>5044</lpage><pub-id pub-id-type="doi">10.1002/anie.200501819</pub-id></element-citation></ref><ref id="B189-pharmaceutics-13-00143"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slowing</surname><given-names>I.I.</given-names></name><name><surname>Vivero-Escoto</surname><given-names>J.L.</given-names></name><name><surname>Trewyn</surname><given-names>B.G.</given-names></name><name><surname>Lin</surname><given-names>V.S.Y.</given-names></name></person-group><article-title>Mesoporous silica nanoparticles: Structural design and applications</article-title><source>J. Mater. Chem.</source><year>2010</year><volume>20</volume><fpage>7924</fpage><lpage>7937</lpage><pub-id pub-id-type="doi">10.1039/c0jm00554a</pub-id></element-citation></ref><ref id="B190-pharmaceutics-13-00143"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>C.-Y.</given-names></name><name><surname>Trewyn</surname><given-names>B.G.</given-names></name><name><surname>Jeftinija</surname><given-names>D.M.</given-names></name><name><surname>Jeftinija</surname><given-names>K.</given-names></name><name><surname>Xu</surname><given-names>S.</given-names></name><name><surname>Jeftinija</surname><given-names>S.</given-names></name><name><surname>Lin</surname><given-names>V.S.Y.</given-names></name></person-group><article-title>A Mesoporous Silica Nanosphere-Based Carrier System with Chemically Removable CdS Nanoparticle Caps for Stimuli-Responsive Controlled Release of Neurotransmitters and Drug Molecules</article-title><source>J. Am. Chem. Soc.</source><year>2003</year><volume>125</volume><fpage>4451</fpage><lpage>4459</lpage><pub-id pub-id-type="doi">10.1021/ja028650l</pub-id><pub-id pub-id-type="pmid">12683815</pub-id></element-citation></ref><ref id="B191-pharmaceutics-13-00143"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>B.</given-names></name><name><surname>Sha</surname><given-names>X.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>W.</given-names></name></person-group><article-title>Thermo and pH dual responsive, polymer shell coated, magnetic mesoporous silica nanoparticles for controlled drug release</article-title><source>J. Mater. Chem.</source><year>2011</year><volume>21</volume><fpage>9239</fpage><lpage>9247</lpage><pub-id pub-id-type="doi">10.1039/c1jm10631g</pub-id></element-citation></ref><ref id="B192-pharmaceutics-13-00143"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Sha</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>W.</given-names></name></person-group><article-title>Bioresponsive Controlled Drug Release Based on Mesoporous Silica Nanoparticles Coated with Reductively Sheddable Polymer Shell</article-title><source>Chem. Mater.</source><year>2013</year><volume>25</volume><fpage>574</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1021/cm3037197</pub-id></element-citation></ref><ref id="B193-pharmaceutics-13-00143"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croissant</surname><given-names>J.G.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Alsaiari</surname><given-names>S.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Deng</surname><given-names>L.</given-names></name><name><surname>Tamanoi</surname><given-names>F.</given-names></name><name><surname>AlMalik</surname><given-names>A.M.</given-names></name><name><surname>Zink</surname><given-names>J.I.</given-names></name><name><surname>Khashab</surname><given-names>N.M.</given-names></name></person-group><article-title>Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging</article-title><source>J. Control. Release</source><year>2016</year><volume>229</volume><fpage>183</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2016.03.030</pub-id><?supplied-pmid 27016140?><pub-id pub-id-type="pmid">27016140</pub-id></element-citation></ref><ref id="B194-pharmaceutics-13-00143"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saleh</surname><given-names>T.</given-names></name><name><surname>Soudi</surname><given-names>T.</given-names></name><name><surname>Shojaosadati</surname><given-names>S.A.</given-names></name></person-group><article-title>Aptamer functionalized curcumin-loaded human serum albumin (HSA) nanoparticles for targeted delivery to HER-2 positive breast cancer cells</article-title><source>Int. J. Biol. Macromol.</source><year>2019</year><volume>130</volume><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2019.02.129</pub-id><pub-id pub-id-type="pmid">30802519</pub-id></element-citation></ref><ref id="B195-pharmaceutics-13-00143"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iraji</surname><given-names>S.</given-names></name><name><surname>Ganji</surname><given-names>F.</given-names></name><name><surname>Rashidi</surname><given-names>L.</given-names></name></person-group><article-title>Surface modified mesoporous silica nanoparticles as sustained-release gallic acid nano-carriers</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2018</year><volume>47</volume><fpage>468</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1016/j.jddst.2018.08.008</pub-id></element-citation></ref><ref id="B196-pharmaceutics-13-00143"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma&#x02019;mani</surname><given-names>L.</given-names></name><name><surname>Nikzad</surname><given-names>S.</given-names></name><name><surname>Kheiri-Manjili</surname><given-names>H.</given-names></name><name><surname>Al-Musawi</surname><given-names>S.</given-names></name><name><surname>Saeedi</surname><given-names>M.</given-names></name><name><surname>Askarlou</surname><given-names>S.</given-names></name><name><surname>Foroumadi</surname><given-names>A.</given-names></name><name><surname>Shafiee</surname><given-names>A.</given-names></name></person-group><article-title>Curcumin-loaded guanidine functionalized PEGylated I3ad mesoporous silica nanoparticles KIT-6: Practical strategy for the breast cancer therapy</article-title><source>Eur. J. Med. Chem.</source><year>2014</year><volume>83</volume><fpage>646</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2014.06.069</pub-id><pub-id pub-id-type="pmid">25014638</pub-id></element-citation></ref><ref id="B197-pharmaceutics-13-00143"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szegedi</surname><given-names>&#x000c1;.</given-names></name><name><surname>Shestakova</surname><given-names>P.</given-names></name><name><surname>Trendafilova</surname><given-names>I.</given-names></name><name><surname>Mihayi</surname><given-names>J.</given-names></name><name><surname>Tsacheva</surname><given-names>I.</given-names></name><name><surname>Mitova</surname><given-names>V.</given-names></name><name><surname>Kyulavska</surname><given-names>M.</given-names></name><name><surname>Koseva</surname><given-names>N.</given-names></name><name><surname>Momekova</surname><given-names>D.</given-names></name><name><surname>Konstantinov</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Modified mesoporous silica nanoparticles coated by polymer complex as novel curcumin delivery carriers</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2019</year><volume>49</volume><fpage>700</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1016/j.jddst.2018.12.016</pub-id></element-citation></ref><ref id="B198-pharmaceutics-13-00143"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sattary</surname><given-names>M.</given-names></name><name><surname>Amini</surname><given-names>J.</given-names></name><name><surname>Hallaj</surname><given-names>R.</given-names></name></person-group><article-title>Antifungal activity of the lemongrass and clove oil encapsulated in mesoporous silica nanoparticles against wheat&#x02019;s take-all disease</article-title><source>Pestic. Biochem. Physiol.</source><year>2020</year><volume>170</volume><fpage>104696</fpage><pub-id pub-id-type="doi">10.1016/j.pestbp.2020.104696</pub-id><pub-id pub-id-type="pmid">32980050</pub-id></element-citation></ref><ref id="B199-pharmaceutics-13-00143"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>B.</given-names></name><name><surname>Du</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Ai</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name></person-group><article-title>Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC)</article-title><source>Biomed. Pharmacother.</source><year>2020</year><volume>125</volume><fpage>109561</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2019.109561</pub-id><pub-id pub-id-type="pmid">32106385</pub-id></element-citation></ref><ref id="B200-pharmaceutics-13-00143"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Fan</surname><given-names>L.</given-names></name><name><surname>Lin</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Shao</surname><given-names>J.</given-names></name></person-group><article-title>pH-Sensitive mesoporous silica nanoparticles anticancer prodrugs for sustained release of ursolic acid and the enhanced anti-cancer efficacy for hepatocellular carcinoma cancer</article-title><source>Eur. J. Pharm. Sci.</source><year>2017</year><volume>96</volume><fpage>456</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2016.10.019</pub-id><pub-id pub-id-type="pmid">27771513</pub-id></element-citation></ref><ref id="B201-pharmaceutics-13-00143"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lungare</surname><given-names>S.</given-names></name><name><surname>Hallam</surname><given-names>K.</given-names></name><name><surname>Badhan</surname><given-names>R.K.S.</given-names></name></person-group><article-title>Phytochemical-loaded mesoporous silica nanoparticles for nose-to-brain olfactory drug delivery</article-title><source>Int. J. Pharm.</source><year>2016</year><volume>513</volume><fpage>280</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2016.09.042</pub-id><?supplied-pmid 27633279?><pub-id pub-id-type="pmid">27633279</pub-id></element-citation></ref><ref id="B202-pharmaceutics-13-00143"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sapino</surname><given-names>S.</given-names></name><name><surname>Ugazio</surname><given-names>E.</given-names></name><name><surname>Gastaldi</surname><given-names>L.</given-names></name><name><surname>Miletto</surname><given-names>I.</given-names></name><name><surname>Berlier</surname><given-names>G.</given-names></name><name><surname>Zonari</surname><given-names>D.</given-names></name><name><surname>Oliaro-Bosso</surname><given-names>S.</given-names></name></person-group><article-title>Mesoporous silica as topical nanocarriers for quercetin: Characterization and in vitro studies</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2015</year><volume>89</volume><fpage>116</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2014.11.022</pub-id><pub-id pub-id-type="pmid">25478737</pub-id></element-citation></ref><ref id="B203-pharmaceutics-13-00143"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kundu</surname><given-names>M.</given-names></name><name><surname>Chatterjee</surname><given-names>S.</given-names></name><name><surname>Ghosh</surname><given-names>N.</given-names></name><name><surname>Manna</surname><given-names>P.</given-names></name><name><surname>Das</surname><given-names>J.</given-names></name><name><surname>Sil</surname><given-names>P.C.</given-names></name></person-group><article-title>Tumor targeted delivery of umbelliferone via a smart mesoporous silica nanoparticles controlled-release drug delivery system for increased anticancer efficiency</article-title><source>Mater. Sci. Eng. C</source><year>2020</year><volume>116</volume><fpage>111239</fpage><pub-id pub-id-type="doi">10.1016/j.msec.2020.111239</pub-id></element-citation></ref><ref id="B204-pharmaceutics-13-00143"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Q.</given-names></name><name><surname>Wu</surname><given-names>B.</given-names></name><name><surname>Shang</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Dong</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Gui</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>Development of a nano-drug delivery system based on mesoporous silica and its anti-lymphoma activity</article-title><source>Appl. Nanosci.</source><year>2020</year><volume>10</volume><fpage>3431</fpage><lpage>3442</lpage><pub-id pub-id-type="doi">10.1007/s13204-020-01465-0</pub-id></element-citation></ref><ref id="B205-pharmaceutics-13-00143"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angelos</surname><given-names>S.</given-names></name><name><surname>Khashab</surname><given-names>N.M.</given-names></name><name><surname>Yang</surname><given-names>Y.-W.</given-names></name><name><surname>Trabolsi</surname><given-names>A.</given-names></name><name><surname>Khatib</surname><given-names>H.A.</given-names></name><name><surname>Stoddart</surname><given-names>J.F.</given-names></name><name><surname>Zink</surname><given-names>J.I.</given-names></name></person-group><article-title>pH Clock-Operated Mechanized Nanoparticles</article-title><source>J. Am. Chem. Soc.</source><year>2009</year><volume>131</volume><fpage>12912</fpage><lpage>12914</lpage><pub-id pub-id-type="doi">10.1021/ja9010157</pub-id><?supplied-pmid 19705840?><pub-id pub-id-type="pmid">19705840</pub-id></element-citation></ref><ref id="B206-pharmaceutics-13-00143"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>K.</given-names></name><name><surname>Angelos</surname><given-names>S.</given-names></name><name><surname>Dichtel</surname><given-names>W.R.</given-names></name><name><surname>Coskun</surname><given-names>A.</given-names></name><name><surname>Yang</surname><given-names>Y.-W.</given-names></name><name><surname>Zink</surname><given-names>J.I.</given-names></name><name><surname>Stoddart</surname><given-names>J.F.</given-names></name></person-group><article-title>Enzyme-Responsive Snap-Top Covered Silica Nanocontainers</article-title><source>J. Am. Chem. Soc.</source><year>2008</year><volume>130</volume><fpage>2382</fpage><lpage>2383</lpage><pub-id pub-id-type="doi">10.1021/ja0772086</pub-id><?supplied-pmid 18232687?><pub-id pub-id-type="pmid">18232687</pub-id></element-citation></ref><ref id="B207-pharmaceutics-13-00143"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>R.</given-names></name><name><surname>Tseng</surname><given-names>H.-R.</given-names></name><name><surname>Wong</surname><given-names>J.W.</given-names></name><name><surname>Stoddart</surname><given-names>J.F.</given-names></name><name><surname>Zink</surname><given-names>J.I.</given-names></name></person-group><article-title>An Operational Supramolecular Nanovalve</article-title><source>J. Am. Chem. Soc.</source><year>2004</year><volume>126</volume><fpage>3370</fpage><lpage>3371</lpage><pub-id pub-id-type="doi">10.1021/ja039424u</pub-id><pub-id pub-id-type="pmid">15025433</pub-id></element-citation></ref><ref id="B208-pharmaceutics-13-00143"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angelos</surname><given-names>S.</given-names></name><name><surname>Johansson</surname><given-names>E.</given-names></name><name><surname>Stoddart</surname><given-names>J.F.</given-names></name><name><surname>Zink</surname><given-names>J.I.</given-names></name></person-group><article-title>Mesostructured Silica Supports for Functional Materials and Molecular Machines</article-title><source>Adv. Funct. Mater.</source><year>2007</year><volume>17</volume><fpage>2261</fpage><lpage>2271</lpage><pub-id pub-id-type="doi">10.1002/adfm.200601217</pub-id></element-citation></ref><ref id="B209-pharmaceutics-13-00143"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khashab</surname><given-names>N.M.</given-names></name><name><surname>Belowich</surname><given-names>M.E.</given-names></name><name><surname>Trabolsi</surname><given-names>A.</given-names></name><name><surname>Friedman</surname><given-names>D.C.</given-names></name><name><surname>Valente</surname><given-names>C.</given-names></name><name><surname>Lau</surname><given-names>Y.</given-names></name><name><surname>Khatib</surname><given-names>H.A.</given-names></name><name><surname>Zink</surname><given-names>J.I.</given-names></name><name><surname>Stoddart</surname><given-names>J.F.</given-names></name></person-group><article-title>pH-Responsive mechanised nanoparticles gated by semirotaxanes</article-title><source>Chem. Commun.</source><year>2009</year><fpage>5371</fpage><lpage>5373</lpage><pub-id pub-id-type="doi">10.1039/b910431c</pub-id></element-citation></ref><ref id="B210-pharmaceutics-13-00143"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croissant</surname><given-names>J.</given-names></name><name><surname>Zink</surname><given-names>J.I.</given-names></name></person-group><article-title>Nanovalve-Controlled Cargo Release Activated by Plasmonic Heating</article-title><source>J. Am. Chem. Soc.</source><year>2012</year><volume>134</volume><fpage>7628</fpage><lpage>7631</lpage><pub-id pub-id-type="doi">10.1021/ja301880x</pub-id><pub-id pub-id-type="pmid">22540671</pub-id></element-citation></ref><ref id="B211-pharmaceutics-13-00143"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croissant</surname><given-names>J.</given-names></name><name><surname>Chaix</surname><given-names>A.</given-names></name><name><surname>Mongin</surname><given-names>O.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Cl&#x000e9;ment</surname><given-names>S.</given-names></name><name><surname>Raehm</surname><given-names>L.</given-names></name><name><surname>Durand</surname><given-names>J.-O.</given-names></name><name><surname>Hugues</surname><given-names>V.</given-names></name><name><surname>Blanchard-Desce</surname><given-names>M.</given-names></name><name><surname>Maynadier</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Two-Photon-Triggered Drug Delivery via Fluorescent Nanovalves</article-title><source>Small</source><year>2014</year><volume>10</volume><fpage>1752</fpage><lpage>1755</lpage><pub-id pub-id-type="doi">10.1002/smll.201400042</pub-id><?supplied-pmid 24678053?><pub-id pub-id-type="pmid">24678053</pub-id></element-citation></ref><ref id="B212-pharmaceutics-13-00143"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambrogio</surname><given-names>M.W.</given-names></name><name><surname>Thomas</surname><given-names>C.R.</given-names></name><name><surname>Zhao</surname><given-names>Y.-L.</given-names></name><name><surname>Zink</surname><given-names>J.I.</given-names></name><name><surname>Stoddart</surname><given-names>J.F.</given-names></name></person-group><article-title>Mechanized Silica Nanoparticles: A New Frontier in Theranostic Nanomedicine</article-title><source>Acc. Chem. Res.</source><year>2011</year><volume>44</volume><fpage>903</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1021/ar200018x</pub-id><?supplied-pmid 21675720?><pub-id pub-id-type="pmid">21675720</pub-id></element-citation></ref><ref id="B213-pharmaceutics-13-00143"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>Q.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Yuan</surname><given-names>Y.</given-names></name><name><surname>Qian</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name></person-group><article-title>A magnetic, reversible pH-responsive nanogated ensemble based on Fe3O4 nanoparticles-capped mesoporous silica</article-title><source>Biomaterials</source><year>2011</year><volume>32</volume><fpage>1932</fpage><lpage>1942</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2010.11.020</pub-id><?supplied-pmid 21131045?><pub-id pub-id-type="pmid">21131045</pub-id></element-citation></ref><ref id="B214-pharmaceutics-13-00143"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Agarwal</surname><given-names>A.</given-names></name><name><surname>Mueller</surname><given-names>L.J.</given-names></name><name><surname>Feng</surname><given-names>P.</given-names></name></person-group><article-title>pH-responsive nanogated ensemble based on gold-capped mesoporous silica through an acid-labile acetal linker</article-title><source>J. Am. Chem. Soc.</source><year>2010</year><volume>132</volume><fpage>1500</fpage><lpage>1501</lpage><pub-id pub-id-type="doi">10.1021/ja907838s</pub-id><pub-id pub-id-type="pmid">20085351</pub-id></element-citation></ref><ref id="B215-pharmaceutics-13-00143"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Liao</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Qi</surname><given-names>X.</given-names></name><name><surname>Qian</surname><given-names>Y.</given-names></name><name><surname>Fenniri</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>P.</given-names></name><name><surname>Shen</surname><given-names>J.</given-names></name></person-group><article-title>Zinc oxide end-capped Fe(3)O(4)@mSiO(2) core-shell nanocarriers as targeted and responsive drug delivery system for chemo-/ions synergistic therapeutics</article-title><source>Drug Deliv.</source><year>2019</year><volume>26</volume><fpage>732</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1080/10717544.2019.1642419</pub-id><pub-id pub-id-type="pmid">31340678</pub-id></element-citation></ref><ref id="B216-pharmaceutics-13-00143"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M.C.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>X.L.</given-names></name><name><surname>Lin</surname><given-names>H.C.</given-names></name><name><surname>Sun</surname><given-names>X.Y.</given-names></name><name><surname>Lu</surname><given-names>J.Z.</given-names></name><name><surname>Li</surname><given-names>Y.Y.</given-names></name><name><surname>Yan</surname><given-names>S.Q.</given-names></name><name><surname>Zhang</surname><given-names>L.Y.</given-names></name><name><surname>Zhao</surname><given-names>P.</given-names></name></person-group><article-title>Calcium carbonate end-capped, folate-mediated Fe(3)O(4)@mSiO(2) core-shell nanocarriers as targeted controlled-release drug delivery system</article-title><source>J. Biomater. Appl.</source><year>2018</year><volume>32</volume><fpage>1090</fpage><lpage>1104</lpage><pub-id pub-id-type="doi">10.1177/0885328217752994</pub-id><pub-id pub-id-type="pmid">29357775</pub-id></element-citation></ref><ref id="B217-pharmaceutics-13-00143"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>K.S.</given-names></name><name><surname>Durfee</surname><given-names>P.N.</given-names></name><name><surname>Theron</surname><given-names>C.</given-names></name><name><surname>Ashley</surname><given-names>C.E.</given-names></name><name><surname>Carnes</surname><given-names>E.C.</given-names></name><name><surname>Brinker</surname><given-names>C.J.</given-names></name></person-group><article-title>Protocells: Modular Mesoporous Silica Nanoparticle-Supported Lipid Bilayers for Drug Delivery</article-title><source>Small</source><year>2016</year><volume>12</volume><fpage>2173</fpage><lpage>2185</lpage><pub-id pub-id-type="doi">10.1002/smll.201502119</pub-id><pub-id pub-id-type="pmid">26780591</pub-id></element-citation></ref><ref id="B218-pharmaceutics-13-00143"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>P.</given-names></name><name><surname>Tambe</surname><given-names>P.</given-names></name><name><surname>Paknikar</surname><given-names>K.M.</given-names></name><name><surname>Gajbhiye</surname><given-names>V.</given-names></name></person-group><article-title>Mesoporous silica nanoparticles as cutting-edge theranostics: Advancement from merely a carrier to tailor-made smart delivery platform</article-title><source>J. Control. Release</source><year>2018</year><volume>287</volume><fpage>35</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2018.08.024</pub-id><pub-id pub-id-type="pmid">30125637</pub-id></element-citation></ref><ref id="B219-pharmaceutics-13-00143"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakhshian Nik</surname><given-names>A.</given-names></name><name><surname>Zare</surname><given-names>H.</given-names></name><name><surname>Razavi</surname><given-names>S.</given-names></name><name><surname>Mohammadi</surname><given-names>H.</given-names></name><name><surname>Torab Ahmadi</surname><given-names>P.</given-names></name><name><surname>Yazdani</surname><given-names>N.</given-names></name><name><surname>Bayandori</surname><given-names>M.</given-names></name><name><surname>Rabiee</surname><given-names>N.</given-names></name><name><surname>Izadi Mobarakeh</surname><given-names>J.</given-names></name></person-group><article-title>Smart drug delivery: Capping strategies for mesoporous silica nanoparticles</article-title><source>Microporous Mesoporous Mater.</source><year>2020</year><volume>299</volume><fpage>110115</fpage><pub-id pub-id-type="doi">10.1016/j.micromeso.2020.110115</pub-id></element-citation></ref><ref id="B220-pharmaceutics-13-00143"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baeza</surname><given-names>A.</given-names></name><name><surname>Colilla</surname><given-names>M.</given-names></name><name><surname>Vallet-Reg&#x000ed;</surname><given-names>M.</given-names></name></person-group><article-title>Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery</article-title><source>Expert Opin. Drug Deliv.</source><year>2015</year><volume>12</volume><fpage>319</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1517/17425247.2014.953051</pub-id><pub-id pub-id-type="pmid">25421898</pub-id></element-citation></ref><ref id="B221-pharmaceutics-13-00143"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manzano</surname><given-names>M.</given-names></name><name><surname>Vallet-Reg&#x000ed;</surname><given-names>M.</given-names></name></person-group><article-title>Mesoporous silica nanoparticles in nanomedicine applications</article-title><source>J. Mater. Sci. Mater. Med.</source><year>2018</year><volume>29</volume><fpage>65</fpage><pub-id pub-id-type="doi">10.1007/s10856-018-6069-x</pub-id><?supplied-pmid 29737405?><pub-id pub-id-type="pmid">29737405</pub-id></element-citation></ref><ref id="B222-pharmaceutics-13-00143"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmadi Nasab</surname><given-names>N.</given-names></name><name><surname>Hassani Kumleh</surname><given-names>H.</given-names></name><name><surname>Beygzadeh</surname><given-names>M.</given-names></name><name><surname>Teimourian</surname><given-names>S.</given-names></name><name><surname>Kazemzad</surname><given-names>M.</given-names></name></person-group><article-title>Delivery of curcumin by a pH-responsive chitosan mesoporous silica nanoparticles for cancer treatment</article-title><source>Artif. Cellsnanomed. Biotechnol.</source><year>2018</year><volume>46</volume><fpage>75</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1080/21691401.2017.1290648</pub-id><?supplied-pmid 28278578?><pub-id pub-id-type="pmid">28278578</pub-id></element-citation></ref><ref id="B223-pharmaceutics-13-00143"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>S.</given-names></name><name><surname>Manna</surname><given-names>K.</given-names></name><name><surname>Kayal</surname><given-names>U.</given-names></name><name><surname>Saha</surname><given-names>M.</given-names></name><name><surname>Chatterjee</surname><given-names>S.</given-names></name><name><surname>Chandra</surname><given-names>D.</given-names></name><name><surname>Hara</surname><given-names>M.</given-names></name><name><surname>Datta</surname><given-names>S.</given-names></name><name><surname>Bhaumik</surname><given-names>A.</given-names></name><name><surname>Das Saha</surname><given-names>K.</given-names></name></person-group><article-title>Folic acid-conjugated magnetic mesoporous silica nanoparticles loaded with quercetin: A theranostic approach for cancer management</article-title><source>RSC Adv.</source><year>2020</year><volume>10</volume><fpage>23148</fpage><lpage>23164</lpage><pub-id pub-id-type="doi">10.1039/D0RA00664E</pub-id></element-citation></ref><ref id="B224-pharmaceutics-13-00143"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rashidi</surname><given-names>L.</given-names></name><name><surname>Vasheghani-Farahani</surname><given-names>E.</given-names></name><name><surname>Rostami</surname><given-names>K.</given-names></name><name><surname>Ganji</surname><given-names>F.</given-names></name><name><surname>Fallahpour</surname><given-names>M.</given-names></name></person-group><article-title>Mesoporous silica nanoparticles with different pore sizes for delivery of pH-sensitive gallic acid</article-title><source>Asia-Pac. J. Chem. Eng.</source><year>2014</year><volume>9</volume><fpage>845</fpage><lpage>853</lpage><pub-id pub-id-type="doi">10.1002/apj.1832</pub-id></element-citation></ref><ref id="B225-pharmaceutics-13-00143"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>N.-X.</given-names></name><name><surname>Yin</surname><given-names>H.-L.</given-names></name><name><surname>Chen</surname><given-names>T.-Y.</given-names></name><name><surname>Yang</surname><given-names>Q.</given-names></name><name><surname>Wu</surname><given-names>M.</given-names></name></person-group><article-title>Thermo- and pH-responsive, Lipid-coated, Mesoporous Silica Nanoparticle-based Dual Drug Delivery System To Improve the Antitumor Effect of Hydrophobic Drugs</article-title><source>Mol. Pharm.</source><year>2019</year><volume>16</volume><fpage>422</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b01073</pub-id><pub-id pub-id-type="pmid">30525641</pub-id></element-citation></ref><ref id="B226-pharmaceutics-13-00143"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name></person-group><article-title>Lysosomes activating chain reactions against cancer cells with a pH-switched prodrug/procatalyst co-delivery nanosystem</article-title><source>J. Mater. Chem. B</source><year>2017</year><volume>5</volume><fpage>996</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1039/C6TB02820A</pub-id><pub-id pub-id-type="pmid">32263878</pub-id></element-citation></ref><ref id="B227-pharmaceutics-13-00143"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>A.</given-names></name><name><surname>DeGraff</surname><given-names>W.</given-names></name><name><surname>Friedman</surname><given-names>N.</given-names></name><name><surname>Mitchell</surname><given-names>J.B.</given-names></name></person-group><article-title>Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs</article-title><source>Cancer Res.</source><year>1986</year><volume>46</volume><fpage>2845</fpage><lpage>2848</lpage><pub-id pub-id-type="pmid">2421885</pub-id></element-citation></ref><ref id="B228-pharmaceutics-13-00143"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J.-T.</given-names></name><name><surname>Ye</surname><given-names>Q.-B.</given-names></name><name><surname>Yang</surname><given-names>Q.-J.</given-names></name><name><surname>Wang</surname><given-names>G.-H.</given-names></name></person-group><article-title>Hierarchical bioresponsive nanocarriers for codelivery of curcumin and doxorubicin</article-title><source>Colloids Surf. B Biointerfaces</source><year>2019</year><volume>180</volume><fpage>93</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2019.04.023</pub-id><pub-id pub-id-type="pmid">31035057</pub-id></element-citation></ref><ref id="B229-pharmaceutics-13-00143"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>L&#x000fc;</surname><given-names>S.</given-names></name><name><surname>Gao</surname><given-names>C.</given-names></name><name><surname>Feng</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Bai</surname><given-names>X.</given-names></name><name><surname>Gao</surname><given-names>N.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name></person-group><article-title>Self-fluorescent and stimuli-responsive mesoporous silica nanoparticles using a double-role curcumin gatekeeper for drug delivery</article-title><source>Chem. Eng. J.</source><year>2016</year><volume>300</volume><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/j.cej.2016.04.087</pub-id></element-citation></ref><ref id="B230-pharmaceutics-13-00143"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaghasiya</surname><given-names>K.</given-names></name><name><surname>Ray</surname><given-names>E.</given-names></name><name><surname>Sharma</surname><given-names>A.</given-names></name><name><surname>Katare</surname><given-names>O.P.</given-names></name><name><surname>Verma</surname><given-names>R.K.</given-names></name></person-group><article-title>Matrix Metalloproteinase-Responsive Mesoporous Silica Nanoparticles Cloaked with Cleavable Protein for &#x0201c;Self-Actuating&#x0201d; On-Demand Controlled Drug Delivery for Cancer Therapy</article-title><source>ACS Appl. Bio Mater.</source><year>2020</year><volume>3</volume><fpage>4987</fpage><lpage>4999</lpage><pub-id pub-id-type="doi">10.1021/acsabm.0c00497</pub-id></element-citation></ref><ref id="B231-pharmaceutics-13-00143"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baeza</surname><given-names>A.</given-names></name><name><surname>Guisasola</surname><given-names>E.</given-names></name><name><surname>Ruiz-Hern&#x000e1;ndez</surname><given-names>E.</given-names></name><name><surname>Vallet-Reg&#x000ed;</surname><given-names>M.</given-names></name></person-group><article-title>Magnetically Triggered Multidrug Release by Hybrid Mesoporous Silica Nanoparticles</article-title><source>Chem. Mater.</source><year>2012</year><volume>24</volume><fpage>517</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1021/cm203000u</pub-id></element-citation></ref><ref id="B232-pharmaceutics-13-00143"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>Y.S.</given-names></name><name><surname>Chang</surname><given-names>Z.M.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>M.M.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Shao</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Berberine-loaded Janus nanocarriers for magnetic field-enhanced therapy against hepatocellular carcinoma</article-title><source>Chem. Biol. Drug Des.</source><year>2017</year><volume>89</volume><fpage>464</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1111/cbdd.12866</pub-id><?supplied-pmid 27618577?><pub-id pub-id-type="pmid">27618577</pub-id></element-citation></ref><ref id="B233-pharmaceutics-13-00143"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asgari</surname><given-names>M.</given-names></name><name><surname>Miri</surname><given-names>T.</given-names></name><name><surname>Soleymani</surname><given-names>M.</given-names></name><name><surname>Barati</surname><given-names>A.</given-names></name></person-group><article-title>A novel method for in situ encapsulation of curcumin in magnetite-silica core-shell nanocomposites: A multifunctional platform for drug delivery and magnetic hyperthermia therapy</article-title><source>J. Mol. Liq.</source><year>2020</year><fpage>114731</fpage><pub-id pub-id-type="doi">10.1016/j.molliq.2020.114731</pub-id></element-citation></ref><ref id="B234-pharmaceutics-13-00143"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Tao</surname><given-names>C.</given-names></name></person-group><article-title>DNA-capped Fe3O4/SiO2 magnetic mesoporous silica nanoparticles for potential controlled drug release and hyperthermia</article-title><source>RSC Adv.</source><year>2015</year><volume>5</volume><fpage>22365</fpage><lpage>22372</lpage><pub-id pub-id-type="doi">10.1039/C5RA00701A</pub-id></element-citation></ref><ref id="B235-pharmaceutics-13-00143"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mal</surname><given-names>N.K.</given-names></name><name><surname>Fujiwara</surname><given-names>M.</given-names></name><name><surname>Tanaka</surname><given-names>Y.</given-names></name></person-group><article-title>Photocontrolled reversible release of guest molecules from coumarin-modified mesoporous silica</article-title><source>Nature</source><year>2003</year><volume>421</volume><fpage>350</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1038/nature01362</pub-id><?supplied-pmid 12540896?><pub-id pub-id-type="pmid">12540896</pub-id></element-citation></ref><ref id="B236-pharmaceutics-13-00143"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferris</surname><given-names>D.P.</given-names></name><name><surname>Zhao</surname><given-names>Y.-L.</given-names></name><name><surname>Khashab</surname><given-names>N.M.</given-names></name><name><surname>Khatib</surname><given-names>H.A.</given-names></name><name><surname>Stoddart</surname><given-names>J.F.</given-names></name><name><surname>Zink</surname><given-names>J.I.</given-names></name></person-group><article-title>Light-Operated Mechanized Nanoparticles</article-title><source>J. Am. Chem. Soc.</source><year>2009</year><volume>131</volume><fpage>1686</fpage><lpage>1688</lpage><pub-id pub-id-type="doi">10.1021/ja807798g</pub-id><pub-id pub-id-type="pmid">19159224</pub-id></element-citation></ref><ref id="B237-pharmaceutics-13-00143"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x000ed;nez-Carmona</surname><given-names>M.</given-names></name><name><surname>Baeza</surname><given-names>A.</given-names></name><name><surname>Rodriguez-Milla</surname><given-names>M.A.</given-names></name><name><surname>Garc&#x000ed;a-Castro</surname><given-names>J.</given-names></name><name><surname>Vallet-Reg&#x000ed;</surname><given-names>M.</given-names></name></person-group><article-title>Mesoporous silica nanoparticles grafted with a light-responsive protein shell for highly cytotoxic antitumoral therapy</article-title><source>J. Mater. Chem. B</source><year>2015</year><volume>3</volume><fpage>5746</fpage><lpage>5752</lpage><pub-id pub-id-type="doi">10.1039/C5TB00304K</pub-id><pub-id pub-id-type="pmid">32262570</pub-id></element-citation></ref><ref id="B238-pharmaceutics-13-00143"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuang</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>He</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Curcumin-loaded PEGylated mesoporous silica nanoparticles for effective photodynamic therapy</article-title><source>RSC Adv.</source><year>2020</year><volume>10</volume><fpage>24624</fpage><lpage>24630</lpage><pub-id pub-id-type="doi">10.1039/D0RA04778C</pub-id></element-citation></ref><ref id="B239-pharmaceutics-13-00143"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.D.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>X.R.</given-names></name><name><surname>Shao</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Ge</surname><given-names>M.F.</given-names></name><name><surname>Chang</surname><given-names>Z.M.</given-names></name><name><surname>Dong</surname><given-names>W.F.</given-names></name></person-group><article-title>Berberine-loaded Janus gold mesoporous silica nanocarriers for chemo/radio/photothermal therapy of liver cancer and radiation-induced injury inhibition</article-title><source>Int. J. Nanomed.</source><year>2019</year><volume>14</volume><fpage>3967</fpage><lpage>3982</lpage><pub-id pub-id-type="doi">10.2147/IJN.S206044</pub-id></element-citation></ref><ref id="B240-pharmaceutics-13-00143"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Tong</surname><given-names>L.</given-names></name><name><surname>Ao</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name></person-group><article-title>Novel design of NIR-triggered plasmonic nanodots capped mesoporous silica nanoparticles loaded with natural capsaicin to inhibition of metastasis of human papillary thyroid carcinoma B-CPAP cells in thyroid cancer chemo-photothermal therapy</article-title><source>J. Photochem. Photobiol. B</source><year>2019</year><volume>197</volume><fpage>111534</fpage><pub-id pub-id-type="doi">10.1016/j.jphotobiol.2019.111534</pub-id><pub-id pub-id-type="pmid">31279897</pub-id></element-citation></ref><ref id="B241-pharmaceutics-13-00143"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sirsi</surname><given-names>S.R.</given-names></name><name><surname>Borden</surname><given-names>M.A.</given-names></name></person-group><article-title>State-of-the-art materials for ultrasound-triggered drug delivery</article-title><source>Adv. Drug Deliv. Rev.</source><year>2014</year><volume>72</volume><fpage>3</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2013.12.010</pub-id><?supplied-pmid 24389162?><pub-id pub-id-type="pmid">24389162</pub-id></element-citation></ref><ref id="B242-pharmaceutics-13-00143"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Pelletier</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Xia</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>High-Frequency Ultrasound-Responsive Block Copolymer Micelle</article-title><source>Langmuir</source><year>2009</year><volume>25</volume><fpage>13201</fpage><lpage>13205</lpage><pub-id pub-id-type="doi">10.1021/la9018794</pub-id><?supplied-pmid 19572509?><pub-id pub-id-type="pmid">19572509</pub-id></element-citation></ref><ref id="B243-pharmaceutics-13-00143"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paris</surname><given-names>J.L.</given-names></name><name><surname>Caba&#x000f1;as</surname><given-names>M.V.</given-names></name><name><surname>Manzano</surname><given-names>M.</given-names></name><name><surname>Vallet-Reg&#x000ed;</surname><given-names>M.</given-names></name></person-group><article-title>Polymer-Grafted Mesoporous Silica Nanoparticles as Ultrasound-Responsive Drug Carriers</article-title><source>ACS Nano</source><year>2015</year><volume>9</volume><fpage>11023</fpage><lpage>11033</lpage><pub-id pub-id-type="doi">10.1021/acsnano.5b04378</pub-id><?supplied-pmid 26456489?><pub-id pub-id-type="pmid">26456489</pub-id></element-citation></ref><ref id="B244-pharmaceutics-13-00143"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paris</surname><given-names>J.L.</given-names></name><name><surname>de la Torre</surname><given-names>P.</given-names></name><name><surname>Victoria Caba&#x000f1;as</surname><given-names>M.</given-names></name><name><surname>Manzano</surname><given-names>M.</given-names></name><name><surname>Grau</surname><given-names>M.</given-names></name><name><surname>Flores</surname><given-names>A.I.</given-names></name><name><surname>Vallet-Reg&#x000ed;</surname><given-names>M.</given-names></name></person-group><article-title>Vectorization of ultrasound-responsive nanoparticles in placental mesenchymal stem cells for cancer therapy</article-title><source>Nanoscale</source><year>2017</year><volume>9</volume><fpage>5528</fpage><lpage>5537</lpage><pub-id pub-id-type="doi">10.1039/C7NR01070B</pub-id><?supplied-pmid 28402365?><pub-id pub-id-type="pmid">28402365</pub-id></element-citation></ref><ref id="B245-pharmaceutics-13-00143"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Xia</surname><given-names>H.</given-names></name></person-group><article-title>Ultrasound Reversible Response Nanocarrier Based on Sodium Alginate Modified Mesoporous Silica Nanoparticles</article-title><source>Front. Chem.</source><year>2019</year><volume>7</volume><fpage>59</fpage><pub-id pub-id-type="doi">10.3389/fchem.2019.00059</pub-id><?supplied-pmid 30805332?><pub-id pub-id-type="pmid">30805332</pub-id></element-citation></ref><ref id="B246-pharmaceutics-13-00143"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Z.</given-names></name><name><surname>Ding</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><name><surname>Xiang</surname><given-names>Y.</given-names></name><name><surname>Zeng</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Yan</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Zhu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Engineering a Hollow Nanocontainer Platform with Multifunctional Molecular Machines for Tumor-Targeted Therapy in Vitro and in Vivo</article-title><source>ACS Nano</source><year>2013</year><volume>7</volume><fpage>10271</fpage><lpage>10284</lpage><pub-id pub-id-type="doi">10.1021/nn404676w</pub-id><?supplied-pmid 24127723?><pub-id pub-id-type="pmid">24127723</pub-id></element-citation></ref><ref id="B247-pharmaceutics-13-00143"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumura</surname><given-names>Y.</given-names></name><name><surname>Maeda</surname><given-names>H.</given-names></name></person-group><article-title>A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs</article-title><source>Cancer Res.</source><year>1986</year><volume>46</volume><fpage>6387</fpage><lpage>6392</lpage><?supplied-pmid 2946403?><pub-id pub-id-type="pmid">2946403</pub-id></element-citation></ref><ref id="B248-pharmaceutics-13-00143"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>H.</given-names></name><name><surname>Fang</surname><given-names>J.</given-names></name><name><surname>Maeda</surname><given-names>H.</given-names></name></person-group><article-title>Development of next-generation macromolecular drugs based on the EPR effect: Challenges and pitfalls</article-title><source>Expert Opin. Drug Deliv.</source><year>2015</year><volume>12</volume><fpage>53</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1517/17425247.2014.955011</pub-id><?supplied-pmid 25425260?><pub-id pub-id-type="pmid">25425260</pub-id></element-citation></ref><ref id="B249-pharmaceutics-13-00143"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danhier</surname><given-names>F.</given-names></name><name><surname>Feron</surname><given-names>O.</given-names></name><name><surname>Pr&#x000e9;at</surname><given-names>V.</given-names></name></person-group><article-title>To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery</article-title><source>J. Control. Release</source><year>2010</year><volume>148</volume><fpage>135</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2010.08.027</pub-id><pub-id pub-id-type="pmid">20797419</pub-id></element-citation></ref><ref id="B250-pharmaceutics-13-00143"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peer</surname><given-names>D.</given-names></name><name><surname>Karp</surname><given-names>J.M.</given-names></name><name><surname>Hong</surname><given-names>S.</given-names></name><name><surname>Farokhzad</surname><given-names>O.C.</given-names></name><name><surname>Margalit</surname><given-names>R.</given-names></name><name><surname>Langer</surname><given-names>R.</given-names></name></person-group><article-title>Nanocarriers as an emerging platform for cancer therapy</article-title><source>Nat. Nanotechnol</source><year>2007</year><volume>2</volume><fpage>751</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1038/nnano.2007.387</pub-id><pub-id pub-id-type="pmid">18654426</pub-id></element-citation></ref><ref id="B251-pharmaceutics-13-00143"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philipp</surname><given-names>A.</given-names></name><name><surname>Meyer</surname><given-names>M.</given-names></name><name><surname>Wagner</surname><given-names>E.</given-names></name></person-group><article-title>Extracellular targeting of synthetic therapeutic nucleic acid formulations</article-title><source>Curr. Gene</source><year>2008</year><volume>8</volume><fpage>324</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.2174/156652308786071023</pub-id><?supplied-pmid 18855630?><pub-id pub-id-type="pmid">18855630</pub-id></element-citation></ref><ref id="B252-pharmaceutics-13-00143"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ang</surname><given-names>C.Y.</given-names></name><name><surname>Tan</surname><given-names>S.Y.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>Recent advances in biocompatible nanocarriers for delivery of chemotherapeutic cargoes towards cancer therapy</article-title><source>Org. Biomol. Chem.</source><year>2014</year><volume>12</volume><fpage>4776</fpage><lpage>4806</lpage><pub-id pub-id-type="doi">10.1039/c4ob00164h</pub-id><?supplied-pmid 24737243?><pub-id pub-id-type="pmid">24737243</pub-id></element-citation></ref><ref id="B253-pharmaceutics-13-00143"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mickler</surname><given-names>F.M.</given-names></name><name><surname>M&#x000f6;ckl</surname><given-names>L.</given-names></name><name><surname>Ruthardt</surname><given-names>N.</given-names></name><name><surname>Ogris</surname><given-names>M.</given-names></name><name><surname>Wagner</surname><given-names>E.</given-names></name><name><surname>Br&#x000e4;uchle</surname><given-names>C.</given-names></name></person-group><article-title>Tuning nanoparticle uptake: Live-cell imaging reveals two distinct endocytosis mechanisms mediated by natural and artificial EGFR targeting ligand</article-title><source>Nano Lett.</source><year>2012</year><volume>12</volume><fpage>3417</fpage><lpage>3423</lpage><pub-id pub-id-type="doi">10.1021/nl300395q</pub-id><?supplied-pmid 22632479?><pub-id pub-id-type="pmid">22632479</pub-id></element-citation></ref><ref id="B254-pharmaceutics-13-00143"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenholm</surname><given-names>J.M.</given-names></name><name><surname>Peuhu</surname><given-names>E.</given-names></name><name><surname>Bate-Eya</surname><given-names>L.T.</given-names></name><name><surname>Eriksson</surname><given-names>J.E.</given-names></name><name><surname>Sahlgren</surname><given-names>C.</given-names></name><name><surname>Lind&#x000e9;n</surname><given-names>M.</given-names></name></person-group><article-title>Cancer-Cell-Specific Induction of Apoptosis Using Mesoporous Silica Nanoparticles as Drug-Delivery Vectors</article-title><source>Small</source><year>2010</year><volume>6</volume><fpage>1234</fpage><lpage>1241</lpage><pub-id pub-id-type="doi">10.1002/smll.200902355</pub-id><?supplied-pmid 20486218?><pub-id pub-id-type="pmid">20486218</pub-id></element-citation></ref><ref id="B255-pharmaceutics-13-00143"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Yuan</surname><given-names>Z.F.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>W.H.</given-names></name><name><surname>Luo</surname><given-names>G.F.</given-names></name><name><surname>Cheng</surname><given-names>S.X.</given-names></name><name><surname>Zhuo</surname><given-names>R.X.</given-names></name><name><surname>Zhang</surname><given-names>X.Z.</given-names></name></person-group><article-title>Multifunctional envelope-type mesoporous silica nanoparticles for tumor-triggered targeting drug delivery</article-title><source>J. Am. Chem. Soc.</source><year>2013</year><volume>135</volume><fpage>5068</fpage><lpage>5073</lpage><pub-id pub-id-type="doi">10.1021/ja312004m</pub-id><pub-id pub-id-type="pmid">23464924</pub-id></element-citation></ref><ref id="B256-pharmaceutics-13-00143"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name></person-group><article-title>A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells</article-title><source>Int. J. Nanomed.</source><year>2019</year><volume>14</volume><fpage>4029</fpage><lpage>4044</lpage><pub-id pub-id-type="doi">10.2147/IJN.S201688</pub-id></element-citation></ref><ref id="B257-pharmaceutics-13-00143"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name><name><surname>Sun</surname><given-names>C.</given-names></name><name><surname>Di</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name></person-group><article-title>Dual-stimuli responsive hyaluronic acid-conjugated mesoporous silica for targeted delivery to CD44-overexpressing cancer cells</article-title><source>Acta Biomater.</source><year>2015</year><volume>23</volume><fpage>147</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2015.05.010</pub-id><pub-id pub-id-type="pmid">25985912</pub-id></element-citation></ref><ref id="B258-pharmaceutics-13-00143"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brevet</surname><given-names>D.</given-names></name><name><surname>Gary-Bobo</surname><given-names>M.</given-names></name><name><surname>Raehm</surname><given-names>L.</given-names></name><name><surname>Richeter</surname><given-names>S.</given-names></name><name><surname>Hocine</surname><given-names>O.</given-names></name><name><surname>Amro</surname><given-names>K.</given-names></name><name><surname>Loock</surname><given-names>B.</given-names></name><name><surname>Couleaud</surname><given-names>P.</given-names></name><name><surname>Frochot</surname><given-names>C.</given-names></name><name><surname>Mor&#x000e8;re</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Mannose-targeted mesoporous silica nanoparticles for photodynamic therapy</article-title><source>Chem. Commun.</source><year>2009</year><fpage>1475</fpage><lpage>1477</lpage><pub-id pub-id-type="doi">10.1039/b900427k</pub-id></element-citation></ref><ref id="B259-pharmaceutics-13-00143"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gisbert-Garzar&#x000e1;n</surname><given-names>M.</given-names></name><name><surname>Vallet-Reg&#x000ed;</surname><given-names>M.</given-names></name></person-group><article-title>Influence of the Surface Functionalization on the Fate and Performance of Mesoporous Silica Nanoparticles</article-title><source>Nanomaterials</source><year>2020</year><volume>10</volume><elocation-id>916</elocation-id><pub-id pub-id-type="doi">10.3390/nano10050916</pub-id></element-citation></ref><ref id="B260-pharmaceutics-13-00143"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Xie</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Feng</surname><given-names>N.</given-names></name></person-group><article-title>Curcumin-loaded redox-responsive mesoporous silica nanoparticles for targeted breast cancer therapy</article-title><source>Artif. Cells Nanomed. Biotechnol.</source><year>2018</year><volume>46</volume><fpage>921</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1080/21691401.2018.1473412</pub-id><pub-id pub-id-type="pmid">29790797</pub-id></element-citation></ref><ref id="B261-pharmaceutics-13-00143"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malekmohammadi</surname><given-names>S.</given-names></name><name><surname>Hadadzadeh</surname><given-names>H.</given-names></name><name><surname>Farrokhpour</surname><given-names>H.</given-names></name><name><surname>Amirghofran</surname><given-names>Z.</given-names></name></person-group><article-title>Immobilization of gold nanoparticles on folate-conjugated dendritic mesoporous silica-coated reduced graphene oxide nanosheets: A new nanoplatform for curcumin pH-controlled and targeted delivery</article-title><source>Soft Matter</source><year>2018</year><volume>14</volume><fpage>2400</fpage><lpage>2410</lpage><pub-id pub-id-type="doi">10.1039/C7SM02248D</pub-id><pub-id pub-id-type="pmid">29512668</pub-id></element-citation></ref><ref id="B262-pharmaceutics-13-00143"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Xue</surname><given-names>X.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Song</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Qin</surname><given-names>M.</given-names></name><name><surname>Liang</surname><given-names>H.</given-names></name><name><surname>Gao</surname><given-names>L.</given-names></name></person-group><article-title>Quercetin and doxorubicin co-delivery using mesoporous silica nanoparticles enhance the efficacy of gastric carcinoma chemotherapy</article-title><source>Int. J. Nanomed.</source><year>2018</year><volume>13</volume><fpage>5113</fpage><lpage>5126</lpage><pub-id pub-id-type="doi">10.2147/IJN.S170862</pub-id><?supplied-pmid 30233175?><pub-id pub-id-type="pmid">30233175</pub-id></element-citation></ref><ref id="B263-pharmaceutics-13-00143"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>B.N.P.</given-names></name><name><surname>Puvvada</surname><given-names>N.</given-names></name><name><surname>Rajput</surname><given-names>S.</given-names></name><name><surname>Sarkar</surname><given-names>S.</given-names></name><name><surname>Mahto</surname><given-names>M.K.</given-names></name><name><surname>Yallapu</surname><given-names>M.M.</given-names></name><name><surname>Pathak</surname><given-names>A.</given-names></name><name><surname>Emdad</surname><given-names>L.</given-names></name><name><surname>Das</surname><given-names>S.K.</given-names></name><name><surname>Reis</surname><given-names>R.L.</given-names></name><etal/></person-group><article-title>Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer</article-title><source>Mol. Pharm.</source><year>2018</year><volume>15</volume><fpage>2698</fpage><lpage>2713</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b00218</pub-id><?supplied-pmid 29787277?><pub-id pub-id-type="pmid">29787277</pub-id></element-citation></ref><ref id="B264-pharmaceutics-13-00143"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murugan</surname><given-names>C.</given-names></name><name><surname>Rayappan</surname><given-names>K.</given-names></name><name><surname>Thangam</surname><given-names>R.</given-names></name><name><surname>Bhanumathi</surname><given-names>R.</given-names></name><name><surname>Shanthi</surname><given-names>K.</given-names></name><name><surname>Vivek</surname><given-names>R.</given-names></name><name><surname>Thirumurugan</surname><given-names>R.</given-names></name><name><surname>Bhattacharyya</surname><given-names>A.</given-names></name><name><surname>Sivasubramanian</surname><given-names>S.</given-names></name><name><surname>Gunasekaran</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Combinatorial nanocarrier based drug delivery approach for amalgamation of anti-tumor agents in breast cancer cells: An improved nanomedicine strategy</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>34053</fpage><pub-id pub-id-type="doi">10.1038/srep34053</pub-id><?supplied-pmid 27725731?><pub-id pub-id-type="pmid">27725731</pub-id></element-citation></ref><ref id="B265-pharmaceutics-13-00143"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarkar</surname><given-names>A.</given-names></name><name><surname>Ghosh</surname><given-names>S.</given-names></name><name><surname>Chowdhury</surname><given-names>S.</given-names></name><name><surname>Pandey</surname><given-names>B.</given-names></name><name><surname>Sil</surname><given-names>P.C.</given-names></name></person-group><article-title>Targeted delivery of quercetin loaded mesoporous silica nanoparticles to the breast cancer cells</article-title><source>Biochim. Biophys. Acta</source><year>2016</year><volume>1860</volume><fpage>2065</fpage><lpage>2075</lpage><pub-id pub-id-type="doi">10.1016/j.bbagen.2016.07.001</pub-id><pub-id pub-id-type="pmid">27392941</pub-id></element-citation></ref><ref id="B266-pharmaceutics-13-00143"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>J.</given-names></name><name><surname>Yao</surname><given-names>J.</given-names></name><name><surname>Xue</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Bao</surname><given-names>B.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>J.J.</given-names></name><name><surname>He</surname><given-names>Z.</given-names></name></person-group><article-title>Tumor-Homing Cell-Penetrating Peptide Linked to Colloidal Mesoporous Silica Encapsulated (-)-Epigallocatechin-3-gallate as Drug Delivery System for Breast Cancer Therapy in Vivo</article-title><source>ACS Appl. Mater. Interfaces</source><year>2015</year><volume>7</volume><fpage>18145</fpage><lpage>18155</lpage><pub-id pub-id-type="doi">10.1021/acsami.5b05618</pub-id><pub-id pub-id-type="pmid">26225796</pub-id></element-citation></ref><ref id="B267-pharmaceutics-13-00143"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Qiu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Ding</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Anti-miRNA21 and resveratrol-loaded polysaccharide-based mesoporous silica nanoparticle for synergistic activity in gastric carcinoma</article-title><source>J. Drug Target.</source><year>2019</year><volume>27</volume><fpage>1135</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.1080/1061186X.2019.1610766</pub-id><pub-id pub-id-type="pmid">31017473</pub-id></element-citation></ref><ref id="B268-pharmaceutics-13-00143"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Favero</surname><given-names>G.</given-names></name><name><surname>Bialas</surname><given-names>F.</given-names></name><name><surname>Grabher</surname><given-names>S.</given-names></name><name><surname>Wittig</surname><given-names>A.</given-names></name><name><surname>Br&#x000e4;uer</surname><given-names>B.</given-names></name><name><surname>Gerthsen</surname><given-names>D.</given-names></name><name><surname>Echalier</surname><given-names>C.</given-names></name><name><surname>Kamalov</surname><given-names>M.</given-names></name><name><surname>Marko</surname><given-names>D.</given-names></name><name><surname>Becker</surname><given-names>C.F.W.</given-names></name></person-group><article-title>Silica particles with a quercetin&#x02013;R5 peptide conjugate are taken up into HT-29 cells and translocate into the nucleus</article-title><source>Chem. Commun.</source><year>2019</year><volume>55</volume><fpage>9649</fpage><lpage>9652</lpage><pub-id pub-id-type="doi">10.1039/C9CC02215E</pub-id></element-citation></ref><ref id="B269-pharmaceutics-13-00143"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Havel</surname><given-names>H.A.</given-names></name></person-group><article-title>Where Are the Nanodrugs? An Industry Perspective on Development of Drug Products Containing Nanomaterials</article-title><source>AAPS J.</source><year>2016</year><volume>18</volume><fpage>1351</fpage><lpage>1353</lpage><pub-id pub-id-type="doi">10.1208/s12248-016-9970-6</pub-id><pub-id pub-id-type="pmid">27520380</pub-id></element-citation></ref><ref id="B270-pharmaceutics-13-00143"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Havel</surname><given-names>H.</given-names></name><name><surname>Finch</surname><given-names>G.</given-names></name><name><surname>Strode</surname><given-names>P.</given-names></name><name><surname>Wolfgang</surname><given-names>M.</given-names></name><name><surname>Zale</surname><given-names>S.</given-names></name><name><surname>Bobe</surname><given-names>I.</given-names></name><name><surname>Youssoufian</surname><given-names>H.</given-names></name><name><surname>Peterson</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name></person-group><article-title>Nanomedicines: From Bench to Bedside and Beyond</article-title><source>AAPS J.</source><year>2016</year><volume>18</volume><fpage>1373</fpage><lpage>1378</lpage><pub-id pub-id-type="doi">10.1208/s12248-016-9961-7</pub-id><pub-id pub-id-type="pmid">27480318</pub-id></element-citation></ref><ref id="B271-pharmaceutics-13-00143"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>S.</given-names></name><name><surname>DeGiovanni</surname><given-names>P.J.</given-names></name><name><surname>Piel</surname><given-names>B.</given-names></name><name><surname>Rai</surname><given-names>P.</given-names></name></person-group><article-title>Cancer nanomedicine: A review of recent success in drug delivery</article-title><source>Clin. Transl. Med.</source><year>2017</year><volume>6</volume><fpage>44</fpage><pub-id pub-id-type="doi">10.1186/s40169-017-0175-0</pub-id><?supplied-pmid 29230567?><pub-id pub-id-type="pmid">29230567</pub-id></element-citation></ref><ref id="B272-pharmaceutics-13-00143"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cragg</surname><given-names>G.M.</given-names></name><name><surname>Pezzuto</surname><given-names>J.M.</given-names></name></person-group><article-title>Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive Agents</article-title><source>Med. Princ. Pract. Int. J. Kuwait Univ. Health Sci. Cent.</source><year>2016</year><volume>25</volume><issue>Suppl. S2</issue><fpage>41</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1159/000443404</pub-id><?supplied-pmid 26679767?><pub-id pub-id-type="pmid">26679767</pub-id></element-citation></ref><ref id="B273-pharmaceutics-13-00143"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nwodo</surname><given-names>J.N.</given-names></name><name><surname>Ibezim</surname><given-names>A.</given-names></name><name><surname>Simoben</surname><given-names>C.V.</given-names></name><name><surname>Ntie-Kang</surname><given-names>F.</given-names></name></person-group><article-title>Exploring Cancer Therapeutics with Natural Products from African Medicinal Plants, Part II: Alkaloids, Terpenoids and Flavonoids</article-title><source>Anticancer Agents Med. Chem.</source><year>2016</year><volume>16</volume><fpage>108</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.2174/1871520615666150520143827</pub-id><?supplied-pmid 25991425?><pub-id pub-id-type="pmid">25991425</pub-id></element-citation></ref><ref id="B274-pharmaceutics-13-00143"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tapiero</surname><given-names>H.</given-names></name><name><surname>Tew</surname><given-names>K.D.</given-names></name><name><surname>Ba</surname><given-names>G.N.</given-names></name><name><surname>Math&#x000e9;</surname><given-names>G.</given-names></name></person-group><article-title>Polyphenols: Do they play a role in the prevention of human pathologies?</article-title><source>Biomed. Pharm.</source><year>2002</year><volume>56</volume><fpage>200</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/S0753-3322(02)00178-6</pub-id></element-citation></ref><ref id="B275-pharmaceutics-13-00143"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sak</surname><given-names>K.</given-names></name></person-group><article-title>Cytotoxicity of dietary flavonoids on different human cancer types</article-title><source>Pharmacogn. Rev.</source><year>2014</year><volume>8</volume><fpage>122</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.4103/0973-7847.134247</pub-id><?supplied-pmid 25125885?><pub-id pub-id-type="pmid">25125885</pub-id></element-citation></ref><ref id="B276-pharmaceutics-13-00143"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Lu</surname><given-names>J.J.</given-names></name><name><surname>Huang</surname><given-names>M.Q.</given-names></name><name><surname>Bao</surname><given-names>J.L.</given-names></name><name><surname>Chen</surname><given-names>X.P.</given-names></name><name><surname>Wang</surname><given-names>Y.T.</given-names></name></person-group><article-title>Terpenoids: Natural products for cancer therapy</article-title><source>Expert Opin. Investig. Drugs</source><year>2012</year><volume>21</volume><fpage>1801</fpage><lpage>1818</lpage><pub-id pub-id-type="doi">10.1517/13543784.2012.727395</pub-id></element-citation></ref><ref id="B277-pharmaceutics-13-00143"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amawi</surname><given-names>H.</given-names></name><name><surname>Ashby</surname><given-names>C.R.</given-names><suffix>Jr.</suffix></name><name><surname>Tiwari</surname><given-names>A.K.</given-names></name></person-group><article-title>Cancer chemoprevention through dietary flavonoids: What&#x02019;s limiting?</article-title><source>Chin. J. Cancer</source><year>2017</year><volume>36</volume><fpage>50</fpage><pub-id pub-id-type="doi">10.1186/s40880-017-0217-4</pub-id><pub-id pub-id-type="pmid">28629389</pub-id></element-citation></ref><ref id="B278-pharmaceutics-13-00143"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V.</given-names></name><name><surname>Bhatt</surname><given-names>P.C.</given-names></name><name><surname>Rahman</surname><given-names>M.</given-names></name><name><surname>Kaithwas</surname><given-names>G.</given-names></name><name><surname>Choudhry</surname><given-names>H.</given-names></name><name><surname>Al-Abbasi</surname><given-names>F.A.</given-names></name><name><surname>Anwar</surname><given-names>F.</given-names></name><name><surname>Verma</surname><given-names>A.</given-names></name></person-group><article-title>Fabrication, optimization, and characterization of umbelliferone &#x003b2;-D-galactopyranoside-loaded PLGA nanoparticles in treatment of hepatocellular carcinoma: In vitro and in vivo studies</article-title><source>Int. J. Nanomed.</source><year>2017</year><volume>12</volume><fpage>6747</fpage><lpage>6758</lpage><pub-id pub-id-type="doi">10.2147/IJN.S136629</pub-id></element-citation></ref><ref id="B279-pharmaceutics-13-00143"><label>279.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seca</surname><given-names>A.M.L.</given-names></name><name><surname>Pinto</surname><given-names>D.</given-names></name></person-group><article-title>Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>263</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19010263</pub-id></element-citation></ref><ref id="B280-pharmaceutics-13-00143"><label>280.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajesh</surname><given-names>E.</given-names></name><name><surname>Sankari</surname><given-names>L.S.</given-names></name><name><surname>Malathi</surname><given-names>L.</given-names></name><name><surname>Krupaa</surname><given-names>J.R.</given-names></name></person-group><article-title>Naturally occurring products in cancer therapy</article-title><source>J. Pharm. Bioallied. Sci.</source><year>2015</year><volume>7</volume><fpage>S181</fpage><lpage>S183</lpage><pub-id pub-id-type="doi">10.4103/0975-7406.155895</pub-id><pub-id pub-id-type="pmid">26015704</pub-id></element-citation></ref><ref id="B281-pharmaceutics-13-00143"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demain</surname><given-names>A.L.</given-names></name><name><surname>Vaishnav</surname><given-names>P.</given-names></name></person-group><article-title>Natural products for cancer chemotherapy</article-title><source>Microb. Biotechnol.</source><year>2011</year><volume>4</volume><fpage>687</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1111/j.1751-7915.2010.00221.x</pub-id><pub-id pub-id-type="pmid">21375717</pub-id></element-citation></ref><ref id="B282-pharmaceutics-13-00143"><label>282.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>L.</given-names></name><name><surname>Odhav</surname><given-names>B.</given-names></name><name><surname>Bhoola</surname><given-names>K.D.</given-names></name></person-group><article-title>Natural products for cancer prevention: A global perspective</article-title><source>Pharmacol. Ther.</source><year>2003</year><volume>99</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/S0163-7258(03)00042-1</pub-id><pub-id pub-id-type="pmid">12804695</pub-id></element-citation></ref><ref id="B283-pharmaceutics-13-00143"><label>283.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zubair</surname><given-names>H.</given-names></name><name><surname>Azim</surname><given-names>S.</given-names></name><name><surname>Ahmad</surname><given-names>A.</given-names></name><name><surname>Khan</surname><given-names>M.A.</given-names></name><name><surname>Patel</surname><given-names>G.K.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Singh</surname><given-names>A.P.</given-names></name></person-group><article-title>Cancer Chemoprevention by Phytochemicals: Nature&#x02019;s Healing Touch</article-title><source>Molecules</source><year>2017</year><volume>22</volume><elocation-id>395</elocation-id><pub-id pub-id-type="doi">10.3390/molecules22030395</pub-id><?supplied-pmid 28273819?><pub-id pub-id-type="pmid">28273819</pub-id></element-citation></ref><ref id="B284-pharmaceutics-13-00143"><label>284.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnett</surname><given-names>J.</given-names></name><name><surname>Newman</surname><given-names>B.</given-names></name><name><surname>Sun</surname><given-names>D.</given-names></name></person-group><article-title>Targeting cancer stem cells with natural products</article-title><source>Curr. Drug Targets</source><year>2012</year><volume>13</volume><fpage>1054</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.2174/138945012802009062</pub-id><?supplied-pmid 22594473?><pub-id pub-id-type="pmid">22594473</pub-id></element-citation></ref><ref id="B285-pharmaceutics-13-00143"><label>285.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kashyap</surname><given-names>D.</given-names></name><name><surname>Tuli</surname><given-names>H.S.</given-names></name><name><surname>Yerer</surname><given-names>M.B.</given-names></name><name><surname>Sharma</surname><given-names>A.</given-names></name><name><surname>Sak</surname><given-names>K.</given-names></name><name><surname>Srivastava</surname><given-names>S.</given-names></name><name><surname>Pandey</surname><given-names>A.</given-names></name><name><surname>Garg</surname><given-names>V.K.</given-names></name><name><surname>Sethi</surname><given-names>G.</given-names></name><name><surname>Bishayee</surname><given-names>A.</given-names></name></person-group><article-title>Natural product-based nanoformulations for cancer therapy: Opportunities and challenges</article-title><source>Semin. Cancer Biol.</source><year>2019</year><pub-id pub-id-type="doi">10.1016/j.semcancer.2019.08.014</pub-id><?supplied-pmid 31421264?><pub-id pub-id-type="pmid">31421264</pub-id></element-citation></ref><ref id="B286-pharmaceutics-13-00143"><label>286.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kashyap</surname><given-names>D.</given-names></name><name><surname>Sharma</surname><given-names>A.</given-names></name><name><surname>Tuli</surname><given-names>H.S.</given-names></name><name><surname>Sak</surname><given-names>K.</given-names></name><name><surname>Punia</surname><given-names>S.</given-names></name><name><surname>Mukherjee</surname><given-names>T.K.</given-names></name></person-group><article-title>Kaempferol&#x02014;A dietary anticancer molecule with multiple mechanisms of action: Recent trends and advancements</article-title><source>J. Funct. Foods</source><year>2017</year><volume>30</volume><fpage>203</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.jff.2017.01.022</pub-id><pub-id pub-id-type="pmid">32288791</pub-id></element-citation></ref><ref id="B287-pharmaceutics-13-00143"><label>287.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Harborne</surname><given-names>J.B.</given-names></name></person-group><article-title>Classes and functions of secondary products from plants</article-title><source>Chemicals from Plants</source><publisher-name>World Scientific/Imperial College Press</publisher-name><publisher-loc>Singapore</publisher-loc><year>1999</year><fpage>1</fpage><lpage>25</lpage></element-citation></ref><ref id="B288-pharmaceutics-13-00143"><label>288.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>M.</given-names></name><name><surname>Ahmad</surname><given-names>M.Z.</given-names></name><name><surname>Kazmi</surname><given-names>I.</given-names></name><name><surname>Akhter</surname><given-names>S.</given-names></name><name><surname>Afzal</surname><given-names>M.</given-names></name><name><surname>Gupta</surname><given-names>G.</given-names></name><name><surname>Sinha</surname><given-names>V.R.</given-names></name></person-group><article-title>Emergence of nanomedicine as cancer targeted magic bullets: Recent development and need to address the toxicity apprehension</article-title><source>Curr. Drug Discov. Technol.</source><year>2012</year><volume>9</volume><fpage>319</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.2174/157016312803305898</pub-id><pub-id pub-id-type="pmid">22725687</pub-id></element-citation></ref><ref id="B289-pharmaceutics-13-00143"><label>289.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>M.</given-names></name><name><surname>Ahmad</surname><given-names>M.Z.</given-names></name><name><surname>Kazmi</surname><given-names>I.</given-names></name><name><surname>Akhter</surname><given-names>S.</given-names></name><name><surname>Afzal</surname><given-names>M.</given-names></name><name><surname>Gupta</surname><given-names>G.</given-names></name><name><surname>Jalees Ahmed</surname><given-names>F.</given-names></name><name><surname>Anwar</surname><given-names>F.</given-names></name></person-group><article-title>Advancement in multifunctional nanoparticles for the effective treatment of cancer</article-title><source>Expert Opin. Drug Deliv.</source><year>2012</year><volume>9</volume><fpage>367</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1517/17425247.2012.668522</pub-id><pub-id pub-id-type="pmid">22400808</pub-id></element-citation></ref><ref id="B290-pharmaceutics-13-00143"><label>290.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bobo</surname><given-names>D.</given-names></name><name><surname>Robinson</surname><given-names>K.J.</given-names></name><name><surname>Islam</surname><given-names>J.</given-names></name><name><surname>Thurecht</surname><given-names>K.J.</given-names></name><name><surname>Corrie</surname><given-names>S.R.</given-names></name></person-group><article-title>Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date</article-title><source>Pharm. Res.</source><year>2016</year><volume>33</volume><fpage>2373</fpage><lpage>2387</lpage><pub-id pub-id-type="doi">10.1007/s11095-016-1958-5</pub-id><pub-id pub-id-type="pmid">27299311</pub-id></element-citation></ref><ref id="B291-pharmaceutics-13-00143"><label>291.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonarduzzi</surname><given-names>G.</given-names></name><name><surname>Testa</surname><given-names>G.</given-names></name><name><surname>Sottero</surname><given-names>B.</given-names></name><name><surname>Gamba</surname><given-names>P.</given-names></name><name><surname>Poli</surname><given-names>G.</given-names></name></person-group><article-title>Design and development of nanovehicle-based delivery systems for preventive or therapeutic supplementation with flavonoids</article-title><source>Curr. Med. Chem.</source><year>2010</year><volume>17</volume><fpage>74</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.2174/092986710789957760</pub-id><pub-id pub-id-type="pmid">19941477</pub-id></element-citation></ref><ref id="B292-pharmaceutics-13-00143"><label>292.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeetah</surname><given-names>R.</given-names></name><name><surname>Bhaw-Luximon</surname><given-names>A.</given-names></name><name><surname>Jhurry</surname><given-names>D.</given-names></name></person-group><article-title>Nanopharmaceutics: Phytochemical-based controlled or sustained drug-delivery systems for cancer treatment</article-title><source>J. Biomed. Nanotechnol.</source><year>2014</year><volume>10</volume><fpage>1810</fpage><lpage>1840</lpage><pub-id pub-id-type="doi">10.1166/jbn.2014.1884</pub-id><pub-id pub-id-type="pmid">25992442</pub-id></element-citation></ref><ref id="B293-pharmaceutics-13-00143"><label>293.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gohulkumar</surname><given-names>M.</given-names></name><name><surname>Gurushankar</surname><given-names>K.</given-names></name><name><surname>Rajendra Prasad</surname><given-names>N.</given-names></name><name><surname>Krishnakumar</surname><given-names>N.</given-names></name></person-group><article-title>Enhanced cytotoxicity and apoptosis-induced anticancer effect of silibinin-loaded nanoparticles in oral carcinoma (KB) cells</article-title><source>Mater. Sci. Eng. C Mater. Biol. Appl.</source><year>2014</year><volume>41</volume><fpage>274</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/j.msec.2014.04.056</pub-id><?supplied-pmid 24907761?><pub-id pub-id-type="pmid">24907761</pub-id></element-citation></ref><ref id="B294-pharmaceutics-13-00143"><label>294.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>N.</given-names></name><name><surname>Bharali</surname><given-names>D.J.</given-names></name><name><surname>Adhami</surname><given-names>V.M.</given-names></name><name><surname>Siddiqui</surname><given-names>I.A.</given-names></name><name><surname>Cui</surname><given-names>H.</given-names></name><name><surname>Shabana</surname><given-names>S.M.</given-names></name><name><surname>Mousa</surname><given-names>S.A.</given-names></name><name><surname>Mukhtar</surname><given-names>H.</given-names></name></person-group><article-title>Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model</article-title><source>Carcinogenesis</source><year>2014</year><volume>35</volume><fpage>415</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgt321</pub-id><?supplied-pmid 24072771?><pub-id pub-id-type="pmid">24072771</pub-id></element-citation></ref><ref id="B295-pharmaceutics-13-00143"><label>295.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majumdar</surname><given-names>D.</given-names></name><name><surname>Jung</surname><given-names>K.-H.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Nannapaneni</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Amin</surname><given-names>A.R.M.R.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>Z.G.</given-names></name><name><surname>Shin</surname><given-names>D.M.</given-names></name></person-group><article-title>Luteolin nanoparticle in chemoprevention: In vitro and in vivo anticancer activity</article-title><source>Cancer Prev. Res.</source><year>2014</year><volume>7</volume><fpage>65</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-13-0230</pub-id><?supplied-pmid 24403290?><pub-id pub-id-type="pmid">24403290</pub-id></element-citation></ref><ref id="B296-pharmaceutics-13-00143"><label>296.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Far</surname><given-names>A.H.</given-names></name><name><surname>Al Jaouni</surname><given-names>S.K.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Mousa</surname><given-names>S.A.</given-names></name></person-group><article-title>Protective Roles of Thymoquinone Nanoformulations: Potential Nanonutraceuticals in Human Diseases</article-title><source>Nutrients</source><year>2018</year><volume>10</volume><elocation-id>1369</elocation-id><pub-id pub-id-type="doi">10.3390/nu10101369</pub-id><?supplied-pmid 30257423?><pub-id pub-id-type="pmid">30257423</pub-id></element-citation></ref><ref id="B297-pharmaceutics-13-00143"><label>297.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballout</surname><given-names>F.</given-names></name><name><surname>Habli</surname><given-names>Z.</given-names></name><name><surname>Rahal</surname><given-names>O.N.</given-names></name><name><surname>Fatfat</surname><given-names>M.</given-names></name><name><surname>Gali-Muhtasib</surname><given-names>H.</given-names></name></person-group><article-title>Thymoquinone-based nanotechnology for cancer therapy: Promises and challenges</article-title><source>Drug Discov. Today</source><year>2018</year><volume>23</volume><fpage>1089</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2018.01.043</pub-id><pub-id pub-id-type="pmid">29374534</pub-id></element-citation></ref><ref id="B298-pharmaceutics-13-00143"><label>298.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazra</surname><given-names>B.</given-names></name><name><surname>Kumar</surname><given-names>B.</given-names></name><name><surname>Biswas</surname><given-names>S.</given-names></name><name><surname>Pandey</surname><given-names>B.N.</given-names></name><name><surname>Mishra</surname><given-names>K.P.</given-names></name></person-group><article-title>Enhancement of the tumour inhibitory activity, in vivo, of diospyrin, a plant-derived quinonoid, through liposomal encapsulation</article-title><source>Toxicol. Lett.</source><year>2005</year><volume>157</volume><fpage>109</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2005.01.016</pub-id><?supplied-pmid 15836998?><pub-id pub-id-type="pmid">15836998</pub-id></element-citation></ref><ref id="B299-pharmaceutics-13-00143"><label>299.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>P.</given-names></name><name><surname>Sundaram</surname><given-names>C.</given-names></name><name><surname>Jhurani</surname><given-names>S.</given-names></name><name><surname>Kunnumakkara</surname><given-names>A.B.</given-names></name><name><surname>Aggarwal</surname><given-names>B.B.</given-names></name></person-group><article-title>Curcumin and cancer: An &#x0201c;old-age&#x0201d; disease with an &#x0201c;age-old&#x0201d; solution</article-title><source>Cancer Lett.</source><year>2008</year><volume>267</volume><fpage>133</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2008.03.025</pub-id><pub-id pub-id-type="pmid">18462866</pub-id></element-citation></ref><ref id="B300-pharmaceutics-13-00143"><label>300.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nirmala</surname><given-names>C.</given-names></name><name><surname>Puvanakrishnan</surname><given-names>R.</given-names></name></person-group><article-title>Protective role of curcumin against isoproterenol induced myocardial infarction in rats</article-title><source>Mol. Cell. Biochem.</source><year>1996</year><volume>159</volume><fpage>85</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1007/BF00420910</pub-id><pub-id pub-id-type="pmid">8858558</pub-id></element-citation></ref><ref id="B301-pharmaceutics-13-00143"><label>301.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>W.C.</given-names></name><name><surname>Drew</surname><given-names>C.R.</given-names></name></person-group><article-title>Curcumin&#x02014;A natural herb with anti-HIV activity</article-title><source>J. Natl. Med. Assoc.</source><year>1996</year><volume>88</volume><fpage>333</fpage><pub-id pub-id-type="pmid">8691490</pub-id></element-citation></ref><ref id="B302-pharmaceutics-13-00143"><label>302.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>T.T.</given-names></name><name><surname>See</surname><given-names>P.</given-names></name><name><surname>Lee</surname><given-names>S.T.</given-names></name><name><surname>Chan</surname><given-names>S.Y.</given-names></name></person-group><article-title>Protective effects of curcumin against oxidative damage on skin cells in vitro: Its implication for wound healing</article-title><source>J. Trauma</source><year>2001</year><volume>51</volume><fpage>927</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1097/00005373-200111000-00017</pub-id><?supplied-pmid 11706342?><pub-id pub-id-type="pmid">11706342</pub-id></element-citation></ref><ref id="B303-pharmaceutics-13-00143"><label>303.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>G.P.</given-names></name><name><surname>Chu</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Beech</surname><given-names>W.</given-names></name><name><surname>Frautschy</surname><given-names>S.A.</given-names></name><name><surname>Cole</surname><given-names>G.M.</given-names></name></person-group><article-title>The Curry Spice Curcumin Reduces Oxidative Damage and Amyloid Pathology in an Alzheimer Transgenic Mouse</article-title><source>J. Neurosci.</source><year>2001</year><volume>21</volume><fpage>8370</fpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.21-21-08370.2001</pub-id><?supplied-pmid 11606625?><pub-id pub-id-type="pmid">11606625</pub-id></element-citation></ref><ref id="B304-pharmaceutics-13-00143"><label>304.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S.C.</given-names></name><name><surname>Patchva</surname><given-names>S.</given-names></name><name><surname>Koh</surname><given-names>W.</given-names></name><name><surname>Aggarwal</surname><given-names>B.B.</given-names></name></person-group><article-title>Discovery of curcumin, a component of golden spice, and its miraculous biological activities</article-title><source>Clin. Exp. Pharmacol. Physiol.</source><year>2012</year><volume>39</volume><fpage>283</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1681.2011.05648.x</pub-id><?supplied-pmid 22118895?><pub-id pub-id-type="pmid">22118895</pub-id></element-citation></ref><ref id="B305-pharmaceutics-13-00143"><label>305.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arablou</surname><given-names>T.</given-names></name><name><surname>Kolahdouz-Mohammadi</surname><given-names>R.</given-names></name></person-group><article-title>Curcumin and endometriosis: Review on potential roles and molecular mechanisms</article-title><source>Biomed. Pharm.</source><year>2018</year><volume>97</volume><fpage>91</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2017.10.119</pub-id></element-citation></ref><ref id="B306-pharmaceutics-13-00143"><label>306.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ak</surname><given-names>T.</given-names></name><name><surname>G&#x000fc;l&#x000e7;in</surname><given-names>&#x00130;.</given-names></name></person-group><article-title>Antioxidant and radical scavenging properties of curcumin</article-title><source>Chem. Biol. Interact.</source><year>2008</year><volume>174</volume><fpage>27</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2008.05.003</pub-id><pub-id pub-id-type="pmid">18547552</pub-id></element-citation></ref><ref id="B307-pharmaceutics-13-00143"><label>307.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>O.P.</given-names></name></person-group><article-title>Antioxidant activity of curcumin and related compounds</article-title><source>Biochem. Pharm.</source><year>1976</year><volume>25</volume><fpage>1811</fpage><lpage>1812</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(76)90421-4</pub-id><pub-id pub-id-type="pmid">942483</pub-id></element-citation></ref><ref id="B308-pharmaceutics-13-00143"><label>308.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharyya</surname><given-names>S.</given-names></name><name><surname>Mandal</surname><given-names>D.</given-names></name><name><surname>Sen</surname><given-names>G.S.</given-names></name><name><surname>Pal</surname><given-names>S.</given-names></name><name><surname>Banerjee</surname><given-names>S.</given-names></name><name><surname>Lahiry</surname><given-names>L.</given-names></name><name><surname>Finke</surname><given-names>J.H.</given-names></name><name><surname>Tannenbaum</surname><given-names>C.S.</given-names></name><name><surname>Das</surname><given-names>T.</given-names></name><name><surname>Sa</surname><given-names>G.</given-names></name></person-group><article-title>Tumor-induced oxidative stress perturbs nuclear factor-kappaB activity-augmenting tumor necrosis factor-alpha-mediated T-cell death: Protection by curcumin</article-title><source>Cancer Res.</source><year>2007</year><volume>67</volume><fpage>362</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-2583</pub-id><pub-id pub-id-type="pmid">17210719</pub-id></element-citation></ref><ref id="B309-pharmaceutics-13-00143"><label>309.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandur</surname><given-names>S.K.</given-names></name><name><surname>Pandey</surname><given-names>M.K.</given-names></name><name><surname>Sung</surname><given-names>B.</given-names></name><name><surname>Ahn</surname><given-names>K.S.</given-names></name><name><surname>Murakami</surname><given-names>A.</given-names></name><name><surname>Sethi</surname><given-names>G.</given-names></name><name><surname>Limtrakul</surname><given-names>P.</given-names></name><name><surname>Badmaev</surname><given-names>V.</given-names></name><name><surname>Aggarwal</surname><given-names>B.B.</given-names></name></person-group><article-title>Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism</article-title><source>Carcinogenesis</source><year>2007</year><volume>28</volume><fpage>1765</fpage><lpage>1773</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgm123</pub-id><pub-id pub-id-type="pmid">17522064</pub-id></element-citation></ref><ref id="B310-pharmaceutics-13-00143"><label>310.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De</surname><given-names>R.</given-names></name><name><surname>Kundu</surname><given-names>P.</given-names></name><name><surname>Swarnakar</surname><given-names>S.</given-names></name><name><surname>Ramamurthy</surname><given-names>T.</given-names></name><name><surname>Chowdhury</surname><given-names>A.</given-names></name><name><surname>Nair</surname><given-names>G.B.</given-names></name><name><surname>Mukhopadhyay</surname><given-names>A.K.</given-names></name></person-group><article-title>Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice</article-title><source>Antimicrob. Agents Chemother.</source><year>2009</year><volume>53</volume><fpage>1592</fpage><lpage>1597</lpage><pub-id pub-id-type="doi">10.1128/AAC.01242-08</pub-id><pub-id pub-id-type="pmid">19204190</pub-id></element-citation></ref><ref id="B311-pharmaceutics-13-00143"><label>311.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mun</surname><given-names>S.H.</given-names></name><name><surname>Joung</surname><given-names>D.K.</given-names></name><name><surname>Kim</surname><given-names>Y.S.</given-names></name><name><surname>Kang</surname><given-names>O.H.</given-names></name><name><surname>Kim</surname><given-names>S.B.</given-names></name><name><surname>Seo</surname><given-names>Y.S.</given-names></name><name><surname>Kim</surname><given-names>Y.C.</given-names></name><name><surname>Lee</surname><given-names>D.S.</given-names></name><name><surname>Shin</surname><given-names>D.W.</given-names></name><name><surname>Kweon</surname><given-names>K.T.</given-names></name><etal/></person-group><article-title>Synergistic antibacterial effect of curcumin against methicillin-resistant Staphylococcus aureus</article-title><source>Phytomedicine</source><year>2013</year><volume>20</volume><fpage>714</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2013.02.006</pub-id><pub-id pub-id-type="pmid">23537748</pub-id></element-citation></ref><ref id="B312-pharmaceutics-13-00143"><label>312.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neelofar</surname><given-names>K.</given-names></name><name><surname>Shreaz</surname><given-names>S.</given-names></name><name><surname>Rimple</surname><given-names>B.</given-names></name><name><surname>Muralidhar</surname><given-names>S.</given-names></name><name><surname>Nikhat</surname><given-names>M.</given-names></name><name><surname>Khan</surname><given-names>L.A.</given-names></name></person-group><article-title>Curcumin as a promising anticandidal of clinical interest</article-title><source>Can. J. Microbiol.</source><year>2011</year><volume>57</volume><fpage>204</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1139/W10-117</pub-id><?supplied-pmid 21358761?><pub-id pub-id-type="pmid">21358761</pub-id></element-citation></ref><ref id="B313-pharmaceutics-13-00143"><label>313.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalil</surname><given-names>O.A.K.</given-names></name><name><surname>de Faria Oliveira</surname><given-names>O.M.M.</given-names></name><name><surname>Vellosa</surname><given-names>J.C.R.</given-names></name><name><surname>de Quadros</surname><given-names>A.U.</given-names></name><name><surname>Dalposso</surname><given-names>L.M.</given-names></name><name><surname>Karam</surname><given-names>T.K.</given-names></name><name><surname>Mainardes</surname><given-names>R.M.</given-names></name><name><surname>Khalil</surname><given-names>N.M.</given-names></name></person-group><article-title>Curcumin antifungal and antioxidant activities are increased in the presence of ascorbic acid</article-title><source>Food Chem.</source><year>2012</year><volume>133</volume><fpage>1001</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2012.02.009</pub-id></element-citation></ref><ref id="B314-pharmaceutics-13-00143"><label>314.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomeh</surname><given-names>M.A.</given-names></name><name><surname>Hadianamrei</surname><given-names>R.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name></person-group><article-title>A Review of Curcumin and Its Derivatives as Anticancer Agents</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><elocation-id>1033</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20051033</pub-id><?supplied-pmid 30818786?><pub-id pub-id-type="pmid">30818786</pub-id></element-citation></ref><ref id="B315-pharmaceutics-13-00143"><label>315.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>He</surname><given-names>Z.M.</given-names></name><name><surname>Wang</surname><given-names>F.L.</given-names></name><name><surname>Zhang</surname><given-names>Z.S.</given-names></name><name><surname>Liu</surname><given-names>X.Z.</given-names></name><name><surname>Zhai</surname><given-names>D.D.</given-names></name><name><surname>Chen</surname><given-names>W.D.</given-names></name></person-group><article-title>Curcumin and its promise as an anticancer drug: An analysis of its anticancer and antifungal effects in cancer and associated complications from invasive fungal infections</article-title><source>Eur. J. Pharm.</source><year>2016</year><volume>772</volume><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2015.12.038</pub-id></element-citation></ref><ref id="B316-pharmaceutics-13-00143"><label>316.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravindranath</surname><given-names>V.</given-names></name><name><surname>Chandrasekhara</surname><given-names>N.</given-names></name></person-group><article-title>Absorption and tissue distribution of curcumin in rats</article-title><source>Toxicology</source><year>1980</year><volume>16</volume><fpage>259</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/0300-483X(80)90122-5</pub-id><pub-id pub-id-type="pmid">7423534</pub-id></element-citation></ref><ref id="B317-pharmaceutics-13-00143"><label>317.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravindranath</surname><given-names>V.</given-names></name><name><surname>Chandrasekhara</surname><given-names>N.</given-names></name></person-group><article-title>In vitro studies on the intestinal absorption of curcumin in rats</article-title><source>Toxicology</source><year>1981</year><volume>20</volume><fpage>251</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/0300-483X(81)90056-1</pub-id><pub-id pub-id-type="pmid">7256789</pub-id></element-citation></ref><ref id="B318-pharmaceutics-13-00143"><label>318.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravindranath</surname><given-names>V.</given-names></name><name><surname>Chandrasekhara</surname><given-names>N.</given-names></name></person-group><article-title>Metabolism of curcumn-studies with [3H]curcumin</article-title><source>Toxicology</source><year>1981</year><volume>22</volume><fpage>337</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1016/0300-483X(81)90027-5</pub-id><pub-id pub-id-type="pmid">7342372</pub-id></element-citation></ref><ref id="B319-pharmaceutics-13-00143"><label>319.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>N.K.</given-names></name><name><surname>Dixit</surname><given-names>V.K.</given-names></name></person-group><article-title>Bioavailability Enhancement of Curcumin by Complexation with Phosphatidyl Choline</article-title><source>J. Pharm. Sci.</source><year>2011</year><volume>100</volume><fpage>1987</fpage><lpage>1995</lpage><pub-id pub-id-type="doi">10.1002/jps.22393</pub-id><?supplied-pmid 21374628?><pub-id pub-id-type="pmid">21374628</pub-id></element-citation></ref><ref id="B320-pharmaceutics-13-00143"><label>320.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bollu</surname><given-names>V.S.</given-names></name><name><surname>Barui</surname><given-names>A.K.</given-names></name><name><surname>Mondal</surname><given-names>S.K.</given-names></name><name><surname>Prashar</surname><given-names>S.</given-names></name><name><surname>Fajardo</surname><given-names>M.</given-names></name><name><surname>Briones</surname><given-names>D.</given-names></name><name><surname>Rodr&#x000ed;guez-Di&#x000e9;guez</surname><given-names>A.</given-names></name><name><surname>Patra</surname><given-names>C.R.</given-names></name><name><surname>G&#x000f3;mez-Ruiz</surname><given-names>S.</given-names></name></person-group><article-title>Curcumin-loaded silica-based mesoporous materials: Synthesis, characterization and cytotoxic properties against cancer cells</article-title><source>Mater. Sci. Eng. C</source><year>2016</year><volume>63</volume><fpage>393</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1016/j.msec.2016.03.011</pub-id></element-citation></ref><ref id="B321-pharmaceutics-13-00143"><label>321.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Datz</surname><given-names>S.</given-names></name><name><surname>Engelke</surname><given-names>H.</given-names></name><name><surname>Schirnding</surname><given-names>C.V.</given-names></name><name><surname>Nguyen</surname><given-names>L.</given-names></name><name><surname>Bein</surname><given-names>T.</given-names></name></person-group><article-title>Lipid bilayer-coated curcumin-based mesoporous organosilica nanoparticles for cellular delivery</article-title><source>Microporous Mesoporous Mater.</source><year>2016</year><volume>225</volume><fpage>371</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1016/j.micromeso.2015.12.006</pub-id></element-citation></ref><ref id="B322-pharmaceutics-13-00143"><label>322.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahmatolahzadeh</surname><given-names>R.</given-names></name><name><surname>Hamadanian</surname><given-names>M.</given-names></name><name><surname>Ma&#x02019;mani</surname><given-names>L.</given-names></name><name><surname>Shafiee</surname><given-names>A.</given-names></name></person-group><article-title>Aspartic acid functionalized PEGylated MSN@GO hybrid as an effective and sustainable nano-system for in-vitro drug delivery</article-title><source>Adv. Med. Sci.</source><year>2018</year><volume>63</volume><fpage>257</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1016/j.advms.2018.01.003</pub-id><?supplied-pmid 29486375?><pub-id pub-id-type="pmid">29486375</pub-id></element-citation></ref><ref id="B323-pharmaceutics-13-00143"><label>323.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Cai</surname><given-names>L.</given-names></name><name><surname>Tian</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>Phytochemical Curcumin-Coformulated, Silver-Decorated Melanin-like Polydopamine/Mesoporous Silica Composites with Improved Antibacterial and Chemotherapeutic Effects against Drug-Resistant Cancer Cells</article-title><source>ACS Omega</source><year>2020</year><volume>5</volume><fpage>15083</fpage><lpage>15094</lpage><pub-id pub-id-type="doi">10.1021/acsomega.0c00912</pub-id><?supplied-pmid 32637781?><pub-id pub-id-type="pmid">32637781</pub-id></element-citation></ref><ref id="B324-pharmaceutics-13-00143"><label>324.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Fan</surname><given-names>K.</given-names></name><name><surname>Jin</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Lin</surname><given-names>J.</given-names></name><etal/></person-group><article-title>PEGylated lipid bilayer coated mesoporous silica nanoparticles co-delivery of paclitaxel and curcumin leads to increased tumor site drug accumulation and reduced tumor burden</article-title><source>Eur. J. Pharm. Sci.</source><year>2019</year><volume>140</volume><fpage>105070</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2019.105070</pub-id><?supplied-pmid 31518679?><pub-id pub-id-type="pmid">31518679</pub-id></element-citation></ref><ref id="B325-pharmaceutics-13-00143"><label>325.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Yang</surname><given-names>L.-Y.</given-names></name><name><surname>Ouyang</surname><given-names>X.-K.</given-names></name><name><surname>Huang</surname><given-names>F.</given-names></name></person-group><article-title>Folic Acid and PEI Modified Mesoporous Silica for Targeted Delivery of Curcumin</article-title><source>Pharmaceutics</source><year>2019</year><volume>11</volume><elocation-id>430</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics11090430</pub-id></element-citation></ref><ref id="B326-pharmaceutics-13-00143"><label>326.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mashayekhi</surname><given-names>S.</given-names></name><name><surname>Rasoulpoor</surname><given-names>S.</given-names></name><name><surname>Shabani</surname><given-names>S.</given-names></name><name><surname>Esmaeilizadeh</surname><given-names>N.</given-names></name><name><surname>Serati-Nouri</surname><given-names>H.</given-names></name><name><surname>Sheervalilou</surname><given-names>R.</given-names></name><name><surname>Pilehvar-Soltanahmadi</surname><given-names>Y.</given-names></name></person-group><article-title>Curcumin-loaded mesoporous silica nanoparticles/nanofiber composites for supporting long-term proliferation and stemness preservation of adipose-derived stem cells</article-title><source>Int. J. Pharm.</source><year>2020</year><volume>587</volume><fpage>119656</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119656</pub-id><?supplied-pmid 32687972?><pub-id pub-id-type="pmid">32687972</pub-id></element-citation></ref><ref id="B327-pharmaceutics-13-00143"><label>327.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Shao</surname><given-names>L.</given-names></name><name><surname>Usman</surname><given-names>I.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Pan</surname><given-names>A.</given-names></name><name><surname>Liang</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name></person-group><article-title>A pH-responsive dissociable mesoporous silica-based nanoplatform enabling efficient dual-drug co-delivery and rapid clearance for cancer therapy</article-title><source>Biomater. Sci.</source><year>2020</year><volume>8</volume><fpage>3418</fpage><lpage>3429</lpage><pub-id pub-id-type="doi">10.1039/D0BM00204F</pub-id><pub-id pub-id-type="pmid">32405634</pub-id></element-citation></ref><ref id="B328-pharmaceutics-13-00143"><label>328.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wibowo</surname><given-names>F.R.</given-names></name><name><surname>Saputra</surname><given-names>O.A.</given-names></name><name><surname>Lestari</surname><given-names>W.W.</given-names></name><name><surname>Koketsu</surname><given-names>M.</given-names></name><name><surname>Mukti</surname><given-names>R.R.</given-names></name><name><surname>Martien</surname><given-names>R.</given-names></name></person-group><article-title>pH-Triggered Drug Release Controlled by Poly(Styrene Sulfonate) Growth Hollow Mesoporous Silica Nanoparticles</article-title><source>ACS Omega</source><year>2020</year><volume>5</volume><fpage>4261</fpage><lpage>4269</lpage><pub-id pub-id-type="doi">10.1021/acsomega.9b04167</pub-id><pub-id pub-id-type="pmid">32149256</pub-id></element-citation></ref><ref id="B329-pharmaceutics-13-00143"><label>329.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>Z.L.</given-names></name><name><surname>Kuo</surname><given-names>H.P.</given-names></name><name><surname>Johnson</surname><given-names>A.</given-names></name><name><surname>Wu</surname><given-names>L.C.</given-names></name><name><surname>Chang</surname><given-names>K.L.B.</given-names></name></person-group><article-title>Curcumin-Loaded Mesoporous Silica Nanoparticles Markedly Enhanced Cytotoxicity in Hepatocellular Carcinoma Cells</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><elocation-id>2918</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20122918</pub-id></element-citation></ref><ref id="B330-pharmaceutics-13-00143"><label>330.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harini</surname><given-names>L.</given-names></name><name><surname>Srivastava</surname><given-names>S.</given-names></name><name><surname>Gnanakumar</surname><given-names>G.P.</given-names></name><name><surname>Karthikeyan</surname><given-names>B.</given-names></name><name><surname>Ross</surname><given-names>C.</given-names></name><name><surname>Krishnakumar</surname><given-names>V.</given-names></name><name><surname>Kannan</surname><given-names>V.R.</given-names></name><name><surname>Sundar</surname><given-names>K.</given-names></name><name><surname>Kathiresan</surname><given-names>T.</given-names></name></person-group><article-title>An ingenious non-spherical mesoporous silica nanoparticle cargo with curcumin induces mitochondria-mediated apoptosis in breast cancer (MCF-7) cells</article-title><source>Oncotarget</source><year>2019</year><volume>10</volume><fpage>1193</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.26623</pub-id><pub-id pub-id-type="pmid">30838091</pub-id></element-citation></ref><ref id="B331-pharmaceutics-13-00143"><label>331.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Sun</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name></person-group><article-title>Rational design of curcumin loaded multifunctional mesoporous silica nanoparticles to enhance the cytotoxicity for targeted and controlled drug release</article-title><source>Mater. Sci. Eng. C</source><year>2018</year><volume>85</volume><fpage>88</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.msec.2017.12.007</pub-id></element-citation></ref><ref id="B332-pharmaceutics-13-00143"><label>332.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Bai</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier</article-title><source>Int. J. Nanomed.</source><year>2017</year><volume>12</volume><fpage>4361</fpage><lpage>4370</lpage><pub-id pub-id-type="doi">10.2147/IJN.S135626</pub-id><?supplied-pmid 28652738?><pub-id pub-id-type="pmid">28652738</pub-id></element-citation></ref><ref id="B333-pharmaceutics-13-00143"><label>333.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harini</surname><given-names>L.</given-names></name><name><surname>Karthikeyan</surname><given-names>B.</given-names></name><name><surname>Srivastava</surname><given-names>S.</given-names></name><name><surname>Suresh</surname><given-names>S.B.</given-names></name><name><surname>Ross</surname><given-names>C.</given-names></name><name><surname>Gnanakumar</surname><given-names>G.</given-names></name><name><surname>Rajagopal</surname><given-names>S.</given-names></name><name><surname>Sundar</surname><given-names>K.</given-names></name><name><surname>Kathiresan</surname><given-names>T.</given-names></name></person-group><article-title>Polyethylenimine-modified curcumin-loaded mesoporus silica nanoparticle (MCM-41) induces cell death in MCF-7 cell line</article-title><source>IET Nanobiotechnol.</source><year>2017</year><volume>11</volume><fpage>57</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1049/iet-nbt.2016.0075</pub-id><?supplied-pmid 28476962?><pub-id pub-id-type="pmid">28476962</pub-id></element-citation></ref><ref id="B334-pharmaceutics-13-00143"><label>334.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiwari</surname><given-names>N.</given-names></name><name><surname>Nawale</surname><given-names>L.</given-names></name><name><surname>Sarkar</surname><given-names>D.</given-names></name><name><surname>Badiger</surname><given-names>M.V.</given-names></name></person-group><article-title>Carboxymethyl Cellulose-Grafted Mesoporous Silica Hybrid Nanogels for Enhanced Cellular Uptake and Release of Curcumin</article-title><source>Gels</source><year>2017</year><volume>3</volume><elocation-id>8</elocation-id><pub-id pub-id-type="doi">10.3390/gels3010008</pub-id><?supplied-pmid 30920505?><pub-id pub-id-type="pmid">30920505</pub-id></element-citation></ref><ref id="B335-pharmaceutics-13-00143"><label>335.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>R.</given-names></name><name><surname>Yu</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name></person-group><article-title>Rational Design of Multifunctional Dendritic Mesoporous Silica Nanoparticles to Load Curcumin and Enhance Efficacy for Breast Cancer Therapy</article-title><source>ACS Appl. Mater. Interfaces</source><year>2016</year><volume>8</volume><fpage>26511</fpage><lpage>26523</lpage><pub-id pub-id-type="doi">10.1021/acsami.6b08400</pub-id><pub-id pub-id-type="pmid">27619078</pub-id></element-citation></ref><ref id="B336-pharmaceutics-13-00143"><label>336.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotcherlakota</surname><given-names>R.</given-names></name><name><surname>Barui</surname><given-names>A.K.</given-names></name><name><surname>Prashar</surname><given-names>S.</given-names></name><name><surname>Fajardo</surname><given-names>M.</given-names></name><name><surname>Briones</surname><given-names>D.</given-names></name><name><surname>Rodr&#x000ed;guez-Di&#x000e9;guez</surname><given-names>A.</given-names></name><name><surname>Patra</surname><given-names>C.R.</given-names></name><name><surname>G&#x000f3;mez-Ruiz</surname><given-names>S.</given-names></name></person-group><article-title>Curcumin loaded mesoporous silica: An effective drug delivery system for cancer treatment</article-title><source>Biomater. Sci.</source><year>2016</year><volume>4</volume><fpage>448</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1039/C5BM00552C</pub-id><pub-id pub-id-type="pmid">26674254</pub-id></element-citation></ref><ref id="B337-pharmaceutics-13-00143"><label>337.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Yao</surname><given-names>J.</given-names></name><name><surname>Han</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Chaudhry</surname><given-names>M.T.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Yin</surname><given-names>Y.</given-names></name></person-group><article-title>Quercetin, Inflammation and Immunity</article-title><source>Nutrients</source><year>2016</year><volume>8</volume><elocation-id>167</elocation-id><pub-id pub-id-type="doi">10.3390/nu8030167</pub-id><pub-id pub-id-type="pmid">26999194</pub-id></element-citation></ref><ref id="B338-pharmaceutics-13-00143"><label>338.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>J.M.</given-names></name><name><surname>Murphy</surname><given-names>E.A.</given-names></name><name><surname>Carmichael</surname><given-names>M.D.</given-names></name></person-group><article-title>Effects of the dietary flavonoid quercetin upon performance and health</article-title><source>Curr. Sports Med. Rep.</source><year>2009</year><volume>8</volume><fpage>206</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1249/JSR.0b013e3181ae8959</pub-id><pub-id pub-id-type="pmid">19584608</pub-id></element-citation></ref><ref id="B339-pharmaceutics-13-00143"><label>339.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamson</surname><given-names>D.W.</given-names></name><name><surname>Brignall</surname><given-names>M.S.</given-names></name></person-group><article-title>Antioxidants and cancer, part 3: Quercetin</article-title><source>Altern. Med. Rev.</source><year>2000</year><volume>5</volume><fpage>196</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">10869101</pub-id></element-citation></ref><ref id="B340-pharmaceutics-13-00143"><label>340.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boots</surname><given-names>A.W.</given-names></name><name><surname>Haenen</surname><given-names>G.R.</given-names></name><name><surname>Bast</surname><given-names>A.</given-names></name></person-group><article-title>Health effects of quercetin: From antioxidant to nutraceutical</article-title><source>Eur. J. Pharm.</source><year>2008</year><volume>585</volume><fpage>325</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2008.03.008</pub-id></element-citation></ref><ref id="B341-pharmaceutics-13-00143"><label>341.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>H.J.</given-names></name><name><surname>Song</surname><given-names>J.H.</given-names></name><name><surname>Park</surname><given-names>K.S.</given-names></name><name><surname>Kwon</surname><given-names>D.H.</given-names></name></person-group><article-title>Inhibitory effects of quercetin 3-rhamnoside on influenza A virus replication</article-title><source>Eur. J. Pharm. Sci.</source><year>2009</year><volume>37</volume><fpage>329</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2009.03.002</pub-id><pub-id pub-id-type="pmid">19491023</pub-id></element-citation></ref><ref id="B342-pharmaceutics-13-00143"><label>342.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rotelli</surname><given-names>A.E.</given-names></name><name><surname>Guardia</surname><given-names>T.</given-names></name><name><surname>Ju&#x000e1;rez</surname><given-names>A.O.</given-names></name><name><surname>de la Rocha</surname><given-names>N.E.</given-names></name><name><surname>Pelzer</surname><given-names>L.E.</given-names></name></person-group><article-title>Comparative study of flavonoids in experimental models of inflammation</article-title><source>Pharm. Res.</source><year>2003</year><volume>48</volume><fpage>601</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1016/S1043-6618(03)00225-1</pub-id></element-citation></ref><ref id="B343-pharmaceutics-13-00143"><label>343.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>B.</given-names></name><name><surname>Gupta</surname><given-names>S.K.</given-names></name><name><surname>Nag</surname><given-names>T.C.</given-names></name><name><surname>Srivastava</surname><given-names>S.</given-names></name><name><surname>Saxena</surname><given-names>R.</given-names></name><name><surname>Jha</surname><given-names>K.A.</given-names></name><name><surname>Srinivasan</surname><given-names>B.P.</given-names></name></person-group><article-title>Retinal neuroprotective effects of quercetin in streptozotocin-induced diabetic rats</article-title><source>Exp. Eye Res.</source><year>2014</year><volume>125</volume><fpage>193</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2014.06.009</pub-id><?supplied-pmid 24952278?><pub-id pub-id-type="pmid">24952278</pub-id></element-citation></ref><ref id="B344-pharmaceutics-13-00143"><label>344.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>X.T.</given-names></name><name><surname>Ding</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>N.</given-names></name><name><surname>Xu</surname><given-names>C.</given-names></name></person-group><article-title>Quercetin protects gastric epithelial cell from oxidative damage in vitro and in vivo</article-title><source>Eur. J. Pharm.</source><year>2015</year><volume>754</volume><fpage>115</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2015.02.007</pub-id><?supplied-pmid 25701726?><pub-id pub-id-type="pmid">25701726</pub-id></element-citation></ref><ref id="B345-pharmaceutics-13-00143"><label>345.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguirre</surname><given-names>L.</given-names></name><name><surname>Arias</surname><given-names>N.</given-names></name><name><surname>Teresa Macarulla</surname><given-names>M.</given-names></name><name><surname>Gracia</surname><given-names>A.</given-names></name><name><surname>Portillo</surname><given-names>M.P.</given-names></name></person-group><article-title>Beneficial effects of quercetin on obesity and diabetes</article-title><source>Open Nutraceuticals J.</source><year>2011</year><volume>4</volume><fpage>189</fpage><lpage>198</lpage></element-citation></ref><ref id="B346-pharmaceutics-13-00143"><label>346.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Liang</surname><given-names>Q.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Fan</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Pan</surname><given-names>H.</given-names></name><name><surname>Fei</surname><given-names>B.</given-names></name></person-group><article-title>Systematic Elucidation of the Mechanism of Quercetin against Gastric Cancer via Network Pharmacology Approach</article-title><source>BioMed Res. Int.</source><year>2020</year><volume>2020</volume><fpage>3860213</fpage><pub-id pub-id-type="doi">10.1155/2020/3860213</pub-id><?supplied-pmid 32964029?><pub-id pub-id-type="pmid">32964029</pub-id></element-citation></ref><ref id="B347-pharmaceutics-13-00143"><label>347.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>M.J.</given-names></name><name><surname>Wang</surname><given-names>Y.Q.</given-names></name><name><surname>Cui</surname><given-names>Y.L.</given-names></name></person-group><article-title>Antioxidant Activities of Quercetin and Its Complexes for Medicinal Application</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>1123</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24061123</pub-id></element-citation></ref><ref id="B348-pharmaceutics-13-00143"><label>348.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauf</surname><given-names>A.</given-names></name><name><surname>Imran</surname><given-names>M.</given-names></name><name><surname>Khan</surname><given-names>I.A.</given-names></name><name><surname>Ur-Rehman</surname><given-names>M.</given-names></name><name><surname>Gilani</surname><given-names>S.A.</given-names></name><name><surname>Mehmood</surname><given-names>Z.</given-names></name><name><surname>Mubarak</surname><given-names>M.S.</given-names></name></person-group><article-title>Anticancer potential of quercetin: A comprehensive review</article-title><source>Phytother. Res.</source><year>2018</year><volume>32</volume><fpage>2109</fpage><lpage>2130</lpage><pub-id pub-id-type="doi">10.1002/ptr.6155</pub-id><pub-id pub-id-type="pmid">30039547</pub-id></element-citation></ref><ref id="B349-pharmaceutics-13-00143"><label>349.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname><given-names>O.K.</given-names></name><name><surname>Chung</surname><given-names>S.J.</given-names></name><name><surname>Song</surname><given-names>W.O.</given-names></name></person-group><article-title>Estimated dietary flavonoid intake and major food sources of U.S. adults</article-title><source>J. Nutr.</source><year>2007</year><volume>137</volume><fpage>1244</fpage><lpage>1252</lpage><pub-id pub-id-type="doi">10.1093/jn/137.5.1244</pub-id><pub-id pub-id-type="pmid">17449588</pub-id></element-citation></ref><ref id="B350-pharmaceutics-13-00143"><label>350.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gugler</surname><given-names>R.</given-names></name><name><surname>Leschik</surname><given-names>M.</given-names></name><name><surname>Dengler</surname><given-names>H.J.</given-names></name></person-group><article-title>Disposition of quercetin in man after single oral and intravenous doses</article-title><source>Eur. J. Clin. Pharm.</source><year>1975</year><volume>9</volume><fpage>229</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1007/BF00614022</pub-id></element-citation></ref><ref id="B351-pharmaceutics-13-00143"><label>351.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egert</surname><given-names>S.</given-names></name><name><surname>Wolffram</surname><given-names>S.</given-names></name><name><surname>Bosy-Westphal</surname><given-names>A.</given-names></name><name><surname>Boesch-Saadatmandi</surname><given-names>C.</given-names></name><name><surname>Wagner</surname><given-names>A.E.</given-names></name><name><surname>Frank</surname><given-names>J.</given-names></name><name><surname>Rimbach</surname><given-names>G.</given-names></name><name><surname>Mueller</surname><given-names>M.J.</given-names></name></person-group><article-title>Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans</article-title><source>J. Nutr.</source><year>2008</year><volume>138</volume><fpage>1615</fpage><lpage>1621</lpage><pub-id pub-id-type="doi">10.1093/jn/138.9.1615</pub-id><pub-id pub-id-type="pmid">18716159</pub-id></element-citation></ref><ref id="B352-pharmaceutics-13-00143"><label>352.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Thangasamy</surname><given-names>T.</given-names></name><name><surname>Sittadjody</surname><given-names>S.</given-names></name><name><surname>Burd</surname><given-names>R.</given-names></name></person-group><article-title>Quercetin: A potential complementary and alternative cancer therapy</article-title><source>Complementary and Alternative Therapies and the Aging Population</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2009</year><fpage>563</fpage><lpage>584</lpage></element-citation></ref><ref id="B353-pharmaceutics-13-00143"><label>353.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novo</surname><given-names>M.C.</given-names></name><name><surname>Osugui</surname><given-names>L.</given-names></name><name><surname>dos Reis</surname><given-names>V.O.</given-names></name><name><surname>Longo-Maug&#x000e9;ri</surname><given-names>I.M.</given-names></name><name><surname>Mariano</surname><given-names>M.</given-names></name><name><surname>Popi</surname><given-names>A.F.</given-names></name></person-group><article-title>Blockage of Wnt/&#x003b2;-catenin signaling by quercetin reduces survival and proliferation of B-1 cells in vitro</article-title><source>Immunobiology</source><year>2015</year><volume>220</volume><fpage>60</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2014.09.001</pub-id><?supplied-pmid 25245014?><pub-id pub-id-type="pmid">25245014</pub-id></element-citation></ref><ref id="B354-pharmaceutics-13-00143"><label>354.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharmila</surname><given-names>G.</given-names></name><name><surname>Bhat</surname><given-names>F.A.</given-names></name><name><surname>Arunkumar</surname><given-names>R.</given-names></name><name><surname>Elumalai</surname><given-names>P.</given-names></name><name><surname>Raja Singh</surname><given-names>P.</given-names></name><name><surname>Senthilkumar</surname><given-names>K.</given-names></name><name><surname>Arunakaran</surname><given-names>J.</given-names></name></person-group><article-title>Chemopreventive effect of quercetin, a natural dietary flavonoid on prostate cancer in in vivo model</article-title><source>Clin. Nutr.</source><year>2014</year><volume>33</volume><fpage>718</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2013.08.011</pub-id><?supplied-pmid 24080313?><pub-id pub-id-type="pmid">24080313</pub-id></element-citation></ref><ref id="B355-pharmaceutics-13-00143"><label>355.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vafadar</surname><given-names>A.</given-names></name><name><surname>Shabaninejad</surname><given-names>Z.</given-names></name><name><surname>Movahedpour</surname><given-names>A.</given-names></name><name><surname>Fallahi</surname><given-names>F.</given-names></name><name><surname>Taghavipour</surname><given-names>M.</given-names></name><name><surname>Ghasemi</surname><given-names>Y.</given-names></name><name><surname>Akbari</surname><given-names>M.</given-names></name><name><surname>Shafiee</surname><given-names>A.</given-names></name><name><surname>Hajighadimi</surname><given-names>S.</given-names></name><name><surname>Moradizarmehri</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Quercetin and cancer: New insights into its therapeutic effects on ovarian cancer cells</article-title><source>Cell. Biosci.</source><year>2020</year><volume>10</volume><fpage>32</fpage><pub-id pub-id-type="doi">10.1186/s13578-020-00397-0</pub-id><pub-id pub-id-type="pmid">32175075</pub-id></element-citation></ref><ref id="B356-pharmaceutics-13-00143"><label>356.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fern&#x000e1;ndez-Palanca</surname><given-names>P.</given-names></name><name><surname>Fondevila</surname><given-names>F.</given-names></name><name><surname>M&#x000e9;ndez-Blanco</surname><given-names>C.</given-names></name><name><surname>Tu&#x000f1;&#x000f3;n</surname><given-names>M.J.</given-names></name><name><surname>Gonz&#x000e1;lez-Gallego</surname><given-names>J.</given-names></name><name><surname>Mauriz</surname><given-names>J.L.</given-names></name></person-group><article-title>Antitumor Effects of Quercetin in Hepatocarcinoma In Vitro and In Vivo Models: A Systematic Review</article-title><source>Nutrients</source><year>2019</year><volume>11</volume><elocation-id>2875</elocation-id><pub-id pub-id-type="doi">10.3390/nu11122875</pub-id><?supplied-pmid 31775362?><pub-id pub-id-type="pmid">31775362</pub-id></element-citation></ref><ref id="B357-pharmaceutics-13-00143"><label>357.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jana</surname><given-names>N.</given-names></name><name><surname>B&#x00159;etislav</surname><given-names>G.</given-names></name><name><surname>Pavel</surname><given-names>S.</given-names></name><name><surname>Pavla</surname><given-names>U.</given-names></name></person-group><article-title>Potential of the Flavonoid Quercetin to Prevent and Treat Cancer&#x02014;Current Status of Research</article-title><source>Klin. Onkol.</source><year>2018</year><volume>31</volume><fpage>184</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.14735/amko2018184</pub-id><?supplied-pmid 30441971?><pub-id pub-id-type="pmid">30441971</pub-id></element-citation></ref><ref id="B358-pharmaceutics-13-00143"><label>358.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>A.B.</given-names></name><name><surname>Mir</surname><given-names>H.</given-names></name><name><surname>Kapur</surname><given-names>N.</given-names></name><name><surname>Gales</surname><given-names>D.N.</given-names></name><name><surname>Carriere</surname><given-names>P.P.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name></person-group><article-title>Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways</article-title><source>World J. Surg. Oncol.</source><year>2018</year><volume>16</volume><fpage>108</fpage><pub-id pub-id-type="doi">10.1186/s12957-018-1400-z</pub-id><?supplied-pmid 29898731?><pub-id pub-id-type="pmid">29898731</pub-id></element-citation></ref><ref id="B359-pharmaceutics-13-00143"><label>359.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>S.M.</given-names></name><name><surname>Deng</surname><given-names>X.T.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Q.P.</given-names></name><name><surname>Ge</surname><given-names>X.X.</given-names></name><name><surname>Miao</surname><given-names>L.</given-names></name></person-group><article-title>Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects</article-title><source>Biomed. Pharm.</source><year>2020</year><volume>121</volume><fpage>109604</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2019.109604</pub-id></element-citation></ref><ref id="B360-pharmaceutics-13-00143"><label>360.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>A.</given-names></name><name><surname>Ashida</surname><given-names>H.</given-names></name><name><surname>Terao</surname><given-names>J.</given-names></name></person-group><article-title>Multitargeted cancer prevention by quercetin</article-title><source>Cancer Lett.</source><year>2008</year><volume>269</volume><fpage>315</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2008.03.046</pub-id><pub-id pub-id-type="pmid">18467024</pub-id></element-citation></ref><ref id="B361-pharmaceutics-13-00143"><label>361.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>X.</given-names></name><name><surname>Fang</surname><given-names>Z.</given-names></name><name><surname>Dou</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>A.</given-names></name><name><surname>Zhai</surname><given-names>G.</given-names></name></person-group><article-title>Bioavailability of quercetin: Problems and promises</article-title><source>Curr. Med. Chem.</source><year>2013</year><volume>20</volume><fpage>2572</fpage><lpage>2582</lpage><pub-id pub-id-type="doi">10.2174/09298673113209990120</pub-id><pub-id pub-id-type="pmid">23514412</pub-id></element-citation></ref><ref id="B362-pharmaceutics-13-00143"><label>362.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niazvand</surname><given-names>F.</given-names></name><name><surname>Orazizadeh</surname><given-names>M.</given-names></name><name><surname>Khorsandi</surname><given-names>L.</given-names></name><name><surname>Abbaspour</surname><given-names>M.</given-names></name><name><surname>Mansouri</surname><given-names>E.</given-names></name><name><surname>Khodadadi</surname><given-names>A.</given-names></name></person-group><article-title>Effects of Quercetin-Loaded Nanoparticles on MCF-7 Human Breast Cancer Cells</article-title><source>Medicina</source><year>2019</year><volume>55</volume><elocation-id>114</elocation-id><pub-id pub-id-type="doi">10.3390/medicina55040114</pub-id></element-citation></ref><ref id="B363-pharmaceutics-13-00143"><label>363.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>J.-S.</given-names></name><name><surname>Sharma</surname><given-names>A.R.</given-names></name><name><surname>Nguyen</surname><given-names>L.T.</given-names></name><name><surname>Chakraborty</surname><given-names>C.</given-names></name><name><surname>Sharma</surname><given-names>G.</given-names></name><name><surname>Lee</surname><given-names>S.-S.</given-names></name></person-group><article-title>Application of Bioactive Quercetin in Oncotherapy: From Nutrition to Nanomedicine</article-title><source>Molecules</source><year>2016</year><volume>21</volume><elocation-id>108</elocation-id><pub-id pub-id-type="doi">10.3390/molecules21010108</pub-id><?supplied-pmid 26797598?><pub-id pub-id-type="pmid">26797598</pub-id></element-citation></ref><ref id="B364-pharmaceutics-13-00143"><label>364.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baksi</surname><given-names>R.</given-names></name><name><surname>Singh</surname><given-names>D.P.</given-names></name><name><surname>Borse</surname><given-names>S.P.</given-names></name><name><surname>Rana</surname><given-names>R.</given-names></name><name><surname>Sharma</surname><given-names>V.</given-names></name><name><surname>Nivsarkar</surname><given-names>M.</given-names></name></person-group><article-title>In vitro and in vivo anticancer efficacy potential of Quercetin loaded polymeric nanoparticles</article-title><source>Biomed. Pharmacother.</source><year>2018</year><volume>106</volume><fpage>1513</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.07.106</pub-id><?supplied-pmid 30119227?><pub-id pub-id-type="pmid">30119227</pub-id></element-citation></ref><ref id="B365-pharmaceutics-13-00143"><label>365.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lou</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>L.-N.</given-names></name><name><surname>Ji</surname><given-names>P.-G.</given-names></name><name><surname>Feng</surname><given-names>F.-Q.</given-names></name><name><surname>Liu</surname><given-names>J.-H.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>B.-F.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>Quercetin nanoparticles induced autophagy and apoptosis through AKT/ERK/Caspase-3 signaling pathway in human neuroglioma cells: In vitro and in vivo</article-title><source>Biomed. Pharmacother.</source><year>2016</year><volume>84</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2016.08.055</pub-id><pub-id pub-id-type="pmid">27621033</pub-id></element-citation></ref><ref id="B366-pharmaceutics-13-00143"><label>366.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajesh Kumar</surname><given-names>S.</given-names></name><name><surname>Priyatharshni</surname><given-names>S.</given-names></name><name><surname>Babu</surname><given-names>V.N.</given-names></name><name><surname>Mangalaraj</surname><given-names>D.</given-names></name><name><surname>Viswanathan</surname><given-names>C.</given-names></name><name><surname>Kannan</surname><given-names>S.</given-names></name><name><surname>Ponpandian</surname><given-names>N.</given-names></name></person-group><article-title>Quercetin conjugated superparamagnetic magnetite nanoparticles for in-vitro analysis of breast cancer cell lines for chemotherapy applications</article-title><source>J. Colloid Interface Sci.</source><year>2014</year><volume>436</volume><fpage>234</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.jcis.2014.08.064</pub-id><pub-id pub-id-type="pmid">25278361</pub-id></element-citation></ref><ref id="B367-pharmaceutics-13-00143"><label>367.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>K.-W.</given-names></name><name><surname>Li</surname><given-names>Y.-H.</given-names></name><name><surname>Wu</surname><given-names>G.</given-names></name><name><surname>Ren</surname><given-names>J.-Z.</given-names></name><name><surname>Lu</surname><given-names>H.-B.</given-names></name><name><surname>Li</surname><given-names>Z.-M.</given-names></name><name><surname>Han</surname><given-names>X.-W.</given-names></name></person-group><article-title>Quercetin nanoparticles display antitumor activity via proliferation inhibition and apoptosis induction in liver cancer cells</article-title><source>Int. J. Oncol.</source><year>2017</year><volume>50</volume><fpage>1299</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.3892/ijo.2017.3886</pub-id><?supplied-pmid 28259895?><pub-id pub-id-type="pmid">28259895</pub-id></element-citation></ref><ref id="B368-pharmaceutics-13-00143"><label>368.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Wan</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name></person-group><article-title>Enhancing the anti-ovarian cancer activity of quercetin using a self-assembling micelle and thermosensitive hydrogel drug delivery system</article-title><source>RSC Adv.</source><year>2018</year><volume>8</volume><fpage>21229</fpage><lpage>21242</lpage><pub-id pub-id-type="doi">10.1039/C8RA03274B</pub-id></element-citation></ref><ref id="B369-pharmaceutics-13-00143"><label>369.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Fu</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Jia</surname><given-names>G.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Ji</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhai</surname><given-names>G.</given-names></name></person-group><article-title>Paclitaxel and quercetin co-loaded functional mesoporous silica nanoparticles overcoming multidrug resistance in breast cancer</article-title><source>Colloids Surf. B Biointerfaces</source><year>2020</year><volume>196</volume><fpage>111284</fpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2020.111284</pub-id><?supplied-pmid 32771817?><pub-id pub-id-type="pmid">32771817</pub-id></element-citation></ref><ref id="B370-pharmaceutics-13-00143"><label>370.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>T.</given-names></name><name><surname>Zhu</surname><given-names>D.</given-names></name><name><surname>Huang</surname><given-names>Q.</given-names></name></person-group><article-title>Enhanced Tumor Targeting and Radiotherapy by Quercetin Loaded Biomimetic Nanoparticles</article-title><source>Front. Chem.</source><year>2020</year><volume>8</volume><fpage>225</fpage><pub-id pub-id-type="doi">10.3389/fchem.2020.00225</pub-id><pub-id pub-id-type="pmid">32296682</pub-id></element-citation></ref><ref id="B371-pharmaceutics-13-00143"><label>371.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>M.</given-names></name><name><surname>Chang</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>K.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>G.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>P.</given-names></name><name><surname>Lu</surname><given-names>B.</given-names></name></person-group><article-title>Polydopamine coated hollow mesoporous silica nanoparticles as pH-sensitive nanocarriers for overcoming multidrug resistance</article-title><source>Colloids Surf. B Biointerfaces</source><year>2019</year><volume>183</volume><fpage>110427</fpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2019.110427</pub-id><pub-id pub-id-type="pmid">31408782</pub-id></element-citation></ref><ref id="B372-pharmaceutics-13-00143"><label>372.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>J.-H.</given-names></name><name><surname>Sethi</surname><given-names>G.</given-names></name><name><surname>Um</surname><given-names>J.-Y.</given-names></name><name><surname>Shanmugam</surname><given-names>M.K.</given-names></name><name><surname>Arfuso</surname><given-names>F.</given-names></name><name><surname>Kumar</surname><given-names>A.P.</given-names></name><name><surname>Bishayee</surname><given-names>A.</given-names></name><name><surname>Ahn</surname><given-names>K.S.</given-names></name></person-group><article-title>The Role of Resveratrol in Cancer Therapy</article-title><source>Int. J. Mol. Sci.</source><year>2017</year><volume>18</volume><elocation-id>2589</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18122589</pub-id></element-citation></ref><ref id="B373-pharmaceutics-13-00143"><label>373.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shukla</surname><given-names>Y.</given-names></name><name><surname>Singh</surname><given-names>R.</given-names></name></person-group><article-title>Resveratrol and cellular mechanisms of cancer prevention</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2011</year><volume>1215</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2010.05870.x</pub-id><?supplied-pmid 21261635?><pub-id pub-id-type="pmid">21261635</pub-id></element-citation></ref><ref id="B374-pharmaceutics-13-00143"><label>374.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>K.R.</given-names></name><name><surname>Brown</surname><given-names>V.A.</given-names></name><name><surname>Jones</surname><given-names>D.J.</given-names></name><name><surname>Britton</surname><given-names>R.G.</given-names></name><name><surname>Hemingway</surname><given-names>D.</given-names></name><name><surname>Miller</surname><given-names>A.S.</given-names></name><name><surname>West</surname><given-names>K.P.</given-names></name><name><surname>Booth</surname><given-names>T.D.</given-names></name><name><surname>Perloff</surname><given-names>M.</given-names></name><name><surname>Crowell</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients</article-title><source>Cancer Res.</source><year>2010</year><volume>70</volume><fpage>7392</fpage><lpage>7399</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2027</pub-id><?supplied-pmid 20841478?><pub-id pub-id-type="pmid">20841478</pub-id></element-citation></ref><ref id="B375-pharmaceutics-13-00143"><label>375.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kjaer</surname><given-names>T.N.</given-names></name><name><surname>Ornstrup</surname><given-names>M.J.</given-names></name><name><surname>Poulsen</surname><given-names>M.M.</given-names></name><name><surname>J&#x000f8;rgensen</surname><given-names>J.O.</given-names></name><name><surname>Hougaard</surname><given-names>D.M.</given-names></name><name><surname>Cohen</surname><given-names>A.S.</given-names></name><name><surname>Neghabat</surname><given-names>S.</given-names></name><name><surname>Richelsen</surname><given-names>B.</given-names></name><name><surname>Pedersen</surname><given-names>S.B.</given-names></name></person-group><article-title>Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men</article-title><source>Prostate</source><year>2015</year><volume>75</volume><fpage>1255</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1002/pros.23006</pub-id><?supplied-pmid 25939591?><pub-id pub-id-type="pmid">25939591</pub-id></element-citation></ref><ref id="B376-pharmaceutics-13-00143"><label>376.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>D.S.L.</given-names></name><name><surname>Tan</surname><given-names>L.T.-H.</given-names></name><name><surname>Chan</surname><given-names>K.-G.</given-names></name><name><surname>Yap</surname><given-names>W.H.</given-names></name><name><surname>Pusparajah</surname><given-names>P.</given-names></name><name><surname>Chuah</surname><given-names>L.-H.</given-names></name><name><surname>Ming</surname><given-names>L.C.</given-names></name><name><surname>Khan</surname><given-names>T.M.</given-names></name><name><surname>Lee</surname><given-names>L.-H.</given-names></name><name><surname>Goh</surname><given-names>B.-H.</given-names></name></person-group><article-title>Resveratrol-Potential Antibacterial Agent against Foodborne Pathogens</article-title><source>Front. Pharmacol.</source><year>2018</year><volume>9</volume><fpage>102</fpage><pub-id pub-id-type="doi">10.3389/fphar.2018.00102</pub-id><pub-id pub-id-type="pmid">29515440</pub-id></element-citation></ref><ref id="B377-pharmaceutics-13-00143"><label>377.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrone</surname><given-names>D.</given-names></name><name><surname>Fuggetta</surname><given-names>M.P.</given-names></name><name><surname>Ardito</surname><given-names>F.</given-names></name><name><surname>Cottarelli</surname><given-names>A.</given-names></name><name><surname>De Filippis</surname><given-names>A.</given-names></name><name><surname>Ravagnan</surname><given-names>G.</given-names></name><name><surname>De Maria</surname><given-names>S.</given-names></name><name><surname>Lo Muzio</surname><given-names>L.</given-names></name></person-group><article-title>Resveratrol (3,5,4&#x02019;-trihydroxystilbene) and its properties in oral diseases</article-title><source>Exp. Med.</source><year>2017</year><volume>14</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.3892/etm.2017.4472</pub-id></element-citation></ref><ref id="B378-pharmaceutics-13-00143"><label>378.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>M.</given-names></name><name><surname>Cai</surname><given-names>L.</given-names></name><name><surname>Udeani</surname><given-names>G.O.</given-names></name><name><surname>Slowing</surname><given-names>K.V.</given-names></name><name><surname>Thomas</surname><given-names>C.F.</given-names></name><name><surname>Beecher</surname><given-names>C.W.</given-names></name><name><surname>Fong</surname><given-names>H.H.</given-names></name><name><surname>Farnsworth</surname><given-names>N.R.</given-names></name><name><surname>Kinghorn</surname><given-names>A.D.</given-names></name><name><surname>Mehta</surname><given-names>R.G.</given-names></name><etal/></person-group><article-title>Cancer chemopreventive activity of resveratrol, a natural product derived from grapes</article-title><source>Science</source><year>1997</year><volume>275</volume><fpage>218</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1126/science.275.5297.218</pub-id><pub-id pub-id-type="pmid">8985016</pub-id></element-citation></ref><ref id="B379-pharmaceutics-13-00143"><label>379.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>C.M.</given-names></name><name><surname>Heinze</surname><given-names>T.M.</given-names></name><name><surname>Schnackenberg</surname><given-names>L.K.</given-names></name><name><surname>Mullis</surname><given-names>L.B.</given-names></name><name><surname>Elkins</surname><given-names>S.A.</given-names></name><name><surname>Elkins</surname><given-names>C.A.</given-names></name><name><surname>Steele</surname><given-names>R.S.</given-names></name><name><surname>Sutherland</surname><given-names>J.B.</given-names></name></person-group><article-title>Interaction of dietary resveratrol with animal-associated bacteria</article-title><source>FEMS Microbiol. Lett.</source><year>2009</year><volume>297</volume><fpage>266</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6968.2009.01691.x</pub-id><pub-id pub-id-type="pmid">19566680</pub-id></element-citation></ref><ref id="B380-pharmaceutics-13-00143"><label>380.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fern&#x000e1;ndez-Mar</surname><given-names>M.I.</given-names></name><name><surname>Mateos</surname><given-names>R.</given-names></name><name><surname>Garc&#x000ed;a-Parrilla</surname><given-names>M.C.</given-names></name><name><surname>Puertas</surname><given-names>B.</given-names></name><name><surname>Cantos-Villar</surname><given-names>E.</given-names></name></person-group><article-title>Bioactive compounds in wine: Resveratrol, hydroxytyrosol and melatonin: A review</article-title><source>Food Chem.</source><year>2012</year><volume>130</volume><fpage>797</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2011.08.023</pub-id></element-citation></ref><ref id="B381-pharmaceutics-13-00143"><label>381.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Athar</surname><given-names>M.</given-names></name><name><surname>Back</surname><given-names>J.H.</given-names></name><name><surname>Tang</surname><given-names>X.</given-names></name><name><surname>Kim</surname><given-names>K.H.</given-names></name><name><surname>Kopelovich</surname><given-names>L.</given-names></name><name><surname>Bickers</surname><given-names>D.R.</given-names></name><name><surname>Kim</surname><given-names>A.L.</given-names></name></person-group><article-title>Resveratrol: A review of preclinical studies for human cancer prevention</article-title><source>Toxicol. Appl. Pharm.</source><year>2007</year><volume>224</volume><fpage>274</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1016/j.taap.2006.12.025</pub-id></element-citation></ref><ref id="B382-pharmaceutics-13-00143"><label>382.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawda</surname><given-names>C.</given-names></name><name><surname>Moussa</surname><given-names>C.</given-names></name><name><surname>Turner</surname><given-names>R.S.</given-names></name></person-group><article-title>Resveratrol for Alzheimer&#x02019;s disease</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2017</year><volume>1403</volume><fpage>142</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1111/nyas.13431</pub-id><pub-id pub-id-type="pmid">28815614</pub-id></element-citation></ref><ref id="B383-pharmaceutics-13-00143"><label>383.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000fc;l&#x000e7;in</surname><given-names>&#x00130;.</given-names></name></person-group><article-title>Antioxidant properties of resveratrol: A structure&#x02013;activity insight</article-title><source>Innov. Food Sci. Emerg. Technol.</source><year>2010</year><volume>11</volume><fpage>210</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/j.ifset.2009.07.002</pub-id></element-citation></ref><ref id="B384-pharmaceutics-13-00143"><label>384.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De S&#x000e1; Coutinho</surname><given-names>D.</given-names></name><name><surname>Pacheco</surname><given-names>M.T.</given-names></name><name><surname>Frozza</surname><given-names>R.L.</given-names></name><name><surname>Bernardi</surname><given-names>A.</given-names></name></person-group><article-title>Anti-Inflammatory Effects of Resveratrol: Mechanistic Insights</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>1812</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19061812</pub-id><?supplied-pmid 29925765?><pub-id pub-id-type="pmid">29925765</pub-id></element-citation></ref><ref id="B385-pharmaceutics-13-00143"><label>385.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>Y.X.</given-names></name><name><surname>Janakiraman</surname><given-names>N.</given-names></name><name><surname>Chapman</surname><given-names>R.A.</given-names></name><name><surname>Gautam</surname><given-names>S.C.</given-names></name></person-group><article-title>Immunomodulatory activity of resveratrol: Suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production</article-title><source>Biochem. Pharm.</source><year>2001</year><volume>62</volume><fpage>1299</fpage><lpage>1308</lpage><pub-id pub-id-type="doi">10.1016/S0006-2952(01)00775-4</pub-id><pub-id pub-id-type="pmid">11705464</pub-id></element-citation></ref><ref id="B386-pharmaceutics-13-00143"><label>386.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trung</surname><given-names>L.Q.</given-names></name><name><surname>An</surname><given-names>D.T.T.</given-names></name></person-group><article-title>Is Resveratrol a Cancer Immunomodulatory Molecule?</article-title><source>Front. Pharmacol.</source><year>2018</year><volume>9</volume><fpage>1255</fpage><pub-id pub-id-type="doi">10.3389/fphar.2018.01255</pub-id><?supplied-pmid 30459616?><pub-id pub-id-type="pmid">30459616</pub-id></element-citation></ref><ref id="B387-pharmaceutics-13-00143"><label>387.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berge</surname><given-names>G.</given-names></name><name><surname>&#x000d8;vreb&#x000f8;</surname><given-names>S.</given-names></name><name><surname>Eilertsen</surname><given-names>E.</given-names></name><name><surname>Haugen</surname><given-names>A.</given-names></name><name><surname>Mollerup</surname><given-names>S.</given-names></name></person-group><article-title>Analysis of resveratrol as a lung cancer chemopreventive agent in A/J mice exposed to benzo[a]pyrene</article-title><source>Br. J. Cancer</source><year>2004</year><volume>91</volume><fpage>1380</fpage><lpage>1383</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6602125</pub-id><?supplied-pmid 15316568?><pub-id pub-id-type="pmid">15316568</pub-id></element-citation></ref><ref id="B388-pharmaceutics-13-00143"><label>388.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Y.H.</given-names></name><name><surname>Chen</surname><given-names>H.A.</given-names></name><name><surname>Chen</surname><given-names>P.S.</given-names></name><name><surname>Cheng</surname><given-names>Y.J.</given-names></name><name><surname>Hsu</surname><given-names>W.H.</given-names></name><name><surname>Chang</surname><given-names>Y.W.</given-names></name><name><surname>Chen</surname><given-names>Y.H.</given-names></name><name><surname>Jan</surname><given-names>Y.</given-names></name><name><surname>Hsiao</surname><given-names>M.</given-names></name><name><surname>Chang</surname><given-names>T.Y.</given-names></name><etal/></person-group><article-title>MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol</article-title><source>Oncogene</source><year>2013</year><volume>32</volume><fpage>431</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.74</pub-id><?supplied-pmid 22410781?><pub-id pub-id-type="pmid">22410781</pub-id></element-citation></ref><ref id="B389-pharmaceutics-13-00143"><label>389.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>H.T.</given-names></name><name><surname>Tian</surname><given-names>Q.Z.</given-names></name><name><surname>Guan</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>X.E.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name></person-group><article-title>In vitro and in vivo evaluation of the antitumor efficiency of resveratrol against lung cancer</article-title><source>Asian Pac. J. Cancer Prev.</source><year>2013</year><volume>14</volume><fpage>1703</fpage><lpage>1706</lpage><pub-id pub-id-type="doi">10.7314/APJCP.2013.14.3.1703</pub-id><?supplied-pmid 23679260?><pub-id pub-id-type="pmid">23679260</pub-id></element-citation></ref><ref id="B390-pharmaceutics-13-00143"><label>390.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>S.K.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Fu</surname><given-names>J.</given-names></name><name><surname>Shankar</surname><given-names>S.</given-names></name><name><surname>Srivastava</surname><given-names>R.K.</given-names></name></person-group><article-title>Resveratrol inhibits growth of orthotopic pancreatic tumors through activation of FOXO transcription factors</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e25166</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0025166</pub-id><?supplied-pmid 21980390?><pub-id pub-id-type="pmid">21980390</pub-id></element-citation></ref><ref id="B391-pharmaceutics-13-00143"><label>391.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>H.C.</given-names></name><name><surname>Chen</surname><given-names>Y.F.</given-names></name><name><surname>Hsu</surname><given-names>W.H.</given-names></name><name><surname>Yang</surname><given-names>C.W.</given-names></name><name><surname>Kao</surname><given-names>C.H.</given-names></name><name><surname>Tsai</surname><given-names>T.F.</given-names></name></person-group><article-title>Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model</article-title><source>Cancer Prev. Res.</source><year>2012</year><volume>5</volume><fpage>952</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-12-0001</pub-id></element-citation></ref><ref id="B392-pharmaceutics-13-00143"><label>392.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carb&#x000f3;</surname><given-names>N.</given-names></name><name><surname>Costelli</surname><given-names>P.</given-names></name><name><surname>Baccino</surname><given-names>F.M.</given-names></name><name><surname>L&#x000f3;pez-Soriano</surname><given-names>F.J.</given-names></name><name><surname>Argil&#x000e9;s</surname><given-names>J.M.</given-names></name></person-group><article-title>Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model</article-title><source>Biochem. Biophys. Res. Commun.</source><year>1999</year><volume>254</volume><fpage>739</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1998.9916</pub-id><pub-id pub-id-type="pmid">9920811</pub-id></element-citation></ref><ref id="B393-pharmaceutics-13-00143"><label>393.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>K.</given-names></name><name><surname>Mukherjee</surname><given-names>S.</given-names></name><name><surname>Vanmanen</surname><given-names>J.</given-names></name><name><surname>Banerjee</surname><given-names>P.</given-names></name><name><surname>Fata</surname><given-names>J.E.</given-names></name></person-group><article-title>Dietary Polyphenols, Resveratrol and Pterostilbene Exhibit Antitumor Activity on an HPV E6-Positive Cervical Cancer Model: An in vitro and in vivo Analysis</article-title><source>Front. Oncol.</source><year>2019</year><volume>9</volume><fpage>352</fpage><pub-id pub-id-type="doi">10.3389/fonc.2019.00352</pub-id><?supplied-pmid 31143704?><pub-id pub-id-type="pmid">31143704</pub-id></element-citation></ref><ref id="B394-pharmaceutics-13-00143"><label>394.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huderson</surname><given-names>A.C.</given-names></name><name><surname>Myers</surname><given-names>J.N.</given-names></name><name><surname>Niaz</surname><given-names>M.S.</given-names></name><name><surname>Washington</surname><given-names>M.K.</given-names></name><name><surname>Ramesh</surname><given-names>A.</given-names></name></person-group><article-title>Chemoprevention of benzo(a)pyrene-induced colon polyps in ApcMin mice by resveratrol</article-title><source>J. Nutr. Biochem.</source><year>2013</year><volume>24</volume><fpage>713</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2012.04.005</pub-id><?supplied-pmid 22889612?><pub-id pub-id-type="pmid">22889612</pub-id></element-citation></ref><ref id="B395-pharmaceutics-13-00143"><label>395.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T.T.</given-names></name><name><surname>Hudson</surname><given-names>T.S.</given-names></name><name><surname>Wang</surname><given-names>T.C.</given-names></name><name><surname>Remsberg</surname><given-names>C.M.</given-names></name><name><surname>Davies</surname><given-names>N.M.</given-names></name><name><surname>Takahashi</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>Y.S.</given-names></name><name><surname>Seifried</surname><given-names>H.</given-names></name><name><surname>Vinyard</surname><given-names>B.T.</given-names></name><name><surname>Perkins</surname><given-names>S.N.</given-names></name><etal/></person-group><article-title>Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo</article-title><source>Carcinogenesis</source><year>2008</year><volume>29</volume><fpage>2001</fpage><lpage>2010</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgn131</pub-id><?supplied-pmid 18586690?><pub-id pub-id-type="pmid">18586690</pub-id></element-citation></ref><ref id="B396-pharmaceutics-13-00143"><label>396.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bove</surname><given-names>K.</given-names></name><name><surname>Lincoln</surname><given-names>D.W.</given-names></name><name><surname>Tsan</surname><given-names>M.F.</given-names></name></person-group><article-title>Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2002</year><volume>291</volume><fpage>1001</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2002.6554</pub-id><?supplied-pmid 11866465?><pub-id pub-id-type="pmid">11866465</pub-id></element-citation></ref><ref id="B397-pharmaceutics-13-00143"><label>397.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garvin</surname><given-names>S.</given-names></name><name><surname>Ollinger</surname><given-names>K.</given-names></name><name><surname>Dabrosin</surname><given-names>C.</given-names></name></person-group><article-title>Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo</article-title><source>Cancer Lett.</source><year>2006</year><volume>231</volume><fpage>113</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2005.01.031</pub-id><pub-id pub-id-type="pmid">16356836</pub-id></element-citation></ref><ref id="B398-pharmaceutics-13-00143"><label>398.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhat</surname><given-names>K.P.</given-names></name><name><surname>Lantvit</surname><given-names>D.</given-names></name><name><surname>Christov</surname><given-names>K.</given-names></name><name><surname>Mehta</surname><given-names>R.G.</given-names></name><name><surname>Moon</surname><given-names>R.C.</given-names></name><name><surname>Pezzuto</surname><given-names>J.M.</given-names></name></person-group><article-title>Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models</article-title><source>Cancer Res.</source><year>2001</year><volume>61</volume><fpage>7456</fpage><lpage>7463</lpage><pub-id pub-id-type="pmid">11606380</pub-id></element-citation></ref><ref id="B399-pharmaceutics-13-00143"><label>399.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>A.V.</given-names></name><name><surname>Martinez</surname><given-names>M.</given-names></name><name><surname>Stamos</surname><given-names>M.J.</given-names></name><name><surname>Moyer</surname><given-names>M.P.</given-names></name><name><surname>Planutis</surname><given-names>K.</given-names></name><name><surname>Hope</surname><given-names>C.</given-names></name><name><surname>Holcombe</surname><given-names>R.F.</given-names></name></person-group><article-title>Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer</article-title><source>Cancer Manag. Res.</source><year>2009</year><volume>1</volume><fpage>25</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">21188121</pub-id></element-citation></ref><ref id="B400-pharmaceutics-13-00143"><label>400.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howells</surname><given-names>L.M.</given-names></name><name><surname>Berry</surname><given-names>D.P.</given-names></name><name><surname>Elliott</surname><given-names>P.J.</given-names></name><name><surname>Jacobson</surname><given-names>E.W.</given-names></name><name><surname>Hoffmann</surname><given-names>E.</given-names></name><name><surname>Hegarty</surname><given-names>B.</given-names></name><name><surname>Brown</surname><given-names>K.</given-names></name><name><surname>Steward</surname><given-names>W.P.</given-names></name><name><surname>Gescher</surname><given-names>A.J.</given-names></name></person-group><article-title>Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics</article-title><source>Cancer Prev. Res.</source><year>2011</year><volume>4</volume><fpage>1419</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-11-0148</pub-id></element-citation></ref><ref id="B401-pharmaceutics-13-00143"><label>401.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cottart</surname><given-names>C.H.</given-names></name><name><surname>Nivet-Antoine</surname><given-names>V.</given-names></name><name><surname>Laguillier-Morizot</surname><given-names>C.</given-names></name><name><surname>Beaudeux</surname><given-names>J.L.</given-names></name></person-group><article-title>Resveratrol bioavailability and toxicity in humans</article-title><source>Mol. Nutr. Food Res.</source><year>2010</year><volume>54</volume><fpage>7</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1002/mnfr.200900437</pub-id><pub-id pub-id-type="pmid">20013887</pub-id></element-citation></ref><ref id="B402-pharmaceutics-13-00143"><label>402.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>K.R.</given-names></name><name><surname>Scott</surname><given-names>E.</given-names></name><name><surname>Brown</surname><given-names>V.A.</given-names></name><name><surname>Gescher</surname><given-names>A.J.</given-names></name><name><surname>Steward</surname><given-names>W.P.</given-names></name><name><surname>Brown</surname><given-names>K.</given-names></name></person-group><article-title>Clinical trials of resveratrol</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2011</year><volume>1215</volume><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2010.05853.x</pub-id><pub-id pub-id-type="pmid">21261655</pub-id></element-citation></ref><ref id="B403-pharmaceutics-13-00143"><label>403.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>J.J.</given-names></name><name><surname>Nihal</surname><given-names>M.</given-names></name><name><surname>Siddiqui</surname><given-names>I.A.</given-names></name><name><surname>Scarlett</surname><given-names>C.O.</given-names></name><name><surname>Bailey</surname><given-names>H.H.</given-names></name><name><surname>Mukhtar</surname><given-names>H.</given-names></name><name><surname>Ahmad</surname><given-names>N.</given-names></name></person-group><article-title>Enhancing the bioavailability of resveratrol by combining it with piperine</article-title><source>Mol. Nutr. Food Res.</source><year>2011</year><volume>55</volume><fpage>1169</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.1002/mnfr.201100117</pub-id><?supplied-pmid 21714124?><pub-id pub-id-type="pmid">21714124</pub-id></element-citation></ref><ref id="B404-pharmaceutics-13-00143"><label>404.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pangeni</surname><given-names>R.</given-names></name><name><surname>Sahni</surname><given-names>J.K.</given-names></name><name><surname>Ali</surname><given-names>J.</given-names></name><name><surname>Sharma</surname><given-names>S.</given-names></name><name><surname>Baboota</surname><given-names>S.</given-names></name></person-group><article-title>Resveratrol: Review on therapeutic potential and recent advances in drug delivery</article-title><source>Expert Opin. Drug Deliv.</source><year>2014</year><volume>11</volume><fpage>1285</fpage><lpage>1298</lpage><pub-id pub-id-type="doi">10.1517/17425247.2014.919253</pub-id><?supplied-pmid 24830814?><pub-id pub-id-type="pmid">24830814</pub-id></element-citation></ref><ref id="B405-pharmaceutics-13-00143"><label>405.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansari</surname><given-names>K.A.</given-names></name><name><surname>Vavia</surname><given-names>P.R.</given-names></name><name><surname>Trotta</surname><given-names>F.</given-names></name><name><surname>Cavalli</surname><given-names>R.</given-names></name></person-group><article-title>Cyclodextrin-based nanosponges for delivery of resveratrol: In vitro characterisation, stability, cytotoxicity and permeation study</article-title><source>AAPS Pharmscitech.</source><year>2011</year><volume>12</volume><fpage>279</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1208/s12249-011-9584-3</pub-id><?supplied-pmid 21240574?><pub-id pub-id-type="pmid">21240574</pub-id></element-citation></ref><ref id="B406-pharmaceutics-13-00143"><label>406.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nastiti</surname><given-names>C.</given-names></name><name><surname>Ponto</surname><given-names>T.</given-names></name><name><surname>Mohammed</surname><given-names>Y.</given-names></name><name><surname>Roberts</surname><given-names>M.S.</given-names></name><name><surname>Benson</surname><given-names>H.A.E.</given-names></name></person-group><article-title>Novel Nanocarriers for Targeted Topical Skin Delivery of the Antioxidant Resveratrol</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>108</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12020108</pub-id><?supplied-pmid 32013204?><pub-id pub-id-type="pmid">32013204</pub-id></element-citation></ref><ref id="B407-pharmaceutics-13-00143"><label>407.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C.W.</given-names></name><name><surname>Yen</surname><given-names>F.L.</given-names></name><name><surname>Huang</surname><given-names>H.W.</given-names></name><name><surname>Wu</surname><given-names>T.H.</given-names></name><name><surname>Ko</surname><given-names>H.H.</given-names></name><name><surname>Tzeng</surname><given-names>W.S.</given-names></name><name><surname>Lin</surname><given-names>C.C.</given-names></name></person-group><article-title>Resveratrol nanoparticle system improves dissolution properties and enhances the hepatoprotective effect of resveratrol through antioxidant and anti-inflammatory pathways</article-title><source>J. Agric. Food Chem</source><year>2012</year><volume>60</volume><fpage>4662</fpage><lpage>4671</lpage><pub-id pub-id-type="doi">10.1021/jf2050137</pub-id><pub-id pub-id-type="pmid">22480310</pub-id></element-citation></ref><ref id="B408-pharmaceutics-13-00143"><label>408.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhary</surname><given-names>Z.</given-names></name><name><surname>Subramaniam</surname><given-names>S.</given-names></name><name><surname>Khan</surname><given-names>G.M.</given-names></name><name><surname>Abeer</surname><given-names>M.M.</given-names></name><name><surname>Qu</surname><given-names>Z.</given-names></name><name><surname>Janjua</surname><given-names>T.</given-names></name><name><surname>Kumeria</surname><given-names>T.</given-names></name><name><surname>Batra</surname><given-names>J.</given-names></name><name><surname>Popat</surname><given-names>A.</given-names></name></person-group><article-title>Encapsulation and Controlled Release of Resveratrol Within Functionalized Mesoporous Silica Nanoparticles for Prostate Cancer Therapy</article-title><source>Front. Bioeng. Biotechnol.</source><year>2019</year><volume>7</volume><fpage>225</fpage><pub-id pub-id-type="doi">10.3389/fbioe.2019.00225</pub-id><?supplied-pmid 31620434?><pub-id pub-id-type="pmid">31620434</pub-id></element-citation></ref><ref id="B409-pharmaceutics-13-00143"><label>409.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Summerlin</surname><given-names>N.</given-names></name><name><surname>Qu</surname><given-names>Z.</given-names></name><name><surname>Pujara</surname><given-names>N.</given-names></name><name><surname>Sheng</surname><given-names>Y.</given-names></name><name><surname>Jambhrunkar</surname><given-names>S.</given-names></name><name><surname>McGuckin</surname><given-names>M.</given-names></name><name><surname>Popat</surname><given-names>A.</given-names></name></person-group><article-title>Colloidal mesoporous silica nanoparticles enhance the biological activity of resveratrol</article-title><source>Colloids Surf. B Biointerfaces</source><year>2016</year><volume>144</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2016.03.076</pub-id><pub-id pub-id-type="pmid">27060664</pub-id></element-citation></ref><ref id="B410-pharmaceutics-13-00143"><label>410.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>D.</given-names></name><name><surname>Hao</surname><given-names>J.</given-names></name><name><surname>Fan</surname><given-names>D.</given-names></name></person-group><article-title>Biological properties and clinical applications of berberine</article-title><source>Front. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s11684-019-0724-6</pub-id></element-citation></ref><ref id="B411-pharmaceutics-13-00143"><label>411.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicero</surname><given-names>A.F.</given-names></name><name><surname>Baggioni</surname><given-names>A.</given-names></name></person-group><article-title>Berberine and Its Role in Chronic Disease</article-title><source>Adv. Exp. Med. Biol</source><year>2016</year><volume>928</volume><fpage>27</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1007/978-3-319-41334-1_2</pub-id><pub-id pub-id-type="pmid">27671811</pub-id></element-citation></ref><ref id="B412-pharmaceutics-13-00143"><label>412.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schor</surname><given-names>J.</given-names></name><name><surname>Fabno</surname><given-names>N.</given-names></name></person-group><article-title>Clinical Applications for Berberine: Potential therapeutic applications in metabolic syndrome, type 2 diabetes, and dyslipidemia</article-title><source>Nat. Med. J.</source><year>2012</year><volume>4</volume><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.naturalmedicinejournal.com/print/587">https://www.naturalmedicinejournal.com/print/587</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-01">(accessed on 1 January 2021)</date-in-citation></element-citation></ref><ref id="B413-pharmaceutics-13-00143"><label>413.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zych</surname><given-names>M.</given-names></name><name><surname>Wojnar</surname><given-names>W.</given-names></name><name><surname>Kielanowska</surname><given-names>M.</given-names></name><name><surname>Folwarczna</surname><given-names>J.</given-names></name><name><surname>Kaczmarczyk-Sedlak</surname><given-names>I.</given-names></name></person-group><article-title>Effect of Berberine on Glycation, Aldose Reductase Activity, and Oxidative Stress in the Lenses of Streptozotocin-Induced Diabetic Rats In Vivo-A Preliminary Study</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>4278</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21124278</pub-id><?supplied-pmid 32560082?><pub-id pub-id-type="pmid">32560082</pub-id></element-citation></ref><ref id="B414-pharmaceutics-13-00143"><label>414.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Tao</surname><given-names>S.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Lan</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Guo</surname><given-names>F.</given-names></name><name><surname>Huang</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose</article-title><source>Arch. Biochem. Biophys.</source><year>2008</year><volume>475</volume><fpage>128</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2008.04.022</pub-id><pub-id pub-id-type="pmid">18471986</pub-id></element-citation></ref><ref id="B415-pharmaceutics-13-00143"><label>415.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Du</surname><given-names>Q.</given-names></name><name><surname>Hao</surname><given-names>P.</given-names></name><name><surname>Cao</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name></person-group><article-title>Berberine Protects Against Simulated Ischemia/Reperfusion Injury-Induced H9C2 Cardiomyocytes Apoptosis In Vitro and Myocardial Ischemia/Reperfusion-Induced Apoptosis In Vivo by Regulating the Mitophagy-Mediated HIF-1&#x003b1;/BNIP3 Pathway</article-title><source>Front. Pharm.</source><year>2020</year><volume>11</volume><fpage>367</fpage><pub-id pub-id-type="doi">10.3389/fphar.2020.00367</pub-id></element-citation></ref><ref id="B416-pharmaceutics-13-00143"><label>416.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>G.L.</given-names></name><name><surname>Yu</surname><given-names>L.M.</given-names></name><name><surname>Gao</surname><given-names>W.L.</given-names></name><name><surname>Duan</surname><given-names>W.X.</given-names></name><name><surname>Jiang</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>X.D.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>Z.H.</given-names></name><name><surname>Zhai</surname><given-names>M.E.</given-names></name><name><surname>Jin</surname><given-names>Z.X.</given-names></name><etal/></person-group><article-title>Berberine protects rat heart from ischemia/reperfusion injury via activating JAK2/STAT3 signaling and attenuating endoplasmic reticulum stress</article-title><source>Acta Pharm. Sin.</source><year>2016</year><volume>37</volume><fpage>354</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1038/aps.2015.136</pub-id></element-citation></ref><ref id="B417-pharmaceutics-13-00143"><label>417.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>C.-L.</given-names></name><name><surname>Chi</surname><given-names>C.-W.</given-names></name><name><surname>Liu</surname><given-names>T.-Y.</given-names></name></person-group><article-title>The anti-inflammatory potential of berberine in vitro and in vivo</article-title><source>Cancer Lett.</source><year>2004</year><volume>203</volume><fpage>127</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2003.09.002</pub-id><?supplied-pmid 14732220?><pub-id pub-id-type="pmid">14732220</pub-id></element-citation></ref><ref id="B418-pharmaceutics-13-00143"><label>418.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Yi</surname><given-names>X.</given-names></name><name><surname>Ghanam</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>T.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name></person-group><article-title>Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption</article-title><source>Metabolism</source><year>2014</year><volume>63</volume><fpage>1167</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2014.05.013</pub-id><?supplied-pmid 25002181?><pub-id pub-id-type="pmid">25002181</pub-id></element-citation></ref><ref id="B419-pharmaceutics-13-00143"><label>419.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Long</surname><given-names>Y.</given-names></name><name><surname>Ni</surname><given-names>L.</given-names></name><name><surname>Yuan</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>N.</given-names></name><name><surname>Wu</surname><given-names>R.</given-names></name><name><surname>Tao</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Anticancer effect of berberine based on experimental animal models of various cancers: A systematic review and meta-analysis</article-title><source>BMC Cancer</source><year>2019</year><volume>19</volume><fpage>589</fpage><pub-id pub-id-type="doi">10.1186/s12885-019-5791-1</pub-id><pub-id pub-id-type="pmid">31208348</pub-id></element-citation></ref><ref id="B420-pharmaceutics-13-00143"><label>420.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>J.</given-names></name><name><surname>Xing</surname><given-names>H.</given-names></name><name><surname>Ye</surname><given-names>J.</given-names></name></person-group><article-title>Efficacy of berberine in patients with type 2 diabetes mellitus</article-title><source>Metab. Clin. Exp.</source><year>2008</year><volume>57</volume><fpage>712</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2008.01.013</pub-id><pub-id pub-id-type="pmid">18442638</pub-id></element-citation></ref><ref id="B421-pharmaceutics-13-00143"><label>421.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicero</surname><given-names>A.</given-names></name><name><surname>Ertek</surname><given-names>S.</given-names></name></person-group><article-title>Metabolic and cardiovascular effects of berberine: From preclinical evidences to clinical trial results</article-title><source>Clin. Lipidol.</source><year>2009</year><volume>4</volume><fpage>553</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.2217/clp.09.41</pub-id></element-citation></ref><ref id="B422-pharmaceutics-13-00143"><label>422.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicero</surname><given-names>A.F.G.</given-names></name><name><surname>Colletti</surname><given-names>A.</given-names></name></person-group><article-title>Role of phytochemicals in the management of metabolic syndrome</article-title><source>Phytomedicine</source><year>2016</year><volume>23</volume><fpage>1134</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2015.11.009</pub-id><pub-id pub-id-type="pmid">26778479</pub-id></element-citation></ref><ref id="B423-pharmaceutics-13-00143"><label>423.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cristiana</surname><given-names>C.</given-names></name><name><surname>Placido</surname><given-names>F.</given-names></name><name><surname>Silvia</surname><given-names>S.</given-names></name><name><surname>Aldo Roda and Arrigo</surname><given-names>F.G.C.</given-names></name></person-group><article-title>Berberine: New Insights from Pharmacological Aspects to Clinical Evidences in the Management of Metabolic Disorders</article-title><source>Curr. Med. Chem.</source><year>2016</year><volume>23</volume><fpage>1460</fpage><lpage>1476</lpage><pub-id pub-id-type="doi">10.2174/0929867323666160411143314</pub-id><pub-id pub-id-type="pmid">27063256</pub-id></element-citation></ref><ref id="B424-pharmaceutics-13-00143"><label>424.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Du</surname><given-names>X.</given-names></name><name><surname>Ma</surname><given-names>H.</given-names></name><name><surname>Yao</surname><given-names>J.</given-names></name></person-group><article-title>The Anti-Cancer Mechanisms of Berberine: A Review</article-title><source>Cancer Manag. Res.</source><year>2020</year><volume>12</volume><fpage>695</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S242329</pub-id><?supplied-pmid 32099466?><pub-id pub-id-type="pmid">32099466</pub-id></element-citation></ref><ref id="B425-pharmaceutics-13-00143"><label>425.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahibzada</surname><given-names>M.U.K.</given-names></name><name><surname>Sadiq</surname><given-names>A.</given-names></name><name><surname>Faidah</surname><given-names>H.S.</given-names></name><name><surname>Khurram</surname><given-names>M.</given-names></name><name><surname>Amin</surname><given-names>M.U.</given-names></name><name><surname>Haseeb</surname><given-names>A.</given-names></name><name><surname>Kakar</surname><given-names>M.</given-names></name></person-group><article-title>Berberine nanoparticles with enhanced in vitro bioavailability: Characterization and antimicrobial activity</article-title><source>Drug Des. Dev. Ther.</source><year>2018</year><volume>12</volume><fpage>303</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S156123</pub-id><?supplied-pmid 29491706?><pub-id pub-id-type="pmid">29491706</pub-id></element-citation></ref><ref id="B426-pharmaceutics-13-00143"><label>426.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirhadi</surname><given-names>E.</given-names></name><name><surname>Rezaee</surname><given-names>M.</given-names></name><name><surname>Malaekeh-Nikouei</surname><given-names>B.</given-names></name></person-group><article-title>Nano strategies for berberine delivery, a natural alkaloid of Berberis</article-title><source>Biomed. Pharm.</source><year>2018</year><volume>104</volume><fpage>465</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.05.067</pub-id><?supplied-pmid 29793179?><pub-id pub-id-type="pmid">29793179</pub-id></element-citation></ref><ref id="B427-pharmaceutics-13-00143"><label>427.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Yuan</surname><given-names>M.</given-names></name><name><surname>Su</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name></person-group><article-title>Berberine-Loaded Nanostructured Lipid Carriers Enhance the Treatment of Ulcerative Colitis</article-title><source>Int. J. Nanomed.</source><year>2020</year><volume>15</volume><fpage>3937</fpage><lpage>3951</lpage><pub-id pub-id-type="doi">10.2147/IJN.S247406</pub-id></element-citation></ref><ref id="B428-pharmaceutics-13-00143"><label>428.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Shao</surname><given-names>D.</given-names></name><name><surname>Chang</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Luo</surname><given-names>S.-Z.</given-names></name><name><surname>Dong</surname><given-names>W.-F.</given-names></name></person-group><article-title>Cancer cell membrane-modified biodegradable mesoporous silica nanocarriers for berberine therapy of liver cancer</article-title><source>RSC Adv.</source><year>2018</year><volume>8</volume><fpage>40288</fpage><lpage>40297</lpage><pub-id pub-id-type="doi">10.1039/C8RA07574C</pub-id></element-citation></ref><ref id="B429-pharmaceutics-13-00143"><label>429.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider-Stock</surname><given-names>R.</given-names></name><name><surname>Fakhoury</surname><given-names>I.H.</given-names></name><name><surname>Zaki</surname><given-names>A.M.</given-names></name><name><surname>El-Baba</surname><given-names>C.O.</given-names></name><name><surname>Gali-Muhtasib</surname><given-names>H.U.</given-names></name></person-group><article-title>Thymoquinone: Fifty years of success in the battle against cancer models</article-title><source>Drug Discov. Today</source><year>2014</year><volume>19</volume><fpage>18</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2013.08.021</pub-id><pub-id pub-id-type="pmid">24001594</pub-id></element-citation></ref><ref id="B430-pharmaceutics-13-00143"><label>430.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurung</surname><given-names>R.L.</given-names></name><name><surname>Lim</surname><given-names>S.N.</given-names></name><name><surname>Khaw</surname><given-names>A.K.</given-names></name><name><surname>Soon</surname><given-names>J.F.</given-names></name><name><surname>Shenoy</surname><given-names>K.</given-names></name><name><surname>Mohamed Ali</surname><given-names>S.</given-names></name><name><surname>Jayapal</surname><given-names>M.</given-names></name><name><surname>Sethu</surname><given-names>S.</given-names></name><name><surname>Baskar</surname><given-names>R.</given-names></name><name><surname>Hande</surname><given-names>M.P.</given-names></name></person-group><article-title>Thymoquinone induces telomere shortening, DNA damage and apoptosis in human glioblastoma cells</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><elocation-id>e12124</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0012124</pub-id><pub-id pub-id-type="pmid">20711342</pub-id></element-citation></ref><ref id="B431-pharmaceutics-13-00143"><label>431.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gali-Muhtasib</surname><given-names>H.</given-names></name><name><surname>Ocker</surname><given-names>M.</given-names></name><name><surname>Kuester</surname><given-names>D.</given-names></name><name><surname>Krueger</surname><given-names>S.</given-names></name><name><surname>El-Hajj</surname><given-names>Z.</given-names></name><name><surname>Diestel</surname><given-names>A.</given-names></name><name><surname>Evert</surname><given-names>M.</given-names></name><name><surname>El-Najjar</surname><given-names>N.</given-names></name><name><surname>Peters</surname><given-names>B.</given-names></name><name><surname>Jurjus</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Thymoquinone reduces mouse colon tumor cell invasion and inhibits tumor growth in murine colon cancer models</article-title><source>J. Cell Mol. Med.</source><year>2008</year><volume>12</volume><fpage>330</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1111/j.1582-4934.2007.00095.x</pub-id><pub-id pub-id-type="pmid">18366456</pub-id></element-citation></ref><ref id="B432-pharmaceutics-13-00143"><label>432.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakaria</surname><given-names>M.</given-names></name><name><surname>Cho</surname><given-names>D.Y.</given-names></name><name><surname>Ezazul Haque</surname><given-names>M.</given-names></name><name><surname>Karthivashan</surname><given-names>G.</given-names></name><name><surname>Kim</surname><given-names>I.S.</given-names></name><name><surname>Ganesan</surname><given-names>P.</given-names></name><name><surname>Choi</surname><given-names>D.K.</given-names></name></person-group><article-title>Neuropharmacological Potential and Delivery Prospects of Thymoquinone for Neurological Disorders</article-title><source>Oxid. Med. Cell. Longev.</source><year>2018</year><volume>2018</volume><fpage>1209801</fpage><pub-id pub-id-type="doi">10.1155/2018/1209801</pub-id><pub-id pub-id-type="pmid">29743967</pub-id></element-citation></ref><ref id="B433-pharmaceutics-13-00143"><label>433.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>A.</given-names></name><name><surname>Mishra</surname><given-names>R.K.</given-names></name><name><surname>Vyawahare</surname><given-names>A.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Rehman</surname><given-names>M.U.</given-names></name><name><surname>Qamar</surname><given-names>W.</given-names></name><name><surname>Khan</surname><given-names>A.Q.</given-names></name><name><surname>Khan</surname><given-names>R.</given-names></name></person-group><article-title>Thymoquinone (2-Isoprpyl-5-methyl-1, 4-benzoquinone) as a chemopreventive/anticancer agent: Chemistry and biological effects</article-title><source>Saudi Pharm. J.</source><year>2019</year><volume>27</volume><fpage>1113</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1016/j.jsps.2019.09.008</pub-id><?supplied-pmid 31885471?><pub-id pub-id-type="pmid">31885471</pub-id></element-citation></ref><ref id="B434-pharmaceutics-13-00143"><label>434.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Majed</surname><given-names>A.A.</given-names></name><name><surname>Al-Omar</surname><given-names>F.A.</given-names></name><name><surname>Nagi</surname><given-names>M.N.</given-names></name></person-group><article-title>Neuroprotective effects of thymoquinone against transient forebrain ischemia in the rat hippocampus</article-title><source>Eur. J. Pharmacol.</source><year>2006</year><volume>543</volume><fpage>40</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2006.05.046</pub-id><?supplied-pmid 16828080?><pub-id pub-id-type="pmid">16828080</pub-id></element-citation></ref><ref id="B435-pharmaceutics-13-00143"><label>435.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umar</surname><given-names>S.</given-names></name><name><surname>Zargan</surname><given-names>J.</given-names></name><name><surname>Umar</surname><given-names>K.</given-names></name><name><surname>Ahmad</surname><given-names>S.</given-names></name><name><surname>Katiyar</surname><given-names>C.K.</given-names></name><name><surname>Khan</surname><given-names>H.A.</given-names></name></person-group><article-title>Modulation of the oxidative stress and inflammatory cytokine response by thymoquinone in the collagen induced arthritis in Wistar rats</article-title><source>Chem. Biol. Interact.</source><year>2012</year><volume>197</volume><fpage>40</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2012.03.003</pub-id><?supplied-pmid 22450443?><pub-id pub-id-type="pmid">22450443</pub-id></element-citation></ref><ref id="B436-pharmaceutics-13-00143"><label>436.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>C.C.</given-names></name><name><surname>Kumar</surname><given-names>A.P.</given-names></name><name><surname>Sethi</surname><given-names>G.</given-names></name><name><surname>Tan</surname><given-names>K.H.B.</given-names></name></person-group><article-title>Thymoquinone: Potential cure for inflammatory disorders and cancer</article-title><source>Biochem. Pharmacol.</source><year>2012</year><volume>83</volume><fpage>443</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2011.09.029</pub-id><pub-id pub-id-type="pmid">22005518</pub-id></element-citation></ref><ref id="B437-pharmaceutics-13-00143"><label>437.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asaduzzaman Khan</surname><given-names>M.</given-names></name><name><surname>Tania</surname><given-names>M.</given-names></name><name><surname>Fu</surname><given-names>S.</given-names></name><name><surname>Fu</surname><given-names>J.</given-names></name></person-group><article-title>Thymoquinone, as an anticancer molecule: From basic research to clinical investigation</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>51907</fpage><lpage>51919</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.17206</pub-id><pub-id pub-id-type="pmid">28881699</pub-id></element-citation></ref><ref id="B438-pharmaceutics-13-00143"><label>438.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaieb</surname><given-names>K.</given-names></name><name><surname>Kouidhi</surname><given-names>B.</given-names></name><name><surname>Jrah</surname><given-names>H.</given-names></name><name><surname>Mahdouani</surname><given-names>K.</given-names></name><name><surname>Bakhrouf</surname><given-names>A.</given-names></name></person-group><article-title>Antibacterial activity of Thymoquinone, an active principle of Nigella sativa and its potency to prevent bacterial biofilm formation</article-title><source>BMC Complement. Altern. Med.</source><year>2011</year><volume>11</volume><elocation-id>29</elocation-id><pub-id pub-id-type="doi">10.1186/1472-6882-11-29</pub-id><pub-id pub-id-type="pmid">21489272</pub-id></element-citation></ref><ref id="B439-pharmaceutics-13-00143"><label>439.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassab</surname><given-names>R.B.</given-names></name><name><surname>El-Hennamy</surname><given-names>R.E.</given-names></name></person-group><article-title>The role of thymoquinone as a potent antioxidant in ameliorating the neurotoxic effect of sodium arsenate in female rat</article-title><source>Egypt. J. Basic Appl. Sci.</source><year>2017</year><volume>4</volume><fpage>160</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/j.ejbas.2017.07.002</pub-id></element-citation></ref><ref id="B440-pharmaceutics-13-00143"><label>440.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bule</surname><given-names>M.</given-names></name><name><surname>Nikfar</surname><given-names>S.</given-names></name><name><surname>Amini</surname><given-names>M.</given-names></name><name><surname>Abdollahi</surname><given-names>M.</given-names></name></person-group><article-title>The antidiabetic effect of thymoquinone: A systematic review and meta-analysis of animal studies</article-title><source>Food Res. Int.</source><year>2020</year><volume>127</volume><fpage>108736</fpage><pub-id pub-id-type="doi">10.1016/j.foodres.2019.108736</pub-id><pub-id pub-id-type="pmid">31882078</pub-id></element-citation></ref><ref id="B441-pharmaceutics-13-00143"><label>441.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Najjar</surname><given-names>N.</given-names></name><name><surname>Ketola</surname><given-names>R.A.</given-names></name><name><surname>Nissil&#x000e4;</surname><given-names>T.</given-names></name><name><surname>Mauriala</surname><given-names>T.</given-names></name><name><surname>Antopolsky</surname><given-names>M.</given-names></name><name><surname>J&#x000e4;nis</surname><given-names>J.</given-names></name><name><surname>Gali-Muhtasib</surname><given-names>H.</given-names></name><name><surname>Urtti</surname><given-names>A.</given-names></name><name><surname>Vuorela</surname><given-names>H.</given-names></name></person-group><article-title>Impact of protein binding on the analytical detectability and anticancer activity of thymoquinone</article-title><source>J. Chem. Biol.</source><year>2011</year><volume>4</volume><fpage>97</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1007/s12154-010-0052-4</pub-id><pub-id pub-id-type="pmid">22229047</pub-id></element-citation></ref><ref id="B442-pharmaceutics-13-00143"><label>442.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pathan</surname><given-names>S.A.</given-names></name><name><surname>Jain</surname><given-names>G.K.</given-names></name><name><surname>Zaidi</surname><given-names>S.M.</given-names></name><name><surname>Akhter</surname><given-names>S.</given-names></name><name><surname>Vohora</surname><given-names>D.</given-names></name><name><surname>Chander</surname><given-names>P.</given-names></name><name><surname>Kole</surname><given-names>P.L.</given-names></name><name><surname>Ahmad</surname><given-names>F.J.</given-names></name><name><surname>Khar</surname><given-names>R.K.</given-names></name></person-group><article-title>Stability-indicating ultra-performance liquid chromatography method for the estimation of thymoquinone and its application in biopharmaceutical studies</article-title><source>Biomed. Chromatogr.</source><year>2011</year><volume>25</volume><fpage>613</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1002/bmc.1492</pub-id><pub-id pub-id-type="pmid">20734352</pub-id></element-citation></ref><ref id="B443-pharmaceutics-13-00143"><label>443.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salmani</surname><given-names>J.M.</given-names></name><name><surname>Asghar</surname><given-names>S.</given-names></name><name><surname>Lv</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name></person-group><article-title>Aqueous solubility and degradation kinetics of the phytochemical anticancer thymoquinone; probing the effects of solvents, pH and light</article-title><source>Molecules</source><year>2014</year><volume>19</volume><fpage>5925</fpage><lpage>5939</lpage><pub-id pub-id-type="doi">10.3390/molecules19055925</pub-id><?supplied-pmid 24815311?><pub-id pub-id-type="pmid">24815311</pub-id></element-citation></ref><ref id="B444-pharmaceutics-13-00143"><label>444.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darakhshan</surname><given-names>S.</given-names></name><name><surname>Bidmeshki Pour</surname><given-names>A.</given-names></name><name><surname>Hosseinzadeh Colagar</surname><given-names>A.</given-names></name><name><surname>Sisakhtnezhad</surname><given-names>S.</given-names></name></person-group><article-title>Thymoquinone and its therapeutic potentials</article-title><source>Pharm. Res.</source><year>2015</year><volume>95&#x02013;96</volume><fpage>138</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2015.03.011</pub-id><?supplied-pmid 25829334?><pub-id pub-id-type="pmid">25829334</pub-id></element-citation></ref><ref id="B445-pharmaceutics-13-00143"><label>445.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rathore</surname><given-names>C.</given-names></name><name><surname>Upadhyay</surname><given-names>N.</given-names></name><name><surname>Kaundal</surname><given-names>R.</given-names></name><name><surname>Dwivedi</surname><given-names>R.P.</given-names></name><name><surname>Rahatekar</surname><given-names>S.</given-names></name><name><surname>John</surname><given-names>A.</given-names></name><name><surname>Dua</surname><given-names>K.</given-names></name><name><surname>Tambuwala</surname><given-names>M.M.</given-names></name><name><surname>Jain</surname><given-names>S.</given-names></name><name><surname>Chaudari</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Enhanced oral bioavailability and hepatoprotective activity of thymoquinone in the form of phospholipidic nano-constructs</article-title><source>Expert Opin. Drug Deliv.</source><year>2020</year><volume>17</volume><fpage>237</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1080/17425247.2020.1716728</pub-id><?supplied-pmid 32003249?><pub-id pub-id-type="pmid">32003249</pub-id></element-citation></ref><ref id="B446-pharmaceutics-13-00143"><label>446.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abukhader</surname><given-names>M.M.</given-names></name><name><surname>Khan</surname><given-names>S.A.</given-names></name></person-group><article-title>Thymoquinone and Nanoparticles: A Promising Approach for the Clinical Trials</article-title><source>J. Bionanosci.</source><year>2017</year><volume>11</volume><fpage>258</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1166/jbns.2017.1447</pub-id></element-citation></ref><ref id="B447-pharmaceutics-13-00143"><label>447.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goel</surname><given-names>S.</given-names></name><name><surname>Mishra</surname><given-names>P.</given-names></name></person-group><article-title>Thymoquinone loaded mesoporous silica nanoparticles retard cell invasion and enhance in vitro cytotoxicity due to ROS mediated apoptosis in HeLa and MCF-7 cell lines</article-title><source>Mater. Sci. Eng. C Mater. Biol. Appl.</source><year>2019</year><volume>104</volume><fpage>109881</fpage><pub-id pub-id-type="doi">10.1016/j.msec.2019.109881</pub-id><pub-id pub-id-type="pmid">31499940</pub-id></element-citation></ref><ref id="B448-pharmaceutics-13-00143"><label>448.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahmy</surname><given-names>H.M.</given-names></name><name><surname>Fathy</surname><given-names>M.M.</given-names></name><name><surname>Abd-elbadia</surname><given-names>R.A.</given-names></name><name><surname>Elshemey</surname><given-names>W.M.</given-names></name></person-group><article-title>Targeting of Thymoquinone-loaded mesoporous silica nanoparticles to different brain areas: In vivo study</article-title><source>Life Sci.</source><year>2019</year><volume>222</volume><fpage>94</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2019.02.058</pub-id><pub-id pub-id-type="pmid">30826496</pub-id></element-citation></ref><ref id="B449-pharmaceutics-13-00143"><label>449.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahkeshani</surname><given-names>N.</given-names></name><name><surname>Farzaei</surname><given-names>F.</given-names></name><name><surname>Fotouhi</surname><given-names>M.</given-names></name><name><surname>Alavi</surname><given-names>S.S.</given-names></name><name><surname>Bahramsoltani</surname><given-names>R.</given-names></name><name><surname>Naseri</surname><given-names>R.</given-names></name><name><surname>Momtaz</surname><given-names>S.</given-names></name><name><surname>Abbasabadi</surname><given-names>Z.</given-names></name><name><surname>Rahimi</surname><given-names>R.</given-names></name><name><surname>Farzaei</surname><given-names>M.H.</given-names></name><etal/></person-group><article-title>Pharmacological effects of gallic acid in health and diseases: A mechanistic review</article-title><source>Iran. J. Basic Med. Sci.</source><year>2019</year><volume>22</volume><fpage>225</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.22038/ijbms.2019.32806.7897</pub-id><pub-id pub-id-type="pmid">31156781</pub-id></element-citation></ref><ref id="B450-pharmaceutics-13-00143"><label>450.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.-J.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Dawuti</surname><given-names>G.</given-names></name><name><surname>Dou</surname><given-names>Q.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>H.-G.</given-names></name><name><surname>Aibai</surname><given-names>S.</given-names></name></person-group><article-title>Antifungal Activity of Gallic Acid In Vitro and In Vivo</article-title><source>Phytother. Res.</source><year>2017</year><volume>31</volume><fpage>1039</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1002/ptr.5823</pub-id><pub-id pub-id-type="pmid">28524381</pub-id></element-citation></ref><ref id="B451-pharmaceutics-13-00143"><label>451.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A.P.</given-names></name><name><surname>John</surname><given-names>A.A.</given-names></name><name><surname>Vellayappan</surname><given-names>M.V.</given-names></name><name><surname>Balaji</surname><given-names>A.</given-names></name><name><surname>Jaganathan</surname><given-names>S.K.</given-names></name><name><surname>Supriyanto</surname><given-names>E.</given-names></name><name><surname>Yusof</surname><given-names>M.</given-names></name></person-group><article-title>Gallic acid: Prospects and molecular mechanisms of its anticancer activity</article-title><source>RSC Adv.</source><year>2015</year><volume>5</volume><fpage>35608</fpage><lpage>35621</lpage><pub-id pub-id-type="doi">10.1039/C5RA02727F</pub-id></element-citation></ref><ref id="B452-pharmaceutics-13-00143"><label>452.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbari</surname><given-names>G.</given-names></name></person-group><article-title>Molecular mechanisms underlying gallic acid effects against cardiovascular diseases: An update review</article-title><source>Avicenna J. Phytomed.</source><year>2020</year><volume>10</volume><fpage>11</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">31921604</pub-id></element-citation></ref><ref id="B453-pharmaceutics-13-00143"><label>453.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>D.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name></person-group><article-title>A Role of Gallic Acid in Oxidative Damage Diseases: A Comprehensive Review</article-title><source>Nat. Prod. Commun.</source><year>2019</year><volume>14</volume><fpage>1934578X19874174</fpage><pub-id pub-id-type="doi">10.1177/1934578X19874174</pub-id></element-citation></ref><ref id="B454-pharmaceutics-13-00143"><label>454.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shabani</surname><given-names>S.</given-names></name><name><surname>Rabiei</surname><given-names>Z.</given-names></name><name><surname>Amini-Khoei</surname><given-names>H.</given-names></name></person-group><article-title>Exploring the multifaceted neuroprotective actions of gallic acid: A review</article-title><source>Int. J. Food Prop.</source><year>2020</year><volume>23</volume><fpage>736</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1080/10942912.2020.1753769</pub-id></element-citation></ref><ref id="B455-pharmaceutics-13-00143"><label>455.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badhani</surname><given-names>B.</given-names></name><name><surname>Sharma</surname><given-names>N.</given-names></name><name><surname>Kakkar</surname><given-names>R.</given-names></name></person-group><article-title>Gallic acid: A versatile antioxidant with promising therapeutic and industrial applications</article-title><source>RSC Adv.</source><year>2015</year><volume>5</volume><fpage>27540</fpage><lpage>27557</lpage><pub-id pub-id-type="doi">10.1039/C5RA01911G</pub-id></element-citation></ref><ref id="B456-pharmaceutics-13-00143"><label>456.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Cristo Soares Alves</surname><given-names>A.</given-names></name><name><surname>Mainardes</surname><given-names>R.M.</given-names></name><name><surname>Khalil</surname><given-names>N.M.</given-names></name></person-group><article-title>Nanoencapsulation of gallic acid and evaluation of its cytotoxicity and antioxidant activity</article-title><source>Mater. Sci. Eng. C Mater. Biol. Appl.</source><year>2016</year><volume>60</volume><fpage>126</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.msec.2015.11.014</pub-id><?supplied-pmid 26706515?><pub-id pub-id-type="pmid">26706515</pub-id></element-citation></ref><ref id="B457-pharmaceutics-13-00143"><label>457.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>B.A.</given-names></name><name><surname>Mahmood</surname><given-names>T.</given-names></name><name><surname>Menaa</surname><given-names>F.</given-names></name><name><surname>Shahzad</surname><given-names>Y.</given-names></name><name><surname>Yousaf</surname><given-names>A.M.</given-names></name><name><surname>Hussain</surname><given-names>T.</given-names></name><name><surname>Ray</surname><given-names>S.D.</given-names></name></person-group><article-title>New Perspectives on the Efficacy of Gallic Acid in Cosmetics &#x00026; Nanocosmeceuticals</article-title><source>Curr. Pharm. Des.</source><year>2018</year><volume>24</volume><fpage>5181</fpage><lpage>5187</lpage><pub-id pub-id-type="doi">10.2174/1381612825666190118150614</pub-id><?supplied-pmid 30657034?><pub-id pub-id-type="pmid">30657034</pub-id></element-citation></ref><ref id="B458-pharmaceutics-13-00143"><label>458.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name></person-group><article-title>Improved Neuroprotective Effects of Gallic Acid-Loaded Chitosan Nanoparticles Against Ischemic Stroke</article-title><source>Rejuvenation Res.</source><year>2019</year><volume>23</volume><fpage>284</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1089/rej.2019.2230</pub-id><pub-id pub-id-type="pmid">31680647</pub-id></element-citation></ref><ref id="B459-pharmaceutics-13-00143"><label>459.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>S.T.</given-names></name><name><surname>Yehya</surname><given-names>W.A.</given-names></name><name><surname>Saad</surname><given-names>O.</given-names></name><name><surname>Simarani</surname><given-names>K.</given-names></name><name><surname>Chowdhury</surname><given-names>Z.</given-names></name><name><surname>Alhadi</surname><given-names>A.A.</given-names></name><name><surname>Al-Ani</surname><given-names>L.A.</given-names></name></person-group><article-title>Surface Functionalization of Iron Oxide Nanoparticles with Gallic Acid as Potential Antioxidant and Antimicrobial Agents</article-title><source>Nanomaterials</source><year>2017</year><volume>7</volume><elocation-id>306</elocation-id><pub-id pub-id-type="doi">10.3390/nano7100306</pub-id></element-citation></ref><ref id="B460-pharmaceutics-13-00143"><label>460.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagpal</surname><given-names>K.</given-names></name><name><surname>Singh</surname><given-names>S.K.</given-names></name><name><surname>Mishra</surname><given-names>D.N.</given-names></name></person-group><article-title>Nanoparticle mediated brain targeted delivery of gallic acid: In vivo behavioral and biochemical studies for improved antioxidant and antidepressant-like activity</article-title><source>Drug Deliv.</source><year>2012</year><volume>19</volume><fpage>378</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.3109/10717544.2012.738437</pub-id><pub-id pub-id-type="pmid">23173579</pub-id></element-citation></ref><ref id="B461-pharmaceutics-13-00143"><label>461.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewandowski</surname><given-names>D.</given-names></name><name><surname>Ruszkowski</surname><given-names>P.</given-names></name><name><surname>Pi&#x00144;ska</surname><given-names>A.</given-names></name><name><surname>Schroeder</surname><given-names>G.</given-names></name><name><surname>Kurczewska</surname><given-names>J.</given-names></name></person-group><article-title>SBA-15 Mesoporous Silica Modified with Gallic Acid and Evaluation of Its Cytotoxic Activity</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0132541</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0132541</pub-id><pub-id pub-id-type="pmid">26151908</pub-id></element-citation></ref><ref id="B462-pharmaceutics-13-00143"><label>462.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rashidi</surname><given-names>L.</given-names></name><name><surname>Vasheghani-Farahani</surname><given-names>E.</given-names></name><name><surname>Soleimani</surname><given-names>M.</given-names></name><name><surname>Atashi</surname><given-names>A.</given-names></name><name><surname>Rostami</surname><given-names>K.</given-names></name><name><surname>Gangi</surname><given-names>F.</given-names></name><name><surname>Fallahpour</surname><given-names>M.</given-names></name><name><surname>Tahouri</surname><given-names>M.T.</given-names></name></person-group><article-title>A cellular uptake and cytotoxicity properties study of gallic acid-loaded mesoporous silica nanoparticles on Caco-2 cells</article-title><source>J. Nanopart. Res.</source><year>2014</year><volume>16</volume><fpage>2285</fpage><pub-id pub-id-type="doi">10.1007/s11051-014-2285-6</pub-id></element-citation></ref><ref id="B463-pharmaceutics-13-00143"><label>463.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lammari</surname><given-names>N.</given-names></name><name><surname>Louaer</surname><given-names>O.</given-names></name><name><surname>Meniai</surname><given-names>A.H.</given-names></name><name><surname>Elaissari</surname><given-names>A.</given-names></name></person-group><article-title>Encapsulation of Essential Oils via Nanoprecipitation Process: Overview, Progress, Challenges and Prospects</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>431</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12050431</pub-id><?supplied-pmid 32392726?><pub-id pub-id-type="pmid">32392726</pub-id></element-citation></ref><ref id="B464-pharmaceutics-13-00143"><label>464.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharifi-Rad</surname><given-names>J.</given-names></name><name><surname>Sureda</surname><given-names>A.</given-names></name><name><surname>Tenore</surname><given-names>G.C.</given-names></name><name><surname>Daglia</surname><given-names>M.</given-names></name><name><surname>Sharifi-Rad</surname><given-names>M.</given-names></name><name><surname>Valussi</surname><given-names>M.</given-names></name><name><surname>Tundis</surname><given-names>R.</given-names></name><name><surname>Loizzo</surname><given-names>M.R.</given-names></name><name><surname>Ademiluyi</surname><given-names>A.O.</given-names></name><name><surname>Sharifi-Rad</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Biological Activities of Essential Oils: From Plant Chemoecology to Traditional Healing Systems</article-title><source>Molecules</source><year>2017</year><volume>22</volume><elocation-id>70</elocation-id><pub-id pub-id-type="doi">10.3390/molecules22010070</pub-id><?supplied-pmid 28045446?><pub-id pub-id-type="pmid">28045446</pub-id></element-citation></ref><ref id="B465-pharmaceutics-13-00143"><label>465.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elshafie</surname><given-names>H.S.</given-names></name><name><surname>Camele</surname><given-names>I.</given-names></name></person-group><article-title>An Overview of the Biological Effects of Some Mediterranean Essential Oils on Human Health</article-title><source>BioMed Res. Int.</source><year>2017</year><volume>2017</volume><fpage>9268468</fpage><pub-id pub-id-type="doi">10.1155/2017/9268468</pub-id><?supplied-pmid 29230418?><pub-id pub-id-type="pmid">29230418</pub-id></element-citation></ref><ref id="B466-pharmaceutics-13-00143"><label>466.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Baser</surname><given-names>K.H.C.</given-names></name><name><surname>Buchbauer</surname><given-names>G.</given-names></name></person-group><source>Handbook of Essential Oils: Science, Technology, and Applications</source><publisher-name>CRC Press</publisher-name><publisher-loc>Boca Raton, FL, USA</publisher-loc><year>2015</year></element-citation></ref><ref id="B467-pharmaceutics-13-00143"><label>467.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>B.</given-names></name><name><surname>Al-Wabel</surname><given-names>N.A.</given-names></name><name><surname>Shams</surname><given-names>S.</given-names></name><name><surname>Ahamad</surname><given-names>A.</given-names></name><name><surname>Khan</surname><given-names>S.A.</given-names></name><name><surname>Anwar</surname><given-names>F.</given-names></name></person-group><article-title>Essential oils used in aromatherapy: A systemic review</article-title><source>Asian Pac. J. Trop. Biomed.</source><year>2015</year><volume>5</volume><fpage>601</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1016/j.apjtb.2015.05.007</pub-id></element-citation></ref><ref id="B468-pharmaceutics-13-00143"><label>468.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhifi</surname><given-names>W.</given-names></name><name><surname>Bellili</surname><given-names>S.</given-names></name><name><surname>Jazi</surname><given-names>S.</given-names></name><name><surname>Bahloul</surname><given-names>N.</given-names></name><name><surname>Mnif</surname><given-names>W.</given-names></name></person-group><article-title>Essential Oils&#x02019; Chemical Characterization and Investigation of Some Biological Activities: A Critical Review</article-title><source>Medicines</source><year>2016</year><volume>3</volume><elocation-id>25</elocation-id><pub-id pub-id-type="doi">10.3390/medicines3040025</pub-id></element-citation></ref><ref id="B469-pharmaceutics-13-00143"><label>469.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrade</surname><given-names>M.A.</given-names></name><name><surname>Braga</surname><given-names>M.A.</given-names></name><name><surname>Cesar</surname><given-names>P.H.S.</given-names></name><name><surname>Trento</surname><given-names>M.V.C.</given-names></name><name><surname>Esp&#x000f3;sito</surname><given-names>M.A.</given-names></name><name><surname>Silva</surname><given-names>L.F.</given-names></name><name><surname>Marcussi</surname><given-names>S.</given-names></name></person-group><article-title>Anticancer Properties of Essential Oils: An Overview</article-title><source>Curr. Cancer Drug Targets</source><year>2018</year><volume>18</volume><fpage>957</fpage><lpage>966</lpage><pub-id pub-id-type="doi">10.2174/1568009618666180102105843</pub-id><pub-id pub-id-type="pmid">29295695</pub-id></element-citation></ref><ref id="B470-pharmaceutics-13-00143"><label>470.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edris</surname><given-names>A.E.</given-names></name></person-group><article-title>Pharmaceutical and therapeutic Potentials of essential oils and their individual volatile constituents: A review</article-title><source>Phytother. Res.</source><year>2007</year><volume>21</volume><fpage>308</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1002/ptr.2072</pub-id><pub-id pub-id-type="pmid">17199238</pub-id></element-citation></ref><ref id="B471-pharmaceutics-13-00143"><label>471.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blowman</surname><given-names>K.</given-names></name><name><surname>Magalh&#x000e3;es</surname><given-names>M.</given-names></name><name><surname>Lemos</surname><given-names>M.F.L.</given-names></name><name><surname>Cabral</surname><given-names>C.</given-names></name><name><surname>Pires</surname><given-names>I.M.</given-names></name></person-group><article-title>Anticancer Properties of Essential Oils and Other Natural Products</article-title><source>Evid.-Based Complement. Altern. Med.</source><year>2018</year><volume>2018</volume><fpage>3149362</fpage><pub-id pub-id-type="doi">10.1155/2018/3149362</pub-id></element-citation></ref><ref id="B472-pharmaceutics-13-00143"><label>472.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautam</surname><given-names>N.</given-names></name><name><surname>Mantha</surname><given-names>A.K.</given-names></name><name><surname>Mittal</surname><given-names>S.</given-names></name></person-group><article-title>Essential Oils and Their Constituents as Anticancer Agents: A Mechanistic View</article-title><source>BioMed Res. Int.</source><year>2014</year><volume>2014</volume><fpage>154106</fpage><pub-id pub-id-type="doi">10.1155/2014/154106</pub-id><pub-id pub-id-type="pmid">25003106</pub-id></element-citation></ref><ref id="B473-pharmaceutics-13-00143"><label>473.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitsiou</surname><given-names>E.</given-names></name><name><surname>Pappa</surname><given-names>A.</given-names></name></person-group><article-title>Anticancer Activity of Essential Oils and Other Extracts from Aromatic Plants Grown in Greece</article-title><source>Antioxidants</source><year>2019</year><volume>8</volume><elocation-id>290</elocation-id><pub-id pub-id-type="doi">10.3390/antiox8080290</pub-id></element-citation></ref><ref id="B474-pharmaceutics-13-00143"><label>474.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhalla</surname><given-names>Y.</given-names></name><name><surname>Gupta</surname><given-names>V.K.</given-names></name><name><surname>Jaitak</surname><given-names>V.</given-names></name></person-group><article-title>Anticancer activity of essential oils: A review</article-title><source>J. Sci. Food Agric.</source><year>2013</year><volume>93</volume><fpage>3643</fpage><lpage>3653</lpage><pub-id pub-id-type="doi">10.1002/jsfa.6267</pub-id><?supplied-pmid 23765679?><pub-id pub-id-type="pmid">23765679</pub-id></element-citation></ref><ref id="B475-pharmaceutics-13-00143"><label>475.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bayala</surname><given-names>B.</given-names></name><name><surname>Bassole</surname><given-names>I.H.</given-names></name><name><surname>Scifo</surname><given-names>R.</given-names></name><name><surname>Gnoula</surname><given-names>C.</given-names></name><name><surname>Morel</surname><given-names>L.</given-names></name><name><surname>Lobaccaro</surname><given-names>J.-M.A.</given-names></name><name><surname>Simpore</surname><given-names>J.</given-names></name></person-group><article-title>Anticancer activity of essential oils and their chemical components&#x02014;A review</article-title><source>Am. J. Cancer Res.</source><year>2014</year><volume>4</volume><fpage>591</fpage><lpage>607</lpage><?supplied-pmid 25520854?><pub-id pub-id-type="pmid">25520854</pub-id></element-citation></ref><ref id="B476-pharmaceutics-13-00143"><label>476.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manjamalai</surname><given-names>A.</given-names></name><name><surname>Kumar</surname><given-names>M.J.</given-names></name><name><surname>Grace</surname><given-names>V.M.</given-names></name></person-group><article-title>Essential oil of Tridax procumbens L induces apoptosis and suppresses angiogenesis and lung metastasis of the B16F-10 cell line in C57BL/6 mice</article-title><source>Asian Pac. J. Cancer Prev.</source><year>2012</year><volume>13</volume><fpage>5887</fpage><lpage>5895</lpage><pub-id pub-id-type="doi">10.7314/APJCP.2012.13.11.5887</pub-id><pub-id pub-id-type="pmid">23317275</pub-id></element-citation></ref><ref id="B477-pharmaceutics-13-00143"><label>477.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manjamalai</surname><given-names>A.</given-names></name><name><surname>Grace</surname><given-names>V.M.</given-names></name></person-group><article-title>The chemotherapeutic effect of essential oil of Plectranthus amboinicus (Lour) on lung metastasis developed by B16F-10 cell line in C57BL/6 mice</article-title><source>Cancer Investig.</source><year>2013</year><volume>31</volume><fpage>74</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.3109/07357907.2012.749268</pub-id><?supplied-pmid 23249189?><pub-id pub-id-type="pmid">23249189</pub-id></element-citation></ref><ref id="B478-pharmaceutics-13-00143"><label>478.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turek</surname><given-names>C.</given-names></name><name><surname>Stintzing</surname><given-names>F.C.</given-names></name></person-group><article-title>Stability of Essential Oils: A Review</article-title><source>Compr. Rev. Food Sci. Food Saf.</source><year>2013</year><volume>12</volume><fpage>40</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1111/1541-4337.12006</pub-id></element-citation></ref><ref id="B479-pharmaceutics-13-00143"><label>479.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Froiio</surname><given-names>F.</given-names></name><name><surname>Ginot</surname><given-names>L.</given-names></name><name><surname>Paolino</surname><given-names>D.</given-names></name><name><surname>Lebaz</surname><given-names>N.</given-names></name><name><surname>Bentaher</surname><given-names>A.</given-names></name><name><surname>Fessi</surname><given-names>H.</given-names></name><name><surname>Elaissari</surname><given-names>A.</given-names></name></person-group><article-title>Essential Oils-Loaded Polymer Particles: Preparation, Characterization and Antimicrobial Property</article-title><source>Polymers</source><year>2019</year><volume>11</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.3390/polym11061017</pub-id><?supplied-pmid 31181851?><pub-id pub-id-type="pmid">31181851</pub-id></element-citation></ref><ref id="B480-pharmaceutics-13-00143"><label>480.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>H.</given-names></name><name><surname>Al-Khalifa</surname><given-names>A.R.</given-names></name><name><surname>Aouf</surname><given-names>A.</given-names></name><name><surname>Boukhebti</surname><given-names>H.</given-names></name><name><surname>Farouk</surname><given-names>A.</given-names></name></person-group><article-title>Effect of nanoencapsulation on volatile constituents, and antioxidant and anticancer activities of Algerian Origanum glandulosum Desf. essential oil</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>2812</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-59686-w</pub-id><pub-id pub-id-type="pmid">32071359</pub-id></element-citation></ref><ref id="B481-pharmaceutics-13-00143"><label>481.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attallah</surname><given-names>O.A.</given-names></name><name><surname>Shetta</surname><given-names>A.</given-names></name><name><surname>Elshishiny</surname><given-names>F.</given-names></name><name><surname>Mamdouh</surname><given-names>W.</given-names></name></person-group><article-title>Essential oil loaded pectin/chitosan nanoparticles preparation and optimization via Box&#x02013;Behnken design against MCF-7 breast cancer cell lines</article-title><source>RSC Adv.</source><year>2020</year><volume>10</volume><fpage>8703</fpage><lpage>8708</lpage><pub-id pub-id-type="doi">10.1039/C9RA10204C</pub-id></element-citation></ref><ref id="B482-pharmaceutics-13-00143"><label>482.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Matos</surname><given-names>S.P.</given-names></name><name><surname>Teixeira</surname><given-names>H.F.</given-names></name><name><surname>de Lima</surname><given-names>&#x000c1;.A.N.</given-names></name><name><surname>Veiga-Junior</surname><given-names>V.F.</given-names></name><name><surname>Koester</surname><given-names>L.S.</given-names></name></person-group><article-title>Essential Oils and Isolated Terpenes in Nanosystems Designed for Topical Administration: A Review</article-title><source>Biomolecules</source><year>2019</year><volume>9</volume><elocation-id>138</elocation-id><pub-id pub-id-type="doi">10.3390/biom9040138</pub-id></element-citation></ref><ref id="B483-pharmaceutics-13-00143"><label>483.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melendez-Rodriguez</surname><given-names>B.</given-names></name><name><surname>Figueroa-Lopez</surname><given-names>K.J.</given-names></name><name><surname>Bernardos</surname><given-names>A.</given-names></name><name><surname>Mart&#x000ed;nez-M&#x000e1;&#x000f1;ez</surname><given-names>R.</given-names></name><name><surname>Cabedo</surname><given-names>L.</given-names></name><name><surname>Torres-Giner</surname><given-names>S.</given-names></name><name><surname>Lagaron</surname><given-names>J.M.</given-names></name></person-group><article-title>Electrospun Antimicrobial Films of Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) Containing Eugenol Essential Oil Encapsulated in Mesoporous Silica Nanoparticles</article-title><source>Nanomaterials</source><year>2019</year><volume>9</volume><elocation-id>227</elocation-id><pub-id pub-id-type="doi">10.3390/nano9020227</pub-id></element-citation></ref><ref id="B484-pharmaceutics-13-00143"><label>484.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebadollahi</surname><given-names>A.</given-names></name><name><surname>Sendi</surname><given-names>J.J.</given-names></name><name><surname>Aliakbar</surname><given-names>A.</given-names></name></person-group><article-title>Efficacy of Nanoencapsulated Thymus eriocalyx and Thymus kotschyanus Essential Oils by a Mesoporous Material MCM-41 Against Tetranychus urticae (Acari: Tetranychidae)</article-title><source>J. Econ. Entomol.</source><year>2017</year><volume>110</volume><fpage>2413</fpage><lpage>2420</lpage><pub-id pub-id-type="doi">10.1093/jee/tox234</pub-id><?supplied-pmid 29029248?><pub-id pub-id-type="pmid">29029248</pub-id></element-citation></ref><ref id="B485-pharmaceutics-13-00143"><label>485.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janatova</surname><given-names>A.</given-names></name><name><surname>Bernardos</surname><given-names>A.</given-names></name><name><surname>Smid</surname><given-names>J.</given-names></name><name><surname>Frankova</surname><given-names>A.</given-names></name><name><surname>Lhotka</surname><given-names>M.</given-names></name><name><surname>Kourimsk&#x000e1;</surname><given-names>L.</given-names></name><name><surname>Pulkrabek</surname><given-names>J.</given-names></name><name><surname>Kloucek</surname><given-names>P.</given-names></name></person-group><article-title>Long-term antifungal activity of volatile essential oil components released from mesoporous silica materials</article-title><source>Ind. Crop. Prod.</source><year>2015</year><volume>67</volume><fpage>216</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.indcrop.2015.01.019</pub-id></element-citation></ref><ref id="B486-pharmaceutics-13-00143"><label>486.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jobdeedamrong</surname><given-names>A.</given-names></name><name><surname>Jenjob</surname><given-names>R.</given-names></name><name><surname>Crespy</surname><given-names>D.</given-names></name></person-group><article-title>Encapsulation and Release of Essential Oils in Functional Silica Nanocontainers</article-title><source>Langmuir</source><year>2018</year><volume>34</volume><fpage>13235</fpage><lpage>13243</lpage><pub-id pub-id-type="doi">10.1021/acs.langmuir.8b01652</pub-id><?supplied-pmid 30300551?><pub-id pub-id-type="pmid">30300551</pub-id></element-citation></ref><ref id="B487-pharmaceutics-13-00143"><label>487.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M.</given-names></name><name><surname>Yeom</surname><given-names>Y.E.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>C.</given-names></name></person-group><article-title>Delayed Volatilization of Lavender Essential Oil Using Mesoporous Silica Nanoparticles</article-title><source>Polymer</source><year>2019</year><volume>43</volume><fpage>327</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.7317/pk.2019.43.3.327</pub-id></element-citation></ref><ref id="B488-pharmaceutics-13-00143"><label>488.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>L.</given-names></name><name><surname>Teng</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>L.</given-names></name><name><surname>Lan</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Sheng</surname><given-names>J.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name></person-group><article-title>Pepper fragrant essential oil (PFEO) and functionalized MCM-41 nanoparticles: Formation, characterization, and bactericidal activity</article-title><source>J. Sci. Food Agric.</source><year>2019</year><volume>99</volume><fpage>5168</fpage><lpage>5175</lpage><pub-id pub-id-type="doi">10.1002/jsfa.9776</pub-id><pub-id pub-id-type="pmid">31056749</pub-id></element-citation></ref><ref id="B489-pharmaceutics-13-00143"><label>489.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bravo Cadena</surname><given-names>M.</given-names></name><name><surname>Preston</surname><given-names>G.M.</given-names></name><name><surname>Van der Hoorn</surname><given-names>R.A.L.</given-names></name><name><surname>Townley</surname><given-names>H.E.</given-names></name><name><surname>Thompson</surname><given-names>I.P.</given-names></name></person-group><article-title>Species-specific antimicrobial activity of essential oils and enhancement by encapsulation in mesoporous silica nanoparticles</article-title><source>Ind. Crop. Prod.</source><year>2018</year><volume>122</volume><fpage>582</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1016/j.indcrop.2018.05.081</pub-id></element-citation></ref><ref id="B490-pharmaceutics-13-00143"><label>490.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernardos</surname><given-names>A.</given-names></name><name><surname>Marina</surname><given-names>T.</given-names></name><name><surname>&#x0017d;&#x000e1;&#x0010d;ek</surname><given-names>P.</given-names></name><name><surname>P&#x000e9;rez-Esteve</surname><given-names>&#x000c9;.</given-names></name><name><surname>Mart&#x000ed;nez-Ma&#x000f1;ez</surname><given-names>R.</given-names></name><name><surname>Lhotka</surname><given-names>M.</given-names></name><name><surname>Kou&#x00159;imsk&#x000e1;</surname><given-names>L.</given-names></name><name><surname>Pulkr&#x000e1;bek</surname><given-names>J.</given-names></name><name><surname>Klou&#x0010d;ek</surname><given-names>P.</given-names></name></person-group><article-title>Antifungal effect of essential oil components against Aspergillus niger when loaded into silica mesoporous supports</article-title><source>J. Sci. Food Agric.</source><year>2015</year><volume>95</volume><fpage>2824</fpage><lpage>2831</lpage><pub-id pub-id-type="doi">10.1002/jsfa.7022</pub-id><?supplied-pmid 25428206?><pub-id pub-id-type="pmid">25428206</pub-id></element-citation></ref><ref id="B491-pharmaceutics-13-00143"><label>491.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>A.C.</given-names></name><name><surname>Bravo Cadena</surname><given-names>M.</given-names></name><name><surname>Townley</surname><given-names>H.E.</given-names></name><name><surname>Fricker</surname><given-names>M.D.</given-names></name><name><surname>Thompson</surname><given-names>I.P.</given-names></name></person-group><article-title>Effective delivery of volatile biocides employing mesoporous silicates for treating biofilms</article-title><source>J. R. Soc. Interface</source><year>2017</year><volume>14</volume><fpage>20160650</fpage><pub-id pub-id-type="doi">10.1098/rsif.2016.0650</pub-id><pub-id pub-id-type="pmid">28077760</pub-id></element-citation></ref><ref id="B492-pharmaceutics-13-00143"><label>492.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crespo-Ortiz</surname><given-names>M.P.</given-names></name><name><surname>Wei</surname><given-names>M.Q.</given-names></name></person-group><article-title>Antitumor activity of artemisinin and its derivatives: From a well-known antimalarial agent to a potential anticancer drug</article-title><source>J. Biomed. Biotechnol.</source><year>2012</year><volume>2012</volume><fpage>247597</fpage><pub-id pub-id-type="doi">10.1155/2012/247597</pub-id><pub-id pub-id-type="pmid">22174561</pub-id></element-citation></ref><ref id="B493-pharmaceutics-13-00143"><label>493.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Guo</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>H.B.</given-names></name><name><surname>Zhou</surname><given-names>J.J.</given-names></name><name><surname>Zhang</surname><given-names>W.J.</given-names></name><name><surname>Chen</surname><given-names>Q.W.</given-names></name></person-group><article-title>Multifunctional mesoporous nanoparticles as pH-responsive Fe(2+) reservoirs and artemisinin vehicles for synergistic inhibition of tumor growth</article-title><source>Biomaterials</source><year>2014</year><volume>35</volume><fpage>6498</fpage><lpage>6507</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.04.028</pub-id><pub-id pub-id-type="pmid">24797880</pub-id></element-citation></ref><ref id="B494-pharmaceutics-13-00143"><label>494.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Sharma</surname><given-names>P.R.</given-names></name><name><surname>Mondhe</surname><given-names>D.M.</given-names></name></person-group><article-title>Potential anticancer role of colchicine-based derivatives: An overview</article-title><source>Anticancer Drugs</source><year>2017</year><volume>28</volume><fpage>250</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1097/CAD.0000000000000464</pub-id><pub-id pub-id-type="pmid">28030380</pub-id></element-citation></ref><ref id="B495-pharmaceutics-13-00143"><label>495.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cauda</surname><given-names>V.</given-names></name><name><surname>Engelke</surname><given-names>H.</given-names></name><name><surname>Sauer</surname><given-names>A.</given-names></name><name><surname>Arcizet</surname><given-names>D.</given-names></name><name><surname>Br&#x000e4;uchle</surname><given-names>C.</given-names></name><name><surname>R&#x000e4;dler</surname><given-names>J.</given-names></name><name><surname>Bein</surname><given-names>T.</given-names></name></person-group><article-title>Colchicine-Loaded Lipid Bilayer-Coated 50 nm Mesoporous Nanoparticles Efficiently Induce Microtubule Depolymerization upon Cell Uptake</article-title><source>Nano Lett.</source><year>2010</year><volume>10</volume><fpage>2484</fpage><lpage>2492</lpage><pub-id pub-id-type="doi">10.1021/nl100991w</pub-id><pub-id pub-id-type="pmid">20515041</pub-id></element-citation></ref><ref id="B496-pharmaceutics-13-00143"><label>496.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hespeler</surname><given-names>D.</given-names></name><name><surname>Kaltenbach</surname><given-names>J.</given-names></name><name><surname>Pyo</surname><given-names>S.M.</given-names></name></person-group><article-title>Glabridin smartPearls&#x02014;Silica selection, production, amorphous stability and enhanced solubility</article-title><source>Int. J. Pharm.</source><year>2019</year><volume>561</volume><fpage>228</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2019.02.028</pub-id><pub-id pub-id-type="pmid">30836152</pub-id></element-citation></ref><ref id="B497-pharmaceutics-13-00143"><label>497.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buda</surname><given-names>V.</given-names></name><name><surname>Brezoiu</surname><given-names>A.M.</given-names></name><name><surname>Berger</surname><given-names>D.</given-names></name><name><surname>Pavel</surname><given-names>I.Z.</given-names></name><name><surname>Muntean</surname><given-names>D.</given-names></name><name><surname>Minda</surname><given-names>D.</given-names></name><name><surname>Dehelean</surname><given-names>C.A.</given-names></name><name><surname>Soica</surname><given-names>C.</given-names></name><name><surname>Diaconeasa</surname><given-names>Z.</given-names></name><name><surname>Folescu</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Biological Evaluation of Black Chokeberry Extract Free and Embedded in Two Mesoporous Silica-Type Matrices</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>838</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12090838</pub-id><?supplied-pmid 32882983?><pub-id pub-id-type="pmid">32882983</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="pharmaceutics-13-00143-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Number of scientific publications (research papers, reviews, book chapters) during the period 2001&#x02013;2020 found by entering key words &#x0201c;mesoporous silica nanoparticles and synthesis&#x0201d;. The search was performed in ScienceDirect 10 September 2020.</p></caption><graphic xlink:href="pharmaceutics-13-00143-g001"/></fig><fig id="pharmaceutics-13-00143-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>The formation mechanism for mesoporous materials by structure-directing agents. (<bold>a</bold>) True liquid&#x02013;crystal template mechanism. (<bold>b</bold>) Cooperative liquid&#x02013;crystal template mechanism. Reproduced with permission from [<xref rid="B52-pharmaceutics-13-00143" ref-type="bibr">52</xref>], WILEY-VCH Verlag GmbH and Co. KGaA, 2006.</p></caption><graphic xlink:href="pharmaceutics-13-00143-g002"/></fig><fig id="pharmaceutics-13-00143-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>(<bold>A</bold>) Scanning electron microscopy (SEM) and (<bold>B</bold>) transmission electron microscopy (TEM) of MCM-41 material. Reproduced with permission from [<xref rid="B23-pharmaceutics-13-00143" ref-type="bibr">23</xref>], Wiley-VCH Verlag GmbH and Co. KGaA, 2010.</p></caption><graphic xlink:href="pharmaceutics-13-00143-g003"/></fig><fig id="pharmaceutics-13-00143-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Electron microscope images of prepared KCC-1 material. (<bold>A</bold>,<bold>B</bold>) Scanning electron microscopy (SEM). (<bold>C</bold>,<bold>D</bold>) Transmission electron microscopy (TEM). Note, the dendritic fibrous 3D mesopore structure is clearly seen by SEM in B. A and C reproduced from [<xref rid="B42-pharmaceutics-13-00143" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-13-00143" ref-type="bibr">43</xref>], Impact Journals, 2018 and MDPI, 2020. B and D reproduced with permission from [<xref rid="B59-pharmaceutics-13-00143" ref-type="bibr">59</xref>], WILEY-VCH Verlag GmbH and Co. KGaA, 2010.</p></caption><graphic xlink:href="pharmaceutics-13-00143-g004"/></fig><fig id="pharmaceutics-13-00143-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>A schematic presentation of the organic functionalization methods for mesoporous silica materials. (<bold>A</bold>) Co-condensation method and (<bold>B</bold>) grafting method. Reproduced with permission from [<xref rid="B52-pharmaceutics-13-00143" ref-type="bibr">52</xref>], WILEY-VCH Verlag GmbH and Co. KGaA, 2006.</p></caption><graphic xlink:href="pharmaceutics-13-00143-g005"/></fig><fig id="pharmaceutics-13-00143-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Different endocytosis pathways across the intestinal villus for particles of different sizes. Reproduced with permission from [<xref rid="B97-pharmaceutics-13-00143" ref-type="bibr">97</xref>], Elsevier Inc., 2020.</p></caption><graphic xlink:href="pharmaceutics-13-00143-g006"/></fig><fig id="pharmaceutics-13-00143-f007" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Confocal laser microscopy images of HeLa cells after incubation with different sizes of MSNs labeled with fluorescein isothiocyanate (FITC) green fluorescence (MSN-FITC) (100 &#x000b5;g mL<sup>&#x02212;1</sup>, green) for 5 h at 37 &#x000b0;C. (<bold>A</bold>) 170 nm, (<bold>B</bold>) 110 nm, (<bold>C</bold>) 50 nm, and (<bold>D</bold>) 30 nm. The cell skeleton was stained with rhodamine-phalloidin (red), and the cell nucleus with 4&#x02032;,6-diamidino-2-phenylindole (DAPI; blue). Reproduced with permission from [<xref rid="B103-pharmaceutics-13-00143" ref-type="bibr">103</xref>], WILEY-VCH Verlag GmbH and Co. KGaA, 2009.</p></caption><graphic xlink:href="pharmaceutics-13-00143-g007"/></fig><fig id="pharmaceutics-13-00143-f008" orientation="portrait" position="float"><label>Figure 8</label><caption><p>Cellular uptake of FITC-MSN-x based on nanoparticle size. Reproduced with permission from [<xref rid="B103-pharmaceutics-13-00143" ref-type="bibr">103</xref>], WILEY-VCH Verlag GmbH and Co. KGaA, 2009.</p></caption><graphic xlink:href="pharmaceutics-13-00143-g008"/></fig><fig id="pharmaceutics-13-00143-f009" orientation="portrait" position="float"><label>Figure 9</label><caption><p>Schematic illustration of the biocompatibility and biotranslocation of MSNs and the main physical&#x02013;chemical characteristics. These highly influence the cellular uptake, intracellular translocation, and cytotoxicity on the in vitro level, and the biodistribution, biodegradation, excretion, and toxicity on the in vivo level. Reproduced with permission from [<xref rid="B131-pharmaceutics-13-00143" ref-type="bibr">131</xref>], WILEY-VCH Verlag GmbH and Co. KGaA, 2012.</p></caption><graphic xlink:href="pharmaceutics-13-00143-g009"/></fig><fig id="pharmaceutics-13-00143-f010" orientation="portrait" position="float"><label>Figure 10</label><caption><p>Characterization of short rod MSN labeled with FITC (NSRFITC) and long rod MSN labeled FITC (NLRFITC). (<bold>A</bold>) TEM image of NSRFITC. (<bold>B</bold>) TEM image showing the mesostructure of NSRFITC. (<bold>C</bold>) TEM image of NLRFITC. (<bold>D</bold>) TEM image showing the mesostructure of NLRFITC. Arrows denote FITC embedded in a particle. Reproduced with permission from [<xref rid="B30-pharmaceutics-13-00143" ref-type="bibr">30</xref>], American Chemical Society, 2011.</p></caption><graphic xlink:href="pharmaceutics-13-00143-g010"/></fig><fig id="pharmaceutics-13-00143-f011" orientation="portrait" position="float"><label>Figure 11</label><caption><p>Biodistribution of differently shaped and poly(ethylene glycol) (PEG)ylated MSNFITC in liver, spleen, and lung observed by confocal microscopy 2 h after intravenous injection. Arrows denote NLRFITC distribution in the lung. Reproduced with permission from [<xref rid="B30-pharmaceutics-13-00143" ref-type="bibr">30</xref>], American Chemical Society, 2011.</p></caption><graphic xlink:href="pharmaceutics-13-00143-g011"/></fig><fig id="pharmaceutics-13-00143-f012" orientation="portrait" position="float"><label>Figure 12</label><caption><p>Quantitative analysis of differently shaped and PEGylated MSNs in organs and blood by ICPOES. Relative Si contents in liver, spleen, and kidney at (<bold>A</bold>) 2 h, (<bold>B</bold>) 24 h, and (<bold>C</bold>) 7 d post-injection. Data are the mean &#x000b1; SD from three separate experiments. * <italic>p</italic> &#x0003c; 0.05; ** <italic>p</italic> &#x0003c; 0.01 for the comparison of Si contents of differently shaped and PEGylated MSNs in organs and blood. Reproduced with permission from [<xref rid="B30-pharmaceutics-13-00143" ref-type="bibr">30</xref>], American Chemical Society, 2011.</p></caption><graphic xlink:href="pharmaceutics-13-00143-g012"/></fig><fig id="pharmaceutics-13-00143-f013" orientation="portrait" position="float"><label>Figure 13</label><caption><p>Schematic representation of the intact and degraded structures of silica material nanoparticles with the mechanisms and regulating factors underlying degradation. Reproduced from [<xref rid="B155-pharmaceutics-13-00143" ref-type="bibr">155</xref>], WILEY-VCH Verlag GmbH and Co. KGaA, 2017.</p></caption><graphic xlink:href="pharmaceutics-13-00143-g013"/></fig><fig id="pharmaceutics-13-00143-f014" orientation="portrait" position="float"><label>Figure 14</label><caption><p>(<bold>A</bold>) Schematic representation of stimuli-responsive release of drugs from MSNs. (<bold>B</bold>) Internal stimuli-responsive release. (<bold>C</bold>) External stimuli-responsive release. Reproduced from [<xref rid="B81-pharmaceutics-13-00143" ref-type="bibr">81</xref>], MDPI, 2017.</p></caption><graphic xlink:href="pharmaceutics-13-00143-g014"/></fig><fig id="pharmaceutics-13-00143-f015" orientation="portrait" position="float"><label>Figure 15</label><caption><p>(<bold>A</bold>) Schematic representation of the delivery design for quercetin &#x0201c;FA-FE-SBA15QN&#x0201d;. (<bold>B</bold>) The release kinetics of quercetin from FA-FE-SBA15QN at different pH (7.4 and 5.5). The values are represented as the mean &#x000b1; SEM. Reproduced with permission from [<xref rid="B223-pharmaceutics-13-00143" ref-type="bibr">223</xref>], The Royal Society of Chemistry, 2020. This article is licensed under a Creative Commons Attribution-Non-commercial 3.0 Unported License.</p></caption><graphic xlink:href="pharmaceutics-13-00143-g015"/></fig><fig id="pharmaceutics-13-00143-f016" orientation="portrait" position="float"><label>Figure 16</label><caption><p>(<bold>A</bold>) Illustration of the dual-response release of p-Cur and Dox co-delivery. (<bold>B</bold>) In vitro release profiles of Cur from MSN/SP/bPEG at 37 &#x000b0;C. Error bars indicate standard deviation. Reproduced with permission from [<xref rid="B228-pharmaceutics-13-00143" ref-type="bibr">228</xref>], Elsevier B.V, 2019.</p></caption><graphic xlink:href="pharmaceutics-13-00143-g016"/></fig><fig id="pharmaceutics-13-00143-f017" orientation="portrait" position="float"><label>Figure 17</label><caption><p>The preparation process for MSN-PEG@Cur and schematic representation of the intracellular photodynamic therapy (PDT) process after endocytosis of MSN-PEG@Cur. Reproduced with permission from [<xref rid="B238-pharmaceutics-13-00143" ref-type="bibr">238</xref>], The Royal Society of Chemistry, 2020. This article is licensed under a Creative Commons Attribution-Non-commercial 3.0 Unported License.</p></caption><graphic xlink:href="pharmaceutics-13-00143-g017"/></fig><fig id="pharmaceutics-13-00143-f018" orientation="portrait" position="float"><label>Figure 18</label><caption><p>Schematic representation of the enhanced permeability and retention (EPR) effect (lift side). (<bold>A</bold>) Normal blood vessels (no fenestrations), showing that MSNs remain in the bloodstream. (<bold>B</bold>) Tumor tissues (defective blood vessels present) showing that MSNs leak out through the endothelial gap&#x02013;gap and eventually accumulate in the tumor. On the right is a schematic depiction of active targeting with a variety of possibilities depending on the MSNs. Reproduced from [<xref rid="B32-pharmaceutics-13-00143" ref-type="bibr">32</xref>,<xref rid="B259-pharmaceutics-13-00143" ref-type="bibr">259</xref>], MDPI, 2020.</p></caption><graphic xlink:href="pharmaceutics-13-00143-g018"/></fig><fig id="pharmaceutics-13-00143-f019" orientation="portrait" position="float"><label>Figure 19</label><caption><p>Schematic representation of the preparation, internalization, and anticancer mechanism of action of the prepared nanosystem in human liver carcinoma (HepG2) cells. This schematic shows the prodrug release into cancer cells and the main anticancer action for inducing apoptosis via activation of caspase-3 for killing HepG2 cancer cells proposed by assistance from important signaling pathways (c-MET, MCL-1, and H2O2). Reproduced from [<xref rid="B42-pharmaceutics-13-00143" ref-type="bibr">42</xref>], Impact Journals, 2018.</p></caption><graphic xlink:href="pharmaceutics-13-00143-g019"/></fig><fig id="pharmaceutics-13-00143-f020" orientation="portrait" position="float"><label>Figure 20</label><caption><p>Chemical structures of various classes of natural compounds (prodrugs). Reproduced with permission from [<xref rid="B285-pharmaceutics-13-00143" ref-type="bibr">285</xref>], Elsevier Ltd., 2019.</p></caption><graphic xlink:href="pharmaceutics-13-00143-g020"/></fig><table-wrap id="pharmaceutics-13-00143-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceutics-13-00143-t001_Table 1</object-id><label>Table 1</label><caption><p>Classification of porous materials by pore size.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type of Porosity</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Size (nm)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microporous</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mesoporous</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2&#x02013;50</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Macroporous</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;50</td></tr></tbody></table></table-wrap><table-wrap id="pharmaceutics-13-00143-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceutics-13-00143-t002_Table 2</object-id><label>Table 2</label><caption><p>The physicochemical properties of the most common mesoporous silica nanoparticles (MSNs) synthesized by various approaches.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">BET-<break/>Specific<break/> Surface Area (m<sup>2</sup> g<sup>&#x02212;1)</sup>)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pore Volume (cm<sup>3</sup> g<sup>&#x02212;1</sup>)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pore Size (nm)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanical Stability (Mpa)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Hydrothermal Stability (&#x000b0;C) (time/h)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Thermal<break/> Stability (&#x000b0;C)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Particle Size</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pore Structure</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Morphology/<break/>Structure</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MCM-41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;1000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7&#x02013;1.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.5&#x02013;10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">707</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~100&#x02013;200 or microns</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ordered hexagonal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Almost spherical</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SBA-15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">700&#x02013;1000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.75&#x02013;1.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5&#x02013;8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">260</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">600</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">microns</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ordered hexagonal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rods</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KCC-1/DFNS/WMS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~450&#x02013;1250</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.54&#x02013;2.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3&#x02013;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">216</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">950 or over</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50&#x02013;1100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disordered</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stober silica</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~10&#x02013;350</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.017&#x02013;0.217</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2&#x02013;5.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20&#x02013;3000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid spheres</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KIT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Few microns</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~290&#x02013;1160</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.85&#x02013;0.95</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~2&#x02013;10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Few nanometers to microns</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Varied</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">porous</td></tr></tbody></table><table-wrap-foot><fn><p>Note: The above-mentioned characteristics of these materials can be controlled and can vary (more or less) from these values. Reproduced with permission from [<xref rid="B75-pharmaceutics-13-00143" ref-type="bibr">75</xref>], Wiley-VCH Verlag GmbH and Co. KGaA, 2017. NA = not available.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pharmaceutics-13-00143-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceutics-13-00143-t003_Table 3</object-id><label>Table 3</label><caption><p>The biocompatibility, biodistribution, and clearance of MSNs with different shapes, sizes, and surface modifications in vitro or in vivo (injection or oral administration).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MSNs</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Biocompatibility</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Biodistribution in Organs</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs (150 to 4000 nm)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous injection<break/>Intravenous injections</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Good biocompatibility on histological level<break/>Death or euthanasia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B139-pharmaceutics-13-00143" ref-type="bibr">139</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bare, functionalized, polyethylene glycol or hyaluronic acid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biocompatible;<break/>do not induce ROS/RNS production;<break/>no changes in mitochondrial membrane potential or cell cycle</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B141-pharmaceutics-13-00143" ref-type="bibr">141</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs and PEGylated MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tail vein injection in mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All treated mice survive well for 1 month after being injected with all MSN and PEG&#x02013;MSN<break/>No pathological abnormality on gross and microscopic histological examinations</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mainly located in liver and spleen;<break/>minority in lung, kidney, and heart</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B142-pharmaceutics-13-00143" ref-type="bibr">142</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs and solid silica nanoparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lateral tail vein in mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver and spleen due to reticulo-endothelial system;<break/>increased accumulation in the lungs due to amine modification;<break/>degraded and excreted by urinary and hepatobiliary routes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B143-pharmaceutics-13-00143" ref-type="bibr">143</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs with different shapes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral administration in mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No abnormalities in liver, lung, heart, and spleen; kidneys show particle shape-dependent tissue damage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver, lung, spleen, kidney, and intestine<break/>Rapidly excreted from feces, and some fraction excreted renally</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B144-pharmaceutics-13-00143" ref-type="bibr">144</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs (spheres and rod)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral administration in mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Long-rod MSNs have longer blood circulation than short-rod and spheres</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mainly found in liver and kidney;<break/>renal excretion-spherical MSNs cleared faster than rod MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B145-pharmaceutics-13-00143" ref-type="bibr">145</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multifunctional MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tail vein injection in mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Good biocompatibility with low toxicity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mainly found in liver and spleen<break/>Excreted in urine and feces</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B21-pharmaceutics-13-00143" ref-type="bibr">21</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Magnetic-doped MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro and in vivo (mouse)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Good biocompatibility</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B146-pharmaceutics-13-00143" ref-type="bibr">146</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biomimetic MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro and in vivo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biocompatible and no obvious toxicity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tendency to be biodistributed in brain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B147-pharmaceutics-13-00143" ref-type="bibr">147</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs with different sizes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous injection in mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Incidence and severity of inflammatory response was obtained with large size;<break/>no abnormal changes obtained for small size</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spleen and liver;<break/>clearance in urine and bile depending on size</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B148-pharmaceutics-13-00143" ref-type="bibr">148</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro and in vivo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No toxicity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver and spleen;<break/>clearance from urine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B82-pharmaceutics-13-00143" ref-type="bibr">82</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="pharmaceutics-13-00143-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceutics-13-00143-t004_Table 4</object-id><label>Table 4</label><caption><p>The toxicity and biosafety of MSNs of various size, shape, surface modification, and route of administration in in vivo studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MSNs</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Route of Administration</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Period</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Toxicity</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs of 110 nm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Repeated dose at 20, 40, and 80 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous injection in mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No death; LD50 of single dose = 1000 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B164-pharmaceutics-13-00143" ref-type="bibr">164</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs of 150 nm, 800 nm, and 4 &#x003bc;m</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Different doses at single dose </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Different routes in rats</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Toxicity depends on route of administration. An amount of 40 mg/kg is safe</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B139-pharmaceutics-13-00143" ref-type="bibr">139</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40 mg/kg in CD-1 mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous injection in mice/rats</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Safe for I.V. administration </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B171-pharmaceutics-13-00143" ref-type="bibr">171</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs with aspect ratios of 1, 1.75, and 5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral administration</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Safe and no changes observed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B144-pharmaceutics-13-00143" ref-type="bibr">144</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs: different sizes and surface modified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose at 25 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lateral tail vein injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No clinical toxicity based on histological evaluations; blood biocompatibility</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B82-pharmaceutics-13-00143" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Functionalized Fe3O4@MSN-PEG and non-modified PEG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous injections in mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-MSN-PEG caused toxicity to liver, kidney, and spleen tissues; modified PEG nanoparticles showed no toxicity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B172-pharmaceutics-13-00143" ref-type="bibr">172</xref>,<xref rid="B173-pharmaceutics-13-00143" ref-type="bibr">173</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs and silymarin loaded-MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">250 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral administration in rats</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No evident toxicity in rats</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B174-pharmaceutics-13-00143" ref-type="bibr">174</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose at 10, 25, and 50 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intraperitoneal application in mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No death; almost all tested parameters in liver within normal range</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B175-pharmaceutics-13-00143" ref-type="bibr">175</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs of 110 nm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous, hypodermic, intramuscular injection and oral administration in mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Caused inflammatory response around the injection sites after intramuscular and hypodermic injection;some toxicity to liver depending on route of application</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmaceutics-13-00143" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs and colloidal silica nanoparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2, 20, and 50 mg/kg/day</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intraperitoneal injection in mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 weeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No overt sign of clinical toxicity; some damage to systemic immunity of spleen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B176-pharmaceutics-13-00143" ref-type="bibr">176</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs with different sizes with no surface modification</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous administration in female and male BALB/c mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 year</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No significant changes in body weight, blood cell count, or plasma biomarker indices; no significant changes in post necropsy examination of internal organs and organ-to-body weight ratio;significant liver inflammation and aggregates of histiocytes with neutrophils within the spleen; no chronic toxicity observed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-pharmaceutics-13-00143" ref-type="bibr">28</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="pharmaceutics-13-00143-t005" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceutics-13-00143-t005_Table 5</object-id><label>Table 5</label><caption><p>Loading capacity for natural prodrugs into MSNs established as recent drug delivery systems for natural medicinal substances.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MSN Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Surface Modification</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Natural Cargo</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Loading Content (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aptamer-functionalized</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Curcumin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B194-pharmaceutics-13-00143" ref-type="bibr">194</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amine-functionalized and chitosan-coated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gallic acid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Up to 58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B195-pharmaceutics-13-00143" ref-type="bibr">195</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KIT-6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Guanidine-functionalized and PEGylated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Curcumin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B196-pharmaceutics-13-00143" ref-type="bibr">196</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KIT-6 and KIL-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amino-modified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Curcumin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5&#x02013;28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B197-pharmaceutics-13-00143" ref-type="bibr">197</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-modified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Essential oils (lemongrass and clove)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29&#x02013;36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B198-pharmaceutics-13-00143" ref-type="bibr">198</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">siRNA, folic acid functionalized</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Myricetin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B199-pharmaceutics-13-00143" ref-type="bibr">199</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amino-modified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ursolic acid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B200-pharmaceutics-13-00143" ref-type="bibr">200</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-modified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Curcumin and chrysin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11&#x02013;14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B201-pharmaceutics-13-00143" ref-type="bibr">201</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-modified and copolymer-grafted MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quercetin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3&#x02013;9.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B202-pharmaceutics-13-00143" ref-type="bibr">202</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-modified, amino-functionalized, folic acid-functionalized</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Umbelliferone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12&#x02013;19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B203-pharmaceutics-13-00143" ref-type="bibr">203</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KCC-1 and MCM-41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Folic acid-functionalized</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quercetin, curcumin, colchicine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2&#x02013;29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-pharmaceutics-13-00143" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KCC-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phosphonate-functionalized</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colchicine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B43-pharmaceutics-13-00143" ref-type="bibr">43</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-modified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thymoquinone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~7.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B44-pharmaceutics-13-00143" ref-type="bibr">44</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-modified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Harmine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B204-pharmaceutics-13-00143" ref-type="bibr">204</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="pharmaceutics-13-00143-t006" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceutics-13-00143-t006_Table 6</object-id><label>Table 6</label><caption><p>Different loading strategies and their relationships to stimuli release under various conditions for MSNs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Strategy</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Nano System Design</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Release</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Molecular or supramolecular</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs-rotaxane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diffusion under pH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B205-pharmaceutics-13-00143" ref-type="bibr">205</xref>,<xref rid="B206-pharmaceutics-13-00143" ref-type="bibr">206</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pseudorotaxane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diffusion under redox, pH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B207-pharmaceutics-13-00143" ref-type="bibr">207</xref>,<xref rid="B208-pharmaceutics-13-00143" ref-type="bibr">208</xref>,<xref rid="B209-pharmaceutics-13-00143" ref-type="bibr">209</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cleavable molecular bridges</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diffusion under plasmonic heating, two-photon irradiation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B210-pharmaceutics-13-00143" ref-type="bibr">210</xref>,<xref rid="B211-pharmaceutics-13-00143" ref-type="bibr">211</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Molecular nanovalves</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diffusion under plasmonic heating, various stimuli</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B210-pharmaceutics-13-00143" ref-type="bibr">210</xref>,<xref rid="B212-pharmaceutics-13-00143" ref-type="bibr">212</xref>]</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Nanoparticles as gatekeepers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Iron oxide nanoparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diffusion under redox, pH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B188-pharmaceutics-13-00143" ref-type="bibr">188</xref>,<xref rid="B213-pharmaceutics-13-00143" ref-type="bibr">213</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cadmium sulfide nanoparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diffusion under redox</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B190-pharmaceutics-13-00143" ref-type="bibr">190</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gold nanoparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diffusion under pH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B214-pharmaceutics-13-00143" ref-type="bibr">214</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zinc nanoparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diffusion under pH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B215-pharmaceutics-13-00143" ref-type="bibr">215</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Calcium carbonate nanoparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diffusion under pH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B216-pharmaceutics-13-00143" ref-type="bibr">216</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Coatings</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polymer coating</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diffusion under pH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B44-pharmaceutics-13-00143" ref-type="bibr">44</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proteins coating</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diffusion under pH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B193-pharmaceutics-13-00143" ref-type="bibr">193</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipid coating</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diffusion under different conditions</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B217-pharmaceutics-13-00143" ref-type="bibr">217</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="pharmaceutics-13-00143-t007" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceutics-13-00143-t007_Table 7</object-id><label>Table 7</label><caption><p>Some examples of targeted delivery systems for anticancer natural prodrugs using MSNs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Prodrug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ligand Used</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cancer Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">In Vitro/In Vivo</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Berberine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro and in vivo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B239-pharmaceutics-13-00143" ref-type="bibr">239</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colchicine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colon cancer cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B43-pharmaceutics-13-00143" ref-type="bibr">43</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Curcumin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver cancer cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-pharmaceutics-13-00143" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Curcumin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro and in vivo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B260-pharmaceutics-13-00143" ref-type="bibr">260</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Curcumin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B261-pharmaceutics-13-00143" ref-type="bibr">261</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quercetin and doxorubicin co-delivery</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gastric carcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vivo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B262-pharmaceutics-13-00143" ref-type="bibr">262</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ZD6474 and epigallocatechin gallate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EGFR, VEGFR2, and Akt</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tamoxifen-resistant breast cancer.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro and in vivo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B263-pharmaceutics-13-00143" ref-type="bibr">263</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Topotecan and quercetin co-delivery</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arginine-glycine-aspartic acid (cRGD) peptide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Triple negative breast cancer and multi-drug resistant breast cancer cells (MCF-7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B264-pharmaceutics-13-00143" ref-type="bibr">264</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quercetin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B265-pharmaceutics-13-00143" ref-type="bibr">265</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Epigallocatechin-3-gallate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vivo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B266-pharmaceutics-13-00143" ref-type="bibr">266</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-miRNA21 and resveratrol co-delivery</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gastric carcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro and in vivo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B267-pharmaceutics-13-00143" ref-type="bibr">267</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thymoquinone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Whey protein, Arabic gum, or chitosan&#x02013;stearic acid </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brain cancers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B44-pharmaceutics-13-00143" ref-type="bibr">44</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quercetin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R5 peptide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colon cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B268-pharmaceutics-13-00143" ref-type="bibr">268</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>FA = folic acid, HA = hyaluronic acid.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pharmaceutics-13-00143-t008" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceutics-13-00143-t008_Table 8</object-id><label>Table 8</label><caption><p>Delivery designs for curcumin in cancer (in vitro/in vivo studies) based on mesoporous silica nanoparticles (MSNs).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Delivery Design</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Trigger Release Effect</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cancer Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Anticancer Mechanism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CUR-loaded MSNs incorporated into poly-&#x003b5;-caprolactone/gelatin (PCL/GEL) hybrid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sustained release</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human adipose-derived stem cells (hADSCs)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Down-regulation of p16INK4A; up-regulation of hTERT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B326-pharmaceutics-13-00143" ref-type="bibr">326</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SBA-15 doped with silver nanoparticles, coated melanin-like polydopamine, and loaded CUR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pH-sensitive release</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human cervical cancer cells (HeLa) and taxol-resistant non-small cell lung cells (A549/TAX)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B323-pharmaceutics-13-00143" ref-type="bibr">323</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Co-delivery: spiropyran- and fluorinated silane-modified MSNs, loaded doxorubicin and CUR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pH-responsive release</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vivo: HepG2-xenografted mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B327-pharmaceutics-13-00143" ref-type="bibr">327</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hollow MSNs, loaded CUR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pH-triggered release</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B328-pharmaceutics-13-00143" ref-type="bibr">328</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Co-delivery: PEGylated lipid bilayer coated MSNs, loaded paclitaxel and CUR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sustained release</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vivo: breast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B324-pharmaceutics-13-00143" ref-type="bibr">324</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targeted delivery with folic acid-modified MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pH-triggered release</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B325-pharmaceutics-13-00143" ref-type="bibr">325</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CUR loaded MSNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatocellular carcinoma cells (HepG2, liver)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B329-pharmaceutics-13-00143" ref-type="bibr">329</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSNs functionalized with PEI and loaded CUR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancers: MCF-7 and MCF-7R cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apoptosis: activation of caspase-9, -6, -12, PARP, CHOP, and PTEN; downregulation of survival protein Akt1; downregulation of ER resident protein: IRE1&#x003b1;, PERK, and GRP78</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B330-pharmaceutics-13-00143" ref-type="bibr">330</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targeted delivery: folic acid-conjugated amine-modified MSNs (KCC-1 and MCM-41), loaded CUR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human hepatocellular carcinoma cells (HepG2) and HeLa cancer cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apoptosis: by specific signaling molecular pathways (caspase-3, H2O2, c-MET, and MCL-1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-pharmaceutics-13-00143" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targeted delivery: MSN-modified hyaluronan (HA) or polyethyleneimine-folic acid and loaded CUR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Redox-responsive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer cell line (MDA-MB-231). In vivo: mouse xenograft model.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B260-pharmaceutics-13-00143" ref-type="bibr">260</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targeted delivery: gold nanoparticles immobilized on folic acid-conjugated dendritic MSNs, coated reduced graphene oxide nanosheets, loaded CUR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pH-sensitive and photothermal potency</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human cancer cell lines (MCF-7, human breast carcinoma cells and A549, human lung carcinoma cells)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B261-pharmaceutics-13-00143" ref-type="bibr">261</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aspartic acid functionalized PEGylated MSNs contained graphene oxide nanohybrid loaded CUR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pH-responsive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer MCF-7 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B322-pharmaceutics-13-00143" ref-type="bibr">322</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targeted delivery: folic acid-modified MSNs, loaded CUR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pH-sensitive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer MCF-7 cell</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B331-pharmaceutics-13-00143" ref-type="bibr">331</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glycyrrhetinic acid-functionalized MSNs, loaded CUR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver hepatocellular carcinoma (HepG2) cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B332-pharmaceutics-13-00143" ref-type="bibr">332</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polyethylenimine-modified curcumin-loaded MCM-41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pH-sensitive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer MCF-7 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B333-pharmaceutics-13-00143" ref-type="bibr">333</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MCM-41 capped by chitosan natural polymer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pH-sensitive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glioblastoma cancer cell line (U87MG)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B222-pharmaceutics-13-00143" ref-type="bibr">222</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Carboxymethyl cellulose-grafted mesoporous silica hybrid nanogels</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human breast cancer cell line (MDA-MB-231)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B334-pharmaceutics-13-00143" ref-type="bibr">334</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targeted delivery: CUR-loaded and calcium-doped dendritic MSNs modified with folic acid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pH-responsive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human breast cancer cells (MCF-7); in vivo animal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apoptosis: increasing intracellular ROS generation; decreasing mitochondrial membrane potential; enhancing cell cycle retardation at G2/M phase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B335-pharmaceutics-13-00143" ref-type="bibr">335</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amine-functionalized KIT-6, MSU-2, and MCM-41; loaded CUR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apoptosis: generation of intracellular ROS; downregulation of poly-ADP ribose polymerase (PARP) enzyme</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B336-pharmaceutics-13-00143" ref-type="bibr">336</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MCM-41 modified, different functionalities, and loaded CUR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sustained release</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human squamous cell carcinoma cell line (SCC25)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apoptosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B124-pharmaceutics-13-00143" ref-type="bibr">124</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KCC-1 and MCM-41 amino-modified and loaded CURC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pH-responsive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B69-pharmaceutics-13-00143" ref-type="bibr">69</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>NA = Not applicable, CUR = curcumin.</p></fn></table-wrap-foot></table-wrap></floats-group></article>